{ "instance": { "bbio-20220630.htm": { "axisCustom": 0, "axisStandard": 35, "contextCount": 465, "dts": { "calculationLink": { "local": [ "bbio-20220630_cal.xml" ] }, "definitionLink": { "local": [ "bbio-20220630_def.xml" ] }, "inline": { "local": [ "bbio-20220630.htm" ] }, "labelLink": { "local": [ "bbio-20220630_lab.xml" ] }, "presentationLink": { "local": [ "bbio-20220630_pre.xml" ] }, "schema": { "local": [ "bbio-20220630.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd", "https://xbrl.fasb.org/srt/2022/elts/srt-roles-2022.xsd", "https://xbrl.fasb.org/srt/2022/elts/srt-types-2022.xsd", "https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd", "https://xbrl.fasb.org/us-gaap/2022/elts/us-roles-2022.xsd", "https://xbrl.fasb.org/us-gaap/2022/elts/us-types-2022.xsd", "https://xbrl.sec.gov/country/2022/country-2022.xsd", "https://xbrl.sec.gov/dei/2022/dei-2022.xsd" ] } }, "elementCount": 830, "entityCount": 1, "hidden": { "http://bridgebio.com/20220630": 6, "http://fasb.org/us-gaap/2022": 4, "http://xbrl.sec.gov/dei/2022": 4, "total": 14 }, "keyCustom": 156, "keyStandard": 325, "memberCustom": 83, "memberStandard": 43, "nsprefix": "bbio", "nsuri": "http://bridgebio.com/20220630", "report": { "R1": { "firstAnchor": { "ancestors": [ "span", "p", "body", "html" ], "baseRef": "bbio-20220630.htm", "contextRef": "C_8193da1f-851b-4ed7-8a0c-b5762fe09616", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "document", "isDefault": "true", "longName": "100000 - Document - Document and Entity Information", "role": "http://bridgebio.com/20220630/taxonomy/role/Role_DocumentDocumentAndEntityInformation", "shortName": "Document and Entity Information", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "p", "body", "html" ], "baseRef": "bbio-20220630.htm", "contextRef": "C_8193da1f-851b-4ed7-8a0c-b5762fe09616", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R10": { "firstAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "bbio-20220630.htm", "contextRef": "C_8193da1f-851b-4ed7-8a0c-b5762fe09616", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SignificantAccountingPoliciesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100100 - Disclosure - Summary of Significant Accounting Policies", "role": "http://bridgebio.com/20220630/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPolicies", "shortName": "Summary of Significant Accounting Policies", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "bbio-20220630.htm", "contextRef": "C_8193da1f-851b-4ed7-8a0c-b5762fe09616", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SignificantAccountingPoliciesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R11": { "firstAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "bbio-20220630.htm", "contextRef": "C_8193da1f-851b-4ed7-8a0c-b5762fe09616", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:FairValueDisclosuresTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100110 - Disclosure - Fair Value Measurements", "role": "http://bridgebio.com/20220630/taxonomy/role/DisclosureFairValueMeasurements", "shortName": "Fair Value Measurements", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "bbio-20220630.htm", "contextRef": "C_8193da1f-851b-4ed7-8a0c-b5762fe09616", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:FairValueDisclosuresTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R12": { "firstAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "bbio-20220630.htm", "contextRef": "C_8193da1f-851b-4ed7-8a0c-b5762fe09616", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:CashCashEquivalentsAndMarketableSecuritiesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100120 - Disclosure - Cash Equivalents and Marketable Securities", "role": "http://bridgebio.com/20220630/taxonomy/role/Role_DisclosureCashEquivalentsAndMarketableSecurities", "shortName": "Cash Equivalents and Marketable Securities", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "bbio-20220630.htm", "contextRef": "C_8193da1f-851b-4ed7-8a0c-b5762fe09616", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:CashCashEquivalentsAndMarketableSecuritiesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R13": { "firstAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "bbio-20220630.htm", "contextRef": "C_8193da1f-851b-4ed7-8a0c-b5762fe09616", "decimals": null, "first": true, "lang": "en-US", "name": "bbio:WhollyOwnedSubsidiaryDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100130 - Disclosure - Eidos", "role": "http://bridgebio.com/20220630/taxonomy/role/Role_DisclosureEidos", "shortName": "Eidos", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "bbio-20220630.htm", "contextRef": "C_8193da1f-851b-4ed7-8a0c-b5762fe09616", "decimals": null, "first": true, "lang": "en-US", "name": "bbio:WhollyOwnedSubsidiaryDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R14": { "firstAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "bbio-20220630.htm", "contextRef": "C_8193da1f-851b-4ed7-8a0c-b5762fe09616", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:MinorityInterestDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100140 - Disclosure - Noncontrolling Interests", "role": "http://bridgebio.com/20220630/taxonomy/role/Role_DisclosureNoncontrollingInterests", "shortName": "Noncontrolling Interests", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "bbio-20220630.htm", "contextRef": "C_8193da1f-851b-4ed7-8a0c-b5762fe09616", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:MinorityInterestDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R15": { "firstAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "bbio-20220630.htm", "contextRef": "C_8193da1f-851b-4ed7-8a0c-b5762fe09616", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:InvestmentTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100150 - Disclosure - Equity Method and Other Equity Investments", "role": "http://bridgebio.com/20220630/taxonomy/role/DisclosureEquityMethodAndOtherEquityInvestments", "shortName": "Equity Method and Other Equity Investments", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "bbio-20220630.htm", "contextRef": "C_8193da1f-851b-4ed7-8a0c-b5762fe09616", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:InvestmentTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R16": { "firstAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "bbio-20220630.htm", "contextRef": "C_8193da1f-851b-4ed7-8a0c-b5762fe09616", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:IntangibleAssetsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100160 - Disclosure - Intangible Assets", "role": "http://bridgebio.com/20220630/taxonomy/role/DisclosureIntangibleAssets", "shortName": "Intangible Assets", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "bbio-20220630.htm", "contextRef": "C_8193da1f-851b-4ed7-8a0c-b5762fe09616", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:IntangibleAssetsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R17": { "firstAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "bbio-20220630.htm", "contextRef": "C_8193da1f-851b-4ed7-8a0c-b5762fe09616", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100170 - Disclosure - Commitments and Contingencies", "role": "http://bridgebio.com/20220630/taxonomy/role/Role_DisclosureCommitmentsAndContingencies", "shortName": "Commitments and Contingencies", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "bbio-20220630.htm", "contextRef": "C_8193da1f-851b-4ed7-8a0c-b5762fe09616", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R18": { "firstAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "bbio-20220630.htm", "contextRef": "C_8193da1f-851b-4ed7-8a0c-b5762fe09616", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DebtDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100180 - Disclosure - Debt", "role": "http://bridgebio.com/20220630/taxonomy/role/Role_DisclosureDebt", "shortName": "Debt", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "bbio-20220630.htm", "contextRef": "C_8193da1f-851b-4ed7-8a0c-b5762fe09616", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DebtDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R19": { "firstAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "bbio-20220630.htm", "contextRef": "C_8193da1f-851b-4ed7-8a0c-b5762fe09616", "decimals": null, "first": true, "lang": "en-US", "name": "bbio:LicenseAndCollaborationAgreementTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100190 - Disclosure - License and Collaboration Agreements", "role": "http://bridgebio.com/20220630/taxonomy/role/DisclosureLicenseAndCollaborationAgreements1", "shortName": "License and Collaboration Agreements", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "bbio-20220630.htm", "contextRef": "C_8193da1f-851b-4ed7-8a0c-b5762fe09616", "decimals": null, "first": true, "lang": "en-US", "name": "bbio:LicenseAndCollaborationAgreementTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R2": { "firstAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "body", "html" ], "baseRef": "bbio-20220630.htm", "contextRef": "C_79a35245-7d52-4fb1-9fb8-8a023229d7aa", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue", "reportCount": 1, "unitRef": "U_USD", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "100010 - Statement - Condensed Consolidated Balance Sheets", "role": "http://bridgebio.com/20220630/taxonomy/role/Role_StatementCondensedConsolidatedBalanceSheets", "shortName": "Condensed Consolidated Balance Sheets", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "body", "html" ], "baseRef": "bbio-20220630.htm", "contextRef": "C_b61804ff-881e-4dcb-8230-c43bbc1e35bf", "decimals": "-3", "lang": null, "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue", "reportCount": 1, "unique": true, "unitRef": "U_USD", "xsiNil": "false" } }, "R20": { "firstAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "bbio-20220630.htm", "contextRef": "C_8193da1f-851b-4ed7-8a0c-b5762fe09616", "decimals": null, "first": true, "lang": "en-US", "name": "bbio:SaleOfNonfinancialAssetsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100200 - Disclosure - Sale of Nonfinancial Assets", "role": "http://bridgebio.com/20220630/taxonomy/role/DisclosureSaleOfNonfinancialAssets1", "shortName": "Sale of Nonfinancial Assets", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "bbio-20220630.htm", "contextRef": "C_8193da1f-851b-4ed7-8a0c-b5762fe09616", "decimals": null, "first": true, "lang": "en-US", "name": "bbio:SaleOfNonfinancialAssetsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R21": { "firstAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "bbio-20220630.htm", "contextRef": "C_8193da1f-851b-4ed7-8a0c-b5762fe09616", "decimals": null, "first": true, "lang": "en-US", "name": "bbio:LesseeOperatingAndFinancingLeasesDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100220 - Disclosure - Leases", "role": "http://bridgebio.com/20220630/taxonomy/role/Role_DisclosureLeases", "shortName": "Leases", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "bbio-20220630.htm", "contextRef": "C_8193da1f-851b-4ed7-8a0c-b5762fe09616", "decimals": null, "first": true, "lang": "en-US", "name": "bbio:LesseeOperatingAndFinancingLeasesDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R22": { "firstAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "bbio-20220630.htm", "contextRef": "C_8193da1f-851b-4ed7-8a0c-b5762fe09616", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100230 - Disclosure - Share Repurchase Program and Shelf Registration", "role": "http://bridgebio.com/20220630/taxonomy/role/Role_DisclosureShareRepurchaseProgramAndShelfRegistration", "shortName": "Share Repurchase Program and Shelf Registration", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "bbio-20220630.htm", "contextRef": "C_8193da1f-851b-4ed7-8a0c-b5762fe09616", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R23": { "firstAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "bbio-20220630.htm", "contextRef": "C_8193da1f-851b-4ed7-8a0c-b5762fe09616", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100240 - Disclosure - Stock-Based Compensation", "role": "http://bridgebio.com/20220630/taxonomy/role/Role_DisclosureStockBasedCompensation", "shortName": "Stock-Based Compensation", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "bbio-20220630.htm", "contextRef": "C_8193da1f-851b-4ed7-8a0c-b5762fe09616", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R24": { "firstAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "bbio-20220630.htm", "contextRef": "C_8193da1f-851b-4ed7-8a0c-b5762fe09616", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:RestructuringAndRelatedActivitiesDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100250 - Disclosure - Restructuring, Impairment and Related Charges", "role": "http://bridgebio.com/20220630/taxonomy/role/DisclosureRestructuringImpairmentAndRelatedCharges1", "shortName": "Restructuring, Impairment and Related Charges", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "bbio-20220630.htm", "contextRef": "C_8193da1f-851b-4ed7-8a0c-b5762fe09616", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:RestructuringAndRelatedActivitiesDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R25": { "firstAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "bbio-20220630.htm", "contextRef": "C_8193da1f-851b-4ed7-8a0c-b5762fe09616", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:IncomeTaxDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100260 - Disclosure - Income Taxes", "role": "http://bridgebio.com/20220630/taxonomy/role/Role_DisclosureIncomeTaxes", "shortName": "Income Taxes", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "bbio-20220630.htm", "contextRef": "C_8193da1f-851b-4ed7-8a0c-b5762fe09616", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:IncomeTaxDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R26": { "firstAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "bbio-20220630.htm", "contextRef": "C_8193da1f-851b-4ed7-8a0c-b5762fe09616", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:EarningsPerShareTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100270 - Disclosure - Net Loss Per Share", "role": "http://bridgebio.com/20220630/taxonomy/role/Role_DisclosureNetLossPerShare", "shortName": "Net Loss Per Share", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "bbio-20220630.htm", "contextRef": "C_8193da1f-851b-4ed7-8a0c-b5762fe09616", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:EarningsPerShareTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R27": { "firstAnchor": { "ancestors": [ "div", "us-gaap:SignificantAccountingPoliciesTextBlock", "div", "body", "html" ], "baseRef": "bbio-20220630.htm", "contextRef": "C_8193da1f-851b-4ed7-8a0c-b5762fe09616", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100280 - Disclosure - Summary of Significant Accounting Policies (Policies)", "role": "http://bridgebio.com/20220630/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies", "shortName": "Summary of Significant Accounting Policies (Policies)", "subGroupType": "policies", "uniqueAnchor": { "ancestors": [ "div", "us-gaap:SignificantAccountingPoliciesTextBlock", "div", "body", "html" ], "baseRef": "bbio-20220630.htm", "contextRef": "C_8193da1f-851b-4ed7-8a0c-b5762fe09616", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R28": { "firstAnchor": { "ancestors": [ "div", "us-gaap:FairValueDisclosuresTextBlock", "div", "body", "html" ], "baseRef": "bbio-20220630.htm", "contextRef": "C_8193da1f-851b-4ed7-8a0c-b5762fe09616", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100290 - Disclosure - Fair Value Measurements (Tables)", "role": "http://bridgebio.com/20220630/taxonomy/role/DisclosureFairValueMeasurementsTables", "shortName": "Fair Value Measurements (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "div", "us-gaap:FairValueDisclosuresTextBlock", "div", "body", "html" ], "baseRef": "bbio-20220630.htm", "contextRef": "C_8193da1f-851b-4ed7-8a0c-b5762fe09616", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R29": { "firstAnchor": { "ancestors": [ "div", "us-gaap:CashCashEquivalentsAndMarketableSecuritiesTextBlock", "div", "body", "html" ], "baseRef": "bbio-20220630.htm", "contextRef": "C_8193da1f-851b-4ed7-8a0c-b5762fe09616", "decimals": null, "first": true, "lang": "en-US", "name": "bbio:ScheduleOfCashEquivalentsAndMarketableSecuritiesTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100300 - Disclosure - Cash Equivalents and Marketable Securities (Tables)", "role": "http://bridgebio.com/20220630/taxonomy/role/Role_DisclosureCashEquivalentsAndMarketableSecuritiesTables", "shortName": "Cash Equivalents and Marketable Securities (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "div", "us-gaap:CashCashEquivalentsAndMarketableSecuritiesTextBlock", "div", "body", "html" ], "baseRef": "bbio-20220630.htm", "contextRef": "C_8193da1f-851b-4ed7-8a0c-b5762fe09616", "decimals": null, "first": true, "lang": "en-US", "name": "bbio:ScheduleOfCashEquivalentsAndMarketableSecuritiesTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R3": { "firstAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "body", "html" ], "baseRef": "bbio-20220630.htm", "contextRef": "C_79a35245-7d52-4fb1-9fb8-8a023229d7aa", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:PreferredStockParOrStatedValuePerShare", "reportCount": 1, "unique": true, "unitRef": "U_UnitedStatesOfAmericaDollarsShare", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "100030 - Statement - Condensed Consolidated Balance Sheets (Parenthetical)", "role": "http://bridgebio.com/20220630/taxonomy/role/Role_StatementCondensedConsolidatedBalanceSheetsParenthetical", "shortName": "Condensed Consolidated Balance Sheets (Parenthetical)", "subGroupType": "parenthetical", "uniqueAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "body", "html" ], "baseRef": "bbio-20220630.htm", "contextRef": "C_79a35245-7d52-4fb1-9fb8-8a023229d7aa", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:PreferredStockParOrStatedValuePerShare", "reportCount": 1, "unique": true, "unitRef": "U_UnitedStatesOfAmericaDollarsShare", "xsiNil": "false" } }, "R30": { "firstAnchor": { "ancestors": [ "div", "us-gaap:IntangibleAssetsDisclosureTextBlock", "div", "body", "html" ], "baseRef": "bbio-20220630.htm", "contextRef": "C_8193da1f-851b-4ed7-8a0c-b5762fe09616", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock", "reportCount": 1, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100310 - Disclosure - Intangible Assets (Tables)", "role": "http://bridgebio.com/20220630/taxonomy/role/DisclosureIntangibleAssetsTables", "shortName": "Intangible Assets (Tables)", "subGroupType": "tables", "uniqueAnchor": null }, "R31": { "firstAnchor": { "ancestors": [ "span", "p", "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "div", "body", "html" ], "baseRef": "bbio-20220630.htm", "contextRef": "C_8193da1f-851b-4ed7-8a0c-b5762fe09616", "decimals": null, "first": true, "lang": "en-US", "name": "bbio:ScheduleOfPotentialMilestoneAmountsAndAccrualsTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100320 - Disclosure - Commitments and Contingencies (Tables)", "role": "http://bridgebio.com/20220630/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesTables", "shortName": "Commitments and Contingencies (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "span", "p", "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "div", "body", "html" ], "baseRef": "bbio-20220630.htm", "contextRef": "C_8193da1f-851b-4ed7-8a0c-b5762fe09616", "decimals": null, "first": true, "lang": "en-US", "name": "bbio:ScheduleOfPotentialMilestoneAmountsAndAccrualsTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R32": { "firstAnchor": { "ancestors": [ "div", "us-gaap:DebtDisclosureTextBlock", "div", "body", "html" ], "baseRef": "bbio-20220630.htm", "contextRef": "C_31f30be6-71da-46d8-83df-4bc7a48e61ca", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfDebtInstrumentsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100330 - Disclosure - Debt (Tables)", "role": "http://bridgebio.com/20220630/taxonomy/role/Role_DisclosureDebtTables", "shortName": "Debt (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "div", "us-gaap:DebtDisclosureTextBlock", "div", "body", "html" ], "baseRef": "bbio-20220630.htm", "contextRef": "C_31f30be6-71da-46d8-83df-4bc7a48e61ca", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfDebtInstrumentsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R33": { "firstAnchor": { "ancestors": [ "div", "us-gaap:IntangibleAssetsDisclosureTextBlock", "div", "body", "html" ], "baseRef": "bbio-20220630.htm", "contextRef": "C_8193da1f-851b-4ed7-8a0c-b5762fe09616", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock", "reportCount": 1, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100340 - Disclosure - Asset Acquisitions and Collaboration Agreement (Tables)", "role": "http://bridgebio.com/20220630/taxonomy/role/DisclosureAssetAcquisitionsAndCollaborationAgreementTables", "shortName": "Asset Acquisitions and Collaboration Agreement (Tables)", "subGroupType": "tables", "uniqueAnchor": null }, "R34": { "firstAnchor": { "ancestors": [ "div", "bbio:LesseeOperatingAndFinancingLeasesDisclosureTextBlock", "div", "body", "html" ], "baseRef": "bbio-20220630.htm", "contextRef": "C_8193da1f-851b-4ed7-8a0c-b5762fe09616", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:LeaseCostTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100350 - Disclosure - Leases (Tables)", "role": "http://bridgebio.com/20220630/taxonomy/role/Role_DisclosureLeasesTables", "shortName": "Leases (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "div", "bbio:LesseeOperatingAndFinancingLeasesDisclosureTextBlock", "div", "body", "html" ], "baseRef": "bbio-20220630.htm", "contextRef": "C_8193da1f-851b-4ed7-8a0c-b5762fe09616", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:LeaseCostTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R35": { "firstAnchor": { "ancestors": [ "div", "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "div", "body", "html" ], "baseRef": "bbio-20220630.htm", "contextRef": "C_8193da1f-851b-4ed7-8a0c-b5762fe09616", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100360 - Disclosure - Stock-Based Compensation (Tables)", "role": "http://bridgebio.com/20220630/taxonomy/role/Role_DisclosureStockBasedCompensationTables", "shortName": "Stock-Based Compensation (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "div", "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "div", "body", "html" ], "baseRef": "bbio-20220630.htm", "contextRef": "C_8193da1f-851b-4ed7-8a0c-b5762fe09616", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R36": { "firstAnchor": { "ancestors": [ "div", "us-gaap:RestructuringAndRelatedActivitiesDisclosureTextBlock", "div", "body", "html" ], "baseRef": "bbio-20220630.htm", "contextRef": "C_8193da1f-851b-4ed7-8a0c-b5762fe09616", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfRestructuringAndRelatedCostsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100370 - Disclosure - Restructuring, Impairment and Related Charges (Tables)", "role": "http://bridgebio.com/20220630/taxonomy/role/DisclosureRestructuringImpairmentAndRelatedChargesTables", "shortName": "Restructuring, Impairment and Related Charges (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "div", "us-gaap:RestructuringAndRelatedActivitiesDisclosureTextBlock", "div", "body", "html" ], "baseRef": "bbio-20220630.htm", "contextRef": "C_8193da1f-851b-4ed7-8a0c-b5762fe09616", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfRestructuringAndRelatedCostsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R37": { "firstAnchor": { "ancestors": [ "div", "us-gaap:EarningsPerShareTextBlock", "div", "body", "html" ], "baseRef": "bbio-20220630.htm", "contextRef": "C_8193da1f-851b-4ed7-8a0c-b5762fe09616", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100380 - Disclosure - Net Loss Per Share (Tables)", "role": "http://bridgebio.com/20220630/taxonomy/role/Role_DisclosureNetLossPerShareTables", "shortName": "Net Loss Per Share (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "div", "us-gaap:EarningsPerShareTextBlock", "div", "body", "html" ], "baseRef": "bbio-20220630.htm", "contextRef": "C_8193da1f-851b-4ed7-8a0c-b5762fe09616", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R38": { "firstAnchor": { "ancestors": [ "span", "p", "us-gaap:BasisOfAccountingPolicyPolicyTextBlock", "div", "us-gaap:SignificantAccountingPoliciesTextBlock", "div", "body", "html" ], "baseRef": "bbio-20220630.htm", "contextRef": "C_0ccf9272-987d-435c-aed4-e12bfb34baf0", "decimals": "2", "first": true, "lang": null, "name": "bbio:VotingInterestEntityInvestmentThresholdPercentage", "reportCount": 1, "unique": true, "unitRef": "U_pure", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100390 - Disclosure - Summary of Significant Accounting Policies - Additional Information (Details)", "role": "http://bridgebio.com/20220630/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails", "shortName": "Summary of Significant Accounting Policies - Additional Information (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "p", "us-gaap:BasisOfAccountingPolicyPolicyTextBlock", "div", "us-gaap:SignificantAccountingPoliciesTextBlock", "div", "body", "html" ], "baseRef": "bbio-20220630.htm", "contextRef": "C_0ccf9272-987d-435c-aed4-e12bfb34baf0", "decimals": "2", "first": true, "lang": null, "name": "bbio:VotingInterestEntityInvestmentThresholdPercentage", "reportCount": 1, "unique": true, "unitRef": "U_pure", "xsiNil": "false" } }, "R39": { "firstAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "bbio:ScheduleOfCashEquivalentsAndMarketableSecuritiesTableTextBlock", "div", "us-gaap:CashCashEquivalentsAndMarketableSecuritiesTextBlock", "div", "body", "html" ], "baseRef": "bbio-20220630.htm", "contextRef": "C_79a35245-7d52-4fb1-9fb8-8a023229d7aa", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:CashAndCashEquivalentsFairValueDisclosure", "reportCount": 1, "unitRef": "U_USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100400 - Disclosure - Fair Value Measurements - Financial Assets and Liabilities Measured at Fair Value on Recurring Basis (Details)", "role": "http://bridgebio.com/20220630/taxonomy/role/DisclosureFairValueMeasurementsFinancialAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails", "shortName": "Fair Value Measurements - Financial Assets and Liabilities Measured at Fair Value on Recurring Basis (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock", "div", "us-gaap:FairValueDisclosuresTextBlock", "div", "body", "html" ], "baseRef": "bbio-20220630.htm", "contextRef": "C_a639d488-6798-4aa3-9a2c-8ff2dd57f27a", "decimals": "-3", "lang": null, "name": "us-gaap:CashAndCashEquivalentsFairValueDisclosure", "reportCount": 1, "unique": true, "unitRef": "U_USD", "xsiNil": "false" } }, "R4": { "firstAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "body", "html" ], "baseRef": "bbio-20220630.htm", "contextRef": "C_3da5d8c2-2b80-443c-9ad1-3072371b08d5", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax", "reportCount": 1, "unitRef": "U_USD", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "100040 - Statement - Condensed Consolidated Statements of Operations (Unaudited)", "role": "http://bridgebio.com/20220630/taxonomy/role/StatementCondensedConsolidatedStatementsOfOperationsUnaudited", "shortName": "Condensed Consolidated Statements of Operations (Unaudited)", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "body", "html" ], "baseRef": "bbio-20220630.htm", "contextRef": "C_3da5d8c2-2b80-443c-9ad1-3072371b08d5", "decimals": "-3", "lang": null, "name": "bbio:CostOfLicenseRevenueAndProductsSold", "reportCount": 1, "unique": true, "unitRef": "U_USD", "xsiNil": "false" } }, "R40": { "firstAnchor": { "ancestors": [ "span", "p", "us-gaap:FairValueDisclosuresTextBlock", "div", "body", "html" ], "baseRef": "bbio-20220630.htm", "contextRef": "C_79a35245-7d52-4fb1-9fb8-8a023229d7aa", "decimals": "INF", "first": true, "lang": null, "name": "bbio:FairValueAssetsTransfersBetweenLevelOneLevelTwoOrLevelThreeAmount", "reportCount": 1, "unitRef": "U_USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100410 - Disclosure - Fair Value Measurements - Additional Information (Details)", "role": "http://bridgebio.com/20220630/taxonomy/role/DisclosureFairValueMeasurementsAdditionalInformationDetails", "shortName": "Fair Value Measurements - Additional Information (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "bbio:FairValueAssetsTransfersBetweenLevelOneLevelTwoOrLevelThreeAmount", "span", "p", "us-gaap:FairValueDisclosuresTextBlock", "div", "body", "html" ], "baseRef": "bbio-20220630.htm", "contextRef": "C_b61804ff-881e-4dcb-8230-c43bbc1e35bf", "decimals": "INF", "lang": null, "name": "bbio:FairValueAssetsTransfersBetweenLevelOneLevelTwoOrLevelThreeAmount", "reportCount": 1, "unique": true, "unitRef": "U_USD", "xsiNil": "false" } }, "R41": { "firstAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "us-gaap:GainLossOnInvestmentsTextBlock", "div", "us-gaap:FairValueDisclosuresTextBlock", "div", "body", "html" ], "baseRef": "bbio-20220630.htm", "contextRef": "C_3da5d8c2-2b80-443c-9ad1-3072371b08d5", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:EquitySecuritiesFvNiRealizedGainLoss", "reportCount": 1, "unique": true, "unitRef": "U_USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100420 - Disclosure - Fair Value Measurements - Summary of Total Realized and Unrealized Gains and Losses Associated with Investment in Equity Securities (Details)", "role": "http://bridgebio.com/20220630/taxonomy/role/DisclosureFairValueMeasurementsSummaryOfTotalRealizedAndUnrealizedGainsAndLossesAssociatedWithInvestmentInEquitySecuritiesDetails", "shortName": "Fair Value Measurements - Summary of Total Realized and Unrealized Gains and Losses Associated with Investment in Equity Securities (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "us-gaap:GainLossOnInvestmentsTextBlock", "div", "us-gaap:FairValueDisclosuresTextBlock", "div", "body", "html" ], "baseRef": "bbio-20220630.htm", "contextRef": "C_3da5d8c2-2b80-443c-9ad1-3072371b08d5", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:EquitySecuritiesFvNiRealizedGainLoss", "reportCount": 1, "unique": true, "unitRef": "U_USD", "xsiNil": "false" } }, "R42": { "firstAnchor": { "ancestors": [ "span", "p", "us-gaap:CashCashEquivalentsAndMarketableSecuritiesTextBlock", "div", "body", "html" ], "baseRef": "bbio-20220630.htm", "contextRef": "C_8193da1f-851b-4ed7-8a0c-b5762fe09616", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:DebtSecuritiesAvailableForSaleRealizedGainLoss", "reportCount": 1, "unique": true, "unitRef": "U_USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100450 - Disclosure - Cash Equivalents and Marketable Securities - Additional Information (Details)", "role": "http://bridgebio.com/20220630/taxonomy/role/Role_DisclosureCashEquivalentsAndMarketableSecuritiesAdditionalInformationDetails", "shortName": "Cash Equivalents and Marketable Securities - Additional Information (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "p", "us-gaap:CashCashEquivalentsAndMarketableSecuritiesTextBlock", "div", "body", "html" ], "baseRef": "bbio-20220630.htm", "contextRef": "C_8193da1f-851b-4ed7-8a0c-b5762fe09616", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:DebtSecuritiesAvailableForSaleRealizedGainLoss", "reportCount": 1, "unique": true, "unitRef": "U_USD", "xsiNil": "false" } }, "R43": { "firstAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "bbio:ScheduleOfCashEquivalentsAndMarketableSecuritiesTableTextBlock", "div", "us-gaap:CashCashEquivalentsAndMarketableSecuritiesTextBlock", "div", "body", "html" ], "baseRef": "bbio-20220630.htm", "contextRef": "C_79a35245-7d52-4fb1-9fb8-8a023229d7aa", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:CashEquivalentsAtCarryingValue", "reportCount": 1, "unique": true, "unitRef": "U_USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100460 - Disclosure - Cash Equivalents and Marketable Securities - Schedule of Cash Equivalent and Marketable Securities Classified as Available-for-Sale (Details)", "role": "http://bridgebio.com/20220630/taxonomy/role/Role_DisclosureCashEquivalentsAndMarketableSecuritiesScheduleOfCashEquivalentAndMarketableSecuritiesClassifiedAsAvailableForSaleDetails", "shortName": "Cash Equivalents and Marketable Securities - Schedule of Cash Equivalent and Marketable Securities Classified as Available-for-Sale (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "bbio:ScheduleOfCashEquivalentsAndMarketableSecuritiesTableTextBlock", "div", "us-gaap:CashCashEquivalentsAndMarketableSecuritiesTextBlock", "div", "body", "html" ], "baseRef": "bbio-20220630.htm", "contextRef": "C_79a35245-7d52-4fb1-9fb8-8a023229d7aa", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:CashEquivalentsAtCarryingValue", "reportCount": 1, "unique": true, "unitRef": "U_USD", "xsiNil": "false" } }, "R44": { "firstAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "body", "html" ], "baseRef": "bbio-20220630.htm", "contextRef": "C_28aaba60-51e2-4602-a96c-2efd7677ec14", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:MinorityInterestDecreaseFromRedemptions", "reportCount": 1, "unitRef": "U_USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100470 - Disclosure - Eidos - Additional Information (Details)", "role": "http://bridgebio.com/20220630/taxonomy/role/Role_DisclosureEidosAdditionalInformationDetails", "shortName": "Eidos - Additional Information (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "p", "bbio:WhollyOwnedSubsidiaryDisclosureTextBlock", "div", "body", "html" ], "baseRef": "bbio-20220630.htm", "contextRef": "C_17985c46-f419-4acd-bec9-0ec60c45bcc2", "decimals": null, "lang": "en-US", "name": "bbio:MergerTransactionsCompletionDate", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R45": { "firstAnchor": { "ancestors": [ "span", "p", "us-gaap:MinorityInterestDisclosureTextBlock", "div", "body", "html" ], "baseRef": "bbio-20220630.htm", "contextRef": "C_3da5d8c2-2b80-443c-9ad1-3072371b08d5", "decimals": "-5", "first": true, "lang": null, "name": "bbio:AdjustmentsOfCarryingValueOfNoncontrollingInterestAdditionalPaidInCapital", "reportCount": 1, "unique": true, "unitRef": "U_USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100480 - Disclosure - Noncontrolling Interests - Additional Information (Details)", "role": "http://bridgebio.com/20220630/taxonomy/role/Role_DisclosureNoncontrollingInterestsAdditionalInformationDetails", "shortName": "Noncontrolling Interests - Additional Information (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "p", "us-gaap:MinorityInterestDisclosureTextBlock", "div", "body", "html" ], "baseRef": "bbio-20220630.htm", "contextRef": "C_3da5d8c2-2b80-443c-9ad1-3072371b08d5", "decimals": "-5", "first": true, "lang": null, "name": "bbio:AdjustmentsOfCarryingValueOfNoncontrollingInterestAdditionalPaidInCapital", "reportCount": 1, "unique": true, "unitRef": "U_USD", "xsiNil": "false" } }, "R46": { "firstAnchor": { "ancestors": [ "span", "p", "us-gaap:InvestmentTextBlock", "div", "body", "html" ], "baseRef": "bbio-20220630.htm", "contextRef": "C_b61804ff-881e-4dcb-8230-c43bbc1e35bf", "decimals": "-5", "first": true, "lang": null, "name": "us-gaap:WarrantsNotSettleableInCashFairValueDisclosure", "reportCount": 1, "unitRef": "U_USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100490 - Disclosure - Equity Method and Other Equity Investments - Additional Information (Detail)", "role": "http://bridgebio.com/20220630/taxonomy/role/DisclosureEquityMethodAndOtherEquityInvestmentsAdditionalInformationDetail", "shortName": "Equity Method and Other Equity Investments - Additional Information (Detail)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "p", "us-gaap:InvestmentTextBlock", "div", "body", "html" ], "baseRef": "bbio-20220630.htm", "contextRef": "C_79a35245-7d52-4fb1-9fb8-8a023229d7aa", "decimals": "-5", "lang": null, "name": "us-gaap:WarrantsNotSettleableInCashFairValueDisclosure", "reportCount": 1, "unique": true, "unitRef": "U_USD", "xsiNil": "false" } }, "R47": { "firstAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock", "div", "us-gaap:IntangibleAssetsDisclosureTextBlock", "div", "body", "html" ], "baseRef": "bbio-20220630.htm", "contextRef": "C_8193da1f-851b-4ed7-8a0c-b5762fe09616", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100500 - Disclosure - Intangible Assets - Summary of Recognized Intangible Assets (Details)", "role": "http://bridgebio.com/20220630/taxonomy/role/DisclosureIntangibleAssetsSummaryOfRecognizedIntangibleAssetsDetails", "shortName": "Intangible Assets - Summary of Recognized Intangible Assets (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock", "div", "us-gaap:IntangibleAssetsDisclosureTextBlock", "div", "body", "html" ], "baseRef": "bbio-20220630.htm", "contextRef": "C_8193da1f-851b-4ed7-8a0c-b5762fe09616", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R48": { "firstAnchor": { "ancestors": [ "span", "p", "us-gaap:IntangibleAssetsDisclosureTextBlock", "div", "body", "html" ], "baseRef": "bbio-20220630.htm", "contextRef": "C_3da5d8c2-2b80-443c-9ad1-3072371b08d5", "decimals": "-5", "first": true, "lang": null, "name": "us-gaap:AmortizationOfIntangibleAssets", "reportCount": 1, "unique": true, "unitRef": "U_USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100510 - Disclosure - Intangible Assets - Additional Information (Details)", "role": "http://bridgebio.com/20220630/taxonomy/role/DisclosureIntangibleAssetsAdditionalInformationDetails", "shortName": "Intangible Assets - Additional Information (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "p", "us-gaap:IntangibleAssetsDisclosureTextBlock", "div", "body", "html" ], "baseRef": "bbio-20220630.htm", "contextRef": "C_3da5d8c2-2b80-443c-9ad1-3072371b08d5", "decimals": "-5", "first": true, "lang": null, "name": "us-gaap:AmortizationOfIntangibleAssets", "reportCount": 1, "unique": true, "unitRef": "U_USD", "xsiNil": "false" } }, "R49": { "firstAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "ix:continuation", "div", "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "div", "body", "html" ], "baseRef": "bbio-20220630.htm", "contextRef": "C_79a35245-7d52-4fb1-9fb8-8a023229d7aa", "decimals": "-3", "first": true, "lang": null, "name": "bbio:PotentialMilestoneFixedMonetaryAmountSettlementInCash", "reportCount": 1, "unique": true, "unitRef": "U_USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100520 - Disclosure - Commitments and Contingencies - Schedule of Potential Milestone Amounts and Accruals (Detail)", "role": "http://bridgebio.com/20220630/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesScheduleOfPotentialMilestoneAmountsAndAccrualsDetail", "shortName": "Commitments and Contingencies - Schedule of Potential Milestone Amounts and Accruals (Detail)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "ix:continuation", "div", "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "div", "body", "html" ], "baseRef": "bbio-20220630.htm", "contextRef": "C_79a35245-7d52-4fb1-9fb8-8a023229d7aa", "decimals": "-3", "first": true, "lang": null, "name": "bbio:PotentialMilestoneFixedMonetaryAmountSettlementInCash", "reportCount": 1, "unique": true, "unitRef": "U_USD", "xsiNil": "false" } }, "R5": { "firstAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "body", "html" ], "baseRef": "bbio-20220630.htm", "contextRef": "C_3da5d8c2-2b80-443c-9ad1-3072371b08d5", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:ProfitLoss", "reportCount": 1, "unitRef": "U_USD", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "100050 - Statement - Condensed Consolidated Statements of Comprehensive Loss (Unaudited)", "role": "http://bridgebio.com/20220630/taxonomy/role/StatementCondensedConsolidatedStatementsOfComprehensiveLossUnaudited", "shortName": "Condensed Consolidated Statements of Comprehensive Loss (Unaudited)", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "body", "html" ], "baseRef": "bbio-20220630.htm", "contextRef": "C_3da5d8c2-2b80-443c-9ad1-3072371b08d5", "decimals": "-3", "lang": null, "name": "us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest", "reportCount": 1, "unique": true, "unitRef": "U_USD", "xsiNil": "false" } }, "R50": { "firstAnchor": { "ancestors": [ "span", "p", "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "div", "body", "html" ], "baseRef": "bbio-20220630.htm", "contextRef": "C_b61804ff-881e-4dcb-8230-c43bbc1e35bf", "decimals": "INF", "first": true, "lang": null, "name": "bbio:AccruedTerminationCharges", "reportCount": 1, "unique": true, "unitRef": "U_USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100530 - Disclosure - Commitments and Contingencies - Additional Information (Detail)", "role": "http://bridgebio.com/20220630/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetail", "shortName": "Commitments and Contingencies - Additional Information (Detail)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "p", "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "div", "body", "html" ], "baseRef": "bbio-20220630.htm", "contextRef": "C_b61804ff-881e-4dcb-8230-c43bbc1e35bf", "decimals": "INF", "first": true, "lang": null, "name": "bbio:AccruedTerminationCharges", "reportCount": 1, "unique": true, "unitRef": "U_USD", "xsiNil": "false" } }, "R51": { "firstAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "body", "html" ], "baseRef": "bbio-20220630.htm", "contextRef": "C_e9078b67-0c1a-4946-ab0f-ce4319df613f", "decimals": "-3", "first": true, "lang": null, "name": "bbio:PurchaseOfCappedCalls", "reportCount": 1, "unitRef": "U_USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100540 - Disclosure - Debt - Additional Information (Details)", "role": "http://bridgebio.com/20220630/taxonomy/role/Role_DisclosureDebtAdditionalInformationDetails", "shortName": "Debt - Additional Information (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "p", "us-gaap:DebtDisclosureTextBlock", "div", "body", "html" ], "baseRef": "bbio-20220630.htm", "contextRef": "C_83c895b4-7e86-4b19-a4f9-ea0228c85743", "decimals": "-5", "lang": null, "name": "bbio:AmountPaidToLenders", "reportCount": 1, "unique": true, "unitRef": "U_USD", "xsiNil": "false" } }, "R52": { "firstAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "us-gaap:ScheduleOfDebtInstrumentsTextBlock", "div", "us-gaap:DebtDisclosureTextBlock", "div", "body", "html" ], "baseRef": "bbio-20220630.htm", "contextRef": "C_8d301ca9-e4e1-4aec-937f-1c7b7475f731", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:DebtInstrumentCarryingAmount", "reportCount": 1, "unique": true, "unitRef": "U_USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100550 - Disclosure - Debt - Schedule of Outstanding Notes Balances (Details)", "role": "http://bridgebio.com/20220630/taxonomy/role/Role_DisclosureDebtScheduleOfOutstandingNotesBalancesDetails", "shortName": "Debt - Schedule of Outstanding Notes Balances (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "us-gaap:ScheduleOfDebtInstrumentsTextBlock", "div", "us-gaap:DebtDisclosureTextBlock", "div", "body", "html" ], "baseRef": "bbio-20220630.htm", "contextRef": "C_8d301ca9-e4e1-4aec-937f-1c7b7475f731", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:DebtInstrumentCarryingAmount", "reportCount": 1, "unique": true, "unitRef": "U_USD", "xsiNil": "false" } }, "R53": { "firstAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "bbio:ScheduleOfInterestExpenseRecognizedAndEffectiveInterestRatesRelatedToNotesTableTextBlock", "div", "us-gaap:DebtDisclosureTextBlock", "div", "body", "html" ], "baseRef": "bbio-20220630.htm", "contextRef": "C_3da5d8c2-2b80-443c-9ad1-3072371b08d5", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:InterestExpenseDebtExcludingAmortization", "reportCount": 1, "unique": true, "unitRef": "U_USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100560 - Disclosure - Debt - Schedule of Total Interest Expense Recognized Related to Notes (Details)", "role": "http://bridgebio.com/20220630/taxonomy/role/Role_DisclosureDebtScheduleOfTotalInterestExpenseRecognizedRelatedToNotesDetails", "shortName": "Debt - Schedule of Total Interest Expense Recognized Related to Notes (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "bbio:ScheduleOfInterestExpenseRecognizedAndEffectiveInterestRatesRelatedToNotesTableTextBlock", "div", "us-gaap:DebtDisclosureTextBlock", "div", "body", "html" ], "baseRef": "bbio-20220630.htm", "contextRef": "C_3da5d8c2-2b80-443c-9ad1-3072371b08d5", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:InterestExpenseDebtExcludingAmortization", "reportCount": 1, "unique": true, "unitRef": "U_USD", "xsiNil": "false" } }, "R54": { "firstAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "srt:ContractualObligationFiscalYearMaturityScheduleTableTextBlock", "div", "us-gaap:DebtDisclosureTextBlock", "div", "body", "html" ], "baseRef": "bbio-20220630.htm", "contextRef": "C_d9a320ed-abd9-4faa-93d9-aa0d3de49e87", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:ContractualObligationFutureMinimumPaymentsDueRemainderOfFiscalYear", "reportCount": 1, "unique": true, "unitRef": "U_USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100570 - Disclosure - Debt - Schedule of Future Minimum Payments under Notes (Details)", "role": "http://bridgebio.com/20220630/taxonomy/role/Role_DisclosureDebtScheduleOfFutureMinimumPaymentsUnderNotesDetails", "shortName": "Debt - Schedule of Future Minimum Payments under Notes (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "srt:ContractualObligationFiscalYearMaturityScheduleTableTextBlock", "div", "us-gaap:DebtDisclosureTextBlock", "div", "body", "html" ], "baseRef": "bbio-20220630.htm", "contextRef": "C_d9a320ed-abd9-4faa-93d9-aa0d3de49e87", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:ContractualObligationFutureMinimumPaymentsDueRemainderOfFiscalYear", "reportCount": 1, "unique": true, "unitRef": "U_USD", "xsiNil": "false" } }, "R55": { "firstAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "us-gaap:ScheduleOfDebtInstrumentsTextBlock", "div", "us-gaap:DebtDisclosureTextBlock", "div", "body", "html" ], "baseRef": "bbio-20220630.htm", "contextRef": "C_00d035b7-361e-4937-90a1-026812e5a24d", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:DebtInstrumentCarryingAmount", "reportCount": 1, "unique": true, "unitRef": "U_USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100580 - Disclosure - Debt - Schedule of Balances of Borrowing under Loan Agreement (Details)", "role": "http://bridgebio.com/20220630/taxonomy/role/DisclosureDebtScheduleOfBalancesOfBorrowingUnderLoanAgreementDetails", "shortName": "Debt - Schedule of Balances of Borrowing under Loan Agreement (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "us-gaap:ScheduleOfDebtInstrumentsTextBlock", "div", "us-gaap:DebtDisclosureTextBlock", "div", "body", "html" ], "baseRef": "bbio-20220630.htm", "contextRef": "C_00d035b7-361e-4937-90a1-026812e5a24d", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:DebtInstrumentCarryingAmount", "reportCount": 1, "unique": true, "unitRef": "U_USD", "xsiNil": "false" } }, "R56": { "firstAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "srt:ContractualObligationFiscalYearMaturityScheduleTableTextBlock", "div", "us-gaap:DebtDisclosureTextBlock", "div", "body", "html" ], "baseRef": "bbio-20220630.htm", "contextRef": "C_3fcde183-38c7-4211-add6-d2d8a8bd4214", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:ContractualObligationFutureMinimumPaymentsDueRemainderOfFiscalYear", "reportCount": 1, "unique": true, "unitRef": "U_USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100590 - Disclosure - Debt - Schedule of Future Minimum Payments Under Term Loan Agreement (Details)", "role": "http://bridgebio.com/20220630/taxonomy/role/DisclosureDebtScheduleOfFutureMinimumPaymentsUnderTermLoanAgreementDetails", "shortName": "Debt - Schedule of Future Minimum Payments Under Term Loan Agreement (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "srt:ContractualObligationFiscalYearMaturityScheduleTableTextBlock", "div", "us-gaap:DebtDisclosureTextBlock", "div", "body", "html" ], "baseRef": "bbio-20220630.htm", "contextRef": "C_3fcde183-38c7-4211-add6-d2d8a8bd4214", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:ContractualObligationFutureMinimumPaymentsDueRemainderOfFiscalYear", "reportCount": 1, "unique": true, "unitRef": "U_USD", "xsiNil": "false" } }, "R57": { "firstAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "body", "html" ], "baseRef": "bbio-20220630.htm", "contextRef": "C_3da5d8c2-2b80-443c-9ad1-3072371b08d5", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax", "reportCount": 1, "unitRef": "U_USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100600 - Disclosure - License and Collaboration Agreements - Additional Information (Details)", "role": "http://bridgebio.com/20220630/taxonomy/role/DisclosureLicenseAndCollaborationAgreementsAdditionalInformationDetails", "shortName": "License and Collaboration Agreements - Additional Information (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "p", "bbio:LicenseAndCollaborationAgreementTextBlock", "div", "body", "html" ], "baseRef": "bbio-20220630.htm", "contextRef": "C_1e77f8a8-3568-46ac-8f45-3a3874d7f0e9", "decimals": "-5", "lang": null, "name": "us-gaap:ResearchAndDevelopmentExpense", "reportCount": 1, "unique": true, "unitRef": "U_USD", "xsiNil": "false" } }, "R58": { "firstAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "body", "html" ], "baseRef": "bbio-20220630.htm", "contextRef": "C_8193da1f-851b-4ed7-8a0c-b5762fe09616", "decimals": "-3", "first": true, "lang": null, "name": "bbio:ProceedsFromSaleOfPriorityReviewVoucher", "reportCount": 1, "unitRef": "U_USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100610 - Disclosure - Sale of Nonfinancial Assets - Additional Information (Details)", "role": "http://bridgebio.com/20220630/taxonomy/role/DisclosureSaleOfNonfinancialAssetsAdditionalInformationDetails", "shortName": "Sale of Nonfinancial Assets - Additional Information (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "p", "bbio:SaleOfNonfinancialAssetsTextBlock", "div", "body", "html" ], "baseRef": "bbio-20220630.htm", "contextRef": "C_5d610417-d83c-46b7-9d4c-5189a72da521", "decimals": "-5", "lang": null, "name": "us-gaap:DisposalGroupIncludingDiscontinuedOperationConsideration", "reportCount": 1, "unique": true, "unitRef": "U_USD", "xsiNil": "false" } }, "R59": { "firstAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "us-gaap:LeaseCostTableTextBlock", "div", "bbio:LesseeOperatingAndFinancingLeasesDisclosureTextBlock", "div", "body", "html" ], "baseRef": "bbio-20220630.htm", "contextRef": "C_3da5d8c2-2b80-443c-9ad1-3072371b08d5", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:OperatingLeaseCost", "reportCount": 1, "unique": true, "unitRef": "U_USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100620 - Disclosure - Leases - Components of Lease Cost (Details)", "role": "http://bridgebio.com/20220630/taxonomy/role/Role_DisclosureLeasesComponentsOfLeaseCostDetails", "shortName": "Leases - Components of Lease Cost (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "us-gaap:LeaseCostTableTextBlock", "div", "bbio:LesseeOperatingAndFinancingLeasesDisclosureTextBlock", "div", "body", "html" ], "baseRef": "bbio-20220630.htm", "contextRef": "C_3da5d8c2-2b80-443c-9ad1-3072371b08d5", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:OperatingLeaseCost", "reportCount": 1, "unique": true, "unitRef": "U_USD", "xsiNil": "false" } }, "R6": { "firstAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "body", "html" ], "baseRef": "bbio-20220630.htm", "contextRef": "C_f2902656-1f3d-494a-9de3-a58c49cd7de4", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest", "reportCount": 1, "unitRef": "U_USD", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "100060 - Statement - Condensed Consolidated Statements of Redeemable Convertible Noncontrolling Interests and Stockholders' Equity (Unaudited)", "role": "http://bridgebio.com/20220630/taxonomy/role/StatementCondensedConsolidatedStatementsOfRedeemableConvertibleNoncontrollingInterestsAndStockholdersEquityUnaudited", "shortName": "Condensed Consolidated Statements of Redeemable Convertible Noncontrolling Interests and Stockholders' Equity (Unaudited)", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "body", "html" ], "baseRef": "bbio-20220630.htm", "contextRef": "C_08a0685c-e8dd-4c1c-95ca-e63a38badccd", "decimals": "-3", "lang": null, "name": "us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation", "reportCount": 1, "unique": true, "unitRef": "U_USD", "xsiNil": "false" } }, "R60": { "firstAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "bbio:ScheduleOfSupplementalCashFlowInformationRelatedToLeasesTableTextBlock", "div", "bbio:LesseeOperatingAndFinancingLeasesDisclosureTextBlock", "div", "body", "html" ], "baseRef": "bbio-20220630.htm", "contextRef": "C_8193da1f-851b-4ed7-8a0c-b5762fe09616", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:OperatingLeasePayments", "reportCount": 1, "unique": true, "unitRef": "U_USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100630 - Disclosure - Leases - Schedule of Supplemental Cash Flow Information Related to Leases (Details)", "role": "http://bridgebio.com/20220630/taxonomy/role/Role_DisclosureLeasesScheduleOfSupplementalCashFlowInformationRelatedToLeasesDetails", "shortName": "Leases - Schedule of Supplemental Cash Flow Information Related to Leases (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "bbio:ScheduleOfSupplementalCashFlowInformationRelatedToLeasesTableTextBlock", "div", "bbio:LesseeOperatingAndFinancingLeasesDisclosureTextBlock", "div", "body", "html" ], "baseRef": "bbio-20220630.htm", "contextRef": "C_8193da1f-851b-4ed7-8a0c-b5762fe09616", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:OperatingLeasePayments", "reportCount": 1, "unique": true, "unitRef": "U_USD", "xsiNil": "false" } }, "R61": { "firstAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "bbio:ScheduleOfSupplementalInformationRelatedToRemainingLeaseTermAndDiscountRateTableTextBlock", "div", "bbio:LesseeOperatingAndFinancingLeasesDisclosureTextBlock", "div", "body", "html" ], "baseRef": "bbio-20220630.htm", "contextRef": "C_79a35245-7d52-4fb1-9fb8-8a023229d7aa", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100640 - Disclosure - Leases - Schedule of Supplemental Information Related to Remaining Lease Term and Discount Rate (Details)", "role": "http://bridgebio.com/20220630/taxonomy/role/Role_DisclosureLeasesScheduleOfSupplementalInformationRelatedToRemainingLeaseTermAndDiscountRateDetails", "shortName": "Leases - Schedule of Supplemental Information Related to Remaining Lease Term and Discount Rate (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "bbio:ScheduleOfSupplementalInformationRelatedToRemainingLeaseTermAndDiscountRateTableTextBlock", "div", "bbio:LesseeOperatingAndFinancingLeasesDisclosureTextBlock", "div", "body", "html" ], "baseRef": "bbio-20220630.htm", "contextRef": "C_79a35245-7d52-4fb1-9fb8-8a023229d7aa", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R62": { "firstAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "bbio:ScheduleOfFutureMinimumLeasePaymentsForNoncancelableOperatingAndFinanceLeasesTableTextBlock", "div", "bbio:LesseeOperatingAndFinancingLeasesDisclosureTextBlock", "div", "body", "html" ], "baseRef": "bbio-20220630.htm", "contextRef": "C_79a35245-7d52-4fb1-9fb8-8a023229d7aa", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear", "reportCount": 1, "unique": true, "unitRef": "U_USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100650 - Disclosure - Leases - Schedule of Future Minimum Lease Payments for Noncancelable Leases (Details)", "role": "http://bridgebio.com/20220630/taxonomy/role/Role_DisclosureLeasesScheduleOfFutureMinimumLeasePaymentsForNoncancelableLeasesDetails", "shortName": "Leases - Schedule of Future Minimum Lease Payments for Noncancelable Leases (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "bbio:ScheduleOfFutureMinimumLeasePaymentsForNoncancelableOperatingAndFinanceLeasesTableTextBlock", "div", "bbio:LesseeOperatingAndFinancingLeasesDisclosureTextBlock", "div", "body", "html" ], "baseRef": "bbio-20220630.htm", "contextRef": "C_79a35245-7d52-4fb1-9fb8-8a023229d7aa", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear", "reportCount": 1, "unique": true, "unitRef": "U_USD", "xsiNil": "false" } }, "R63": { "firstAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "body", "html" ], "baseRef": "bbio-20220630.htm", "contextRef": "C_8193da1f-851b-4ed7-8a0c-b5762fe09616", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:ImpairmentOfLongLivedAssetsHeldForUse", "reportCount": 1, "unitRef": "U_USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100660 - Disclosure - Leases - Additional Information (Details)", "role": "http://bridgebio.com/20220630/taxonomy/role/Role_DisclosureLeasesAdditionalInformationDetails", "shortName": "Leases - Additional Information (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "p", "bbio:LesseeOperatingAndFinancingLeasesDisclosureTextBlock", "div", "body", "html" ], "baseRef": "bbio-20220630.htm", "contextRef": "C_3da5d8c2-2b80-443c-9ad1-3072371b08d5", "decimals": "-3", "lang": null, "name": "us-gaap:OperatingLeaseImpairmentLoss", "reportCount": 1, "unique": true, "unitRef": "U_USD", "xsiNil": "false" } }, "R64": { "firstAnchor": { "ancestors": [ "span", "p", "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "div", "body", "html" ], "baseRef": "bbio-20220630.htm", "contextRef": "C_ea475c0b-4f2a-4145-ab4b-fe49644f8526", "decimals": "-5", "first": true, "lang": null, "name": "bbio:AggregateOfferingIssuanceAndSalePriceOfCommonStockToBeIssued", "reportCount": 1, "unique": true, "unitRef": "U_USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100670 - Disclosure - Share Repurchase Program and Shelf Registration - Additional Information (Details)", "role": "http://bridgebio.com/20220630/taxonomy/role/Role_DisclosureShareRepurchaseProgramAndShelfRegistrationAdditionalInformationDetails", "shortName": "Share Repurchase Program and Shelf Registration - Additional Information (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "p", "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "div", "body", "html" ], "baseRef": "bbio-20220630.htm", "contextRef": "C_ea475c0b-4f2a-4145-ab4b-fe49644f8526", "decimals": "-5", "first": true, "lang": null, "name": "bbio:AggregateOfferingIssuanceAndSalePriceOfCommonStockToBeIssued", "reportCount": 1, "unique": true, "unitRef": "U_USD", "xsiNil": "false" } }, "R65": { "firstAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock", "div", "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "div", "body", "html" ], "baseRef": "bbio-20220630.htm", "contextRef": "C_3da5d8c2-2b80-443c-9ad1-3072371b08d5", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:AllocatedShareBasedCompensationExpense", "reportCount": 1, "unitRef": "U_USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100680 - Disclosure - Stock-Based Compensation - Summary of Stock Based Compensation for Employees and Non Employees (Details)", "role": "http://bridgebio.com/20220630/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfStockBasedCompensationForEmployeesAndNonEmployeesDetails", "shortName": "Stock-Based Compensation - Summary of Stock Based Compensation for Employees and Non Employees (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock", "div", "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "div", "body", "html" ], "baseRef": "bbio-20220630.htm", "contextRef": "C_16c5d50b-0b39-4a02-a0c1-d1050f6d60dc", "decimals": "-3", "lang": null, "name": "us-gaap:AllocatedShareBasedCompensationExpense", "reportCount": 1, "unique": true, "unitRef": "U_USD", "xsiNil": "false" } }, "R66": { "firstAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock", "div", "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "div", "body", "html" ], "baseRef": "bbio-20220630.htm", "contextRef": "C_3da5d8c2-2b80-443c-9ad1-3072371b08d5", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:AllocatedShareBasedCompensationExpense", "reportCount": 1, "unitRef": "U_USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100690 - Disclosure - Stock-Based Compensation - Additional Information (Details)", "role": "http://bridgebio.com/20220630/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetails", "shortName": "Stock-Based Compensation - Additional Information (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "p", "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "div", "body", "html" ], "baseRef": "bbio-20220630.htm", "contextRef": "C_5f0db38f-7995-4766-ac9d-f6452711045f", "decimals": "-5", "lang": null, "name": "us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardCompensationCost1", "reportCount": 1, "unique": true, "unitRef": "U_USD", "xsiNil": "false" } }, "R67": { "firstAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "div", "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "div", "body", "html" ], "baseRef": "bbio-20220630.htm", "contextRef": "C_454fb2f6-618d-4949-9351-854341ecdbb7", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber", "reportCount": 1, "unitRef": "U_shares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100700 - Disclosure - Stock-Based Compensation - Summary of Stock Option Activity under Plans (Details)", "role": "http://bridgebio.com/20220630/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfStockOptionActivityUnderPlansDetails", "shortName": "Stock-Based Compensation - Summary of Stock Option Activity under Plans (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "div", "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "div", "body", "html" ], "baseRef": "bbio-20220630.htm", "contextRef": "C_2b8bc0f0-4c0d-4538-992d-26ee8407e61b", "decimals": "INF", "lang": null, "name": "us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised", "reportCount": 1, "unique": true, "unitRef": "U_shares", "xsiNil": "false" } }, "R68": { "firstAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "us-gaap:ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock", "div", "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "div", "body", "html" ], "baseRef": "bbio-20220630.htm", "contextRef": "C_97b2e67e-d7bf-43e2-9183-8d2af22b0435", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber", "reportCount": 1, "unique": true, "unitRef": "U_shares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100710 - Disclosure - Stock-Based Compensation - Summary of Restricted Stock Units Activity (Details)", "role": "http://bridgebio.com/20220630/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfRestrictedStockUnitsActivityDetails", "shortName": "Stock-Based Compensation - Summary of Restricted Stock Units Activity (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "us-gaap:ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock", "div", "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "div", "body", "html" ], "baseRef": "bbio-20220630.htm", "contextRef": "C_97b2e67e-d7bf-43e2-9183-8d2af22b0435", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber", "reportCount": 1, "unique": true, "unitRef": "U_shares", "xsiNil": "false" } }, "R69": { "firstAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "us-gaap:ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock", "div", "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "div", "body", "html" ], "baseRef": "bbio-20220630.htm", "contextRef": "C_ed54b0a3-7e13-42e1-bad5-7988ae81da43", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber", "reportCount": 1, "unique": true, "unitRef": "U_shares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100720 - Disclosure - Stock-Based Compensation - Summary of Restricted Stock Award Activity under Plans (Details)", "role": "http://bridgebio.com/20220630/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfRestrictedStockAwardActivityUnderPlansDetails", "shortName": "Stock-Based Compensation - Summary of Restricted Stock Award Activity under Plans (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "us-gaap:ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock", "div", "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "div", "body", "html" ], "baseRef": "bbio-20220630.htm", "contextRef": "C_ed54b0a3-7e13-42e1-bad5-7988ae81da43", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber", "reportCount": 1, "unique": true, "unitRef": "U_shares", "xsiNil": "false" } }, "R7": { "firstAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "body", "html" ], "baseRef": "bbio-20220630.htm", "contextRef": "C_1d016b91-385e-40e9-b273-4e3b7fa85c2c", "decimals": "-3", "first": true, "lang": null, "name": "bbio:RepurchaseOfNoncontrollingInterestsTransactionCosts", "reportCount": 1, "unique": true, "unitRef": "U_USD", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "100070 - Statement - Condensed Consolidated Statements of Redeemable Convertible Noncontrolling Interests and Stockholders' Equity (Unaudited) (Parenthetical)", "role": "http://bridgebio.com/20220630/taxonomy/role/StatementCondensedConsolidatedStatementsOfRedeemableConvertibleNoncontrollingInterestsAndStockholdersEquityUnauditedParenthetical", "shortName": "Condensed Consolidated Statements of Redeemable Convertible Noncontrolling Interests and Stockholders' Equity (Unaudited) (Parenthetical)", "subGroupType": "parenthetical", "uniqueAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "body", "html" ], "baseRef": "bbio-20220630.htm", "contextRef": "C_1d016b91-385e-40e9-b273-4e3b7fa85c2c", "decimals": "-3", "first": true, "lang": null, "name": "bbio:RepurchaseOfNoncontrollingInterestsTransactionCosts", "reportCount": 1, "unique": true, "unitRef": "U_USD", "xsiNil": "false" } }, "R70": { "firstAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock", "div", "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "div", "body", "html" ], "baseRef": "bbio-20220630.htm", "contextRef": "C_3da5d8c2-2b80-443c-9ad1-3072371b08d5", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:AllocatedShareBasedCompensationExpense", "reportCount": 1, "unitRef": "U_USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100730 - Disclosure - Stock-Based Compensation - Summary of Recognized Stock-based Compensation Expense Related to Restricted Stock Award Activity (Details)", "role": "http://bridgebio.com/20220630/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfRecognizedStockBasedCompensationExpenseRelatedToRestrictedStockAwardActivityDetails", "shortName": "Stock-Based Compensation - Summary of Recognized Stock-based Compensation Expense Related to Restricted Stock Award Activity (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock", "div", "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "div", "body", "html" ], "baseRef": "bbio-20220630.htm", "contextRef": "C_470773e7-43b8-4ebd-a1b1-807a652bc977", "decimals": "-3", "lang": null, "name": "us-gaap:AllocatedShareBasedCompensationExpense", "reportCount": 1, "unique": true, "unitRef": "U_USD", "xsiNil": "false" } }, "R71": { "firstAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock", "div", "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "div", "body", "html" ], "baseRef": "bbio-20220630.htm", "contextRef": "C_0be2509d-2b17-4086-b6f6-ec6eb1938c6b", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100740 - Disclosure - Stock-Based Compensation - Schedule of Assumptions Used to Determine Fair Value of Stock Purchase Rights under ESPP (Details)", "role": "http://bridgebio.com/20220630/taxonomy/role/DisclosureStockbasedCompensationScheduleOfAssumptionsUsedToDetermineFairValueOfStockPurchaseRightsUnderEsppDetails", "shortName": "Stock-Based Compensation - Schedule of Assumptions Used to Determine Fair Value of Stock Purchase Rights under ESPP (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock", "div", "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "div", "body", "html" ], "baseRef": "bbio-20220630.htm", "contextRef": "C_0be2509d-2b17-4086-b6f6-ec6eb1938c6b", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R72": { "firstAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "body", "html" ], "baseRef": "bbio-20220630.htm", "contextRef": "C_3da5d8c2-2b80-443c-9ad1-3072371b08d5", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:RestructuringCharges", "reportCount": 1, "unitRef": "U_USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100750 - Disclosure - Restructuring, Impairment and Related Charges - Additional Information (Details)", "role": "http://bridgebio.com/20220630/taxonomy/role/DisclosureRestructuringImpairmentAndRelatedChargesAdditionalInformationDetails", "shortName": "Restructuring, Impairment and Related Charges - Additional Information (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "p", "us-gaap:RestructuringAndRelatedActivitiesDisclosureTextBlock", "div", "body", "html" ], "baseRef": "bbio-20220630.htm", "contextRef": "C_41193461-9d80-4668-aa6f-1201d5070517", "decimals": "-5", "lang": null, "name": "us-gaap:RestructuringAndRelatedCostExpectedCost1", "reportCount": 1, "unique": true, "unitRef": "U_USD", "xsiNil": "false" } }, "R73": { "firstAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "body", "html" ], "baseRef": "bbio-20220630.htm", "contextRef": "C_8193da1f-851b-4ed7-8a0c-b5762fe09616", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:ImpairmentOfLongLivedAssetsHeldForUse", "reportCount": 1, "unitRef": "U_USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100760 - Disclosure - Restructuring, Impairment and Related Charges - Summary of Restructuring, Impairment and Related Charges (Details)", "role": "http://bridgebio.com/20220630/taxonomy/role/DisclosureRestructuringImpairmentAndRelatedChargesSummaryOfRestructuringImpairmentAndRelatedChargesDetails", "shortName": "Restructuring, Impairment and Related Charges - Summary of Restructuring, Impairment and Related Charges (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "us-gaap:ScheduleOfRestructuringAndRelatedCostsTextBlock", "div", "us-gaap:RestructuringAndRelatedActivitiesDisclosureTextBlock", "div", "body", "html" ], "baseRef": "bbio-20220630.htm", "contextRef": "C_3da5d8c2-2b80-443c-9ad1-3072371b08d5", "decimals": "-3", "lang": null, "name": "us-gaap:SeveranceCosts1", "reportCount": 1, "unique": true, "unitRef": "U_USD", "xsiNil": "false" } }, "R74": { "firstAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "ix:continuation", "div", "us-gaap:RestructuringAndRelatedActivitiesDisclosureTextBlock", "div", "body", "html" ], "baseRef": "bbio-20220630.htm", "contextRef": "C_b86822ad-d884-4071-ae4b-fc57268a8359", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:RestructuringReserveCurrent", "reportCount": 1, "unitRef": "U_USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100770 - Disclosure - Restructuring, Impairment and Related Charges - Schedule of Activity Related to Restructuring Liabilities Associated to Restructuring Initiatives (Details)", "role": "http://bridgebio.com/20220630/taxonomy/role/DisclosureRestructuringImpairmentAndRelatedChargesScheduleOfActivityRelatedToRestructuringLiabilitiesAssociatedToRestructuringInitiativesDeta", "shortName": "Restructuring, Impairment and Related Charges - Schedule of Activity Related to Restructuring Liabilities Associated to Restructuring Initiatives (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "ix:continuation", "div", "us-gaap:RestructuringAndRelatedActivitiesDisclosureTextBlock", "div", "body", "html" ], "baseRef": "bbio-20220630.htm", "contextRef": "C_8193da1f-851b-4ed7-8a0c-b5762fe09616", "decimals": "-3", "lang": null, "name": "bbio:ReclassificationOfFinalPaymentObligationRelatedToManufacturingAgreementRecognizedInPriorPeriod", "reportCount": 1, "unique": true, "unitRef": "U_USD", "xsiNil": "false" } }, "R75": { "firstAnchor": { "ancestors": [ "us-gaap:IncomeTaxExpenseBenefit", "us-gaap:IncomeTaxExpenseBenefit", "span", "p", "us-gaap:IncomeTaxDisclosureTextBlock", "div", "body", "html" ], "baseRef": "bbio-20220630.htm", "contextRef": "C_3da5d8c2-2b80-443c-9ad1-3072371b08d5", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:IncomeTaxExpenseBenefit", "reportCount": 1, "unique": true, "unitRef": "U_USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100780 - Disclosure - Income Taxes - Additional Information (Details)", "role": "http://bridgebio.com/20220630/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetails", "shortName": "Income Taxes - Additional Information (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "us-gaap:IncomeTaxExpenseBenefit", "us-gaap:IncomeTaxExpenseBenefit", "span", "p", "us-gaap:IncomeTaxDisclosureTextBlock", "div", "body", "html" ], "baseRef": "bbio-20220630.htm", "contextRef": "C_3da5d8c2-2b80-443c-9ad1-3072371b08d5", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:IncomeTaxExpenseBenefit", "reportCount": 1, "unique": true, "unitRef": "U_USD", "xsiNil": "false" } }, "R76": { "firstAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock", "div", "us-gaap:EarningsPerShareTextBlock", "div", "body", "html" ], "baseRef": "bbio-20220630.htm", "contextRef": "C_8193da1f-851b-4ed7-8a0c-b5762fe09616", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "reportCount": 1, "unique": true, "unitRef": "U_shares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100790 - Disclosure - Net Loss Per Share - Schedule of Common Stock Equivalents were Excluded from Computation of Diluted Net Loss per Share (Detail)", "role": "http://bridgebio.com/20220630/taxonomy/role/Role_DisclosureNetLossPerShareScheduleOfCommonStockEquivalentsWereExcludedFromComputationOfDilutedNetLossPerShareDetail", "shortName": "Net Loss Per Share - Schedule of Common Stock Equivalents were Excluded from Computation of Diluted Net Loss per Share (Detail)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock", "div", "us-gaap:EarningsPerShareTextBlock", "div", "body", "html" ], "baseRef": "bbio-20220630.htm", "contextRef": "C_8193da1f-851b-4ed7-8a0c-b5762fe09616", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "reportCount": 1, "unique": true, "unitRef": "U_shares", "xsiNil": "false" } }, "R8": { "firstAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "body", "html" ], "baseRef": "bbio-20220630.htm", "contextRef": "C_8193da1f-851b-4ed7-8a0c-b5762fe09616", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:ProfitLoss", "reportCount": 1, "unitRef": "U_USD", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "100080 - Statement - Condensed Consolidated Statements of Cash Flows (Unaudited)", "role": "http://bridgebio.com/20220630/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited", "shortName": "Condensed Consolidated Statements of Cash Flows (Unaudited)", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "body", "html" ], "baseRef": "bbio-20220630.htm", "contextRef": "C_8193da1f-851b-4ed7-8a0c-b5762fe09616", "decimals": "-3", "lang": null, "name": "us-gaap:ShareBasedCompensation", "reportCount": 1, "unique": true, "unitRef": "U_USD", "xsiNil": "false" } }, "R9": { "firstAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "bbio-20220630.htm", "contextRef": "C_8193da1f-851b-4ed7-8a0c-b5762fe09616", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:NatureOfOperations", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100090 - Disclosure - Organization and Description of Business", "role": "http://bridgebio.com/20220630/taxonomy/role/Role_DisclosureOrganizationAndDescriptionOfBusiness", "shortName": "Organization and Description of Business", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "bbio-20220630.htm", "contextRef": "C_8193da1f-851b-4ed7-8a0c-b5762fe09616", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:NatureOfOperations", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } } }, "segmentCount": 131, "tag": { "bbio_AccrualForMilestonesNotProbable": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Accrual for milestones not probable.", "label": "Accrual for Milestones Not Probable", "terseLabel": "Accrual for milestones not probable" } } }, "localname": "AccrualForMilestonesNotProbable", "nsuri": "http://bridgebio.com/20220630", "presentation": [ "http://bridgebio.com/20220630/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetail" ], "xbrltype": "monetaryItemType" }, "bbio_AccruedCompensationAndBenefitsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Accrued compensation and benefits.", "label": "Accrued Compensation and Benefits [Member]", "terseLabel": "Accrued Compensation and Benefits" } } }, "localname": "AccruedCompensationAndBenefitsMember", "nsuri": "http://bridgebio.com/20220630", "presentation": [ "http://bridgebio.com/20220630/taxonomy/role/DisclosureRestructuringImpairmentAndRelatedChargesScheduleOfActivityRelatedToRestructuringLiabilitiesAssociatedToRestructuringInitiativesDeta" ], "xbrltype": "domainItemType" }, "bbio_AccruedProfessionalServicesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Accrued professional services.", "label": "Accrued Professional Services [Member]", "terseLabel": "Accrued Professional Services" } } }, "localname": "AccruedProfessionalServicesMember", "nsuri": "http://bridgebio.com/20220630", "presentation": [ "http://bridgebio.com/20220630/taxonomy/role/DisclosureRestructuringImpairmentAndRelatedChargesScheduleOfActivityRelatedToRestructuringLiabilitiesAssociatedToRestructuringInitiativesDeta" ], "xbrltype": "domainItemType" }, "bbio_AccruedResearchAndDevelopmentLiabilitiesCurrent": { "auth_ref": [], "calculation": { "http://bridgebio.com/20220630/taxonomy/role/Role_StatementCondensedConsolidatedBalanceSheets": { "order": 2.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Accrued research and development liabilities current.", "label": "Accrued Research And Development Liabilities Current", "terseLabel": "Accrued research and development liabilities" } } }, "localname": "AccruedResearchAndDevelopmentLiabilitiesCurrent", "nsuri": "http://bridgebio.com/20220630", "presentation": [ "http://bridgebio.com/20220630/taxonomy/role/Role_StatementCondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "bbio_AccruedResearchAndDevelopmentLiabilitiesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Accrued research and development liabilities.", "label": "Accrued Research and Development Liabilities [Member]", "terseLabel": "Accrued Research and Development Liabilities" } } }, "localname": "AccruedResearchAndDevelopmentLiabilitiesMember", "nsuri": "http://bridgebio.com/20220630", "presentation": [ "http://bridgebio.com/20220630/taxonomy/role/DisclosureRestructuringImpairmentAndRelatedChargesScheduleOfActivityRelatedToRestructuringLiabilitiesAssociatedToRestructuringInitiativesDeta", "http://bridgebio.com/20220630/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "bbio_AccruedTerminationCharges": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Accrued termination charges.", "label": "Accrued Termination Charges", "terseLabel": "Accrued termination charges" } } }, "localname": "AccruedTerminationCharges", "nsuri": "http://bridgebio.com/20220630", "presentation": [ "http://bridgebio.com/20220630/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetail" ], "xbrltype": "monetaryItemType" }, "bbio_AdjustmentsOfCarryingValueOfNoncontrollingInterestAdditionalPaidInCapital": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Adjustments of carrying value of noncontrolling interest additional paid-in capital.", "label": "Adjustments Of Carrying Value Of Noncontrolling Interest Additional Paid In Capital", "terseLabel": "Adjustments of carrying value of noncontrolling interest additional paid-in capital" } } }, "localname": "AdjustmentsOfCarryingValueOfNoncontrollingInterestAdditionalPaidInCapital", "nsuri": "http://bridgebio.com/20220630", "presentation": [ "http://bridgebio.com/20220630/taxonomy/role/Role_DisclosureNoncontrollingInterestsAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "bbio_AdjustmentsToAdditionalPaidInCapitalPurchaseOfCappedCalls": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Adjustments to additional paid In capital purchase of capped calls.", "label": "Adjustments To Additional Paid In Capital Purchase Of Capped Calls", "terseLabel": "Purchase of capped calls" } } }, "localname": "AdjustmentsToAdditionalPaidInCapitalPurchaseOfCappedCalls", "nsuri": "http://bridgebio.com/20220630", "presentation": [ "http://bridgebio.com/20220630/taxonomy/role/StatementCondensedConsolidatedStatementsOfRedeemableConvertibleNoncontrollingInterestsAndStockholdersEquityUnaudited" ], "xbrltype": "monetaryItemType" }, "bbio_AdjustmentsToAdditionalPaidInCapitalRelatedToPremiumPayments": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Adjustments to additional paid in capital related to premium payments.", "label": "Adjustments To Additional Paid In Capital Related To Premium Payments", "terseLabel": "Adjustments to additional paid in capital related to premium payments" } } }, "localname": "AdjustmentsToAdditionalPaidInCapitalRelatedToPremiumPayments", "nsuri": "http://bridgebio.com/20220630", "presentation": [ "http://bridgebio.com/20220630/taxonomy/role/Role_DisclosureDebtAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "bbio_AgencyDiscountNotesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Agency discount notes.", "label": "Agency Discount Notes [Member]", "terseLabel": "Agency Discount Notes" } } }, "localname": "AgencyDiscountNotesMember", "nsuri": "http://bridgebio.com/20220630", "presentation": [ "http://bridgebio.com/20220630/taxonomy/role/DisclosureFairValueMeasurementsFinancialAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails", "http://bridgebio.com/20220630/taxonomy/role/Role_DisclosureCashEquivalentsAndMarketableSecuritiesScheduleOfCashEquivalentAndMarketableSecuritiesClassifiedAsAvailableForSaleDetails" ], "xbrltype": "domainItemType" }, "bbio_AggregateOfferingIssuanceAndSalePriceOfCommonStockToBeIssued": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Aggregate offering issuance and sale price of common stock to be issued.", "label": "Aggregate Offering Issuance And Sale Price Of Common Stock To Be Issued", "verboseLabel": "Aggregate offering, issuance and sale price of common stock to be issued" } } }, "localname": "AggregateOfferingIssuanceAndSalePriceOfCommonStockToBeIssued", "nsuri": "http://bridgebio.com/20220630", "presentation": [ "http://bridgebio.com/20220630/taxonomy/role/Role_DisclosureShareRepurchaseProgramAndShelfRegistrationAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "bbio_AggregateOfferingPriceOfCommonStockThatMayBeIssued": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Aggregate offering price of common stock that may be issued.", "label": "Aggregate Offering Price Of Common Stock That May Be Issued" } } }, "localname": "AggregateOfferingPriceOfCommonStockThatMayBeIssued", "nsuri": "http://bridgebio.com/20220630", "presentation": [ "http://bridgebio.com/20220630/taxonomy/role/Role_DisclosureEidosAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "bbio_AgreementAndPlanOfMergerMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Agreement and Plan of Merger.", "label": "Agreement And Plan Of Merger [Member]", "terseLabel": "Merger Agreement" } } }, "localname": "AgreementAndPlanOfMergerMember", "nsuri": "http://bridgebio.com/20220630", "presentation": [ "http://bridgebio.com/20220630/taxonomy/role/Role_DisclosureEidosAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "bbio_AllocationOfTransactionPriceForResearchAndDevelopment": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Allocation Of Transaction Price for Research and Development.", "label": "Allocation Of Transaction Price for Research and Development", "terseLabel": "Allocation Of transaction price for research and development" } } }, "localname": "AllocationOfTransactionPriceForResearchAndDevelopment", "nsuri": "http://bridgebio.com/20220630", "presentation": [ "http://bridgebio.com/20220630/taxonomy/role/DisclosureLicenseAndCollaborationAgreementsAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "bbio_AllocationOfTransactionPriceToLicenses": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Allocation of transaction price to licenses.", "label": "Allocation Of Transaction Price To Licenses", "terseLabel": "Allocation of transaction price to licenses" } } }, "localname": "AllocationOfTransactionPriceToLicenses", "nsuri": "http://bridgebio.com/20220630", "presentation": [ "http://bridgebio.com/20220630/taxonomy/role/DisclosureLicenseAndCollaborationAgreementsAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "bbio_AllocationOfTransactionPriceToTransferOfExistingInventory": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Allocation of transaction price to transfer of existing inventory.", "label": "Allocation Of Transaction Price To Transfer Of Existing Inventory", "terseLabel": "Allocation of transaction price to transfer of certain existing inventory" } } }, "localname": "AllocationOfTransactionPriceToTransferOfExistingInventory", "nsuri": "http://bridgebio.com/20220630", "presentation": [ "http://bridgebio.com/20220630/taxonomy/role/DisclosureLicenseAndCollaborationAgreementsAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "bbio_AmountPaidToLenders": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount paid to lenders.", "label": "Amount paid to Lenders", "terseLabel": "Amount paid to lenders" } } }, "localname": "AmountPaidToLenders", "nsuri": "http://bridgebio.com/20220630", "presentation": [ "http://bridgebio.com/20220630/taxonomy/role/Role_DisclosureDebtAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "bbio_AmountPaidToVendors": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount paid to vendors.", "label": "Amount Paid To Vendors", "terseLabel": "Due to vendors" } } }, "localname": "AmountPaidToVendors", "nsuri": "http://bridgebio.com/20220630", "presentation": [ "http://bridgebio.com/20220630/taxonomy/role/Role_DisclosureLeasesAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "bbio_AssetAcquisitionsAndInLicensingAgreementDisclosureTextblock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Asset acquisitions and in-licensing agreement disclosure.", "label": "Asset Acquisitions and In-licensing Agreement Disclosure [TextBlock]", "terseLabel": "Asset Acquisitions and Collaboration Agreement" } } }, "localname": "AssetAcquisitionsAndInLicensingAgreementDisclosureTextblock", "nsuri": "http://bridgebio.com/20220630", "presentation": [ "http://bridgebio.com/20220630/taxonomy/role/DisclosureAssetAcquisitionsAndCollaborationAgreement1" ], "xbrltype": "textBlockItemType" }, "bbio_AssetsAcquisitionRequiredMilestonePayments": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Assets acquisition required milestone payments.", "label": "Assets Acquisition Required Milestone Payments", "terseLabel": "Assets acquisition required milestone payments" } } }, "localname": "AssetsAcquisitionRequiredMilestonePayments", "nsuri": "http://bridgebio.com/20220630", "presentation": [ "http://bridgebio.com/20220630/taxonomy/role/DisclosureIntangibleAssetsAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "bbio_AssumedConversionOfTwoThousandTwentyNineNotesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Assumed conversion of two thousand twenty nine notes.", "label": "Assumed Conversion Of Two Thousand Twenty Nine Notes [Member]", "terseLabel": "Assumed Conversion of 2029 Notes" } } }, "localname": "AssumedConversionOfTwoThousandTwentyNineNotesMember", "nsuri": "http://bridgebio.com/20220630", "presentation": [ "http://bridgebio.com/20220630/taxonomy/role/Role_DisclosureNetLossPerShareScheduleOfCommonStockEquivalentsWereExcludedFromComputationOfDilutedNetLossPerShareDetail" ], "xbrltype": "domainItemType" }, "bbio_AssumedConversionOfTwoThousandTwentySevenNotesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Assumed conversion of two thousand twenty seven notes.", "label": "Assumed Conversion Of Two Thousand Twenty Seven Notes [Member]", "terseLabel": "Assumed Conversion of 2027 Notes" } } }, "localname": "AssumedConversionOfTwoThousandTwentySevenNotesMember", "nsuri": "http://bridgebio.com/20220630", "presentation": [ "http://bridgebio.com/20220630/taxonomy/role/Role_DisclosureNetLossPerShareScheduleOfCommonStockEquivalentsWereExcludedFromComputationOfDilutedNetLossPerShareDetail" ], "xbrltype": "domainItemType" }, "bbio_AtTheMarketOfferingMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "At-the-market offerings.", "label": "At The Market Offering [Member]", "terseLabel": "At-the-Market Offerings" } } }, "localname": "AtTheMarketOfferingMember", "nsuri": "http://bridgebio.com/20220630", "presentation": [ "http://bridgebio.com/20220630/taxonomy/role/Role_DisclosureShareRepurchaseProgramAndShelfRegistrationAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "bbio_BridgeBioPharmaLimitedLiabilityCompanyMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "BridgeBio pharma limited liability company.", "label": "Bridge Bio Pharma Limited Liability Company [Member]", "terseLabel": "Bridge Bio Pharma Limited Liability Company" } } }, "localname": "BridgeBioPharmaLimitedLiabilityCompanyMember", "nsuri": "http://bridgebio.com/20220630", "presentation": [ "http://bridgebio.com/20220630/taxonomy/role/DisclosureEquityMethodAndOtherEquityInvestmentsAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "bbio_BridgeBioServicesIncMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "BridgeBio Services, Inc.", "label": "Bridge Bio Services Inc [Member]", "terseLabel": "BridgeBio Equity Plan" } } }, "localname": "BridgeBioServicesIncMember", "nsuri": "http://bridgebio.com/20220630", "presentation": [ "http://bridgebio.com/20220630/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetails", "http://bridgebio.com/20220630/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfStockBasedCompensationForEmployeesAndNonEmployeesDetails" ], "xbrltype": "domainItemType" }, "bbio_BristolMyersSquibbCompanyMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Bristol-Myers Squibb Company.", "label": "Bristol Myers Squibb Company [Member]", "terseLabel": "BMS" } } }, "localname": "BristolMyersSquibbCompanyMember", "nsuri": "http://bridgebio.com/20220630", "presentation": [ "http://bridgebio.com/20220630/taxonomy/role/DisclosureLicenseAndCollaborationAgreementsAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "bbio_BusinessAcquisitionCashPerShare": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Business acquisition cash per share.", "label": "Business Acquisition Cash Per Share", "terseLabel": "Cash per share in transaction" } } }, "localname": "BusinessAcquisitionCashPerShare", "nsuri": "http://bridgebio.com/20220630", "presentation": [ "http://bridgebio.com/20220630/taxonomy/role/Role_DisclosureEidosAdditionalInformationDetails" ], "xbrltype": "perShareItemType" }, "bbio_BusinessAcquisitionCommonShare": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Business acquisition common share.", "label": "Business Acquisition Common Share", "terseLabel": "Right to receive of common stock" } } }, "localname": "BusinessAcquisitionCommonShare", "nsuri": "http://bridgebio.com/20220630", "presentation": [ "http://bridgebio.com/20220630/taxonomy/role/Role_DisclosureEidosAdditionalInformationDetails" ], "xbrltype": "sharesItemType" }, "bbio_BusinessAcquisitionEquityInterestsIssuedOrIssuableFairValue": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Business acquisition equity interests issued or issuable fair value.", "label": "Business Acquisition Equity Interests Issued Or Issuable Fair Value", "terseLabel": "Total fair value" } } }, "localname": "BusinessAcquisitionEquityInterestsIssuedOrIssuableFairValue", "nsuri": "http://bridgebio.com/20220630", "presentation": [ "http://bridgebio.com/20220630/taxonomy/role/Role_DisclosureEidosAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "bbio_BusinessCombinationPotentialCashConsideration": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Business combination potential cash consideration.", "label": "Business Combination Potential Cash Consideration", "terseLabel": "Cash consideration" } } }, "localname": "BusinessCombinationPotentialCashConsideration", "nsuri": "http://bridgebio.com/20220630", "presentation": [ "http://bridgebio.com/20220630/taxonomy/role/Role_DisclosureEidosAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "bbio_CallOptionExpenseIncome": { "auth_ref": [], "calculation": { "http://bridgebio.com/20220630/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited": { "order": 13.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Call option expense (income).", "label": "Call Option Expense Income", "terseLabel": "LEO call option income", "verboseLabel": "Gain on remeasurement of LEO call option liability" } } }, "localname": "CallOptionExpenseIncome", "nsuri": "http://bridgebio.com/20220630", "presentation": [ "http://bridgebio.com/20220630/taxonomy/role/DisclosureFairValueMeasurementsAdditionalInformationDetails", "http://bridgebio.com/20220630/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "bbio_CallOptionLiabilityFairValueDisclosure": { "auth_ref": [], "calculation": { "http://bridgebio.com/20220630/taxonomy/role/DisclosureFairValueMeasurementsFinancialAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails": { "order": 0.0, "parentTag": "us-gaap_FinancialLiabilitiesFairValueDisclosure", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Call option liability fair value disclosure.", "label": "Call Option Liability Fair Value Disclosure", "terseLabel": "LEO call option liability" } } }, "localname": "CallOptionLiabilityFairValueDisclosure", "nsuri": "http://bridgebio.com/20220630", "presentation": [ "http://bridgebio.com/20220630/taxonomy/role/DisclosureFairValueMeasurementsFinancialAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails" ], "xbrltype": "monetaryItemType" }, "bbio_CappedCallTransactionsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Capped call transactions.", "label": "Capped Call Transactions [Member]", "terseLabel": "2020 Capped Call Transactions" } } }, "localname": "CappedCallTransactionsMember", "nsuri": "http://bridgebio.com/20220630", "presentation": [ "http://bridgebio.com/20220630/taxonomy/role/Role_DisclosureDebtAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "bbio_CashAndCashEquivalentsFairValueDisclosureAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Cash and cash equivalents fair value disclosure.", "label": "Cash And Cash Equivalents Fair Value Disclosure [Abstract]", "terseLabel": "Cash equivalents:" } } }, "localname": "CashAndCashEquivalentsFairValueDisclosureAbstract", "nsuri": "http://bridgebio.com/20220630", "presentation": [ "http://bridgebio.com/20220630/taxonomy/role/DisclosureFairValueMeasurementsFinancialAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails" ], "xbrltype": "stringItemType" }, "bbio_CashCashEquivalentsAndRestrictedCashMaturityPeriod": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Cash cash equivalents and restricted cash maturity period.", "label": "Cash Cash Equivalents And Restricted Cash Maturity Period", "terseLabel": "Cash, cash equivalents and restricted cash maturity period" } } }, "localname": "CashCashEquivalentsAndRestrictedCashMaturityPeriod", "nsuri": "http://bridgebio.com/20220630", "presentation": [ "http://bridgebio.com/20220630/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails" ], "xbrltype": "durationItemType" }, "bbio_CashEquivalentsAndMarketableSecuritiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Cash equivalents and marketable securities.", "label": "Cash Equivalents And Marketable Securities [Abstract]" } } }, "localname": "CashEquivalentsAndMarketableSecuritiesAbstract", "nsuri": "http://bridgebio.com/20220630", "xbrltype": "stringItemType" }, "bbio_CashEquivalentsUnrealizedLosses": { "auth_ref": [], "calculation": { "http://bridgebio.com/20220630/taxonomy/role/Role_DisclosureCashEquivalentsAndMarketableSecuritiesScheduleOfCashEquivalentAndMarketableSecuritiesClassifiedAsAvailableForSaleDetails": { "order": 1.0, "parentTag": "us-gaap_CashAndCashEquivalentsFairValueDisclosure", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Cash Equivalents Unrealized Losses", "label": "Cash Equivalents Unrealized Losses", "negatedLabel": "Unrealized Losses", "terseLabel": "Unrealized Losses" } } }, "localname": "CashEquivalentsUnrealizedLosses", "nsuri": "http://bridgebio.com/20220630", "presentation": [ "http://bridgebio.com/20220630/taxonomy/role/Role_DisclosureCashEquivalentsAndMarketableSecuritiesScheduleOfCashEquivalentAndMarketableSecuritiesClassifiedAsAvailableForSaleDetails" ], "xbrltype": "monetaryItemType" }, "bbio_CommitmentsAndContingenciesLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Commitments and Contingencies.", "label": "Commitments And Contingencies [Line Items]", "terseLabel": "Commitments And Contingencies [Line Items]" } } }, "localname": "CommitmentsAndContingenciesLineItems", "nsuri": "http://bridgebio.com/20220630", "presentation": [ "http://bridgebio.com/20220630/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetail" ], "xbrltype": "stringItemType" }, "bbio_CommitmentsAndContingenciesTable": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Commitments and Contingencies.", "label": "Commitments And Contingencies [Table]", "terseLabel": "Commitments And Contingencies [Table]" } } }, "localname": "CommitmentsAndContingenciesTable", "nsuri": "http://bridgebio.com/20220630", "presentation": [ "http://bridgebio.com/20220630/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetail" ], "xbrltype": "stringItemType" }, "bbio_CommonStockOptionsIssuedAndOutstandingMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Common stock options issued and outstanding.", "label": "Common Stock Options Issued And Outstanding [Member]", "terseLabel": "Common Stock Options Issued and Outstanding" } } }, "localname": "CommonStockOptionsIssuedAndOutstandingMember", "nsuri": "http://bridgebio.com/20220630", "presentation": [ "http://bridgebio.com/20220630/taxonomy/role/Role_DisclosureNetLossPerShareScheduleOfCommonStockEquivalentsWereExcludedFromComputationOfDilutedNetLossPerShareDetail" ], "xbrltype": "domainItemType" }, "bbio_ContractualObligationDueAfterFourthYear": { "auth_ref": [], "calculation": { "http://bridgebio.com/20220630/taxonomy/role/Role_DisclosureDebtScheduleOfFutureMinimumPaymentsUnderNotesDetails": { "order": 5.0, "parentTag": "us-gaap_ContractualObligation", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Contractual obligation due after fourth year.", "label": "Contractual Obligation Due After Fourth Year", "terseLabel": "Thereafter" } } }, "localname": "ContractualObligationDueAfterFourthYear", "nsuri": "http://bridgebio.com/20220630", "presentation": [ "http://bridgebio.com/20220630/taxonomy/role/Role_DisclosureDebtScheduleOfFutureMinimumPaymentsUnderNotesDetails" ], "xbrltype": "monetaryItemType" }, "bbio_ContractualObligationExitFee": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Contractual obligation exit fee", "label": "Contractual Obligation Exit Fee", "negatedLabel": "Less exit fee" } } }, "localname": "ContractualObligationExitFee", "nsuri": "http://bridgebio.com/20220630", "presentation": [ "http://bridgebio.com/20220630/taxonomy/role/DisclosureDebtScheduleOfFutureMinimumPaymentsUnderTermLoanAgreementDetails" ], "xbrltype": "monetaryItemType" }, "bbio_ContractualObligationInterestPortion": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Contractual obligation interest portion.", "label": "Contractual Obligation Interest Portion", "negatedLabel": "Less amounts representing interest" } } }, "localname": "ContractualObligationInterestPortion", "nsuri": "http://bridgebio.com/20220630", "presentation": [ "http://bridgebio.com/20220630/taxonomy/role/DisclosureDebtScheduleOfFutureMinimumPaymentsUnderTermLoanAgreementDetails", "http://bridgebio.com/20220630/taxonomy/role/Role_DisclosureDebtScheduleOfFutureMinimumPaymentsUnderNotesDetails" ], "xbrltype": "monetaryItemType" }, "bbio_CostOfLicenseRevenueAndProductsSold": { "auth_ref": [], "calculation": { "http://bridgebio.com/20220630/taxonomy/role/StatementCondensedConsolidatedStatementsOfOperationsUnaudited": { "order": 1.0, "parentTag": "us-gaap_CostsAndExpenses", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Cost of license revenue and products sold.", "label": "Cost of License Revenue and Products Sold", "terseLabel": "Cost of license revenue and products sold" } } }, "localname": "CostOfLicenseRevenueAndProductsSold", "nsuri": "http://bridgebio.com/20220630", "presentation": [ "http://bridgebio.com/20220630/taxonomy/role/StatementCondensedConsolidatedStatementsOfOperationsUnaudited" ], "xbrltype": "monetaryItemType" }, "bbio_CostRelatedToManufacturingSuiteAndAdditionalEquipment": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Cost related to manufacturing suite and additional equipment.", "label": "Cost Related to Manufacturing Suite and Additional Equipment", "terseLabel": "Cost related to manufacturing suite and additional equipment" } } }, "localname": "CostRelatedToManufacturingSuiteAndAdditionalEquipment", "nsuri": "http://bridgebio.com/20220630", "presentation": [ "http://bridgebio.com/20220630/taxonomy/role/Role_DisclosureLeasesAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "bbio_DebtInstrumentAccruedInterestConvertibleIntoPrincipal": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Debt instrument accrued interest convertible into principal.", "label": "Debt Instrument Accrued Interest Convertible into Principal", "terseLabel": "Accrued interest convertible into principal" } } }, "localname": "DebtInstrumentAccruedInterestConvertibleIntoPrincipal", "nsuri": "http://bridgebio.com/20220630", "presentation": [ "http://bridgebio.com/20220630/taxonomy/role/Role_DisclosureDebtAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "bbio_DebtInstrumentAdditionalIncreaseAvailableInLoanFacilities": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Debt instrument additional increase available in loan facilities.", "label": "Debt Instrument Additional Increase Available In Loan Facilities", "terseLabel": "Debt instrument, additional available in loan facilities" } } }, "localname": "DebtInstrumentAdditionalIncreaseAvailableInLoanFacilities", "nsuri": "http://bridgebio.com/20220630", "presentation": [ "http://bridgebio.com/20220630/taxonomy/role/Role_DisclosureDebtAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "bbio_DebtInstrumentAdditionalIncreaseAvailableInLoanFacilitiesNoLaterThanFourteenMonths": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Debt instrument additional increase available in loan facilities no later than fourteen months.", "label": "Debt Instrument Additional Increase Available In Loan Facilities No Later Than Fourteen Months", "terseLabel": "Debt instrument, additional increase available in loan facilities no later than June 15, 2022" } } }, "localname": "DebtInstrumentAdditionalIncreaseAvailableInLoanFacilitiesNoLaterThanFourteenMonths", "nsuri": "http://bridgebio.com/20220630", "presentation": [ "http://bridgebio.com/20220630/taxonomy/role/Role_DisclosureDebtAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "bbio_DebtInstrumentAdditionalIncreaseAvailableInLoanFacilitiesUponAchievementOfCertainPerformanceMilestones": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Debt instrument additional increase available in loan facilities upon achievement of certain performance milestones.", "label": "Debt Instrument Additional Increase Available In Loan Facilities Upon Achievement Of Certain Performance Milestones", "terseLabel": "Debt Instrument additional increase available in loan facilities upon achievement of certain performance milestones" } } }, "localname": "DebtInstrumentAdditionalIncreaseAvailableInLoanFacilitiesUponAchievementOfCertainPerformanceMilestones", "nsuri": "http://bridgebio.com/20220630", "presentation": [ "http://bridgebio.com/20220630/taxonomy/role/Role_DisclosureDebtAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "bbio_DebtInstrumentAdditionalIncreaseAvailableInLoanFacilitiesYearThree": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Debt instrument additional increase available in loan facilities year three.", "label": "Debt Instrument Additional Increase Available In Loan Facilities Year Three", "terseLabel": "Debt instrument, additional increase available in loan facilities no later than December 15, 2023" } } }, "localname": "DebtInstrumentAdditionalIncreaseAvailableInLoanFacilitiesYearThree", "nsuri": "http://bridgebio.com/20220630", "presentation": [ "http://bridgebio.com/20220630/taxonomy/role/Role_DisclosureDebtAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "bbio_DebtInstrumentAdditionalPrincipalBorrowingAmount": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Debt instrument additional principal borrowing amount.", "label": "Debt Instrument Additional Principal Borrowing Amount", "terseLabel": "Debt instrument additional principal borrowing amount" } } }, "localname": "DebtInstrumentAdditionalPrincipalBorrowingAmount", "nsuri": "http://bridgebio.com/20220630", "presentation": [ "http://bridgebio.com/20220630/taxonomy/role/Role_DisclosureDebtAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "bbio_DebtInstrumentAmendedMaturityExtensionDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Debt instrument amended maturity extension date", "label": "Debt Instrument Amended Maturity Extension Date", "terseLabel": "Debt instrument amended maturity extended date" } } }, "localname": "DebtInstrumentAmendedMaturityExtensionDate", "nsuri": "http://bridgebio.com/20220630", "presentation": [ "http://bridgebio.com/20220630/taxonomy/role/Role_DisclosureDebtAdditionalInformationDetails" ], "xbrltype": "dateItemType" }, "bbio_DebtInstrumentCappedCallTransactionCapPricePerShare": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Debt instrument capped call transaction cap price per share.", "label": "Debt Instrument Capped Call Transaction Cap Price Per Share", "terseLabel": "Capped call transaction, cap price per share" } } }, "localname": "DebtInstrumentCappedCallTransactionCapPricePerShare", "nsuri": "http://bridgebio.com/20220630", "presentation": [ "http://bridgebio.com/20220630/taxonomy/role/Role_DisclosureDebtAdditionalInformationDetails" ], "xbrltype": "perShareItemType" }, "bbio_DebtInstrumentConvertibleIncreaseInConversionRateNumberOfCommonStockIssuable": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Debt instrument, convertible, increase in conversion rate, number of common stock issuable.", "label": "Debt Instrument Convertible Increase In Conversion Rate Number Of Common Stock Issuable", "terseLabel": "Debt instrument, increase in conversion rate, number of shares issuable" } } }, "localname": "DebtInstrumentConvertibleIncreaseInConversionRateNumberOfCommonStockIssuable", "nsuri": "http://bridgebio.com/20220630", "presentation": [ "http://bridgebio.com/20220630/taxonomy/role/Role_DisclosureDebtAdditionalInformationDetails" ], "xbrltype": "sharesItemType" }, "bbio_DebtInstrumentConvertibleThresholdBusinessDays": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Debt instrument convertible threshold business days.", "label": "Debt Instrument Convertible Threshold Business Days", "terseLabel": "Number of business days in consideration of conversion of notes" } } }, "localname": "DebtInstrumentConvertibleThresholdBusinessDays", "nsuri": "http://bridgebio.com/20220630", "presentation": [ "http://bridgebio.com/20220630/taxonomy/role/Role_DisclosureDebtAdditionalInformationDetails" ], "xbrltype": "durationItemType" }, "bbio_DebtInstrumentConvertibleThresholdConsecutiveTradingDayPeriod": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Debt instrument convertible threshold consecutive trading day period.", "label": "Debt Instrument Convertible Threshold Consecutive Trading Day Period", "terseLabel": "Number of consecutive trading day period (Measurement period) for conversion of notes" } } }, "localname": "DebtInstrumentConvertibleThresholdConsecutiveTradingDayPeriod", "nsuri": "http://bridgebio.com/20220630", "presentation": [ "http://bridgebio.com/20220630/taxonomy/role/Role_DisclosureDebtAdditionalInformationDetails" ], "xbrltype": "durationItemType" }, "bbio_DebtInstrumentFinalPaymentChargePercentage": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Debt instrument, final payment charge percentage.", "label": "Debt Instrument Final Payment Charge Percentage", "terseLabel": "Final payment charge percentage" } } }, "localname": "DebtInstrumentFinalPaymentChargePercentage", "nsuri": "http://bridgebio.com/20220630", "presentation": [ "http://bridgebio.com/20220630/taxonomy/role/Role_DisclosureDebtAdditionalInformationDetails" ], "xbrltype": "percentItemType" }, "bbio_DebtInstrumentInterestOnlyExtensionDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Debt instrument interest only extension date.", "label": "Debt Instrument Interest Only Extension Date", "terseLabel": "Debt instrument interest only extension date" } } }, "localname": "DebtInstrumentInterestOnlyExtensionDate", "nsuri": "http://bridgebio.com/20220630", "presentation": [ "http://bridgebio.com/20220630/taxonomy/role/Role_DisclosureDebtAdditionalInformationDetails" ], "xbrltype": "dateItemType" }, "bbio_DebtInstrumentInterestOnlyExtensionDateOne": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Debt instrument interest only extension date one.", "label": "Debt Instrument Interest Only Extension Date One", "terseLabel": "Debt instrument interest only extension date, one" } } }, "localname": "DebtInstrumentInterestOnlyExtensionDateOne", "nsuri": "http://bridgebio.com/20220630", "presentation": [ "http://bridgebio.com/20220630/taxonomy/role/Role_DisclosureDebtAdditionalInformationDetails" ], "xbrltype": "dateItemType" }, "bbio_DebtInstrumentMandatoryPrepaymentsPercentageOfNetCashProceedsFromPrepaymentEventTransaction": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Debt instrument mandatory prepayments percentage of net cash proceeds from prepayment event transaction.", "label": "Debt Instrument Mandatory Prepayments Percentage of Net Cash Proceeds from Prepayment Event Transaction", "terseLabel": "Debt instrument mandatory prepayments percentage of net cash proceeds from prepayment event transaction" } } }, "localname": "DebtInstrumentMandatoryPrepaymentsPercentageOfNetCashProceedsFromPrepaymentEventTransaction", "nsuri": "http://bridgebio.com/20220630", "presentation": [ "http://bridgebio.com/20220630/taxonomy/role/Role_DisclosureDebtAdditionalInformationDetails" ], "xbrltype": "percentItemType" }, "bbio_DebtInstrumentMaturityDateExtension": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Debt instrument maturity date extension.", "label": "Debt Instrument Maturity Date Extension", "terseLabel": "Debt instrument maturity date extension" } } }, "localname": "DebtInstrumentMaturityDateExtension", "nsuri": "http://bridgebio.com/20220630", "presentation": [ "http://bridgebio.com/20220630/taxonomy/role/Role_DisclosureDebtAdditionalInformationDetails" ], "xbrltype": "dateItemType" }, "bbio_DebtInstrumentOptionToPurchaseAdditionalNotes": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Debt instrument option to purchase additional notes.", "label": "Debt Instrument Option To Purchase Additional Notes", "terseLabel": "Debt instrument option to purchase additional notes" } } }, "localname": "DebtInstrumentOptionToPurchaseAdditionalNotes", "nsuri": "http://bridgebio.com/20220630", "presentation": [ "http://bridgebio.com/20220630/taxonomy/role/Role_DisclosureDebtAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "bbio_DebtInstrumentOptionToPurchaseAdditionalNotesExercised": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Debt Instrument Option to Purchase Additional Notes Exercised.", "label": "Debt Instrument Option To Purchase Additional Notes Exercised", "terseLabel": "Proceeds from exercise of option to purchase additional notes" } } }, "localname": "DebtInstrumentOptionToPurchaseAdditionalNotesExercised", "nsuri": "http://bridgebio.com/20220630", "presentation": [ "http://bridgebio.com/20220630/taxonomy/role/Role_DisclosureDebtAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "bbio_DebtInstrumentOptionToPurchaseAdditionalNotesRemainingPortionExercised": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Debt instrument, option to purchase additional notes remaining portion exercised.", "label": "Debt Instrument Option To Purchase Additional Notes Remaining Portion Exercised", "terseLabel": "Proceeds from exercise of remaining portion of option to purchase additional notes" } } }, "localname": "DebtInstrumentOptionToPurchaseAdditionalNotesRemainingPortionExercised", "nsuri": "http://bridgebio.com/20220630", "presentation": [ "http://bridgebio.com/20220630/taxonomy/role/Role_DisclosureDebtAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "bbio_DebtInstrumentPaymentAmortizationDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Debt Instrument Payment Amortization Date", "label": "Debt Instrument Payment Amortization Date", "terseLabel": "Debt instrument payment amortization date" } } }, "localname": "DebtInstrumentPaymentAmortizationDate", "nsuri": "http://bridgebio.com/20220630", "presentation": [ "http://bridgebio.com/20220630/taxonomy/role/Role_DisclosureDebtAdditionalInformationDetails" ], "xbrltype": "dateItemType" }, "bbio_DebtInstrumentPercentageOfPrepaymentFee": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Debt instrument percentage of prepayment fee.", "label": "Debt Instrument Percentage Of Prepayment Fee", "terseLabel": "Percentage of prepayment fee" } } }, "localname": "DebtInstrumentPercentageOfPrepaymentFee", "nsuri": "http://bridgebio.com/20220630", "presentation": [ "http://bridgebio.com/20220630/taxonomy/role/Role_DisclosureDebtAdditionalInformationDetails" ], "xbrltype": "percentItemType" }, "bbio_DebtInstrumentPotentialPaymentExtendedAmortizationDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Debt instrument potential payment extended amortization date.", "label": "Debt Instrument Potential Payment Extended Amortization Date", "terseLabel": "Debt instrument potential payment extended amortization date" } } }, "localname": "DebtInstrumentPotentialPaymentExtendedAmortizationDate", "nsuri": "http://bridgebio.com/20220630", "presentation": [ "http://bridgebio.com/20220630/taxonomy/role/Role_DisclosureDebtAdditionalInformationDetails" ], "xbrltype": "dateItemType" }, "bbio_DebtInstrumentPrepayment": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Debt instrument prepayment.", "label": "Debt Instrument Prepayment", "terseLabel": "Debt instrument prepaid" } } }, "localname": "DebtInstrumentPrepayment", "nsuri": "http://bridgebio.com/20220630", "presentation": [ "http://bridgebio.com/20220630/taxonomy/role/Role_DisclosureDebtAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "bbio_DebtInstrumentPrepaymentPremiumPercentage": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Debt instrument prepayment premium percentage.", "label": "Debt Instrument Prepayment Premium Percentage", "terseLabel": "Debt instrument prepayment premium percentage" } } }, "localname": "DebtInstrumentPrepaymentPremiumPercentage", "nsuri": "http://bridgebio.com/20220630", "presentation": [ "http://bridgebio.com/20220630/taxonomy/role/Role_DisclosureDebtAdditionalInformationDetails" ], "xbrltype": "percentItemType" }, "bbio_DebtInstrumentPrincipalAmountDenominationForConversionIntoCommonStock": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Debt instrument principal amount denomination for conversion into common stock.", "label": "Debt Instrument Principal Amount Denomination For Conversion Into Common Stock", "terseLabel": "Denomination of the principal amount of debt in consideration conversion of the notes" } } }, "localname": "DebtInstrumentPrincipalAmountDenominationForConversionIntoCommonStock", "nsuri": "http://bridgebio.com/20220630", "presentation": [ "http://bridgebio.com/20220630/taxonomy/role/Role_DisclosureDebtAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "bbio_DebtInstrumentTrancheFourMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Debt instrument tranche four.", "label": "Debt Instrument Tranche Four [Member]", "terseLabel": "Tranche IV" } } }, "localname": "DebtInstrumentTrancheFourMember", "nsuri": "http://bridgebio.com/20220630", "presentation": [ "http://bridgebio.com/20220630/taxonomy/role/Role_DisclosureDebtAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "bbio_DebtInstrumentTrancheOneMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Debt instrument tranche one.", "label": "Debt Instrument Tranche One [Member]", "terseLabel": "Tranche I" } } }, "localname": "DebtInstrumentTrancheOneMember", "nsuri": "http://bridgebio.com/20220630", "presentation": [ "http://bridgebio.com/20220630/taxonomy/role/Role_DisclosureDebtAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "bbio_DebtInstrumentTrancheThreeMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Debt instrument tranche three.", "label": "Debt Instrument Tranche Three [Member]", "terseLabel": "Tranche III" } } }, "localname": "DebtInstrumentTrancheThreeMember", "nsuri": "http://bridgebio.com/20220630", "presentation": [ "http://bridgebio.com/20220630/taxonomy/role/Role_DisclosureDebtAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "bbio_DebtInstrumentTrancheTwoMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Debt Instrument tranche two.", "label": "Debt Instrument Tranche Two [Member]", "terseLabel": "Tranche II" } } }, "localname": "DebtInstrumentTrancheTwoMember", "nsuri": "http://bridgebio.com/20220630", "presentation": [ "http://bridgebio.com/20220630/taxonomy/role/Role_DisclosureDebtAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "bbio_DebtInstrumentUnamortizedDiscountPremiumDebtIssuanceCostsAndExitFeesAccretion": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Debt instrument unamortized discount premium debt issuance costs and exit fees accretion.", "label": "Debt Instrument Unamortized Discount Premium Debt Issuance Costs And Exit Fees Accretion", "negatedLabel": "Debt discount, issuance costs and exit fee accretion" } } }, "localname": "DebtInstrumentUnamortizedDiscountPremiumDebtIssuanceCostsAndExitFeesAccretion", "nsuri": "http://bridgebio.com/20220630", "presentation": [ "http://bridgebio.com/20220630/taxonomy/role/DisclosureDebtScheduleOfBalancesOfBorrowingUnderLoanAgreementDetails" ], "xbrltype": "monetaryItemType" }, "bbio_DebtInstrumentsMaturityYear": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Debt instruments maturity year.", "label": "Debt Instruments Maturity Year", "terseLabel": "Maturity year" } } }, "localname": "DebtInstrumentsMaturityYear", "nsuri": "http://bridgebio.com/20220630", "presentation": [ "http://bridgebio.com/20220630/taxonomy/role/Role_DisclosureDebtAdditionalInformationDetails" ], "xbrltype": "gYearItemType" }, "bbio_DerecognitionOfCapitalizedFiniteLivedIntangibleAssetNet": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Derecognition of capitalized finite lived Intangible asset net.", "label": "Derecognition of Capitalized Finite Lived Intangible Asset Net", "terseLabel": "Derecognition of capitalized intangible asset net." } } }, "localname": "DerecognitionOfCapitalizedFiniteLivedIntangibleAssetNet", "nsuri": "http://bridgebio.com/20220630", "presentation": [ "http://bridgebio.com/20220630/taxonomy/role/DisclosureIntangibleAssetsAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "bbio_DerivativeLiabilityExpectedTerm": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Derivative liability expected term.", "label": "Derivative Liability Expected Term", "terseLabel": "Expected term (in years)" } } }, "localname": "DerivativeLiabilityExpectedTerm", "nsuri": "http://bridgebio.com/20220630", "presentation": [ "http://bridgebio.com/20220630/taxonomy/role/DisclosureFairValueMeasurementsScheduleOfEstimatedFairValueOfLiabilityDetails" ], "xbrltype": "durationItemType" }, "bbio_DirectOfferingExpense": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Direct offering expense.", "label": "Direct Offering Expense", "terseLabel": "Direct offering expense" } } }, "localname": "DirectOfferingExpense", "nsuri": "http://bridgebio.com/20220630", "presentation": [ "http://bridgebio.com/20220630/taxonomy/role/Role_DisclosureDebtAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "bbio_DirectTransactionCostsInRepurchaseOfNoncontrollingInterestIncludedInAccountsPayableAndAccruedProfessionalService": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Direct transaction costs in the repurchase of Eidos noncontrolling interest included in \u201caccounts payable\u201d and \u201caccrued professional services\u201d", "label": "Direct Transaction Costs in Repurchase of Noncontrolling Interest Included in Accounts Payable and Accrued Professional Service", "terseLabel": "Direct transaction costs in the repurchase of Eidos noncontrolling interest included in \"Accounts payable\" and \"Accrued professional services\"" } } }, "localname": "DirectTransactionCostsInRepurchaseOfNoncontrollingInterestIncludedInAccountsPayableAndAccruedProfessionalService", "nsuri": "http://bridgebio.com/20220630", "presentation": [ "http://bridgebio.com/20220630/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "bbio_DirectTransactionCostsInRepurchaseOfNoncontrollingInterestRecordedInAdditionalPaidInCapitalPreviouslyClassifiedInPrepaidExpensesAndOtherCurrentAssets": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Direct transaction costs in repurchase of noncontrolling interest recorded in additional paid-in capital previously classified in prepaid expenses and other current assets.", "label": "Direct Transaction Costs In Repurchase Of Noncontrolling Interest Recorded In Additional Paid In Capital Previously Classified In Prepaid Expenses And Other Current Assets", "terseLabel": "Direct transaction costs in the repurchase of Eidos recorded in \"Additional paid-in capital\" previously classified in \"Prepaid expenses and other current assets\"" } } }, "localname": "DirectTransactionCostsInRepurchaseOfNoncontrollingInterestRecordedInAdditionalPaidInCapitalPreviouslyClassifiedInPrepaidExpensesAndOtherCurrentAssets", "nsuri": "http://bridgebio.com/20220630", "presentation": [ "http://bridgebio.com/20220630/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "bbio_DueAmountsPaidToVendor": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Due amounts paid to vendor.", "label": "Due Amounts Paid to Vendor" } } }, "localname": "DueAmountsPaidToVendor", "nsuri": "http://bridgebio.com/20220630", "presentation": [ "http://bridgebio.com/20220630/taxonomy/role/Role_DisclosureLeasesAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "bbio_EidosAwardExchangePlanMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Eidos Award Exchange Plan.", "label": "Eidos Award Exchange Plan [Member]", "terseLabel": "Eidos Award Exchange Plan" } } }, "localname": "EidosAwardExchangePlanMember", "nsuri": "http://bridgebio.com/20220630", "presentation": [ "http://bridgebio.com/20220630/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "bbio_EidosTherapeuticsIncMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Eidos Therapeutics, Inc.", "label": "Eidos Therapeutics Inc [Member]", "terseLabel": "Eidos" } } }, "localname": "EidosTherapeuticsIncMember", "nsuri": "http://bridgebio.com/20220630", "presentation": [ "http://bridgebio.com/20220630/taxonomy/role/Role_DisclosureDebtAdditionalInformationDetails", "http://bridgebio.com/20220630/taxonomy/role/Role_DisclosureEidosAdditionalInformationDetails", "http://bridgebio.com/20220630/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetails", "http://bridgebio.com/20220630/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfStockBasedCompensationForEmployeesAndNonEmployeesDetails", "http://bridgebio.com/20220630/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfStockOptionActivityUnderPlansDetails" ], "xbrltype": "domainItemType" }, "bbio_EmployeeAndNonEmployeeServiceShareBasedCompensationLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Employee and non-employee service share based compensation.", "label": "Employee And Non Employee Service Share Based Compensation [Line Items]", "terseLabel": "Employee And Non Employee Service Share Based Compensation [Line Items]" } } }, "localname": "EmployeeAndNonEmployeeServiceShareBasedCompensationLineItems", "nsuri": "http://bridgebio.com/20220630", "presentation": [ "http://bridgebio.com/20220630/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfStockBasedCompensationForEmployeesAndNonEmployeesDetails" ], "xbrltype": "stringItemType" }, "bbio_EntitiesAffiliatedWithPerceptiveLifeSciencesMasterFundLtdMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Entities affiliated with Perceptive Life Sciences Master Fund Ltd.", "label": "Entities Affiliated With Perceptive Life Sciences Master Fund Ltd [Member]", "terseLabel": "Entities Affiliated With Perceptive Life Sciences Master Fund Ltd" } } }, "localname": "EntitiesAffiliatedWithPerceptiveLifeSciencesMasterFundLtdMember", "nsuri": "http://bridgebio.com/20220630", "presentation": [ "http://bridgebio.com/20220630/taxonomy/role/DisclosureEquityMethodAndOtherEquityInvestmentsAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "bbio_EquityMethodAndCostMethodInvestmentAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Equity Method And Cost Method Investment [Abstract]" } } }, "localname": "EquityMethodAndCostMethodInvestmentAbstract", "nsuri": "http://bridgebio.com/20220630", "xbrltype": "stringItemType" }, "bbio_EquityMethodInvesteesIpoMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Equity Method Investee's IPO.", "label": "Equity Method Investee's IPO [Member]", "terseLabel": "Equity Method Investee's IPO" } } }, "localname": "EquityMethodInvesteesIpoMember", "nsuri": "http://bridgebio.com/20220630", "presentation": [ "http://bridgebio.com/20220630/taxonomy/role/DisclosureEquityMethodAndOtherEquityInvestmentsAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "bbio_EstimatedFairValueOfOutstandingTermLoan": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Estimated fair value of outstanding term loan.", "label": "Estimated Fair Value of Outstanding Term Loan", "terseLabel": "Estimated fair value of outstanding term loan" } } }, "localname": "EstimatedFairValueOfOutstandingTermLoan", "nsuri": "http://bridgebio.com/20220630", "presentation": [ "http://bridgebio.com/20220630/taxonomy/role/DisclosureFairValueMeasurementsAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "bbio_EstimatedSharesIssuableEmployeeStockPurchasePlanMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Estimated shares issuable employee stock purchase plan.", "label": "Estimated Shares Issuable Employee Stock Purchase Plan [Member]", "terseLabel": "Estimated Shares Issuable Under the ESPP" } } }, "localname": "EstimatedSharesIssuableEmployeeStockPurchasePlanMember", "nsuri": "http://bridgebio.com/20220630", "presentation": [ "http://bridgebio.com/20220630/taxonomy/role/Role_DisclosureNetLossPerShareScheduleOfCommonStockEquivalentsWereExcludedFromComputationOfDilutedNetLossPerShareDetail" ], "xbrltype": "domainItemType" }, "bbio_EstimatedSharesIssuablePerformanceBasedMilestoneCompensationArrangementMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Estimated shares issuable performance based milestone compensation arrangement.", "label": "Estimated Shares Issuable Performance Based Milestone Compensation Arrangement [Member]", "terseLabel": "Estimated Shares Issuable Performance Based Milestone Compensation Arrangement", "verboseLabel": "Estimated Shares Issuable Under Performance-Based Milestone Compensation Arrangements" } } }, "localname": "EstimatedSharesIssuablePerformanceBasedMilestoneCompensationArrangementMember", "nsuri": "http://bridgebio.com/20220630", "presentation": [ "http://bridgebio.com/20220630/taxonomy/role/Role_DisclosureNetLossPerShareScheduleOfCommonStockEquivalentsWereExcludedFromComputationOfDilutedNetLossPerShareDetail" ], "xbrltype": "domainItemType" }, "bbio_ExitFees": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Exit fees.", "label": "Exit Fees", "terseLabel": "Exit fee" } } }, "localname": "ExitFees", "nsuri": "http://bridgebio.com/20220630", "presentation": [ "http://bridgebio.com/20220630/taxonomy/role/Role_DisclosureDebtAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "bbio_FairValueAssetsTransfersBetweenLevelOneLevelTwoOrLevelThreeAmount": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Fair value assets transfers between level one level two or level three amount.", "label": "Fair Value Assets Transfers Between Level One Level Two Or Level Three Amount", "terseLabel": "Fair value assets, transfers between Level 1, Level 2 or Level 3" } } }, "localname": "FairValueAssetsTransfersBetweenLevelOneLevelTwoOrLevelThreeAmount", "nsuri": "http://bridgebio.com/20220630", "presentation": [ "http://bridgebio.com/20220630/taxonomy/role/DisclosureFairValueMeasurementsAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "bbio_FairValueLiabilitiesTransfersBetweenLevelOneLevelTwoOrLevelThreeAmount": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Fair value liabilities transfers between level one level two or level three amount.", "label": "Fair Value Liabilities Transfers Between Level One Level Two Or Level Three Amount", "terseLabel": "Fair value liabilities, transfers between Level 1, Level 2 or Level 3" } } }, "localname": "FairValueLiabilitiesTransfersBetweenLevelOneLevelTwoOrLevelThreeAmount", "nsuri": "http://bridgebio.com/20220630", "presentation": [ "http://bridgebio.com/20220630/taxonomy/role/DisclosureFairValueMeasurementsAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "bbio_FairValueOfSharesIssuedUnderLicenseAgreements": { "auth_ref": [], "calculation": { "http://bridgebio.com/20220630/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited": { "order": 8.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Fair value of shares issued under license agreements.", "label": "Fair Value Of Shares Issued Under License Agreements", "terseLabel": "Fair value of shares issued under a license agreements" } } }, "localname": "FairValueOfSharesIssuedUnderLicenseAgreements", "nsuri": "http://bridgebio.com/20220630", "presentation": [ "http://bridgebio.com/20220630/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "bbio_FiniteLivedIntangibleAssetsAmortizationExpenseRollingAfterYearFour": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Finite lived intangible assets amortization expense rolling after year four.", "label": "Finite Lived Intangible Assets Amortization Expense Rolling After Year Four", "terseLabel": "Amortization expenses, thereafter" } } }, "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseRollingAfterYearFour", "nsuri": "http://bridgebio.com/20220630", "presentation": [ "http://bridgebio.com/20220630/taxonomy/role/DisclosureIntangibleAssetsAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "bbio_FoundationMedicineDiagnosticsAgreementMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Foundation medicine diagnostics agreement.", "label": "Foundation Medicine Diagnostics Agreement [Member]", "terseLabel": "Foundation Medicine Diagnostics Agreement" } } }, "localname": "FoundationMedicineDiagnosticsAgreementMember", "nsuri": "http://bridgebio.com/20220630", "presentation": [ "http://bridgebio.com/20220630/taxonomy/role/DisclosureIntangibleAssetsAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "bbio_FoundationMedicineIncMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Foundation Medicine, Inc.", "label": "Foundation Medicine Inc [Member]", "terseLabel": "Foundation Medicine, Inc" } } }, "localname": "FoundationMedicineIncMember", "nsuri": "http://bridgebio.com/20220630", "presentation": [ "http://bridgebio.com/20220630/taxonomy/role/DisclosureIntangibleAssetsAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "bbio_FuturePotentialDevelopmentAndSalesMilestonePaymentsYetToBeReceived": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Future potential development and sales milestone payments yet to be received.", "label": "Future Potential Development And Sales Milestone Payments Yet To Be Received", "terseLabel": "Future potential development and sales milestone payments yet to receive" } } }, "localname": "FuturePotentialDevelopmentAndSalesMilestonePaymentsYetToBeReceived", "nsuri": "http://bridgebio.com/20220630", "presentation": [ "http://bridgebio.com/20220630/taxonomy/role/DisclosureLicenseAndCollaborationAgreementsAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "bbio_GainFromConversionOfEquityMethodInvestmentToInvestmentInEquitySecurities": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Gain from conversion of equity method investment to investment in equity securities.", "label": "Gain from Conversion of Equity Method Investment to Investment in Equity Securities", "terseLabel": "Gain on conversion from equity method investment to investment in equity securities" } } }, "localname": "GainFromConversionOfEquityMethodInvestmentToInvestmentInEquitySecurities", "nsuri": "http://bridgebio.com/20220630", "presentation": [ "http://bridgebio.com/20220630/taxonomy/role/DisclosureEquityMethodAndOtherEquityInvestmentsAdditionalInformationDetail" ], "xbrltype": "monetaryItemType" }, "bbio_GainFromRecognitionOfReceivableFromLicensingAndCollaborationAgreements": { "auth_ref": [], "calculation": { "http://bridgebio.com/20220630/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited": { "order": 6.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Gain from recognition of receivable from licensing and collaboration agreements.", "label": "Gain From Recognition Of Receivable From Licensing And Collaboration Agreements", "negatedLabel": "Gain from recognition of receivable from licensing and collaboration agreement" } } }, "localname": "GainFromRecognitionOfReceivableFromLicensingAndCollaborationAgreements", "nsuri": "http://bridgebio.com/20220630", "presentation": [ "http://bridgebio.com/20220630/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "bbio_GainFromSaleOfPriorityReviewVoucherExcludingTransactionCosts": { "auth_ref": [], "calculation": { "http://bridgebio.com/20220630/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited": { "order": 5.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Gain from sale of Priority Review Voucher, excluding transaction costs.", "label": "Gain from Sale of Priority Review Voucher, Excluding Transaction Costs", "negatedLabel": "Gain from sale of priority review voucher, excluding transaction costs" } } }, "localname": "GainFromSaleOfPriorityReviewVoucherExcludingTransactionCosts", "nsuri": "http://bridgebio.com/20220630", "presentation": [ "http://bridgebio.com/20220630/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "bbio_GainFromSaleOfPriorityReviewVoucherNet": { "auth_ref": [], "calculation": { "http://bridgebio.com/20220630/taxonomy/role/StatementCondensedConsolidatedStatementsOfOperationsUnaudited": { "order": 2.0, "parentTag": "us-gaap_NonoperatingIncomeExpense", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Gain from sale of priority review voucher, net", "label": "Gain From Sale Of Priority Review Voucher, Net", "terseLabel": "Gain from sale of priority review voucher, net" } } }, "localname": "GainFromSaleOfPriorityReviewVoucherNet", "nsuri": "http://bridgebio.com/20220630", "presentation": [ "http://bridgebio.com/20220630/taxonomy/role/StatementCondensedConsolidatedStatementsOfOperationsUnaudited" ], "xbrltype": "monetaryItemType" }, "bbio_GainLossOnDebtModification": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Gain loss on debt modification.", "label": "Gain Loss On Debt Modification", "terseLabel": "Gains or losses on debt modification" } } }, "localname": "GainLossOnDebtModification", "nsuri": "http://bridgebio.com/20220630", "presentation": [ "http://bridgebio.com/20220630/taxonomy/role/Role_DisclosureDebtAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "bbio_GainLossOnRemeasurementOfLEOCallOptionLiability": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Gain loss on remeasurement of LEO call option liability.", "label": "Gain Loss On Remeasurement Of L E O Call Option Liability", "terseLabel": "Gain on remeasurement of LEO call option liability" } } }, "localname": "GainLossOnRemeasurementOfLEOCallOptionLiability", "nsuri": "http://bridgebio.com/20220630", "presentation": [ "http://bridgebio.com/20220630/taxonomy/role/DisclosureEquityMethodAndOtherEquityInvestmentsAdditionalInformationDetail" ], "xbrltype": "monetaryItemType" }, "bbio_HelsinnTherapeuticsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Helsinn Therapeutics.", "label": "Helsinn Therapeutics [Member]", "terseLabel": "Helsinn Therapeutics" } } }, "localname": "HelsinnTherapeuticsMember", "nsuri": "http://bridgebio.com/20220630", "presentation": [ "http://bridgebio.com/20220630/taxonomy/role/DisclosureLicenseAndCollaborationAgreementsAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "bbio_HerculesCapitalIncMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Hercules Capital, Inc.", "label": "Hercules Capital Inc [Member]", "terseLabel": "Hercules Capital, Inc" } } }, "localname": "HerculesCapitalIncMember", "nsuri": "http://bridgebio.com/20220630", "presentation": [ "http://bridgebio.com/20220630/taxonomy/role/Role_DisclosureDebtAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "bbio_IncreaseDecreaseInAccruedProfessionalService": { "auth_ref": [], "calculation": { "http://bridgebio.com/20220630/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited": { "order": 24.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Increase decrease in accrued professional service.", "label": "Increase Decrease In Accrued Professional Service", "terseLabel": "Accrued professional services" } } }, "localname": "IncreaseDecreaseInAccruedProfessionalService", "nsuri": "http://bridgebio.com/20220630", "presentation": [ "http://bridgebio.com/20220630/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "bbio_IncreaseDecreaseInAccruedResearchAndDevelopmentLiabilities": { "auth_ref": [], "calculation": { "http://bridgebio.com/20220630/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited": { "order": 23.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Increase (decrease) in accrued research and development liabilities.", "label": "Increase Decrease In Accrued Research And Development Liabilities", "terseLabel": "Accrued research and development liabilities" } } }, "localname": "IncreaseDecreaseInAccruedResearchAndDevelopmentLiabilities", "nsuri": "http://bridgebio.com/20220630", "presentation": [ "http://bridgebio.com/20220630/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "bbio_IncreaseDecreaseInTermLoanAggregateAmountAdvance": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Increase decrease in term loan aggregate amount advance.", "label": "Increase decrease in term loan aggregate amount advance" } } }, "localname": "IncreaseDecreaseInTermLoanAggregateAmountAdvance", "nsuri": "http://bridgebio.com/20220630", "presentation": [ "http://bridgebio.com/20220630/taxonomy/role/Role_DisclosureDebtAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "bbio_IncreaseDecreaseReceivableFromLicensingAndCollaborationAgreements": { "auth_ref": [], "calculation": { "http://bridgebio.com/20220630/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited": { "order": 17.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Increase (decrease) receivable from licensing and collaboration agreements.", "label": "Increase Decrease Receivable From Licensing And Collaboration Agreements", "negatedLabel": "Receivable from licensing and collaboration agreements" } } }, "localname": "IncreaseDecreaseReceivableFromLicensingAndCollaborationAgreements", "nsuri": "http://bridgebio.com/20220630", "presentation": [ "http://bridgebio.com/20220630/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "bbio_IncreaseInInitialTransactionPriceForLicenseAndCollaborationAgreement": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Increase in initial transaction price for license and collaboration agreement.", "label": "Increase in Initial Transaction Price for License and Collaboration Agreement", "terseLabel": "Increase in initial transaction price for license and collaboration agreement" } } }, "localname": "IncreaseInInitialTransactionPriceForLicenseAndCollaborationAgreement", "nsuri": "http://bridgebio.com/20220630", "presentation": [ "http://bridgebio.com/20220630/taxonomy/role/DisclosureLicenseAndCollaborationAgreementsAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "bbio_IncrementalCompensationCostForAwardsModification": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Incremental compensation cost for awards modification.", "label": "Incremental Compensation Cost For Awards Modification", "terseLabel": "Incremental compensation cost for awards modification" } } }, "localname": "IncrementalCompensationCostForAwardsModification", "nsuri": "http://bridgebio.com/20220630", "presentation": [ "http://bridgebio.com/20220630/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "bbio_InitialTransactionPriceForLicenseAndCollaborationAgreement": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Initial transaction price for license and collaboration agreement.", "label": "Initial Transaction Price For License And Collaboration Agreement", "terseLabel": "Initial transaction price for the license and collaboration agreement" } } }, "localname": "InitialTransactionPriceForLicenseAndCollaborationAgreement", "nsuri": "http://bridgebio.com/20220630", "presentation": [ "http://bridgebio.com/20220630/taxonomy/role/DisclosureLicenseAndCollaborationAgreementsAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "bbio_InterestAdjustOnTwoPointFiveZeroPercentageConvertibleSeniorNotesDueTwoThousandAndTwentySevenMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Interest Adjust on two point five zero percentage convertible senior notes due two thousand and twenty seven.", "label": "Interest Adjust On Two Point Five Zero Percentage Convertible Senior Notes Due Two Thousand And Twenty Seven [Member]", "terseLabel": "Interest on 2027 Notes" } } }, "localname": "InterestAdjustOnTwoPointFiveZeroPercentageConvertibleSeniorNotesDueTwoThousandAndTwentySevenMember", "nsuri": "http://bridgebio.com/20220630", "presentation": [ "http://bridgebio.com/20220630/taxonomy/role/Role_DisclosureDebtScheduleOfFutureMinimumPaymentsUnderNotesDetails" ], "xbrltype": "domainItemType" }, "bbio_InterestAdjustOnTwoPointTwoFivePercentageConvertibleSeniorNotesDueTwoThousandAndTwentyNineMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Interest adjust on two point two five percentage convertible senior notes due two thousand and twenty nine.", "label": "Interest Adjust On Two Point Two Five Percentage Convertible Senior Notes Due Two Thousand And Twenty Nine [Member]", "terseLabel": "Interest on 2029 Notes" } } }, "localname": "InterestAdjustOnTwoPointTwoFivePercentageConvertibleSeniorNotesDueTwoThousandAndTwentyNineMember", "nsuri": "http://bridgebio.com/20220630", "presentation": [ "http://bridgebio.com/20220630/taxonomy/role/Role_DisclosureDebtScheduleOfFutureMinimumPaymentsUnderNotesDetails" ], "xbrltype": "domainItemType" }, "bbio_InterestTwoThousandAndTwentySevenAndTwoThousandAndAndTwentyNineMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Interest two thousand and twenty seven and two thousand and twenty nine.", "label": "Interest Two Thousand and Twenty Seven and Two Thousand and and Twenty Nine [Member]", "terseLabel": "Interest on 2027 and 2029 Notes" } } }, "localname": "InterestTwoThousandAndTwentySevenAndTwoThousandAndAndTwentyNineMember", "nsuri": "http://bridgebio.com/20220630", "presentation": [ "http://bridgebio.com/20220630/taxonomy/role/Role_DisclosureDebtScheduleOfFutureMinimumPaymentsUnderNotesDetails" ], "xbrltype": "domainItemType" }, "bbio_IssuanceRepurchaseOfNoncontrollingInterest": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Issuance (repurchase) of noncontrolling interest.", "label": "Issuance Repurchase Of Noncontrolling Interest", "terseLabel": "Issuance of noncontrolling interests" } } }, "localname": "IssuanceRepurchaseOfNoncontrollingInterest", "nsuri": "http://bridgebio.com/20220630", "presentation": [ "http://bridgebio.com/20220630/taxonomy/role/StatementCondensedConsolidatedStatementsOfRedeemableConvertibleNoncontrollingInterestsAndStockholdersEquityUnaudited" ], "xbrltype": "monetaryItemType" }, "bbio_LEOCallOptionLiabilityCurrent": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "LEO call option liability current.", "label": "L E O Call Option Liability Current", "terseLabel": "LEO call option liability" } } }, "localname": "LEOCallOptionLiabilityCurrent", "nsuri": "http://bridgebio.com/20220630", "presentation": [ "http://bridgebio.com/20220630/taxonomy/role/DisclosureEquityMethodAndOtherEquityInvestmentsAdditionalInformationDetail", "http://bridgebio.com/20220630/taxonomy/role/DisclosureFairValueMeasurementsAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "bbio_LEOCallOptionMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "LEO call option.", "label": "L E O Call Option [Member]", "terseLabel": "LEO Call Option" } } }, "localname": "LEOCallOptionMember", "nsuri": "http://bridgebio.com/20220630", "presentation": [ "http://bridgebio.com/20220630/taxonomy/role/DisclosureFairValueMeasurementsScheduleOfEstimatedFairValueOfLiabilityDetails", "http://bridgebio.com/20220630/taxonomy/role/DisclosureFairValueMeasurementsSummaryOfChangeInEstimatedFairValueOfLiabilityRecordedInOtherIncomeExpenseNetDetails", "http://bridgebio.com/20220630/taxonomy/role/DisclosureFairValueMeasurementsTables" ], "xbrltype": "domainItemType" }, "bbio_LaunchMilestonePayment": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Launch milestone payment.", "label": "Launch Milestone Payment", "terseLabel": "Launch milestone payment" } } }, "localname": "LaunchMilestonePayment", "nsuri": "http://bridgebio.com/20220630", "presentation": [ "http://bridgebio.com/20220630/taxonomy/role/DisclosureLicenseAndCollaborationAgreementsAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "bbio_LeaseAgreementExpiration": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Lease agreement expiration.", "label": "Lease Agreement Expiration", "terseLabel": "Lease agreement expiration" } } }, "localname": "LeaseAgreementExpiration", "nsuri": "http://bridgebio.com/20220630", "presentation": [ "http://bridgebio.com/20220630/taxonomy/role/Role_DisclosureLeasesAdditionalInformationDetails" ], "xbrltype": "durationItemType" }, "bbio_LesseeOperatingAndFinancingLeasesDisclosureTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Lessee operating and financing leases disclosure.", "label": "Lessee Operating And Financing Leases Disclosure [Text Block]", "terseLabel": "Leases" } } }, "localname": "LesseeOperatingAndFinancingLeasesDisclosureTextBlock", "nsuri": "http://bridgebio.com/20220630", "presentation": [ "http://bridgebio.com/20220630/taxonomy/role/Role_DisclosureLeases" ], "xbrltype": "textBlockItemType" }, "bbio_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour": { "auth_ref": [], "calculation": { "http://bridgebio.com/20220630/taxonomy/role/Role_DisclosureLeasesScheduleOfFutureMinimumLeasePaymentsForNoncancelableLeasesDetails": { "order": 5.0, "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Lessee operating lease liability payments due after year four.", "label": "Lessee Operating Lease Liability Payments Due After Year Four", "terseLabel": "Operating leases, Thereafter" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour", "nsuri": "http://bridgebio.com/20220630", "presentation": [ "http://bridgebio.com/20220630/taxonomy/role/Role_DisclosureLeasesScheduleOfFutureMinimumLeasePaymentsForNoncancelableLeasesDetails" ], "xbrltype": "monetaryItemType" }, "bbio_LianBioMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "LianBio.", "label": "Lian Bio [Member]", "terseLabel": "LianBio" } } }, "localname": "LianBioMember", "nsuri": "http://bridgebio.com/20220630", "presentation": [ "http://bridgebio.com/20220630/taxonomy/role/DisclosureEquityMethodAndOtherEquityInvestmentsAdditionalInformationDetail", "http://bridgebio.com/20220630/taxonomy/role/DisclosureFairValueMeasurementsAdditionalInformationDetails", "http://bridgebio.com/20220630/taxonomy/role/DisclosureLicenseAndCollaborationAgreementsAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "bbio_LicenseAgreementMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "License agreement.", "label": "License Agreement [Member]", "terseLabel": "License Agreement" } } }, "localname": "LicenseAgreementMember", "nsuri": "http://bridgebio.com/20220630", "presentation": [ "http://bridgebio.com/20220630/taxonomy/role/DisclosureLicenseAndCollaborationAgreementsAdditionalInformationDetails", "http://bridgebio.com/20220630/taxonomy/role/Role_DisclosureDebtAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "bbio_LicenseAgreementPercentageShareOfProfitsAndLosses": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "License agreement percentage share of profits and losses.", "label": "License Agreement Percentage Share Of Profits And Losses", "terseLabel": "License agreement percentage share of profits and losses" } } }, "localname": "LicenseAgreementPercentageShareOfProfitsAndLosses", "nsuri": "http://bridgebio.com/20220630", "presentation": [ "http://bridgebio.com/20220630/taxonomy/role/DisclosureLicenseAndCollaborationAgreementsAdditionalInformationDetails" ], "xbrltype": "percentItemType" }, "bbio_LicenseAgreementsShareOfCoCommercializationLossAsReductionToSellingGeneralAndAdministrativeExpenses": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "License agreements share of co-commercialization loss as reduction to selling, general and administrative expenses.", "label": "License Agreements Share Of Co Commercialization Loss As Reduction To Selling General And Administrative Expenses", "terseLabel": "License agreements share of co-commercialization loss as reduction to selling, general and administrative expenses" } } }, "localname": "LicenseAgreementsShareOfCoCommercializationLossAsReductionToSellingGeneralAndAdministrativeExpenses", "nsuri": "http://bridgebio.com/20220630", "presentation": [ "http://bridgebio.com/20220630/taxonomy/role/DisclosureLicenseAndCollaborationAgreementsAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "bbio_LicenseAndCollaborationAgreementAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "License and collaboration agreement.", "label": "License And Collaboration Agreement [Abstract]" } } }, "localname": "LicenseAndCollaborationAgreementAbstract", "nsuri": "http://bridgebio.com/20220630", "xbrltype": "stringItemType" }, "bbio_LicenseAndCollaborationAgreementMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "License and collaboration agreement.", "label": "License And Collaboration Agreement [Member]", "terseLabel": "License and Collaboration Agreement" } } }, "localname": "LicenseAndCollaborationAgreementMember", "nsuri": "http://bridgebio.com/20220630", "presentation": [ "http://bridgebio.com/20220630/taxonomy/role/DisclosureLicenseAndCollaborationAgreementsAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "bbio_LicenseAndCollaborationAgreementTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "License and collaboration agreement.", "label": "License And Collaboration Agreement [Text Block]", "terseLabel": "License and Collaboration Agreements" } } }, "localname": "LicenseAndCollaborationAgreementTextBlock", "nsuri": "http://bridgebio.com/20220630", "presentation": [ "http://bridgebio.com/20220630/taxonomy/role/DisclosureLicenseAndCollaborationAgreements1" ], "xbrltype": "textBlockItemType" }, "bbio_LoanAgreementMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Loan Agreement [Member]", "label": "Loan Agreement [Member]", "terseLabel": "Loan Agreement" } } }, "localname": "LoanAgreementMember", "nsuri": "http://bridgebio.com/20220630", "presentation": [ "http://bridgebio.com/20220630/taxonomy/role/DisclosureDebtScheduleOfBalancesOfBorrowingUnderLoanAgreementDetails", "http://bridgebio.com/20220630/taxonomy/role/Role_DisclosureDebtAdditionalInformationDetails", "http://bridgebio.com/20220630/taxonomy/role/Role_DisclosureDebtTables" ], "xbrltype": "domainItemType" }, "bbio_ManufacturingAgreementMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Manufacturing agreement.", "label": "Manufacturing Agreement [Member]", "terseLabel": "Manufacturing Agreement" } } }, "localname": "ManufacturingAgreementMember", "nsuri": "http://bridgebio.com/20220630", "presentation": [ "http://bridgebio.com/20220630/taxonomy/role/Role_DisclosureLeasesAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "bbio_MaximumPotentialPerformanceBasedMilestoneAwardsToBeSettledInShares": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Maximum potential performance based milestone awards to be settled in shares.", "label": "Maximum Potential Performance Based Milestone Awards To Be Settled In Shares", "terseLabel": "Maximum potential milestone performance-based awards to be settled in fully-vested RSA" } } }, "localname": "MaximumPotentialPerformanceBasedMilestoneAwardsToBeSettledInShares", "nsuri": "http://bridgebio.com/20220630", "presentation": [ "http://bridgebio.com/20220630/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "bbio_MeasurementInputProbabilityOfMilestoneAchievementMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Measurement input probability of milestone achievement.", "label": "Measurement Input Probability Of Milestone Achievement [Member]", "terseLabel": "Probability of Milestone Achievement" } } }, "localname": "MeasurementInputProbabilityOfMilestoneAchievementMember", "nsuri": "http://bridgebio.com/20220630", "presentation": [ "http://bridgebio.com/20220630/taxonomy/role/DisclosureFairValueMeasurementsScheduleOfEstimatedFairValueOfLiabilityDetails" ], "xbrltype": "domainItemType" }, "bbio_MergerTransactionsCompletionDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Merger transactions completion date.", "label": "Merger Transactions Completion Date", "terseLabel": "Merger transactions completion date" } } }, "localname": "MergerTransactionsCompletionDate", "nsuri": "http://bridgebio.com/20220630", "presentation": [ "http://bridgebio.com/20220630/taxonomy/role/Role_DisclosureEidosAdditionalInformationDetails" ], "xbrltype": "dateItemType" }, "bbio_MinimumThresholdPercentageOfAggregatePrincipalByTrusteeOrHolders": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Minimum threshold percentage of aggregate principal by trustee or holders.", "label": "Minimum Threshold Percentage Of Aggregate Principal By Trustee Or Holders", "terseLabel": "Minimum threshold percentage of aggregate principal by trustee or holders" } } }, "localname": "MinimumThresholdPercentageOfAggregatePrincipalByTrusteeOrHolders", "nsuri": "http://bridgebio.com/20220630", "presentation": [ "http://bridgebio.com/20220630/taxonomy/role/Role_DisclosureDebtAdditionalInformationDetails" ], "xbrltype": "percentItemType" }, "bbio_NavireBmsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Navire BMS", "label": "Navire BMS [Member]", "terseLabel": "Navire BMS" } } }, "localname": "NavireBmsMember", "nsuri": "http://bridgebio.com/20220630", "presentation": [ "http://bridgebio.com/20220630/taxonomy/role/Role_DisclosureDebtAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "bbio_NavirePharmaIncMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Navire Pharma, Inc.", "label": "Navire Pharma Inc [Member]", "terseLabel": "Navire Pharma, Inc", "verboseLabel": "Navire" } } }, "localname": "NavirePharmaIncMember", "nsuri": "http://bridgebio.com/20220630", "presentation": [ "http://bridgebio.com/20220630/taxonomy/role/DisclosureLicenseAndCollaborationAgreementsAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "bbio_NetIncomeLossExcludingRedeemableNoncontrollingInterestsNetIncomeLoss": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Net income (loss) excluding redeemable noncontrolling interests net income (loss).", "label": "Net Income Loss Excluding Redeemable Noncontrolling Interests Net Income Loss", "terseLabel": "Net income (loss)" } } }, "localname": "NetIncomeLossExcludingRedeemableNoncontrollingInterestsNetIncomeLoss", "nsuri": "http://bridgebio.com/20220630", "presentation": [ "http://bridgebio.com/20220630/taxonomy/role/StatementCondensedConsolidatedStatementsOfRedeemableConvertibleNoncontrollingInterestsAndStockholdersEquityUnaudited" ], "xbrltype": "monetaryItemType" }, "bbio_NetNonCashPortionOfRepurchaseOfNoncontrollingInterests": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Net non-cash portion of repurchase of noncontrolling interests.", "label": "Net Non Cash Portion Of Repurchase Of Noncontrolling Interests", "terseLabel": "Net noncash portion of repurchase of Eidos noncontrolling interests" } } }, "localname": "NetNonCashPortionOfRepurchaseOfNoncontrollingInterests", "nsuri": "http://bridgebio.com/20220630", "presentation": [ "http://bridgebio.com/20220630/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "bbio_NewAccountingPronouncementEffectOfAdoption": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "New accounting pronouncement effect of adoption.", "label": "New Accounting Pronouncement Effect Of Adoption", "terseLabel": "New accounting pronouncement effect of adoption" } } }, "localname": "NewAccountingPronouncementEffectOfAdoption", "nsuri": "http://bridgebio.com/20220630", "presentation": [ "http://bridgebio.com/20220630/taxonomy/role/Role_DisclosureLeasesAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "bbio_NoncashLeaseExpense": { "auth_ref": [], "calculation": { "http://bridgebio.com/20220630/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited": { "order": 3.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Noncash Lease Expense", "label": "Noncash Lease Expense", "terseLabel": "Noncash lease expense" } } }, "localname": "NoncashLeaseExpense", "nsuri": "http://bridgebio.com/20220630", "presentation": [ "http://bridgebio.com/20220630/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "bbio_NoncashOrPartNoncashContributionsMadeByNoncontrollingInterests": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Noncash or Part Noncash contributions made by noncontrolling interests.", "label": "Noncash Or Part Noncash Contributions Made By Noncontrolling Interests", "terseLabel": "Noncash contribution by a noncontrolling interest" } } }, "localname": "NoncashOrPartNoncashContributionsMadeByNoncontrollingInterests", "nsuri": "http://bridgebio.com/20220630", "presentation": [ "http://bridgebio.com/20220630/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "bbio_NoncashOrPartNoncashInvestingTransferFromToNoncontrollingInterest": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Noncash or part noncash investing transfer (from) to noncontrolling interest.", "label": "Noncash Or Part Noncash Investing Transfer From To Noncontrolling Interest", "terseLabel": "Transfers from noncontrolling interests (Note 6)" } } }, "localname": "NoncashOrPartNoncashInvestingTransferFromToNoncontrollingInterest", "nsuri": "http://bridgebio.com/20220630", "presentation": [ "http://bridgebio.com/20220630/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "bbio_NonrefundableUpfrontLicenseFees": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Nonrefundable upfront license fees.", "label": "Nonrefundable Upfront License Fees", "terseLabel": "Nonrefundable upfront license fee" } } }, "localname": "NonrefundableUpfrontLicenseFees", "nsuri": "http://bridgebio.com/20220630", "presentation": [ "http://bridgebio.com/20220630/taxonomy/role/DisclosureLicenseAndCollaborationAgreementsAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "bbio_NonrefundableUpfrontPaymentReceivable": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Nonrefundable upfront payment receivable.", "label": "Nonrefundable Upfront Payment Receivable", "terseLabel": "Nonrefundable upfront payment receivable" } } }, "localname": "NonrefundableUpfrontPaymentReceivable", "nsuri": "http://bridgebio.com/20220630", "presentation": [ "http://bridgebio.com/20220630/taxonomy/role/DisclosureLicenseAndCollaborationAgreementsAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "bbio_NumberOfDirectorsAppointOrRemoval": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number of directors appoint or removal", "label": "Number of directors appoint or removal" } } }, "localname": "NumberOfDirectorsAppointOrRemoval", "nsuri": "http://bridgebio.com/20220630", "presentation": [ "http://bridgebio.com/20220630/taxonomy/role/DisclosureEquityMethodAndOtherEquityInvestmentsAdditionalInformationDetail" ], "xbrltype": "integerItemType" }, "bbio_NumberOfEmployeesForReplacementAwards": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number of employees for replacement awards.", "label": "Number Of Employees For Replacement Awards", "terseLabel": "Number of employees for replacement awards" } } }, "localname": "NumberOfEmployeesForReplacementAwards", "nsuri": "http://bridgebio.com/20220630", "presentation": [ "http://bridgebio.com/20220630/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetails" ], "xbrltype": "integerItemType" }, "bbio_NumberOfOptionsIssuedInExchangeOfSubsidiaryEquity": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number of options issued in exchange of subsidiary equity.", "label": "Number Of Options Issued In Exchange Of Subsidiary Equity", "terseLabel": "Number of options issued in exchange of subsidiary equity" } } }, "localname": "NumberOfOptionsIssuedInExchangeOfSubsidiaryEquity", "nsuri": "http://bridgebio.com/20220630", "presentation": [ "http://bridgebio.com/20220630/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetails" ], "xbrltype": "sharesItemType" }, "bbio_NumberOfPerformanceBasedRestrictedStockAwardsIssuedInExchangeOfSubsidiaryEquity": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number of performance-based restricted stock awards issued in exchange of subsidiary equity.", "label": "Number Of Performance Based Restricted Stock Awards Issued In Exchange Of Subsidiary Equity", "terseLabel": "Number of Performance-Based RSAs issued in exchange of subsidiary equity" } } }, "localname": "NumberOfPerformanceBasedRestrictedStockAwardsIssuedInExchangeOfSubsidiaryEquity", "nsuri": "http://bridgebio.com/20220630", "presentation": [ "http://bridgebio.com/20220630/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetails" ], "xbrltype": "sharesItemType" }, "bbio_NumberOfPerformanceBasedStockOptionsIssuedInExchangeOfSubsidiaryEquity": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number of performance-based stock options issued in exchange of subsidiary equity.", "label": "Number Of Performance Based Stock Options Issued In Exchange Of Subsidiary Equity", "terseLabel": "Number of Performance-Based stock options issued in exchange of subsidiary equity" } } }, "localname": "NumberOfPerformanceBasedStockOptionsIssuedInExchangeOfSubsidiaryEquity", "nsuri": "http://bridgebio.com/20220630", "presentation": [ "http://bridgebio.com/20220630/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetails" ], "xbrltype": "sharesItemType" }, "bbio_NumberOfRestrictedStockAwardsIssuedInExchangeOfSubsidiaryEquity": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number of restricted stock awards issued in exchange of subsidiary equity.", "label": "Number Of Restricted Stock Awards Issued In Exchange Of Subsidiary Equity", "terseLabel": "Number of RSAs issued in exchange of subsidiary equity" } } }, "localname": "NumberOfRestrictedStockAwardsIssuedInExchangeOfSubsidiaryEquity", "nsuri": "http://bridgebio.com/20220630", "presentation": [ "http://bridgebio.com/20220630/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetails" ], "xbrltype": "sharesItemType" }, "bbio_NumberOfRestrictedStockUnitsIssuedInExchangeOfSubsidiaryEquity": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number of restricted stock units issued in exchange of subsidiary equity.", "label": "Number Of Restricted Stock Units Issued In Exchange Of Subsidiary Equity", "terseLabel": "Number of RSUs issued in exchange of subsidiary equity" } } }, "localname": "NumberOfRestrictedStockUnitsIssuedInExchangeOfSubsidiaryEquity", "nsuri": "http://bridgebio.com/20220630", "presentation": [ "http://bridgebio.com/20220630/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetails" ], "xbrltype": "sharesItemType" }, "bbio_NumberOfSharesCoveredByCappedCalls": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number of shares covered by capped calls.", "label": "Number Of Shares Covered By Capped Calls", "terseLabel": "Number of shares covered by capped calls" } } }, "localname": "NumberOfSharesCoveredByCappedCalls", "nsuri": "http://bridgebio.com/20220630", "presentation": [ "http://bridgebio.com/20220630/taxonomy/role/Role_DisclosureDebtAdditionalInformationDetails" ], "xbrltype": "sharesItemType" }, "bbio_NumberOfSharesIssuedInExchangeOfSubsidiaryEquity": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number of shares issued in exchange of subsidiary equity.", "label": "Number Of Shares Issued In Exchange Of Subsidiary Equity", "terseLabel": "Number of shares issued in exchange of subsidiary equity" } } }, "localname": "NumberOfSharesIssuedInExchangeOfSubsidiaryEquity", "nsuri": "http://bridgebio.com/20220630", "presentation": [ "http://bridgebio.com/20220630/taxonomy/role/Role_DisclosureEidosAdditionalInformationDetails", "http://bridgebio.com/20220630/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetails" ], "xbrltype": "sharesItemType" }, "bbio_OneTimeFeesReceivableNoncurrent": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "One time fees receivable noncurrent.", "label": "One Time Fees Receivable Noncurrent", "terseLabel": "One time fees asset non-current" } } }, "localname": "OneTimeFeesReceivableNoncurrent", "nsuri": "http://bridgebio.com/20220630", "presentation": [ "http://bridgebio.com/20220630/taxonomy/role/Role_DisclosureLeasesAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "bbio_OriginAndSentynlTherapeuticsIncMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Origin and sentynl therapeutics, inc.", "label": "Origin and Sentynl Therapeutics, Inc. [Member]", "terseLabel": "Origin-Sentynl APA" } } }, "localname": "OriginAndSentynlTherapeuticsIncMember", "nsuri": "http://bridgebio.com/20220630", "presentation": [ "http://bridgebio.com/20220630/taxonomy/role/DisclosureIntangibleAssetsAdditionalInformationDetails", "http://bridgebio.com/20220630/taxonomy/role/DisclosureSaleOfNonfinancialAssetsAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "bbio_OriginBiosciencesIncMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Origin Biosciences, Inc.", "label": "Origin Biosciences Inc [Member]", "terseLabel": "Origin Biosciences, Inc." } } }, "localname": "OriginBiosciencesIncMember", "nsuri": "http://bridgebio.com/20220630", "presentation": [ "http://bridgebio.com/20220630/taxonomy/role/DisclosureIntangibleAssetsAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "bbio_OtherAccruedLiabilitiesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Other accrued liabilities.", "label": "Other Accrued Liabilities [Member]", "terseLabel": "Other Accrued Liabilities" } } }, "localname": "OtherAccruedLiabilitiesMember", "nsuri": "http://bridgebio.com/20220630", "presentation": [ "http://bridgebio.com/20220630/taxonomy/role/DisclosureRestructuringImpairmentAndRelatedChargesScheduleOfActivityRelatedToRestructuringLiabilitiesAssociatedToRestructuringInitiativesDeta" ], "xbrltype": "domainItemType" }, "bbio_OtherConsolidatedEntitiesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Other Consolidated Entities.", "label": "Other Consolidated Entities [Member]", "terseLabel": "Other Subsidiaries Equity Plan" } } }, "localname": "OtherConsolidatedEntitiesMember", "nsuri": "http://bridgebio.com/20220630", "presentation": [ "http://bridgebio.com/20220630/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfStockBasedCompensationForEmployeesAndNonEmployeesDetails" ], "xbrltype": "domainItemType" }, "bbio_OtherRSAsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Other RSAs", "label": "Other R S As [Member]", "terseLabel": "Other RSAs" } } }, "localname": "OtherRSAsMember", "nsuri": "http://bridgebio.com/20220630", "presentation": [ "http://bridgebio.com/20220630/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfRecognizedStockBasedCompensationExpenseRelatedToRestrictedStockAwardActivityDetails" ], "xbrltype": "domainItemType" }, "bbio_PayableRelatedToManufacturingSuite": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Payable related to manufacturing suite.", "label": "Payable Related To Manufacturing Suite", "verboseLabel": "Remaining payable related to dedicated manufacturing suite" } } }, "localname": "PayableRelatedToManufacturingSuite", "nsuri": "http://bridgebio.com/20220630", "presentation": [ "http://bridgebio.com/20220630/taxonomy/role/Role_DisclosureLeasesAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "bbio_PayableTerminationFeesForOtherExistingServices": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Payable termination fees for other existing services.", "label": "Payable Termination Fees for Other Existing Services", "terseLabel": "Payable related to termination fees for other existing services" } } }, "localname": "PayableTerminationFeesForOtherExistingServices", "nsuri": "http://bridgebio.com/20220630", "presentation": [ "http://bridgebio.com/20220630/taxonomy/role/Role_DisclosureLeasesAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "bbio_PaymentFollowingFDAApprovalOfTruseltiqMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Payment following FDA approval of Truseltiq.", "label": "Payment Following F D A Approval Of Truseltiq [Member]", "terseLabel": "Payment Following FDA Approval of Truseltiq" } } }, "localname": "PaymentFollowingFDAApprovalOfTruseltiqMember", "nsuri": "http://bridgebio.com/20220630", "presentation": [ "http://bridgebio.com/20220630/taxonomy/role/DisclosureIntangibleAssetsAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "bbio_PaymentForAnIntangibleAsset": { "auth_ref": [], "calculation": { "http://bridgebio.com/20220630/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited": { "order": 9.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Payment for an intangible asset.", "label": "Payment for an Intangible Asset", "negatedLabel": "Payment for an intangible asset" } } }, "localname": "PaymentForAnIntangibleAsset", "nsuri": "http://bridgebio.com/20220630", "presentation": [ "http://bridgebio.com/20220630/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "bbio_PaymentInKindInterestAddedToPrincipalOfTermLoan": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Payment-in-kind interest added to principal of term loan.", "label": "Payment-in-kind Interest Added to Principal of Term Loan", "terseLabel": "Payment-in-kind interest added to principal of term loan" } } }, "localname": "PaymentInKindInterestAddedToPrincipalOfTermLoan", "nsuri": "http://bridgebio.com/20220630", "presentation": [ "http://bridgebio.com/20220630/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "bbio_PaymentsOfFirstInstallmentDueAmountRelatedToRegulatoryMilestonePayments": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Payments of first installment due amount related to regulatory milestone payments.", "label": "Payments of First Installment Due Amount Related to Regulatory Milestone Payments", "terseLabel": "First installment due amount, paid" } } }, "localname": "PaymentsOfFirstInstallmentDueAmountRelatedToRegulatoryMilestonePayments", "nsuri": "http://bridgebio.com/20220630", "presentation": [ "http://bridgebio.com/20220630/taxonomy/role/DisclosureIntangibleAssetsAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "bbio_PaymentsToVendor": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Payments to vendor.", "label": "Payments To Vendor", "terseLabel": "Amounts due paid to vendor" } } }, "localname": "PaymentsToVendor", "nsuri": "http://bridgebio.com/20220630", "presentation": [ "http://bridgebio.com/20220630/taxonomy/role/Role_DisclosureLeasesAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "bbio_PercentageOfCashCommissionOnGrossProceedsOfSalesOfCommonStock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Percentage of cash commission on gross proceeds of sales of common stock.", "label": "Percentage Of Cash Commission On Gross Proceeds Of Sales Of Common Stock", "terseLabel": "Percentage of cash commission" } } }, "localname": "PercentageOfCashCommissionOnGrossProceedsOfSalesOfCommonStock", "nsuri": "http://bridgebio.com/20220630", "presentation": [ "http://bridgebio.com/20220630/taxonomy/role/Role_DisclosureEidosAdditionalInformationDetails", "http://bridgebio.com/20220630/taxonomy/role/Role_DisclosureShareRepurchaseProgramAndShelfRegistrationAdditionalInformationDetails" ], "xbrltype": "percentItemType" }, "bbio_PercentageOfPrincipalAmountToBeRepurchasedInFundamentalChange": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Percentage of principal amount to be repurchased in fundamental change.", "label": "Percentage Of Principal Amount To Be Repurchased In Fundamental Change", "terseLabel": "Percentage of principal amount to be repurchased in fundamental change" } } }, "localname": "PercentageOfPrincipalAmountToBeRepurchasedInFundamentalChange", "nsuri": "http://bridgebio.com/20220630", "presentation": [ "http://bridgebio.com/20220630/taxonomy/role/Role_DisclosureDebtAdditionalInformationDetails" ], "xbrltype": "percentItemType" }, "bbio_PercentageShareOfGlobalDevelopmentCosts": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Percentage share of global development costs.", "label": "Percentage Share Of Global Development Costs", "terseLabel": "Percentage share of global development costs" } } }, "localname": "PercentageShareOfGlobalDevelopmentCosts", "nsuri": "http://bridgebio.com/20220630", "presentation": [ "http://bridgebio.com/20220630/taxonomy/role/DisclosureLicenseAndCollaborationAgreementsAdditionalInformationDetails" ], "xbrltype": "percentItemType" }, "bbio_PerformanceBasedMilestoneAwards": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Performance-based milestone awards.", "label": "Performance Based Milestone Awards", "terseLabel": "Performance-based milestone awards" } } }, "localname": "PerformanceBasedMilestoneAwards", "nsuri": "http://bridgebio.com/20220630", "presentation": [ "http://bridgebio.com/20220630/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "bbio_PerformanceBasedMilestoneAwardsCompensationExpense": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Performance based milestone awards compensation expense.", "label": "Performance Based Milestone Awards Compensation Expense", "terseLabel": "Performance-based milestone awards compensation expense" } } }, "localname": "PerformanceBasedMilestoneAwardsCompensationExpense", "nsuri": "http://bridgebio.com/20220630", "presentation": [ "http://bridgebio.com/20220630/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "bbio_PerformanceBasedMilestoneAwardsCompensationExpenseSettledWithEquity": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Performance based milestone awards compensation expense settled with equity.", "label": "Performance Based Milestone Awards Compensation Expense Settled With Equity", "terseLabel": "Performance based milestone awards compensation expense settled with equity" } } }, "localname": "PerformanceBasedMilestoneAwardsCompensationExpenseSettledWithEquity", "nsuri": "http://bridgebio.com/20220630", "presentation": [ "http://bridgebio.com/20220630/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "bbio_PerformanceBasedMilestoneAwardsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Performance-based milestone awards.", "label": "Performance-Based Milestone Awards [Member]", "terseLabel": "Performance-Based Milestone Awards" } } }, "localname": "PerformanceBasedMilestoneAwardsMember", "nsuri": "http://bridgebio.com/20220630", "presentation": [ "http://bridgebio.com/20220630/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "bbio_PerformanceBasedMilestoneAwardsPeriodForRecognition": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Performance based milestone awards period for recognition.", "label": "Performance Based Milestone Awards Period For Recognition", "terseLabel": "Performance-based milestone awards period for recognition" } } }, "localname": "PerformanceBasedMilestoneAwardsPeriodForRecognition", "nsuri": "http://bridgebio.com/20220630", "presentation": [ "http://bridgebio.com/20220630/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetails" ], "xbrltype": "durationItemType" }, "bbio_PerformanceBasedRestrictedStockAwardsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Performance based restricted stock awards.", "label": "Performance Based Restricted Stock Awards [Member]", "verboseLabel": "Performance-Based RSAs" } } }, "localname": "PerformanceBasedRestrictedStockAwardsMember", "nsuri": "http://bridgebio.com/20220630", "presentation": [ "http://bridgebio.com/20220630/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "bbio_PerformanceBasedStockOptionsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Performance based stock options.", "label": "Performance Based Stock Options [Member]", "terseLabel": "Performance-Based Stock Options" } } }, "localname": "PerformanceBasedStockOptionsMember", "nsuri": "http://bridgebio.com/20220630", "presentation": [ "http://bridgebio.com/20220630/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "bbio_PotentialMilestoneAccruedAmountSettlementInCash": { "auth_ref": [], "calculation": { "http://bridgebio.com/20220630/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesScheduleOfPotentialMilestoneAmountsAndAccrualsDetail": { "order": 0.0, "parentTag": "bbio_PotentialMilestoneAccruedSettlementAmount", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Potential milestone accrued amount settlement in cash.", "label": "Potential Milestone Accrued Amount Settlement In Cash", "terseLabel": "Accrued Amount Settlement in Cash" } } }, "localname": "PotentialMilestoneAccruedAmountSettlementInCash", "nsuri": "http://bridgebio.com/20220630", "presentation": [ "http://bridgebio.com/20220630/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesScheduleOfPotentialMilestoneAmountsAndAccrualsDetail" ], "xbrltype": "monetaryItemType" }, "bbio_PotentialMilestoneAccruedAmountSettlementInCashOrStockAtSoleDiscretion": { "auth_ref": [], "calculation": { "http://bridgebio.com/20220630/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesScheduleOfPotentialMilestoneAmountsAndAccrualsDetail": { "order": 2.0, "parentTag": "bbio_PotentialMilestoneAccruedSettlementAmount", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Potential milestone accrued amount settlement in cash or stock at sole discretion.", "label": "Potential Milestone Accrued Amount Settlement In Cash Or Stock At Sole Discretion", "terseLabel": "Accrued Amount Settlement in Cash or stock at our sole discretion" } } }, "localname": "PotentialMilestoneAccruedAmountSettlementInCashOrStockAtSoleDiscretion", "nsuri": "http://bridgebio.com/20220630", "presentation": [ "http://bridgebio.com/20220630/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesScheduleOfPotentialMilestoneAmountsAndAccrualsDetail" ], "xbrltype": "monetaryItemType" }, "bbio_PotentialMilestoneAccruedAmountSettlementInStock": { "auth_ref": [], "calculation": { "http://bridgebio.com/20220630/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesScheduleOfPotentialMilestoneAmountsAndAccrualsDetail": { "order": 1.0, "parentTag": "bbio_PotentialMilestoneAccruedSettlementAmount", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Potential milestone accrued amount settlement in stock.", "label": "Potential Milestone Accrued Amount Settlement In Stock", "terseLabel": "Accrued Amount Settlement in Stock" } } }, "localname": "PotentialMilestoneAccruedAmountSettlementInStock", "nsuri": "http://bridgebio.com/20220630", "presentation": [ "http://bridgebio.com/20220630/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesScheduleOfPotentialMilestoneAmountsAndAccrualsDetail" ], "xbrltype": "monetaryItemType" }, "bbio_PotentialMilestoneAccruedSettlementAmount": { "auth_ref": [], "calculation": { "http://bridgebio.com/20220630/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesScheduleOfPotentialMilestoneAmountsAndAccrualsDetail": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Potential milestone accrued settlement amount.", "label": "Potential Milestone Accrued Settlement Amount", "totalLabel": "Total Accrued Settlement Amount" } } }, "localname": "PotentialMilestoneAccruedSettlementAmount", "nsuri": "http://bridgebio.com/20220630", "presentation": [ "http://bridgebio.com/20220630/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesScheduleOfPotentialMilestoneAmountsAndAccrualsDetail" ], "xbrltype": "monetaryItemType" }, "bbio_PotentialMilestoneFixedMonetaryAmountSettlementInCash": { "auth_ref": [], "calculation": { "http://bridgebio.com/20220630/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesScheduleOfPotentialMilestoneAmountsAndAccrualsDetail": { "order": 0.0, "parentTag": "bbio_PotentialMilestoneFixedMonetarySettlementAmount", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Potential milestone fixed monetary amount settlement in cash.", "label": "Potential Milestone Fixed Monetary Amount Settlement In Cash", "terseLabel": "Potential Fixed Monetary Amount Settlement in Cash" } } }, "localname": "PotentialMilestoneFixedMonetaryAmountSettlementInCash", "nsuri": "http://bridgebio.com/20220630", "presentation": [ "http://bridgebio.com/20220630/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesScheduleOfPotentialMilestoneAmountsAndAccrualsDetail" ], "xbrltype": "monetaryItemType" }, "bbio_PotentialMilestoneFixedMonetaryAmountSettlementInCashOrStockAtSoleDiscretion": { "auth_ref": [], "calculation": { "http://bridgebio.com/20220630/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesScheduleOfPotentialMilestoneAmountsAndAccrualsDetail": { "order": 2.0, "parentTag": "bbio_PotentialMilestoneFixedMonetarySettlementAmount", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Potential milestone fixed monetary amount settlement in cash or stock at sole discretion.", "label": "Potential Milestone Fixed Monetary Amount Settlement In Cash Or Stock At Sole Discretion", "terseLabel": "Potential Fixed Monetary Amount Settlement in Cash or stock at our sole discretion" } } }, "localname": "PotentialMilestoneFixedMonetaryAmountSettlementInCashOrStockAtSoleDiscretion", "nsuri": "http://bridgebio.com/20220630", "presentation": [ "http://bridgebio.com/20220630/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesScheduleOfPotentialMilestoneAmountsAndAccrualsDetail" ], "xbrltype": "monetaryItemType" }, "bbio_PotentialMilestoneFixedMonetaryAmountSettlementInStock": { "auth_ref": [], "calculation": { "http://bridgebio.com/20220630/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesScheduleOfPotentialMilestoneAmountsAndAccrualsDetail": { "order": 1.0, "parentTag": "bbio_PotentialMilestoneFixedMonetarySettlementAmount", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Potential milestone fixed monetary amount settlement in stock.", "label": "Potential Milestone Fixed Monetary Amount Settlement In Stock", "terseLabel": "Potential Fixed Monetary Amount Settlement in Stock" } } }, "localname": "PotentialMilestoneFixedMonetaryAmountSettlementInStock", "nsuri": "http://bridgebio.com/20220630", "presentation": [ "http://bridgebio.com/20220630/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesScheduleOfPotentialMilestoneAmountsAndAccrualsDetail" ], "xbrltype": "monetaryItemType" }, "bbio_PotentialMilestoneFixedMonetarySettlementAmount": { "auth_ref": [], "calculation": { "http://bridgebio.com/20220630/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesScheduleOfPotentialMilestoneAmountsAndAccrualsDetail": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Potential milestone fixed monetary settlement amount.", "label": "Potential Milestone Fixed Monetary Settlement Amount", "totalLabel": "Total Potential Fixed Monetary Settlement Amount" } } }, "localname": "PotentialMilestoneFixedMonetarySettlementAmount", "nsuri": "http://bridgebio.com/20220630", "presentation": [ "http://bridgebio.com/20220630/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesScheduleOfPotentialMilestoneAmountsAndAccrualsDetail" ], "xbrltype": "monetaryItemType" }, "bbio_PotentialMilestonePayments": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Potential milestone payments.", "label": "Potential Milestone Payments", "terseLabel": "Milestone payments" } } }, "localname": "PotentialMilestonePayments", "nsuri": "http://bridgebio.com/20220630", "presentation": [ "http://bridgebio.com/20220630/taxonomy/role/DisclosureLicenseAndCollaborationAgreementsAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "bbio_PotentialRegulatoryMilestonePayments": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Potential regulatory milestone payments.", "label": "Potential Regulatory Milestone Payments", "terseLabel": "Potential regulatory milestone payments" } } }, "localname": "PotentialRegulatoryMilestonePayments", "nsuri": "http://bridgebio.com/20220630", "presentation": [ "http://bridgebio.com/20220630/taxonomy/role/DisclosureIntangibleAssetsAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "bbio_PotentialSalesMilestonePayments": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Potential sales milestone payments.", "label": "Potential Sales Milestone Payments", "terseLabel": "Potential sales milestone payments" } } }, "localname": "PotentialSalesMilestonePayments", "nsuri": "http://bridgebio.com/20220630", "presentation": [ "http://bridgebio.com/20220630/taxonomy/role/DisclosureIntangibleAssetsAdditionalInformationDetails", "http://bridgebio.com/20220630/taxonomy/role/DisclosureSaleOfNonfinancialAssetsAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "bbio_PreTaxImpairmentGainLossOnAsset": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Pre-tax impairment gain (loss) on asset.", "label": "Pre-tax Impairment Gain (Loss) on Asset", "terseLabel": "Pre-tax impairment loss on asset" } } }, "localname": "PreTaxImpairmentGainLossOnAsset", "nsuri": "http://bridgebio.com/20220630", "presentation": [ "http://bridgebio.com/20220630/taxonomy/role/Role_DisclosureLeasesAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "bbio_PreferredStockOwnershipPercentage": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Preferred stock ownership percentage.", "label": "Preferred Stock Ownership Percentage", "terseLabel": "Preferred stock ownership percentage" } } }, "localname": "PreferredStockOwnershipPercentage", "nsuri": "http://bridgebio.com/20220630", "presentation": [ "http://bridgebio.com/20220630/taxonomy/role/DisclosureEquityMethodAndOtherEquityInvestmentsAdditionalInformationDetail" ], "xbrltype": "percentItemType" }, "bbio_PrincipalValueAndInterestOnTwoPointFiveZeroPercentageConvertibleSeniorNotesDueTwoThousandAndTwentySevenMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Principal value and interest on two point five zero percentage convertible senior notes due two thousand and twenty seven.", "label": "Principal Value And Interest On Two Point Five Zero Percentage Convertible Senior Notes Due Two Thousand And Twenty Seven [Member]", "terseLabel": "2027 Notes and Interest on 2027 Notes" } } }, "localname": "PrincipalValueAndInterestOnTwoPointFiveZeroPercentageConvertibleSeniorNotesDueTwoThousandAndTwentySevenMember", "nsuri": "http://bridgebio.com/20220630", "presentation": [ "http://bridgebio.com/20220630/taxonomy/role/Role_DisclosureDebtScheduleOfFutureMinimumPaymentsUnderNotesDetails" ], "xbrltype": "domainItemType" }, "bbio_PrincipalValueAndInterestOnTwoPointTwoFivePercentageConvertibleSeniorNotesDueTwoThousandAndTwentyNineMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Principal value and interest on two point two five percentage convertible senior notes due two thousand and twenty nine.", "label": "Principal Value And Interest On Two Point Two Five Percentage Convertible Senior Notes Due Two Thousand And Twenty Nine [Member]", "terseLabel": "2029 Notes and Interest on 2029 Notes" } } }, "localname": "PrincipalValueAndInterestOnTwoPointTwoFivePercentageConvertibleSeniorNotesDueTwoThousandAndTwentyNineMember", "nsuri": "http://bridgebio.com/20220630", "presentation": [ "http://bridgebio.com/20220630/taxonomy/role/Role_DisclosureDebtScheduleOfFutureMinimumPaymentsUnderNotesDetails" ], "xbrltype": "domainItemType" }, "bbio_PrincipalValueAndInterestOnTwoThousandAndTwentySevenAndTwoThousandAndTwentyNineMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Principal value and interest on two thousand and twenty seven and two thousand and twenty nine.", "label": "Principal Value and Interest on Two Thousand and Twenty Seven and Two Thousand and Twenty Nine [Member]", "terseLabel": "2027 Notes and Interest on 2027 Notes and 2029 Notes and Interest on 2029 Notes" } } }, "localname": "PrincipalValueAndInterestOnTwoThousandAndTwentySevenAndTwoThousandAndTwentyNineMember", "nsuri": "http://bridgebio.com/20220630", "presentation": [ "http://bridgebio.com/20220630/taxonomy/role/Role_DisclosureDebtScheduleOfFutureMinimumPaymentsUnderNotesDetails" ], "xbrltype": "domainItemType" }, "bbio_PrincipalValueInterestOnTermLoansAndExitFeeOfTermLoanAgreementMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Principal value interest on term loans and exit fee of term loan agreement.", "label": "Principal Value Interest on Term Loans and Exit Fee of Term Loan Agreement [Member]", "terseLabel": "Term Loans, Interest on Term Loans and Exit Fee of Term Loan Agreement" } } }, "localname": "PrincipalValueInterestOnTermLoansAndExitFeeOfTermLoanAgreementMember", "nsuri": "http://bridgebio.com/20220630", "presentation": [ "http://bridgebio.com/20220630/taxonomy/role/DisclosureDebtScheduleOfFutureMinimumPaymentsUnderTermLoanAgreementDetails" ], "xbrltype": "domainItemType" }, "bbio_PrincipalValueOfConvertibleSeniorNotesDueTwoThousandAndTwentyNineAndTwoThousandAndTwentySevenMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Principal value of convertible senior notes due two thousand and twenty nine and two thousand and twenty seven.", "label": "Principal Value Of Convertible Senior Notes Due Two Thousand And Twenty Nine And Two Thousand And Twenty Seven [Member]", "terseLabel": "2029 Notes and 2027 Notes" } } }, "localname": "PrincipalValueOfConvertibleSeniorNotesDueTwoThousandAndTwentyNineAndTwoThousandAndTwentySevenMember", "nsuri": "http://bridgebio.com/20220630", "presentation": [ "http://bridgebio.com/20220630/taxonomy/role/Role_DisclosureDebtScheduleOfFutureMinimumPaymentsUnderNotesDetails" ], "xbrltype": "domainItemType" }, "bbio_PrincipalValueOfTwoPointFiveZeroPercentageConvertibleSeniorNotesDueTwoThousandAndTwentySevenMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Principal value of two point five zero percentage convertible senior notes due two thousand and twenty seven.", "label": "Principal Value Of Two Point Five Zero Percentage Convertible Senior Notes Due Two Thousand And Twenty Seven [Member]", "terseLabel": "2027 Notes" } } }, "localname": "PrincipalValueOfTwoPointFiveZeroPercentageConvertibleSeniorNotesDueTwoThousandAndTwentySevenMember", "nsuri": "http://bridgebio.com/20220630", "presentation": [ "http://bridgebio.com/20220630/taxonomy/role/Role_DisclosureDebtScheduleOfFutureMinimumPaymentsUnderNotesDetails" ], "xbrltype": "domainItemType" }, "bbio_PrincipalValueOnTwoPointTwoFivePercentageConvertibleSeniorNotesDueTwoThousandAndTwentyNineMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Principal value on two point two five percentage convertible senior notes due two thousand and twenty nine.", "label": "Principal Value On Two Point Two Five Percentage Convertible Senior Notes Due Two Thousand And Twenty Nine [Member]", "terseLabel": "2029 Notes" } } }, "localname": "PrincipalValueOnTwoPointTwoFivePercentageConvertibleSeniorNotesDueTwoThousandAndTwentyNineMember", "nsuri": "http://bridgebio.com/20220630", "presentation": [ "http://bridgebio.com/20220630/taxonomy/role/Role_DisclosureDebtScheduleOfFutureMinimumPaymentsUnderNotesDetails" ], "xbrltype": "domainItemType" }, "bbio_PrincipleAmountPaidToLenders": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Principle amount paid to lenders.", "label": "Principle Amount Paid To Lenders", "terseLabel": "Principle amount paid to lenders" } } }, "localname": "PrincipleAmountPaidToLenders", "nsuri": "http://bridgebio.com/20220630", "presentation": [ "http://bridgebio.com/20220630/taxonomy/role/Role_DisclosureDebtAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "bbio_PriorityReviewVoucherMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Priority Review Voucher.", "label": "Priority Review Voucher [Member]", "terseLabel": "Priority Review Voucher" } } }, "localname": "PriorityReviewVoucherMember", "nsuri": "http://bridgebio.com/20220630", "presentation": [ "http://bridgebio.com/20220630/taxonomy/role/DisclosureSaleOfNonfinancialAssetsAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "bbio_ProceedsFromConsolidationOfEntities": { "auth_ref": [], "calculation": { "http://bridgebio.com/20220630/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited": { "order": 6.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Proceeds from consolidation of entities.", "label": "Proceeds From Consolidation Of Entities", "terseLabel": "Increase in cash and cash equivalents from consolidation of PellePharm" } } }, "localname": "ProceedsFromConsolidationOfEntities", "nsuri": "http://bridgebio.com/20220630", "presentation": [ "http://bridgebio.com/20220630/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "bbio_ProceedsFromIssuanceOfNoncontrollingInterest": { "auth_ref": [], "calculation": { "http://bridgebio.com/20220630/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited": { "order": 6.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Proceeds from issuance of noncontrolling interest.", "label": "Proceeds From Issuance Of Noncontrolling Interest", "terseLabel": "Transactions with noncontrolling interests" } } }, "localname": "ProceedsFromIssuanceOfNoncontrollingInterest", "nsuri": "http://bridgebio.com/20220630", "presentation": [ "http://bridgebio.com/20220630/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "bbio_ProceedsFromIssuanceOfNotesAfterDeductingDiscountAndOfferingExpenses": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Proceeds from issuance of notes after deducting discount and offering expenses.", "label": "Proceeds From Issuance Of Notes After Deducting Discount And Offering Expenses", "terseLabel": "Proceeds from issuance of notes after deducting discount and offering expenses" } } }, "localname": "ProceedsFromIssuanceOfNotesAfterDeductingDiscountAndOfferingExpenses", "nsuri": "http://bridgebio.com/20220630", "presentation": [ "http://bridgebio.com/20220630/taxonomy/role/Role_DisclosureDebtAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "bbio_ProceedsFromIssuanceOfTermLoansAfterDeductingDebtDiscountAndIssuanceCosts": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Proceeds from issuance of term loans after deducting debt discount and issuance costs.", "label": "Proceeds from Issuance of Term Loans After Deducting Debt Discount and Issuance Costs", "terseLabel": "Proceeds from issuance of Term Loans after deducting debt discount and issuance costs" } } }, "localname": "ProceedsFromIssuanceOfTermLoansAfterDeductingDebtDiscountAndIssuanceCosts", "nsuri": "http://bridgebio.com/20220630", "presentation": [ "http://bridgebio.com/20220630/taxonomy/role/Role_DisclosureDebtAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "bbio_ProceedsFromSaleOfPriorityReviewVoucher": { "auth_ref": [], "calculation": { "http://bridgebio.com/20220630/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited": { "order": 7.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Proceeds from sale of priority review voucher.", "label": "Proceeds From Sale Of Priority Review Voucher", "terseLabel": "Proceeds from sale of priority review voucher" } } }, "localname": "ProceedsFromSaleOfPriorityReviewVoucher", "nsuri": "http://bridgebio.com/20220630", "presentation": [ "http://bridgebio.com/20220630/taxonomy/role/DisclosureSaleOfNonfinancialAssetsAdditionalInformationDetails", "http://bridgebio.com/20220630/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "bbio_PurchaseOfCappedCalls": { "auth_ref": [], "calculation": { "http://bridgebio.com/20220630/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited": { "order": 3.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Purchase of capped calls.", "label": "Purchase Of Capped Calls", "negatedLabel": "Purchase of capped calls", "terseLabel": "Purchase of capped calls" } } }, "localname": "PurchaseOfCappedCalls", "nsuri": "http://bridgebio.com/20220630", "presentation": [ "http://bridgebio.com/20220630/taxonomy/role/Role_DisclosureDebtAdditionalInformationDetails", "http://bridgebio.com/20220630/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "bbio_QEDTherapeuticsIncMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "QED Therapeutics, Inc.", "label": "Q E D Therapeutics Inc [Member]", "terseLabel": "QED Therapeutics, Inc" } } }, "localname": "QEDTherapeuticsIncMember", "nsuri": "http://bridgebio.com/20220630", "presentation": [ "http://bridgebio.com/20220630/taxonomy/role/DisclosureIntangibleAssetsAdditionalInformationDetails", "http://bridgebio.com/20220630/taxonomy/role/DisclosureLicenseAndCollaborationAgreementsAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "bbio_ReceivableFromLicensingAndCollaborationAgreementsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Receivable from licensing and collaboration agreements.", "label": "Receivable from Licensing and Collaboration Agreements [Member]" } } }, "localname": "ReceivableFromLicensingAndCollaborationAgreementsMember", "nsuri": "http://bridgebio.com/20220630", "presentation": [ "http://bridgebio.com/20220630/taxonomy/role/DisclosureLicenseAndCollaborationAgreementsAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "bbio_ReclassificationOfFinalPaymentObligationRelatedToManufacturingAgreementRecognizedInPriorPeriod": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Reclassification of final payment obligation related to manufacturing agreement recognized in prior period.", "label": "Reclassification Of Final Payment Obligation Related To Manufacturing Agreement Recognized in Prior Period", "terseLabel": "Reclassification of final payment obligation related to a manufacturing agreement that was recognized in the prior period (see Note 14)" } } }, "localname": "ReclassificationOfFinalPaymentObligationRelatedToManufacturingAgreementRecognizedInPriorPeriod", "nsuri": "http://bridgebio.com/20220630", "presentation": [ "http://bridgebio.com/20220630/taxonomy/role/DisclosureRestructuringImpairmentAndRelatedChargesScheduleOfActivityRelatedToRestructuringLiabilitiesAssociatedToRestructuringInitiativesDeta" ], "xbrltype": "monetaryItemType" }, "bbio_RecognizedIntangibleAssetRecordedInAccruedResearchAndDevelopmentLiabilities": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Recognized intangible asset recorded in Accrued research and development liabilities.", "label": "Recognized Intangible Asset Recorded In Accrued Research And Development Liabilities", "terseLabel": "Recognized intangible asset recorded in \"Accrued research and development liabilities\"" } } }, "localname": "RecognizedIntangibleAssetRecordedInAccruedResearchAndDevelopmentLiabilities", "nsuri": "http://bridgebio.com/20220630", "presentation": [ "http://bridgebio.com/20220630/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "bbio_RedeemableConvertibleNoncontrollingInterestsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Redeemable convertible noncontrolling interests.", "label": "Redeemable Convertible Noncontrolling Interests [Member]", "terseLabel": "Redeemable Convertible Noncontrolling Interests" } } }, "localname": "RedeemableConvertibleNoncontrollingInterestsMember", "nsuri": "http://bridgebio.com/20220630", "presentation": [ "http://bridgebio.com/20220630/taxonomy/role/StatementCondensedConsolidatedStatementsOfRedeemableConvertibleNoncontrollingInterestsAndStockholdersEquityUnaudited" ], "xbrltype": "domainItemType" }, "bbio_RegularEquityProgramMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Regular equity program member.", "label": "Regular Equity Program Member", "terseLabel": "Regular Equity Program" } } }, "localname": "RegularEquityProgramMember", "nsuri": "http://bridgebio.com/20220630", "presentation": [ "http://bridgebio.com/20220630/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfRestrictedStockAwardActivityUnderPlansDetails", "http://bridgebio.com/20220630/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfStockOptionActivityUnderPlansDetails" ], "xbrltype": "domainItemType" }, "bbio_RegulatoryAndSalesBasedMilestonePaymentsYetToBeReceived": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Regulatory and sales-based milestone payments yet to be received.", "label": "Regulatory and Sales-based Milestone Payments Yet to be Received", "terseLabel": "Regulatory and sales-based milestone payments yet to be received" } } }, "localname": "RegulatoryAndSalesBasedMilestonePaymentsYetToBeReceived", "nsuri": "http://bridgebio.com/20220630", "presentation": [ "http://bridgebio.com/20220630/taxonomy/role/DisclosureLicenseAndCollaborationAgreementsAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "bbio_RegulatoryMilestonePaymentsTerm": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Regulatory milestone payments term.", "label": "Regulatory Milestone Payments Term", "terseLabel": "Regulatory milestone payments term" } } }, "localname": "RegulatoryMilestonePaymentsTerm", "nsuri": "http://bridgebio.com/20220630", "presentation": [ "http://bridgebio.com/20220630/taxonomy/role/DisclosureIntangibleAssetsAdditionalInformationDetails" ], "xbrltype": "durationItemType" }, "bbio_ReimbursementPercentageOfCommercialActivityCostsIncurred": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Reimbursement percentage of commercial activity costs incurred.", "label": "Reimbursement Percentage of Commercial Activity Costs Incurred", "terseLabel": "Reimbursement percentage of commercial activity costs incurred" } } }, "localname": "ReimbursementPercentageOfCommercialActivityCostsIncurred", "nsuri": "http://bridgebio.com/20220630", "presentation": [ "http://bridgebio.com/20220630/taxonomy/role/DisclosureLicenseAndCollaborationAgreementsAdditionalInformationDetails" ], "xbrltype": "percentItemType" }, "bbio_ReimbursementPercentageOfResearchAndDevelopmentCostsIncurred": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Reimbursement percentage of research and development costs incurred.", "label": "Reimbursement Percentage of Research and Development Costs Incurred", "terseLabel": "Reimbursement percentage of research and development costs incurred" } } }, "localname": "ReimbursementPercentageOfResearchAndDevelopmentCostsIncurred", "nsuri": "http://bridgebio.com/20220630", "presentation": [ "http://bridgebio.com/20220630/taxonomy/role/DisclosureLicenseAndCollaborationAgreementsAdditionalInformationDetails" ], "xbrltype": "percentItemType" }, "bbio_RepurchaseOfNoncontrollingInterestIncludingDirectTransactionCosts": { "auth_ref": [], "calculation": { "http://bridgebio.com/20220630/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited": { "order": 7.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Repurchase of noncontrolling interest including direct transaction costs.", "label": "Repurchase Of Noncontrolling Interest Including Direct Transaction Costs", "negatedLabel": "Repurchase of Eidos noncontrolling interest, including direct transaction costs" } } }, "localname": "RepurchaseOfNoncontrollingInterestIncludingDirectTransactionCosts", "nsuri": "http://bridgebio.com/20220630", "presentation": [ "http://bridgebio.com/20220630/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "bbio_RepurchaseOfNoncontrollingInterestsForCashAndSharesIncludingTransactionCostsShares": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Repurchase of noncontrolling interests for cash and shares, including transaction costs shares.", "label": "Repurchase Of Noncontrolling Interests For Cash And Shares Including Transaction Costs Shares", "terseLabel": "Repurchase of noncontrolling interests for cash and shares, including transaction costs shares" } } }, "localname": "RepurchaseOfNoncontrollingInterestsForCashAndSharesIncludingTransactionCostsShares", "nsuri": "http://bridgebio.com/20220630", "presentation": [ "http://bridgebio.com/20220630/taxonomy/role/StatementCondensedConsolidatedStatementsOfRedeemableConvertibleNoncontrollingInterestsAndStockholdersEquityUnaudited" ], "xbrltype": "sharesItemType" }, "bbio_RepurchaseOfNoncontrollingInterestsTransactionCosts": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Repurchase of noncontrolling interests transaction costs.", "label": "Repurchase Of Noncontrolling Interests Transaction Costs", "terseLabel": "Repurchase of Eidos noncontrolling interests for cash and shares, transaction costs" } } }, "localname": "RepurchaseOfNoncontrollingInterestsTransactionCosts", "nsuri": "http://bridgebio.com/20220630", "presentation": [ "http://bridgebio.com/20220630/taxonomy/role/StatementCondensedConsolidatedStatementsOfRedeemableConvertibleNoncontrollingInterestsAndStockholdersEquityUnauditedParenthetical" ], "xbrltype": "monetaryItemType" }, "bbio_RestructuringImpairmentAndRelatedChargesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Restructuring, impairment and related charges.", "label": "Restructuring, Impairment and Related Charges [Member]", "terseLabel": "Restructuring, Impairment and Related Charges" } } }, "localname": "RestructuringImpairmentAndRelatedChargesMember", "nsuri": "http://bridgebio.com/20220630", "presentation": [ "http://bridgebio.com/20220630/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfStockBasedCompensationForEmployeesAndNonEmployeesDetails" ], "xbrltype": "domainItemType" }, "bbio_RisksAndUncertaintiesPolicyTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Risks and uncertainties policy.", "label": "Risks And Uncertainties Policy [Text Block]", "terseLabel": "Risks and Uncertainties" } } }, "localname": "RisksAndUncertaintiesPolicyTextBlock", "nsuri": "http://bridgebio.com/20220630", "presentation": [ "http://bridgebio.com/20220630/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "bbio_SaleOfExistingInventory": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Sale of existing inventory.", "label": "Sale Of Existing Inventory", "terseLabel": "Sale of certain existing inventory" } } }, "localname": "SaleOfExistingInventory", "nsuri": "http://bridgebio.com/20220630", "presentation": [ "http://bridgebio.com/20220630/taxonomy/role/DisclosureLicenseAndCollaborationAgreementsAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "bbio_SaleOfNonfinancialAssetsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Sale of Nonfinancial Assets.", "label": "Sale of Nonfinancial Assets [Abstract]" } } }, "localname": "SaleOfNonfinancialAssetsAbstract", "nsuri": "http://bridgebio.com/20220630", "xbrltype": "stringItemType" }, "bbio_SaleOfNonfinancialAssetsTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Sale of Nonfinancial Assets.", "label": "Sale of Nonfinancial Assets [Text Block]", "terseLabel": "Sale of Nonfinancial Assets" } } }, "localname": "SaleOfNonfinancialAssetsTextBlock", "nsuri": "http://bridgebio.com/20220630", "presentation": [ "http://bridgebio.com/20220630/taxonomy/role/DisclosureSaleOfNonfinancialAssets1" ], "xbrltype": "textBlockItemType" }, "bbio_SaleOfStockPremiumOverLastReportedSalePricePercentage": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Sale of stock premium over last reported sale price percentage.", "label": "Sale Of Stock Premium Over Last Reported Sale Price Percentage", "terseLabel": "Premium over last reported sale price percentage" } } }, "localname": "SaleOfStockPremiumOverLastReportedSalePricePercentage", "nsuri": "http://bridgebio.com/20220630", "presentation": [ "http://bridgebio.com/20220630/taxonomy/role/Role_DisclosureDebtAdditionalInformationDetails" ], "xbrltype": "percentItemType" }, "bbio_SalesOfNonfinancialAssetsPolicyTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Sales of nonfinancial assets.", "label": "Sales of Nonfinancial Assets Policy Text Block", "terseLabel": "Sales of Nonfinancial Assets" } } }, "localname": "SalesOfNonfinancialAssetsPolicyTextBlock", "nsuri": "http://bridgebio.com/20220630", "presentation": [ "http://bridgebio.com/20220630/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "bbio_SatisfyTaxWithholdingMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Satisfy tax withholding.", "label": "Satisfy Tax Withholding [Member]", "terseLabel": "Satisfy Tax Withholding" } } }, "localname": "SatisfyTaxWithholdingMember", "nsuri": "http://bridgebio.com/20220630", "presentation": [ "http://bridgebio.com/20220630/taxonomy/role/StatementCondensedConsolidatedStatementsOfRedeemableConvertibleNoncontrollingInterestsAndStockholdersEquityUnaudited" ], "xbrltype": "domainItemType" }, "bbio_ScheduleOfCashEquivalentsAndMarketableSecuritiesTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Schedule of cash equivalents and marketable securities.", "label": "Schedule Of Cash Equivalents And Marketable Securities Table [Text Block]", "terseLabel": "Schedule of Cash Equivalent and Marketable Securities Classified as Available-for-Sale" } } }, "localname": "ScheduleOfCashEquivalentsAndMarketableSecuritiesTableTextBlock", "nsuri": "http://bridgebio.com/20220630", "presentation": [ "http://bridgebio.com/20220630/taxonomy/role/Role_DisclosureCashEquivalentsAndMarketableSecuritiesTables" ], "xbrltype": "textBlockItemType" }, "bbio_ScheduleOfEmployeesAndNonEmployeesServiceShareBasedCompensationTable": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Schedule of employees and non-employees service share-based compensation.", "label": "Schedule Of Employees And Non Employees Service Share Based Compensation [Table]", "terseLabel": "Schedule Of Employees And Non Employees Service Share Based Compensation [Table]" } } }, "localname": "ScheduleOfEmployeesAndNonEmployeesServiceShareBasedCompensationTable", "nsuri": "http://bridgebio.com/20220630", "presentation": [ "http://bridgebio.com/20220630/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfStockBasedCompensationForEmployeesAndNonEmployeesDetails" ], "xbrltype": "stringItemType" }, "bbio_ScheduleOfFutureMinimumLeasePaymentsForNoncancelableOperatingAndFinanceLeasesTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Schedule of future minimum lease payments for noncancelable operating and finance leases.", "label": "Schedule Of Future Minimum Lease Payments For Noncancelable Operating And Finance Leases Table [Text Block]", "terseLabel": "Schedule of Future Minimum Lease Payments for Noncancelable Leases" } } }, "localname": "ScheduleOfFutureMinimumLeasePaymentsForNoncancelableOperatingAndFinanceLeasesTableTextBlock", "nsuri": "http://bridgebio.com/20220630", "presentation": [ "http://bridgebio.com/20220630/taxonomy/role/Role_DisclosureLeasesTables" ], "xbrltype": "textBlockItemType" }, "bbio_ScheduleOfInterestExpenseRecognizedAndEffectiveInterestRatesRelatedToNotesTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Schedule of interest expense recognized and effective interest rates related to notes.", "label": "Schedule Of Interest Expense Recognized And Effective Interest Rates Related To Notes [Table Text Block]", "terseLabel": "Schedule of Total Interest Expense Recognized and Effective Interest Related to Notes" } } }, "localname": "ScheduleOfInterestExpenseRecognizedAndEffectiveInterestRatesRelatedToNotesTableTextBlock", "nsuri": "http://bridgebio.com/20220630", "presentation": [ "http://bridgebio.com/20220630/taxonomy/role/Role_DisclosureDebtTables" ], "xbrltype": "textBlockItemType" }, "bbio_ScheduleOfPotentialMilestoneAmountsAndAccrualsTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Schedule of potential milestone amounts and accruals.", "label": "Schedule Of Potential Milestone Amounts And Accruals Table [Text Block]", "terseLabel": "Schedule of Potential Milestone Amounts and Accruals" } } }, "localname": "ScheduleOfPotentialMilestoneAmountsAndAccrualsTableTextBlock", "nsuri": "http://bridgebio.com/20220630", "presentation": [ "http://bridgebio.com/20220630/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesTables" ], "xbrltype": "textBlockItemType" }, "bbio_ScheduleOfSupplementalCashFlowInformationRelatedToLeasesTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Schedule of supplemental cash flow information related to leases.", "label": "Schedule Of Supplemental Cash Flow Information Related To Leases Table [Text Block]", "terseLabel": "Schedule of Supplemental Cash Flow Information Related to Leases" } } }, "localname": "ScheduleOfSupplementalCashFlowInformationRelatedToLeasesTableTextBlock", "nsuri": "http://bridgebio.com/20220630", "presentation": [ "http://bridgebio.com/20220630/taxonomy/role/Role_DisclosureLeasesTables" ], "xbrltype": "textBlockItemType" }, "bbio_ScheduleOfSupplementalInformationRelatedToRemainingLeaseTermAndDiscountRateTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Schedule of supplemental information related to remaining lease term and discount rate.", "label": "Schedule Of Supplemental Information Related To Remaining Lease Term And Discount Rate Table [Text Block]", "terseLabel": "Schedule of Supplemental Information Related to Remaining Lease Term and Discount Rate" } } }, "localname": "ScheduleOfSupplementalInformationRelatedToRemainingLeaseTermAndDiscountRateTableTextBlock", "nsuri": "http://bridgebio.com/20220630", "presentation": [ "http://bridgebio.com/20220630/taxonomy/role/Role_DisclosureLeasesTables" ], "xbrltype": "textBlockItemType" }, "bbio_ShareRepurchaseProgramAndShelfRegistrationAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Share repurchase program and shelf registration.", "label": "Share Repurchase Program And Shelf Registration [Abstract]" } } }, "localname": "ShareRepurchaseProgramAndShelfRegistrationAbstract", "nsuri": "http://bridgebio.com/20220630", "xbrltype": "stringItemType" }, "bbio_ShareRepurchaseProgramAndShelfRegistrationLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Share repurchase program and shelf registration.", "label": "Share Repurchase Program And Shelf Registration [Line Items]", "terseLabel": "Share Repurchase Program And Shelf Registration [Line Items]" } } }, "localname": "ShareRepurchaseProgramAndShelfRegistrationLineItems", "nsuri": "http://bridgebio.com/20220630", "presentation": [ "http://bridgebio.com/20220630/taxonomy/role/Role_DisclosureShareRepurchaseProgramAndShelfRegistrationAdditionalInformationDetails" ], "xbrltype": "stringItemType" }, "bbio_ShareRepurchaseProgramAndShelfRegistrationTable": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Share repurchase program and shelf registration.", "label": "Share Repurchase Program And Shelf Registration [Table]", "terseLabel": "Share Repurchase Program And Shelf Registration [Table]" } } }, "localname": "ShareRepurchaseProgramAndShelfRegistrationTable", "nsuri": "http://bridgebio.com/20220630", "presentation": [ "http://bridgebio.com/20220630/taxonomy/role/Role_DisclosureShareRepurchaseProgramAndShelfRegistrationAdditionalInformationDetails" ], "xbrltype": "stringItemType" }, "bbio_ShareRepurchaseTransactionsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Share repurchase transactions.", "label": "Share Repurchase Transactions [Member]", "terseLabel": "Share Repurchase Transactions" } } }, "localname": "ShareRepurchaseTransactionsMember", "nsuri": "http://bridgebio.com/20220630", "presentation": [ "http://bridgebio.com/20220630/taxonomy/role/Role_DisclosureDebtAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "bbio_ShortTermMarketableSecuritiesContractualMaturities": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Short term marketable securities contractual maturities.", "label": "Short Term Marketable Securities Contractual Maturities", "terseLabel": "Short-term marketable securities contractual maturities" } } }, "localname": "ShortTermMarketableSecuritiesContractualMaturities", "nsuri": "http://bridgebio.com/20220630", "presentation": [ "http://bridgebio.com/20220630/taxonomy/role/Role_DisclosureCashEquivalentsAndMarketableSecuritiesAdditionalInformationDetails" ], "xbrltype": "durationItemType" }, "bbio_SiliconValleyBankAndHerculesLoanMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Silicon valley bank and Hercules loan.", "label": "Silicon Valley Bank And Hercules Loan [Member]", "terseLabel": "Silicon Valley Bank and Hercules Loan Agreement" } } }, "localname": "SiliconValleyBankAndHerculesLoanMember", "nsuri": "http://bridgebio.com/20220630", "presentation": [ "http://bridgebio.com/20220630/taxonomy/role/Role_DisclosureDebtAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "bbio_SummaryOfSignificantAccountingPoliciesLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Summary of significant accounting policies.", "label": "Summary Of Significant Accounting Policies [Line Items]", "terseLabel": "Summary Of Significant Accounting Policies [Line Items]" } } }, "localname": "SummaryOfSignificantAccountingPoliciesLineItems", "nsuri": "http://bridgebio.com/20220630", "presentation": [ "http://bridgebio.com/20220630/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails" ], "xbrltype": "stringItemType" }, "bbio_SummaryOfSignificantAccountingPoliciesTable": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Summary of significant accounting policies.", "label": "Summary Of Significant Accounting Policies [Table]", "terseLabel": "Summary Of Significant Accounting Policies [Table]" } } }, "localname": "SummaryOfSignificantAccountingPoliciesTable", "nsuri": "http://bridgebio.com/20220630", "presentation": [ "http://bridgebio.com/20220630/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails" ], "xbrltype": "stringItemType" }, "bbio_SupplementalAgreementMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Supplemental agreement.", "label": "Supplemental Agreement [Member]", "terseLabel": "Supplemental Agreement" } } }, "localname": "SupplementalAgreementMember", "nsuri": "http://bridgebio.com/20220630", "presentation": [ "http://bridgebio.com/20220630/taxonomy/role/Role_DisclosureLeasesAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "bbio_SupranationalDebtSecuritiesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Supranational debt securities.", "label": "Supranational Debt Securities [Member]", "terseLabel": "Supranational Debt Securities" } } }, "localname": "SupranationalDebtSecuritiesMember", "nsuri": "http://bridgebio.com/20220630", "presentation": [ "http://bridgebio.com/20220630/taxonomy/role/DisclosureFairValueMeasurementsFinancialAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails", "http://bridgebio.com/20220630/taxonomy/role/Role_DisclosureCashEquivalentsAndMarketableSecuritiesScheduleOfCashEquivalentAndMarketableSecuritiesClassifiedAsAvailableForSaleDetails" ], "xbrltype": "domainItemType" }, "bbio_TemporaryEquityCarryingAmountNetIncludingPortionAttributableToNoncontrollingInterests": { "auth_ref": [], "calculation": { "http://bridgebio.com/20220630/taxonomy/role/Role_StatementCondensedConsolidatedBalanceSheets": { "order": 2.0, "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Temporary equity carrying amount net including portion attributable to noncontrolling interests", "label": "Temporary Equity Carrying Amount Net Including Portion Attributable To Noncontrolling Interests", "periodEndLabel": "Temporary equity, ending balance", "periodStartLabel": "Temporary equity, beginning balance", "terseLabel": "Redeemable convertible noncontrolling interests" } } }, "localname": "TemporaryEquityCarryingAmountNetIncludingPortionAttributableToNoncontrollingInterests", "nsuri": "http://bridgebio.com/20220630", "presentation": [ "http://bridgebio.com/20220630/taxonomy/role/Role_StatementCondensedConsolidatedBalanceSheets", "http://bridgebio.com/20220630/taxonomy/role/StatementCondensedConsolidatedStatementsOfRedeemableConvertibleNoncontrollingInterestsAndStockholdersEquityUnaudited" ], "xbrltype": "monetaryItemType" }, "bbio_TemporaryEquityFairValueOfNoncontrollingInterest": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Temporary equity fair value of noncontrolling interest.", "label": "Temporary Equity Fair Value Of Noncontrolling Interest", "terseLabel": "Fair value of PellePharm noncontrolling interest on consolidation" } } }, "localname": "TemporaryEquityFairValueOfNoncontrollingInterest", "nsuri": "http://bridgebio.com/20220630", "presentation": [ "http://bridgebio.com/20220630/taxonomy/role/StatementCondensedConsolidatedStatementsOfRedeemableConvertibleNoncontrollingInterestsAndStockholdersEquityUnaudited" ], "xbrltype": "monetaryItemType" }, "bbio_TemporaryEquityIssuanceRepurchaseOfNoncontrollingInterestValue": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Temporary equity issuance (repurchase) of noncontrolling interest, value.", "label": "Temporary Equity Issuance Repurchase Of Noncontrolling Interest Value", "terseLabel": "Temporary Equity, issuance (repurchase) of noncontrolling interest" } } }, "localname": "TemporaryEquityIssuanceRepurchaseOfNoncontrollingInterestValue", "nsuri": "http://bridgebio.com/20220630", "presentation": [ "http://bridgebio.com/20220630/taxonomy/role/StatementCondensedConsolidatedStatementsOfRedeemableConvertibleNoncontrollingInterestsAndStockholdersEquityUnaudited" ], "xbrltype": "monetaryItemType" }, "bbio_TemporaryEquityTransferToFromNoncontrollingInterest": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Temporary equity transfer to (from) noncontrolling interest.", "label": "Temporary Equity Transfer To From Noncontrolling Interest", "terseLabel": "Temporary Equity, transfers from (to) noncontrolling interest" } } }, "localname": "TemporaryEquityTransferToFromNoncontrollingInterest", "nsuri": "http://bridgebio.com/20220630", "presentation": [ "http://bridgebio.com/20220630/taxonomy/role/StatementCondensedConsolidatedStatementsOfRedeemableConvertibleNoncontrollingInterestsAndStockholdersEquityUnaudited" ], "xbrltype": "monetaryItemType" }, "bbio_TermLoanAgreementMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Term loan agreement.", "label": "Term Loan Agreement [Member]", "terseLabel": "Term Loan Agreement" } } }, "localname": "TermLoanAgreementMember", "nsuri": "http://bridgebio.com/20220630", "presentation": [ "http://bridgebio.com/20220630/taxonomy/role/DisclosureDebtScheduleOfFutureMinimumPaymentsUnderTermLoanAgreementDetails" ], "xbrltype": "domainItemType" }, "bbio_TerminationAgreementMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Termination agreement.", "label": "Termination Agreement [Member]", "terseLabel": "Termination Agreement" } } }, "localname": "TerminationAgreementMember", "nsuri": "http://bridgebio.com/20220630", "presentation": [ "http://bridgebio.com/20220630/taxonomy/role/Role_DisclosureLeasesAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "bbio_ThresholdPercentageOfStockPriceTriggerInMeasurementPeriod": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Threshold percentage of stock price trigger in measurement period.", "label": "Threshold Percentage Of Stock Price Trigger In Measurement Period", "terseLabel": "Threshold percentage of stock price trigger in measurement period" } } }, "localname": "ThresholdPercentageOfStockPriceTriggerInMeasurementPeriod", "nsuri": "http://bridgebio.com/20220630", "presentation": [ "http://bridgebio.com/20220630/taxonomy/role/Role_DisclosureDebtAdditionalInformationDetails" ], "xbrltype": "percentItemType" }, "bbio_TrancheALoanMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Tranche A loan.", "label": "Tranche A Loan [Member]", "terseLabel": "Tranche A Loan" } } }, "localname": "TrancheALoanMember", "nsuri": "http://bridgebio.com/20220630", "presentation": [ "http://bridgebio.com/20220630/taxonomy/role/Role_DisclosureDebtAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "bbio_TrancheOneAdvanceMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Tranche one advance.", "label": "Tranche One Advance [Member]", "terseLabel": "Tranche 1 Advance" } } }, "localname": "TrancheOneAdvanceMember", "nsuri": "http://bridgebio.com/20220630", "presentation": [ "http://bridgebio.com/20220630/taxonomy/role/Role_DisclosureDebtAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "bbio_TrancheTwoAdvanceMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Tranche two advance", "label": "Tranche Two Advance [Member]", "terseLabel": "Tranche 2 Advance" } } }, "localname": "TrancheTwoAdvanceMember", "nsuri": "http://bridgebio.com/20220630", "presentation": [ "http://bridgebio.com/20220630/taxonomy/role/Role_DisclosureDebtAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "bbio_TransactionCostsIncurredInMergerTransactions": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Transaction costs incurred in merger transactions.", "label": "Transaction Costs Incurred In Merger Transactions", "terseLabel": "Transaction costs incurred" } } }, "localname": "TransactionCostsIncurredInMergerTransactions", "nsuri": "http://bridgebio.com/20220630", "presentation": [ "http://bridgebio.com/20220630/taxonomy/role/Role_DisclosureEidosAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "bbio_TwoPointFiveZeroPercentageConvertibleSeniorNotesDueTwoThousandAndTwentySevenAndTwoThousandAndTwentyNineMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Two point five zero percentage convertible senior notes due two thousand and twenty seven and two thousand and twenty nine.", "label": "Two Point Five Zero Percentage Convertible Senior Notes Due Two Thousand And Twenty Seven And Two Thousand And Twenty Nine [Member]", "terseLabel": "2027 and 2029 Notes" } } }, "localname": "TwoPointFiveZeroPercentageConvertibleSeniorNotesDueTwoThousandAndTwentySevenAndTwoThousandAndTwentyNineMember", "nsuri": "http://bridgebio.com/20220630", "presentation": [ "http://bridgebio.com/20220630/taxonomy/role/Role_DisclosureDebtTables" ], "xbrltype": "domainItemType" }, "bbio_TwoPointFiveZeroPercentageConvertibleSeniorNotesDueTwoThousandAndTwentySevenMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Two point five zero percentage convertible senior notes due two thousand and twenty seven.", "label": "Two Point Five Zero Percentage Convertible Senior Notes Due Two Thousand And Twenty Seven [Member]", "terseLabel": "2027 Notes" } } }, "localname": "TwoPointFiveZeroPercentageConvertibleSeniorNotesDueTwoThousandAndTwentySevenMember", "nsuri": "http://bridgebio.com/20220630", "presentation": [ "http://bridgebio.com/20220630/taxonomy/role/DisclosureFairValueMeasurementsAdditionalInformationDetails", "http://bridgebio.com/20220630/taxonomy/role/Role_DisclosureDebtAdditionalInformationDetails", "http://bridgebio.com/20220630/taxonomy/role/Role_DisclosureDebtScheduleOfOutstandingNotesBalancesDetails", "http://bridgebio.com/20220630/taxonomy/role/Role_DisclosureDebtScheduleOfTotalInterestExpenseRecognizedRelatedToNotesDetails", "http://bridgebio.com/20220630/taxonomy/role/Role_StatementCondensedConsolidatedBalanceSheets" ], "xbrltype": "domainItemType" }, "bbio_TwoPointTwoFivePercentageConvertibleSeniorNotesDueTwoThousandAndTwentyNineMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Two Point Two Five Percentage Convertible Senior Notes Due Two Thousand And Twenty Nine [Member]", "label": "Two Point Two Five Percentage Convertible Senior Notes Due Two Thousand And Twenty Nine [Member]", "terseLabel": "2029 Notes" } } }, "localname": "TwoPointTwoFivePercentageConvertibleSeniorNotesDueTwoThousandAndTwentyNineMember", "nsuri": "http://bridgebio.com/20220630", "presentation": [ "http://bridgebio.com/20220630/taxonomy/role/DisclosureFairValueMeasurementsAdditionalInformationDetails", "http://bridgebio.com/20220630/taxonomy/role/Role_DisclosureDebtAdditionalInformationDetails", "http://bridgebio.com/20220630/taxonomy/role/Role_DisclosureDebtScheduleOfOutstandingNotesBalancesDetails", "http://bridgebio.com/20220630/taxonomy/role/Role_DisclosureDebtScheduleOfTotalInterestExpenseRecognizedRelatedToNotesDetails", "http://bridgebio.com/20220630/taxonomy/role/Role_StatementCondensedConsolidatedBalanceSheets" ], "xbrltype": "domainItemType" }, "bbio_TwoThousandNineteenEmployeeStockPurchasePlanMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Two thousand nineteen employee stock purchase plan.", "label": "Two Thousand Nineteen Employee Stock Purchase Plan [Member]", "terseLabel": "2019 Employee Stock Purchase Plan" } } }, "localname": "TwoThousandNineteenEmployeeStockPurchasePlanMember", "nsuri": "http://bridgebio.com/20220630", "presentation": [ "http://bridgebio.com/20220630/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetails", "http://bridgebio.com/20220630/taxonomy/role/Role_DisclosureStockBasedCompensationTables" ], "xbrltype": "domainItemType" }, "bbio_TwoThousandNineteenInducementEquityPlansMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Two thousand nineteen inducement equity plan.", "label": "Two Thousand Nineteen Inducement Equity Plans [Member]", "terseLabel": "2019 Inducement Plan" } } }, "localname": "TwoThousandNineteenInducementEquityPlansMember", "nsuri": "http://bridgebio.com/20220630", "presentation": [ "http://bridgebio.com/20220630/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "bbio_TwoThousandNineteenStockOptionAndIncentivePlanAndInducementEquityPlanMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Two thousand nineteen stock option and incentive plan and inducement equity plan.", "label": "Two Thousand Nineteen Stock Option And Incentive Plan And Inducement Equity Plan [Member]", "terseLabel": "A&R 2019 Plan and 2019 Inducement Plan" } } }, "localname": "TwoThousandNineteenStockOptionAndIncentivePlanAndInducementEquityPlanMember", "nsuri": "http://bridgebio.com/20220630", "presentation": [ "http://bridgebio.com/20220630/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetails", "http://bridgebio.com/20220630/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfRecognizedStockBasedCompensationExpenseRelatedToRestrictedStockAwardActivityDetails", "http://bridgebio.com/20220630/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfRestrictedStockAwardActivityUnderPlansDetails", "http://bridgebio.com/20220630/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfRestrictedStockUnitsActivityDetails", "http://bridgebio.com/20220630/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfStockOptionActivityUnderPlansDetails" ], "xbrltype": "domainItemType" }, "bbio_TwoThousandNineteenStockOptionAndIncentivePlanMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Two thousand nineteen stock option and incentive plan.", "label": "Two Thousand Nineteen Stock Option And Incentive Plan [Member]", "terseLabel": "A&R 2019 Plan" } } }, "localname": "TwoThousandNineteenStockOptionAndIncentivePlanMember", "nsuri": "http://bridgebio.com/20220630", "presentation": [ "http://bridgebio.com/20220630/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "bbio_TwoThousandSixteenEquityIncentivePlanAndTwoThousandEighteenStockOptionAndIncentivePlanMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Two thousand sixteen equity incentive plan and two thousand eighteen stock option and incentive plan.", "label": "Two Thousand Sixteen Equity Incentive Plan And Two Thousand Eighteen Stock Option And Incentive Plan [Member]", "terseLabel": "Eidos 2016 and 2018 Plans" } } }, "localname": "TwoThousandSixteenEquityIncentivePlanAndTwoThousandEighteenStockOptionAndIncentivePlanMember", "nsuri": "http://bridgebio.com/20220630", "presentation": [ "http://bridgebio.com/20220630/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "bbio_TwoThousandTwentyOneCappedCallTransactionsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Two thousand twenty one capped call transactions.", "label": "Two Thousand Twenty One Capped Call Transactions [Member]", "terseLabel": "2021 Capped Call Transactions" } } }, "localname": "TwoThousandTwentyOneCappedCallTransactionsMember", "nsuri": "http://bridgebio.com/20220630", "presentation": [ "http://bridgebio.com/20220630/taxonomy/role/Role_DisclosureDebtAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "bbio_TwoThousandTwentyOneShareRepurchaseProgramMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Two thousand twenty one share repurchase program.", "label": "Two Thousand Twenty One Share Repurchase Program [Member]", "terseLabel": "2021 Share Repurchase Program" } } }, "localname": "TwoThousandTwentyOneShareRepurchaseProgramMember", "nsuri": "http://bridgebio.com/20220630", "presentation": [ "http://bridgebio.com/20220630/taxonomy/role/Role_DisclosureShareRepurchaseProgramAndShelfRegistrationAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "bbio_TwoThousandTwentyOneStockOptionAndIncentivePlanMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Two thousand twenty one stock option and incentive plan.", "label": "Two Thousand Twenty One Stock Option And Incentive Plan [Member]", "terseLabel": "2021 A&R Plan" } } }, "localname": "TwoThousandTwentyOneStockOptionAndIncentivePlanMember", "nsuri": "http://bridgebio.com/20220630", "presentation": [ "http://bridgebio.com/20220630/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "bbio_TwoThousandTwentyStockAndEquityAwardExchangeProgramMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Two thousand twenty stock and equity award exchange program.", "label": "Two Thousand Twenty Stock And Equity Award Exchange Program [Member]", "terseLabel": "2020 Stock and Equity Award Exchange Program", "verboseLabel": "2020 Stock and Equity Award Exchange Program" } } }, "localname": "TwoThousandTwentyStockAndEquityAwardExchangeProgramMember", "nsuri": "http://bridgebio.com/20220630", "presentation": [ "http://bridgebio.com/20220630/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetails", "http://bridgebio.com/20220630/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfRecognizedStockBasedCompensationExpenseRelatedToRestrictedStockAwardActivityDetails", "http://bridgebio.com/20220630/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfRestrictedStockAwardActivityUnderPlansDetails", "http://bridgebio.com/20220630/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfStockOptionActivityUnderPlansDetails" ], "xbrltype": "domainItemType" }, "bbio_TwoThousandTwentyStockAndEquityExchangeProgramMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Two thousand twenty stock and equity exchange program member.", "label": "Two Thousand Twenty Stock And Equity Exchange Program [Member]", "terseLabel": "2020 Stock and Equity Exchange Program" } } }, "localname": "TwoThousandTwentyStockAndEquityExchangeProgramMember", "nsuri": "http://bridgebio.com/20220630", "presentation": [ "http://bridgebio.com/20220630/taxonomy/role/StatementCondensedConsolidatedStatementsOfRedeemableConvertibleNoncontrollingInterestsAndStockholdersEquityUnaudited" ], "xbrltype": "domainItemType" }, "bbio_UnvestedPerformanceBasedRestrictedStockUnitMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Unvested performance-based restricted stock unit.", "label": "Unvested Performance Based Restricted Stock Unit [Member]", "terseLabel": "Unvested Performance-Based RSUs" } } }, "localname": "UnvestedPerformanceBasedRestrictedStockUnitMember", "nsuri": "http://bridgebio.com/20220630", "presentation": [ "http://bridgebio.com/20220630/taxonomy/role/Role_DisclosureNetLossPerShareScheduleOfCommonStockEquivalentsWereExcludedFromComputationOfDilutedNetLossPerShareDetail" ], "xbrltype": "domainItemType" }, "bbio_UnvestedRestrictedStockAwardMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Unvested restricted stock award.", "label": "Unvested Restricted Stock Award [Member]", "terseLabel": "Unvested RSAs" } } }, "localname": "UnvestedRestrictedStockAwardMember", "nsuri": "http://bridgebio.com/20220630", "presentation": [ "http://bridgebio.com/20220630/taxonomy/role/Role_DisclosureNetLossPerShareScheduleOfCommonStockEquivalentsWereExcludedFromComputationOfDilutedNetLossPerShareDetail" ], "xbrltype": "domainItemType" }, "bbio_UnvestedRestrictedStockUnitMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Unvested restricted stock unit.", "label": "Unvested Restricted Stock Unit [Member]", "terseLabel": "Unvested RSUs" } } }, "localname": "UnvestedRestrictedStockUnitMember", "nsuri": "http://bridgebio.com/20220630", "presentation": [ "http://bridgebio.com/20220630/taxonomy/role/Role_DisclosureNetLossPerShareScheduleOfCommonStockEquivalentsWereExcludedFromComputationOfDilutedNetLossPerShareDetail" ], "xbrltype": "domainItemType" }, "bbio_UpfrontPaymentReceived": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Upfront payment received.", "label": "Upfront Payment Received", "terseLabel": "Upfront payment received" } } }, "localname": "UpfrontPaymentReceived", "nsuri": "http://bridgebio.com/20220630", "presentation": [ "http://bridgebio.com/20220630/taxonomy/role/DisclosureSaleOfNonfinancialAssetsAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "bbio_UpfrontPaymentYetToBeReceived": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Upfront payment yet to be received.", "label": "Upfront Payment Yet To Be Received", "terseLabel": "Upfront payment yet to be received" } } }, "localname": "UpfrontPaymentYetToBeReceived", "nsuri": "http://bridgebio.com/20220630", "presentation": [ "http://bridgebio.com/20220630/taxonomy/role/DisclosureLicenseAndCollaborationAgreementsAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "bbio_UpfrontRegulatoryAndLaunchMilestonePaymentsYetToBeReceived": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Upfront, regulatory and launch milestone payments yet to be received.", "label": "Upfront Regulatory And Launch Milestone Payments Yet To Be Received", "terseLabel": "Upfront, regulatory and launch milestone payments yet to be received" } } }, "localname": "UpfrontRegulatoryAndLaunchMilestonePaymentsYetToBeReceived", "nsuri": "http://bridgebio.com/20220630", "presentation": [ "http://bridgebio.com/20220630/taxonomy/role/DisclosureLicenseAndCollaborationAgreementsAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "bbio_VotingInterestEntityInvestmentThresholdPercentage": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Voting interest entity investment threshold, percentage.", "label": "Voting Interest Entity Investment Threshold Percentage", "verboseLabel": "Percentage of voting shares" } } }, "localname": "VotingInterestEntityInvestmentThresholdPercentage", "nsuri": "http://bridgebio.com/20220630", "presentation": [ "http://bridgebio.com/20220630/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails" ], "xbrltype": "percentItemType" }, "bbio_WarrantToPurchasePercentage": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Warrant to purchase percentage.", "label": "Warrant To Purchase Percentage", "terseLabel": "Warrant to purchase percentage" } } }, "localname": "WarrantToPurchasePercentage", "nsuri": "http://bridgebio.com/20220630", "presentation": [ "http://bridgebio.com/20220630/taxonomy/role/DisclosureEquityMethodAndOtherEquityInvestmentsAdditionalInformationDetail" ], "xbrltype": "percentItemType" }, "bbio_WarrantToPurchaseSharesOfCommonStock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Warrant to purchase shares of common stock", "label": "Warrant to Purchase shares of common stock", "terseLabel": "Warrants to purchase common stock" } } }, "localname": "WarrantToPurchaseSharesOfCommonStock", "nsuri": "http://bridgebio.com/20220630", "presentation": [ "http://bridgebio.com/20220630/taxonomy/role/DisclosureEquityMethodAndOtherEquityInvestmentsAdditionalInformationDetail" ], "xbrltype": "sharesItemType" }, "bbio_WarrantsFairValueDisclosure": { "auth_ref": [], "calculation": { "http://bridgebio.com/20220630/taxonomy/role/DisclosureFairValueMeasurementsFinancialAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails": { "order": 4.0, "parentTag": "us-gaap_AssetsFairValueDisclosure", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Warrants, fair value disclosure.", "label": "Warrants Fair Value Disclosure", "terseLabel": "LianBio Warrant" } } }, "localname": "WarrantsFairValueDisclosure", "nsuri": "http://bridgebio.com/20220630", "presentation": [ "http://bridgebio.com/20220630/taxonomy/role/DisclosureFairValueMeasurementsFinancialAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails" ], "xbrltype": "monetaryItemType" }, "bbio_WeightedAverageDiscountRateAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Weighted-average discount rate.", "label": "Weighted Average Discount Rate [Abstract]", "terseLabel": "Weighted-average discount rate" } } }, "localname": "WeightedAverageDiscountRateAbstract", "nsuri": "http://bridgebio.com/20220630", "presentation": [ "http://bridgebio.com/20220630/taxonomy/role/Role_DisclosureLeasesScheduleOfSupplementalInformationRelatedToRemainingLeaseTermAndDiscountRateDetails" ], "xbrltype": "stringItemType" }, "bbio_WeightedAverageRemainingLeaseTermAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Weighted-average remaining lease term.", "label": "Weighted Average Remaining Lease Term [Abstract]", "terseLabel": "Weighted-average remaining lease term (in years)" } } }, "localname": "WeightedAverageRemainingLeaseTermAbstract", "nsuri": "http://bridgebio.com/20220630", "presentation": [ "http://bridgebio.com/20220630/taxonomy/role/Role_DisclosureLeasesScheduleOfSupplementalInformationRelatedToRemainingLeaseTermAndDiscountRateDetails" ], "xbrltype": "stringItemType" }, "bbio_WhollyOwnedSubsidiaryDisclosureAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Wholly owned subsidiary disclosure.", "label": "Wholly Owned Subsidiary Disclosure [Abstract]" } } }, "localname": "WhollyOwnedSubsidiaryDisclosureAbstract", "nsuri": "http://bridgebio.com/20220630", "xbrltype": "stringItemType" }, "bbio_WhollyOwnedSubsidiaryDisclosureTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Wholly Owned Subsidiary Disclosure.", "label": "Wholly Owned Subsidiary Disclosure [Text Block]", "terseLabel": "Eidos" } } }, "localname": "WhollyOwnedSubsidiaryDisclosureTextBlock", "nsuri": "http://bridgebio.com/20220630", "presentation": [ "http://bridgebio.com/20220630/taxonomy/role/Role_DisclosureEidos" ], "xbrltype": "textBlockItemType" }, "dei_AmendmentFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.", "label": "Amendment Flag", "verboseLabel": "Amendment Flag" } } }, "localname": "AmendmentFlag", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://bridgebio.com/20220630/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_CityAreaCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Area code of city", "label": "City Area Code", "terseLabel": "City Area Code" } } }, "localname": "CityAreaCode", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://bridgebio.com/20220630/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_CoverAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Cover page.", "label": "Cover [Abstract]" } } }, "localname": "CoverAbstract", "nsuri": "http://xbrl.sec.gov/dei/2022", "xbrltype": "stringItemType" }, "dei_CurrentFiscalYearEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "End date of current fiscal year in the format --MM-DD.", "label": "Current Fiscal Year End Date", "terseLabel": "Current Fiscal Year End Date" } } }, "localname": "CurrentFiscalYearEndDate", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://bridgebio.com/20220630/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "xbrltype": "gMonthDayItemType" }, "dei_DocumentFiscalPeriodFocus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.", "label": "Document Fiscal Period Focus", "terseLabel": "Document Fiscal Period Focus" } } }, "localname": "DocumentFiscalPeriodFocus", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://bridgebio.com/20220630/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "xbrltype": "fiscalPeriodItemType" }, "dei_DocumentFiscalYearFocus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.", "label": "Document Fiscal Year Focus", "terseLabel": "Document Fiscal Year Focus" } } }, "localname": "DocumentFiscalYearFocus", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://bridgebio.com/20220630/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "xbrltype": "gYearItemType" }, "dei_DocumentPeriodEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.", "label": "Document Period End Date", "terseLabel": "Document Period End Date" } } }, "localname": "DocumentPeriodEndDate", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://bridgebio.com/20220630/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "xbrltype": "dateItemType" }, "dei_DocumentQuarterlyReport": { "auth_ref": [ "r715" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as an quarterly report.", "label": "Document Quarterly Report", "terseLabel": "Document Quarterly Report" } } }, "localname": "DocumentQuarterlyReport", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://bridgebio.com/20220630/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_DocumentTransitionReport": { "auth_ref": [ "r716" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as a transition report.", "label": "Document Transition Report", "terseLabel": "Document Transition Report" } } }, "localname": "DocumentTransitionReport", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://bridgebio.com/20220630/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_DocumentType": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.", "label": "Document Type", "verboseLabel": "Document Type" } } }, "localname": "DocumentType", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://bridgebio.com/20220630/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "xbrltype": "submissionTypeItemType" }, "dei_EntityAddressAddressLine1": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 1 such as Attn, Building Name, Street Name", "label": "Entity Address, Address Line One", "terseLabel": "Entity Address, Address Line One" } } }, "localname": "EntityAddressAddressLine1", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://bridgebio.com/20220630/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCityOrTown": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the City or Town", "label": "Entity Address, City or Town", "terseLabel": "Entity Address, City or Town" } } }, "localname": "EntityAddressCityOrTown", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://bridgebio.com/20220630/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressPostalZipCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Code for the postal or zip code", "label": "Entity Address, Postal Zip Code", "terseLabel": "Entity Address, Postal Zip Code" } } }, "localname": "EntityAddressPostalZipCode", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://bridgebio.com/20220630/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressStateOrProvince": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the state or province.", "label": "Entity Address, State or Province", "terseLabel": "Entity Address, State or Province" } } }, "localname": "EntityAddressStateOrProvince", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://bridgebio.com/20220630/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "xbrltype": "stateOrProvinceItemType" }, "dei_EntityCentralIndexKey": { "auth_ref": [ "r713" ], "lang": { "en-us": { "role": { "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.", "label": "Entity Central Index Key", "terseLabel": "Entity Central Index Key" } } }, "localname": "EntityCentralIndexKey", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://bridgebio.com/20220630/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "xbrltype": "centralIndexKeyItemType" }, "dei_EntityCommonStockSharesOutstanding": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.", "label": "Entity Common Stock, Shares Outstanding", "terseLabel": "Entity Common Stock, Shares Outstanding" } } }, "localname": "EntityCommonStockSharesOutstanding", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://bridgebio.com/20220630/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "xbrltype": "sharesItemType" }, "dei_EntityCurrentReportingStatus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Current Reporting Status", "terseLabel": "Entity Current Reporting Status" } } }, "localname": "EntityCurrentReportingStatus", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://bridgebio.com/20220630/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "xbrltype": "yesNoItemType" }, "dei_EntityDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "All the names of the entities being reported upon in a document. Any legal structure used to conduct activities or to hold assets. Some examples of such structures are corporations, partnerships, limited liability companies, grantor trusts, and other trusts. This item does not include business and geographical segments which are included in the geographical or business segments domains.", "label": "Entity [Domain]", "terseLabel": "Entity" } } }, "localname": "EntityDomain", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://bridgebio.com/20220630/taxonomy/role/DisclosureEquityMethodAndOtherEquityInvestmentsAdditionalInformationDetail", "http://bridgebio.com/20220630/taxonomy/role/DisclosureIntangibleAssetsAdditionalInformationDetails", "http://bridgebio.com/20220630/taxonomy/role/DisclosureSaleOfNonfinancialAssetsAdditionalInformationDetails", "http://bridgebio.com/20220630/taxonomy/role/Role_DisclosureEidosAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "dei_EntityEmergingGrowthCompany": { "auth_ref": [ "r713" ], "lang": { "en-us": { "role": { "documentation": "Indicate if registrant meets the emerging growth company criteria.", "label": "Entity Emerging Growth Company", "terseLabel": "Entity Emerging Growth Company" } } }, "localname": "EntityEmergingGrowthCompany", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://bridgebio.com/20220630/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_EntityFileNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.", "label": "Entity File Number", "terseLabel": "Entity File Number" } } }, "localname": "EntityFileNumber", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://bridgebio.com/20220630/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "xbrltype": "fileNumberItemType" }, "dei_EntityFilerCategory": { "auth_ref": [ "r713" ], "lang": { "en-us": { "role": { "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Filer Category", "terseLabel": "Entity Filer Category" } } }, "localname": "EntityFilerCategory", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://bridgebio.com/20220630/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "xbrltype": "filerCategoryItemType" }, "dei_EntityIncorporationStateCountryCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Two-character EDGAR code representing the state or country of incorporation.", "label": "Entity Incorporation, State or Country Code", "terseLabel": "Entity Incorporation, State or Country Code" } } }, "localname": "EntityIncorporationStateCountryCode", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://bridgebio.com/20220630/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "xbrltype": "edgarStateCountryItemType" }, "dei_EntityInteractiveDataCurrent": { "auth_ref": [ "r725" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).", "label": "Entity Interactive Data Current", "terseLabel": "Entity Interactive Data Current" } } }, "localname": "EntityInteractiveDataCurrent", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://bridgebio.com/20220630/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "xbrltype": "yesNoItemType" }, "dei_EntityRegistrantName": { "auth_ref": [ "r713" ], "lang": { "en-us": { "role": { "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.", "label": "Entity Registrant Name", "terseLabel": "Entity Registrant Name" } } }, "localname": "EntityRegistrantName", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://bridgebio.com/20220630/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityShellCompany": { "auth_ref": [ "r713" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.", "label": "Entity Shell Company", "terseLabel": "Entity Shell Company" } } }, "localname": "EntityShellCompany", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://bridgebio.com/20220630/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_EntitySmallBusiness": { "auth_ref": [ "r713" ], "lang": { "en-us": { "role": { "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).", "label": "Entity Small Business", "terseLabel": "Entity Small Business" } } }, "localname": "EntitySmallBusiness", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://bridgebio.com/20220630/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_EntityTaxIdentificationNumber": { "auth_ref": [ "r713" ], "lang": { "en-us": { "role": { "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.", "label": "Entity Tax Identification Number", "terseLabel": "Entity Tax Identification Number" } } }, "localname": "EntityTaxIdentificationNumber", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://bridgebio.com/20220630/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "xbrltype": "employerIdItemType" }, "dei_LegalEntityAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The set of legal entities associated with a report.", "label": "Legal Entity [Axis]", "terseLabel": "Legal Entity" } } }, "localname": "LegalEntityAxis", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://bridgebio.com/20220630/taxonomy/role/DisclosureEquityMethodAndOtherEquityInvestmentsAdditionalInformationDetail", "http://bridgebio.com/20220630/taxonomy/role/DisclosureIntangibleAssetsAdditionalInformationDetails", "http://bridgebio.com/20220630/taxonomy/role/DisclosureSaleOfNonfinancialAssetsAdditionalInformationDetails", "http://bridgebio.com/20220630/taxonomy/role/Role_DisclosureEidosAdditionalInformationDetails" ], "xbrltype": "stringItemType" }, "dei_LocalPhoneNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Local phone number for entity.", "label": "Local Phone Number", "terseLabel": "Local Phone Number" } } }, "localname": "LocalPhoneNumber", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://bridgebio.com/20220630/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_Security12bTitle": { "auth_ref": [ "r712" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(b) registered security.", "label": "Title of 12(b) Security", "terseLabel": "Title of 12(b) Security" } } }, "localname": "Security12bTitle", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://bridgebio.com/20220630/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "xbrltype": "securityTitleItemType" }, "dei_SecurityExchangeName": { "auth_ref": [ "r714" ], "lang": { "en-us": { "role": { "documentation": "Name of the Exchange on which a security is registered.", "label": "Security Exchange Name", "terseLabel": "Security Exchange Name" } } }, "localname": "SecurityExchangeName", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://bridgebio.com/20220630/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "xbrltype": "edgarExchangeCodeItemType" }, "dei_TradingSymbol": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Trading symbol of an instrument as listed on an exchange.", "label": "Trading Symbol", "terseLabel": "Trading Symbol" } } }, "localname": "TradingSymbol", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://bridgebio.com/20220630/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "xbrltype": "tradingSymbolItemType" }, "srt_ConsolidatedEntitiesAxis": { "auth_ref": [ "r122", "r288", "r292", "r297", "r475", "r476", "r481", "r482", "r580", "r708", "r727", "r728", "r729", "r730" ], "lang": { "en-us": { "role": { "documentation": "Information by consolidated entity or group of entities.", "label": "Consolidated Entities [Axis]", "terseLabel": "Consolidated Entities" } } }, "localname": "ConsolidatedEntitiesAxis", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://bridgebio.com/20220630/taxonomy/role/Role_DisclosureDebtAdditionalInformationDetails", "http://bridgebio.com/20220630/taxonomy/role/Role_DisclosureEidosAdditionalInformationDetails", "http://bridgebio.com/20220630/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetails", "http://bridgebio.com/20220630/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfStockBasedCompensationForEmployeesAndNonEmployeesDetails", "http://bridgebio.com/20220630/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfStockOptionActivityUnderPlansDetails" ], "xbrltype": "stringItemType" }, "srt_ConsolidatedEntitiesDomain": { "auth_ref": [ "r122", "r288", "r292", "r297", "r475", "r476", "r481", "r482", "r580", "r708", "r727", "r728", "r729", "r730" ], "lang": { "en-us": { "role": { "documentation": "Entity or group of entities consolidated into reporting entity.", "label": "Consolidated Entities [Domain]", "terseLabel": "Consolidated Entities" } } }, "localname": "ConsolidatedEntitiesDomain", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://bridgebio.com/20220630/taxonomy/role/Role_DisclosureDebtAdditionalInformationDetails", "http://bridgebio.com/20220630/taxonomy/role/Role_DisclosureEidosAdditionalInformationDetails", "http://bridgebio.com/20220630/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetails", "http://bridgebio.com/20220630/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfStockBasedCompensationForEmployeesAndNonEmployeesDetails", "http://bridgebio.com/20220630/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfStockOptionActivityUnderPlansDetails" ], "xbrltype": "domainItemType" }, "srt_ContractualObligationFiscalYearMaturityScheduleTableTextBlock": { "auth_ref": [ "r724" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of contractual obligation by timing of payment due. Includes, but is not limited to, long-term debt obligation, lease obligation, and purchase obligation.", "label": "Contractual Obligation, Fiscal Year Maturity [Table Text Block]", "terseLabel": "Schedule of Future Minimum Payments" } } }, "localname": "ContractualObligationFiscalYearMaturityScheduleTableTextBlock", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://bridgebio.com/20220630/taxonomy/role/Role_DisclosureDebtTables" ], "xbrltype": "textBlockItemType" }, "srt_CounterpartyNameAxis": { "auth_ref": [ "r52", "r54", "r120", "r121", "r303", "r343", "r731" ], "lang": { "en-us": { "role": { "documentation": "Information by name of counterparty. A counterparty is the other party that participates in a financial transaction. Examples include, but not limited to, the name of the financial institution.", "label": "Counterparty Name [Axis]", "terseLabel": "Counterparty Name" } } }, "localname": "CounterpartyNameAxis", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://bridgebio.com/20220630/taxonomy/role/DisclosureIntangibleAssetsAdditionalInformationDetails", "http://bridgebio.com/20220630/taxonomy/role/DisclosureLicenseAndCollaborationAgreementsAdditionalInformationDetails", "http://bridgebio.com/20220630/taxonomy/role/Role_DisclosureDebtAdditionalInformationDetails" ], "xbrltype": "stringItemType" }, "srt_CumulativeEffectPeriodOfAdoptionAdjustedBalanceMember": { "auth_ref": [ "r2", "r127", "r135", "r227", "r431", "r432", "r433", "r448", "r449", "r503", "r508", "r509", "r574" ], "lang": { "en-us": { "role": { "documentation": "Represents amount after cumulative-effect adjustment to financial statements in period of adoption of amendment to accounting standards.", "label": "Cumulative Effect, Period of Adoption, Adjusted Balance [Member]", "terseLabel": "Cumulative Effect, Period of Adoption, Adjusted Balance" } } }, "localname": "CumulativeEffectPeriodOfAdoptionAdjustedBalanceMember", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://bridgebio.com/20220630/taxonomy/role/StatementCondensedConsolidatedStatementsOfRedeemableConvertibleNoncontrollingInterestsAndStockholdersEquityUnaudited" ], "xbrltype": "domainItemType" }, "srt_CumulativeEffectPeriodOfAdoptionAxis": { "auth_ref": [ "r2", "r127", "r135", "r141", "r227", "r431", "r432", "r433", "r448", "r449", "r503", "r506", "r508", "r509", "r574" ], "lang": { "en-us": { "role": { "documentation": "Information by cumulative-effect adjustment to financial statements in period of adoption of amendment to accounting standards.", "label": "Cumulative Effect, Period of Adoption [Axis]", "terseLabel": "Cumulative Effect, Period of Adoption" } } }, "localname": "CumulativeEffectPeriodOfAdoptionAxis", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://bridgebio.com/20220630/taxonomy/role/StatementCondensedConsolidatedStatementsOfRedeemableConvertibleNoncontrollingInterestsAndStockholdersEquityUnaudited" ], "xbrltype": "stringItemType" }, "srt_CumulativeEffectPeriodOfAdoptionDomain": { "auth_ref": [ "r2", "r127", "r135", "r141", "r227", "r431", "r432", "r433", "r448", "r449", "r503", "r506", "r508", "r509", "r574" ], "lang": { "en-us": { "role": { "documentation": "Cumulative-effect adjustment to financial statements in period of adoption of amendment to accounting standards.", "label": "Cumulative Effect, Period of Adoption [Domain]", "terseLabel": "Cumulative Effect, Period of Adoption" } } }, "localname": "CumulativeEffectPeriodOfAdoptionDomain", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://bridgebio.com/20220630/taxonomy/role/StatementCondensedConsolidatedStatementsOfRedeemableConvertibleNoncontrollingInterestsAndStockholdersEquityUnaudited" ], "xbrltype": "domainItemType" }, "srt_EquityMethodInvesteeNameDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of investment including named security. Excludes entity that is consolidated.", "label": "Investment, Name [Domain]", "terseLabel": "Investment, Name" } } }, "localname": "EquityMethodInvesteeNameDomain", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://bridgebio.com/20220630/taxonomy/role/DisclosureEquityMethodAndOtherEquityInvestmentsAdditionalInformationDetail", "http://bridgebio.com/20220630/taxonomy/role/DisclosureFairValueMeasurementsAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "srt_MaximumMember": { "auth_ref": [ "r281", "r282", "r283", "r284", "r302", "r342", "r381", "r384", "r592", "r593", "r594", "r595", "r596", "r597", "r619", "r675", "r677", "r709", "r710" ], "lang": { "en-us": { "role": { "documentation": "Upper limit of the provided range.", "label": "Maximum [Member]", "terseLabel": "Maximum" } } }, "localname": "MaximumMember", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://bridgebio.com/20220630/taxonomy/role/DisclosureFairValueMeasurementsScheduleOfEstimatedFairValueOfLiabilityDetails", "http://bridgebio.com/20220630/taxonomy/role/DisclosureIntangibleAssetsAdditionalInformationDetails", "http://bridgebio.com/20220630/taxonomy/role/DisclosureLicenseAndCollaborationAgreementsAdditionalInformationDetails", "http://bridgebio.com/20220630/taxonomy/role/DisclosureRestructuringImpairmentAndRelatedChargesAdditionalInformationDetails", "http://bridgebio.com/20220630/taxonomy/role/DisclosureSaleOfNonfinancialAssetsAdditionalInformationDetails", "http://bridgebio.com/20220630/taxonomy/role/DisclosureStockbasedCompensationScheduleOfAssumptionsUsedToDetermineFairValueOfStockPurchaseRightsUnderEsppDetails", "http://bridgebio.com/20220630/taxonomy/role/Role_DisclosureDebtAdditionalInformationDetails", "http://bridgebio.com/20220630/taxonomy/role/Role_DisclosureEidosAdditionalInformationDetails", "http://bridgebio.com/20220630/taxonomy/role/Role_DisclosureShareRepurchaseProgramAndShelfRegistrationAdditionalInformationDetails", "http://bridgebio.com/20220630/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetails", "http://bridgebio.com/20220630/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "srt_MinimumMember": { "auth_ref": [ "r281", "r282", "r283", "r284", "r302", "r342", "r381", "r384", "r592", "r593", "r594", "r595", "r596", "r597", "r619", "r675", "r677", "r709", "r710" ], "lang": { "en-us": { "role": { "documentation": "Lower limit of the provided range.", "label": "Minimum [Member]", "terseLabel": "Minimum", "verboseLabel": "Minimum" } } }, "localname": "MinimumMember", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://bridgebio.com/20220630/taxonomy/role/DisclosureFairValueMeasurementsScheduleOfEstimatedFairValueOfLiabilityDetails", "http://bridgebio.com/20220630/taxonomy/role/DisclosureRestructuringImpairmentAndRelatedChargesAdditionalInformationDetails", "http://bridgebio.com/20220630/taxonomy/role/DisclosureStockbasedCompensationScheduleOfAssumptionsUsedToDetermineFairValueOfStockPurchaseRightsUnderEsppDetails", "http://bridgebio.com/20220630/taxonomy/role/Role_DisclosureDebtAdditionalInformationDetails", "http://bridgebio.com/20220630/taxonomy/role/Role_DisclosureEidosAdditionalInformationDetails", "http://bridgebio.com/20220630/taxonomy/role/Role_DisclosureShareRepurchaseProgramAndShelfRegistrationAdditionalInformationDetails", "http://bridgebio.com/20220630/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetails", "http://bridgebio.com/20220630/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "srt_OwnershipAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Information by name of entity in which ownership interest is disclosed. Excludes equity method investee and named security investment.", "label": "Ownership [Axis]", "terseLabel": "Ownership" } } }, "localname": "OwnershipAxis", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://bridgebio.com/20220630/taxonomy/role/DisclosureLicenseAndCollaborationAgreementsAdditionalInformationDetails" ], "xbrltype": "stringItemType" }, "srt_OwnershipDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of entity in which ownership interest is disclosed. Excludes equity method investee and named security investment.", "label": "Ownership [Domain]", "terseLabel": "Ownership" } } }, "localname": "OwnershipDomain", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://bridgebio.com/20220630/taxonomy/role/DisclosureLicenseAndCollaborationAgreementsAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "srt_ProductOrServiceAxis": { "auth_ref": [ "r189", "r282", "r283", "r367", "r368", "r621", "r674", "r676" ], "lang": { "en-us": { "role": { "documentation": "Information by product and service, or group of similar products and similar services.", "label": "Product and Service [Axis]", "terseLabel": "Product and Service" } } }, "localname": "ProductOrServiceAxis", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://bridgebio.com/20220630/taxonomy/role/DisclosureLicenseAndCollaborationAgreementsAdditionalInformationDetails", "http://bridgebio.com/20220630/taxonomy/role/StatementCondensedConsolidatedStatementsOfOperationsUnaudited" ], "xbrltype": "stringItemType" }, "srt_ProductsAndServicesDomain": { "auth_ref": [ "r189", "r282", "r283", "r367", "r368", "r621", "r674", "r676" ], "lang": { "en-us": { "role": { "documentation": "Product or service, or a group of similar products or similar services.", "label": "Product and Service [Domain]", "terseLabel": "Product and Service" } } }, "localname": "ProductsAndServicesDomain", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://bridgebio.com/20220630/taxonomy/role/DisclosureLicenseAndCollaborationAgreementsAdditionalInformationDetails", "http://bridgebio.com/20220630/taxonomy/role/StatementCondensedConsolidatedStatementsOfOperationsUnaudited" ], "xbrltype": "domainItemType" }, "srt_RangeAxis": { "auth_ref": [ "r257", "r281", "r282", "r283", "r284", "r302", "r342", "r370", "r381", "r384", "r418", "r419", "r420", "r592", "r593", "r594", "r595", "r596", "r597", "r619", "r675", "r677", "r709", "r710" ], "lang": { "en-us": { "role": { "documentation": "Information by statistical measurement. Includes, but is not limited to, minimum, maximum, weighted average, arithmetic average, and median.", "label": "Statistical Measurement [Axis]", "terseLabel": "Statistical Measurement" } } }, "localname": "RangeAxis", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://bridgebio.com/20220630/taxonomy/role/DisclosureFairValueMeasurementsScheduleOfEstimatedFairValueOfLiabilityDetails", "http://bridgebio.com/20220630/taxonomy/role/DisclosureIntangibleAssetsAdditionalInformationDetails", "http://bridgebio.com/20220630/taxonomy/role/DisclosureLicenseAndCollaborationAgreementsAdditionalInformationDetails", "http://bridgebio.com/20220630/taxonomy/role/DisclosureRestructuringImpairmentAndRelatedChargesAdditionalInformationDetails", "http://bridgebio.com/20220630/taxonomy/role/DisclosureSaleOfNonfinancialAssetsAdditionalInformationDetails", "http://bridgebio.com/20220630/taxonomy/role/DisclosureStockbasedCompensationScheduleOfAssumptionsUsedToDetermineFairValueOfStockPurchaseRightsUnderEsppDetails", "http://bridgebio.com/20220630/taxonomy/role/Role_DisclosureDebtAdditionalInformationDetails", "http://bridgebio.com/20220630/taxonomy/role/Role_DisclosureEidosAdditionalInformationDetails", "http://bridgebio.com/20220630/taxonomy/role/Role_DisclosureShareRepurchaseProgramAndShelfRegistrationAdditionalInformationDetails", "http://bridgebio.com/20220630/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetails", "http://bridgebio.com/20220630/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails" ], "xbrltype": "stringItemType" }, "srt_RangeMember": { "auth_ref": [ "r257", "r281", "r282", "r283", "r284", "r302", "r342", "r370", "r381", "r384", "r418", "r419", "r420", "r592", "r593", "r594", "r595", "r596", "r597", "r619", "r675", "r677", "r709", "r710" ], "lang": { "en-us": { "role": { "documentation": "Statistical measurement. Includes, but is not limited to, minimum, maximum, weighted average, arithmetic average, and median.", "label": "Statistical Measurement [Domain]", "terseLabel": "Statistical Measurement" } } }, "localname": "RangeMember", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://bridgebio.com/20220630/taxonomy/role/DisclosureFairValueMeasurementsScheduleOfEstimatedFairValueOfLiabilityDetails", "http://bridgebio.com/20220630/taxonomy/role/DisclosureIntangibleAssetsAdditionalInformationDetails", "http://bridgebio.com/20220630/taxonomy/role/DisclosureLicenseAndCollaborationAgreementsAdditionalInformationDetails", "http://bridgebio.com/20220630/taxonomy/role/DisclosureRestructuringImpairmentAndRelatedChargesAdditionalInformationDetails", "http://bridgebio.com/20220630/taxonomy/role/DisclosureSaleOfNonfinancialAssetsAdditionalInformationDetails", "http://bridgebio.com/20220630/taxonomy/role/DisclosureStockbasedCompensationScheduleOfAssumptionsUsedToDetermineFairValueOfStockPurchaseRightsUnderEsppDetails", "http://bridgebio.com/20220630/taxonomy/role/Role_DisclosureDebtAdditionalInformationDetails", "http://bridgebio.com/20220630/taxonomy/role/Role_DisclosureEidosAdditionalInformationDetails", "http://bridgebio.com/20220630/taxonomy/role/Role_DisclosureShareRepurchaseProgramAndShelfRegistrationAdditionalInformationDetails", "http://bridgebio.com/20220630/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetails", "http://bridgebio.com/20220630/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "srt_RepurchaseAgreementCounterpartyNameDomain": { "auth_ref": [ "r53", "r54", "r120", "r121", "r303", "r343" ], "lang": { "en-us": { "role": { "documentation": "Named other party that participates in a financial transaction. Examples include, but not limited to, the name of the financial institution.", "label": "Counterparty Name [Domain]", "terseLabel": "Counterparty Name" } } }, "localname": "RepurchaseAgreementCounterpartyNameDomain", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://bridgebio.com/20220630/taxonomy/role/DisclosureIntangibleAssetsAdditionalInformationDetails", "http://bridgebio.com/20220630/taxonomy/role/DisclosureLicenseAndCollaborationAgreementsAdditionalInformationDetails", "http://bridgebio.com/20220630/taxonomy/role/Role_DisclosureDebtAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "srt_ScenarioForecastMember": { "auth_ref": [ "r136", "r382", "r726" ], "lang": { "en-us": { "role": { "documentation": "Information reported for future period. Excludes information expected to be reported in future period for effect on historical fact.", "label": "Forecast [Member]", "terseLabel": "Scenario Forecast" } } }, "localname": "ScenarioForecastMember", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://bridgebio.com/20220630/taxonomy/role/DisclosureRestructuringImpairmentAndRelatedChargesAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "srt_ScenarioUnspecifiedDomain": { "auth_ref": [ "r136", "r141", "r280", "r382" ], "lang": { "en-us": { "role": { "documentation": "Scenario reported, distinguishing information from actual fact. Includes, but is not limited to, pro forma and forecast. Excludes actual facts.", "label": "Scenario [Domain]" } } }, "localname": "ScenarioUnspecifiedDomain", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://bridgebio.com/20220630/taxonomy/role/DisclosureRestructuringImpairmentAndRelatedChargesAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis": { "auth_ref": [ "r215" ], "lang": { "en-us": { "role": { "documentation": "Information by name of investment including named security. Excludes entity that is consolidated.", "label": "Investment, Name [Axis]", "terseLabel": "Investment, Name" } } }, "localname": "ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://bridgebio.com/20220630/taxonomy/role/DisclosureEquityMethodAndOtherEquityInvestmentsAdditionalInformationDetail", "http://bridgebio.com/20220630/taxonomy/role/DisclosureFairValueMeasurementsAdditionalInformationDetails" ], "xbrltype": "stringItemType" }, "srt_StatementScenarioAxis": { "auth_ref": [ "r136", "r141", "r280", "r382", "r585" ], "lang": { "en-us": { "role": { "documentation": "Information by scenario reported, distinguishing information from actual fact. Includes, but is not limited to, pro forma and forecast. Excludes actual facts.", "label": "Scenario [Axis]" } } }, "localname": "StatementScenarioAxis", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://bridgebio.com/20220630/taxonomy/role/DisclosureRestructuringImpairmentAndRelatedChargesAdditionalInformationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_AccountingPoliciesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Accounting Policies [Abstract]" } } }, "localname": "AccountingPoliciesAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_AccountingStandardsUpdate201409Member": { "auth_ref": [ "r369" ], "lang": { "en-us": { "role": { "documentation": "Accounting Standards Update 2014-09 Revenue from Contracts with Customers (Topic 606).", "label": "Accounting Standards Update 2014-09 [Member]", "terseLabel": "ASC 606" } } }, "localname": "AccountingStandardsUpdate201409Member", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://bridgebio.com/20220630/taxonomy/role/DisclosureLicenseAndCollaborationAgreementsAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_AccountingStandardsUpdate201818Member": { "auth_ref": [ "r466", "r467" ], "lang": { "en-us": { "role": { "documentation": "Accounting Standards Update 2018-18 Collaborative Arrangements (Topic 808): Clarifying the Interaction between Topic 808 and Topic 606.", "label": "Accounting Standards Update 2018-18 [Member]", "terseLabel": "ASC 808" } } }, "localname": "AccountingStandardsUpdate201818Member", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://bridgebio.com/20220630/taxonomy/role/DisclosureLicenseAndCollaborationAgreementsAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_AccountingStandardsUpdate202006Member": { "auth_ref": [ "r500", "r501", "r502", "r503", "r504", "r505", "r506", "r507", "r508", "r509", "r510" ], "lang": { "en-us": { "role": { "documentation": "Accounting Standards Update 2020-06 Debt - Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging - Contracts in Entity's Own Equity (Subtopic 815-40): Accounting for Convertible Instruments and Contracts in an Entity's Own Equity.", "label": "Accounting Standards Update 2020-06 [Member]", "terseLabel": "(ASU 2020-06)" } } }, "localname": "AccountingStandardsUpdate202006Member", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://bridgebio.com/20220630/taxonomy/role/StatementCondensedConsolidatedStatementsOfRedeemableConvertibleNoncontrollingInterestsAndStockholdersEquityUnaudited" ], "xbrltype": "domainItemType" }, "us-gaap_AccountsPayableCurrent": { "auth_ref": [ "r33", "r583" ], "calculation": { "http://bridgebio.com/20220630/taxonomy/role/Role_StatementCondensedConsolidatedBalanceSheets": { "order": 0.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).", "label": "Accounts Payable, Current", "terseLabel": "Accounts payable", "totalLabel": "Accounts Payable, Current, Total" } } }, "localname": "AccountsPayableCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://bridgebio.com/20220630/taxonomy/role/Role_StatementCondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccountsPayableMember": { "auth_ref": [ "r11" ], "lang": { "en-us": { "role": { "documentation": "Obligations incurred and payable to vendors for goods and services received.", "label": "Accounts Payable [Member]", "terseLabel": "Accounts Payable" } } }, "localname": "AccountsPayableMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://bridgebio.com/20220630/taxonomy/role/DisclosureRestructuringImpairmentAndRelatedChargesScheduleOfActivityRelatedToRestructuringLiabilitiesAssociatedToRestructuringInitiativesDeta" ], "xbrltype": "domainItemType" }, "us-gaap_AccretionExpense": { "auth_ref": [ "r258", "r262" ], "calculation": { "http://bridgebio.com/20220630/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited": { "order": 9.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount recognized for the passage of time, typically for liabilities, that have been discounted to their net present values. Excludes accretion associated with asset retirement obligations.", "label": "Accretion Expense", "terseLabel": "Accretion of debt" } } }, "localname": "AccretionExpense", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://bridgebio.com/20220630/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccruedProfessionalFeesCurrent": { "auth_ref": [ "r37" ], "calculation": { "http://bridgebio.com/20220630/taxonomy/role/Role_StatementCondensedConsolidatedBalanceSheets": { "order": 3.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying value as of the balance sheet date of obligations incurred through that date and payable for professional fees, such as for legal and accounting services received. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).", "label": "Accrued Professional Fees, Current", "terseLabel": "Accrued professional services" } } }, "localname": "AccruedProfessionalFeesCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://bridgebio.com/20220630/taxonomy/role/Role_StatementCondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax": { "auth_ref": [ "r28", "r57", "r58", "r59", "r661", "r685", "r689" ], "calculation": { "http://bridgebio.com/20220630/taxonomy/role/Role_StatementCondensedConsolidatedBalanceSheets": { "order": 4.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Accumulated change in equity from transactions and other events and circumstances from non-owner sources, net of tax effect, at period end. Excludes Net Income (Loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners. Includes foreign currency translation items, certain pension adjustments, unrealized gains and losses on certain investments in debt and equity securities, other than temporary impairment (OTTI) losses related to factors other than credit losses on available-for-sale and held-to-maturity debt securities that an entity does not intend to sell and it is not more likely than not that the entity will be required to sell before recovery of the amortized cost basis, as well as changes in the fair value of derivatives related to the effective portion of a designated cash flow hedge.", "label": "Accumulated Other Comprehensive Income (Loss), Net of Tax", "terseLabel": "Accumulated other comprehensive loss", "totalLabel": "Accumulated Other Comprehensive Income (Loss), Net of Tax, Total" } } }, "localname": "AccumulatedOtherComprehensiveIncomeLossNetOfTax", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://bridgebio.com/20220630/taxonomy/role/Role_StatementCondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccumulatedOtherComprehensiveIncomeMember": { "auth_ref": [ "r56", "r59", "r65", "r66", "r67", "r124", "r125", "r126", "r480", "r576", "r680", "r681" ], "lang": { "en-us": { "role": { "documentation": "Accumulated increase (decrease) in equity from transactions and other events and circumstances from non-owner sources, attributable to the parent. Excludes net income (loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners.", "label": "AOCI Attributable to Parent [Member]", "terseLabel": "Accumulated Other Comprehensive Income (Loss)" } } }, "localname": "AccumulatedOtherComprehensiveIncomeMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://bridgebio.com/20220630/taxonomy/role/StatementCondensedConsolidatedStatementsOfRedeemableConvertibleNoncontrollingInterestsAndStockholdersEquityUnaudited" ], "xbrltype": "domainItemType" }, "us-gaap_AcquiredFiniteLivedIntangibleAssetsLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Acquired Finite-Lived Intangible Assets [Line Items]" } } }, "localname": "AcquiredFiniteLivedIntangibleAssetsLineItems", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://bridgebio.com/20220630/taxonomy/role/DisclosureIntangibleAssetsSummaryOfRecognizedIntangibleAssetsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife": { "auth_ref": [ "r244" ], "lang": { "en-us": { "role": { "documentation": "Weighted average amortization period of finite-lived intangible assets acquired either individually or as part of a group of assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.", "label": "Acquired Finite-Lived Intangible Assets, Weighted Average Useful Life", "terseLabel": "Weighted average Estimated Useful Lives" } } }, "localname": "AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://bridgebio.com/20220630/taxonomy/role/DisclosureIntangibleAssetsSummaryOfRecognizedIntangibleAssetsDetails" ], "xbrltype": "durationItemType" }, "us-gaap_AdditionalPaidInCapitalCommonStock": { "auth_ref": [ "r26" ], "calculation": { "http://bridgebio.com/20220630/taxonomy/role/Role_StatementCondensedConsolidatedBalanceSheets": { "order": 3.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Value received from shareholders in common stock-related transactions that are in excess of par value or stated value and amounts received from other stock-related transactions. Includes only common stock transactions (excludes preferred stock transactions). May be called contributed capital, capital in excess of par, capital surplus, or paid-in capital.", "label": "Additional Paid in Capital, Common Stock", "periodEndLabel": "Additional Paid in Capital, Common Stock, Ending Balance", "periodStartLabel": "Additional Paid in Capital, Common Stock, Beginning Balance", "terseLabel": "Additional paid-in capital" } } }, "localname": "AdditionalPaidInCapitalCommonStock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://bridgebio.com/20220630/taxonomy/role/Role_StatementCondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AdditionalPaidInCapitalMember": { "auth_ref": [ "r124", "r125", "r126", "r431", "r432", "r433", "r508" ], "lang": { "en-us": { "role": { "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders.", "label": "Additional Paid-in Capital [Member]", "terseLabel": "Additional Paid-in Capital" } } }, "localname": "AdditionalPaidInCapitalMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://bridgebio.com/20220630/taxonomy/role/Role_DisclosureEidosAdditionalInformationDetails", "http://bridgebio.com/20220630/taxonomy/role/StatementCondensedConsolidatedStatementsOfRedeemableConvertibleNoncontrollingInterestsAndStockholdersEquityUnaudited" ], "xbrltype": "domainItemType" }, "us-gaap_AdjustmentsForNewAccountingPronouncementsAxis": { "auth_ref": [ "r0", "r1", "r2", "r3", "r4", "r129", "r130", "r131", "r132", "r141", "r193", "r194", "r224", "r225", "r226", "r227", "r228", "r229", "r431", "r432", "r433", "r446", "r447", "r448", "r449", "r457", "r458", "r459", "r500", "r501", "r502", "r503", "r504", "r505", "r506", "r507", "r508", "r509", "r510", "r511", "r524", "r525", "r527", "r528", "r529", "r530", "r531", "r532", "r541", "r542", "r550", "r551", "r552", "r553", "r571", "r572", "r573", "r574", "r575", "r576", "r623", "r624", "r625", "r678", "r679", "r680", "r681", "r682", "r683", "r684", "r685", "r686", "r687", "r688", "r689" ], "lang": { "en-us": { "role": { "documentation": "Information by amendment to accounting standards.", "label": "Accounting Standards Update [Axis]", "terseLabel": "Accounting Standards Update" } } }, "localname": "AdjustmentsForNewAccountingPronouncementsAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://bridgebio.com/20220630/taxonomy/role/DisclosureLicenseAndCollaborationAgreementsAdditionalInformationDetails", "http://bridgebio.com/20220630/taxonomy/role/StatementCondensedConsolidatedStatementsOfRedeemableConvertibleNoncontrollingInterestsAndStockholdersEquityUnaudited" ], "xbrltype": "stringItemType" }, "us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of decrease to equity for grantee's tax withholding obligation for award under share-based payment arrangement.", "label": "Share-Based Payment Arrangement, Decrease for Tax Withholding Obligation", "negatedLabel": "Repurchase of shares to satisfy tax withholding" } } }, "localname": "AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://bridgebio.com/20220630/taxonomy/role/StatementCondensedConsolidatedStatementsOfRedeemableConvertibleNoncontrollingInterestsAndStockholdersEquityUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebtSubsequentAdjustments": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The amount of subsequent adjustments to additional paid in capital for convertible financial instruments where a component of equity and a component of debt are recognized.", "label": "Adjustments to Additional Paid in Capital, Equity Component of Convertible Debt, Subsequent Adjustments", "terseLabel": "Equity component of 2027 Notes, net of issuance costs and deferred tax liability" } } }, "localname": "AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebtSubsequentAdjustments", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://bridgebio.com/20220630/taxonomy/role/StatementCondensedConsolidatedStatementsOfRedeemableConvertibleNoncontrollingInterestsAndStockholdersEquityUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue": { "auth_ref": [ "r386", "r435", "r436" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.", "label": "APIC, Share-Based Payment Arrangement, Increase for Cost Recognition", "terseLabel": "Stock-based compensation", "totalLabel": "APIC, Share-based Payment Arrangement, Increase for Cost Recognition, Total" } } }, "localname": "AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://bridgebio.com/20220630/taxonomy/role/StatementCondensedConsolidatedStatementsOfRedeemableConvertibleNoncontrollingInterestsAndStockholdersEquityUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts": { "auth_ref": [ "r356", "r362" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of decrease in additional paid in capital (APIC) resulting from direct costs associated with issuing stock. Includes, but is not limited to, legal and accounting fees and direct costs associated with stock issues under a shelf registration.", "label": "Adjustments to Additional Paid in Capital, Stock Issued, Issuance Costs", "terseLabel": "Debt issuance costs allocated to equity component" } } }, "localname": "AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://bridgebio.com/20220630/taxonomy/role/Role_DisclosureDebtAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]", "terseLabel": "Adjustments to reconcile net loss to net cash used in operating activities:" } } }, "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://bridgebio.com/20220630/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited" ], "xbrltype": "stringItemType" }, "us-gaap_AllocatedShareBasedCompensationExpense": { "auth_ref": [ "r423" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.", "label": "Share-Based Payment Arrangement, Expense", "terseLabel": "Total stock-based compensation", "verboseLabel": "Stock-based compensation" } } }, "localname": "AllocatedShareBasedCompensationExpense", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://bridgebio.com/20220630/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetails", "http://bridgebio.com/20220630/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfRecognizedStockBasedCompensationExpenseRelatedToRestrictedStockAwardActivityDetails", "http://bridgebio.com/20220630/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfStockBasedCompensationForEmployeesAndNonEmployeesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AmortizationOfDebtDiscountPremium": { "auth_ref": [ "r80", "r100", "r322", "r544" ], "calculation": { "http://bridgebio.com/20220630/taxonomy/role/Role_DisclosureDebtScheduleOfTotalInterestExpenseRecognizedRelatedToNotesDetails": { "order": 1.0, "parentTag": "us-gaap_InterestExpenseDebt", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of noncash expense included in interest expense to amortize debt discount and premium associated with the related debt instruments. Excludes amortization of financing costs. Alternate captions include noncash interest expense.", "label": "Amortization of Debt Discount (Premium)", "terseLabel": "Amortization of debt discount" } } }, "localname": "AmortizationOfDebtDiscountPremium", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://bridgebio.com/20220630/taxonomy/role/Role_DisclosureDebtScheduleOfTotalInterestExpenseRecognizedRelatedToNotesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AmortizationOfFinancingCosts": { "auth_ref": [ "r74", "r100", "r322", "r546" ], "calculation": { "http://bridgebio.com/20220630/taxonomy/role/Role_DisclosureDebtScheduleOfTotalInterestExpenseRecognizedRelatedToNotesDetails": { "order": 2.0, "parentTag": "us-gaap_InterestExpenseDebt", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of amortization expense attributable to debt issuance costs.", "label": "Amortization of Debt Issuance Costs", "verboseLabel": "Amortization of debt issuance costs" } } }, "localname": "AmortizationOfFinancingCosts", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://bridgebio.com/20220630/taxonomy/role/Role_DisclosureDebtScheduleOfTotalInterestExpenseRecognizedRelatedToNotesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AmortizationOfFinancingCostsAndDiscounts": { "auth_ref": [ "r100", "r322", "r336", "r337", "r546" ], "calculation": { "http://bridgebio.com/20220630/taxonomy/role/Role_DisclosureDebtScheduleOfTotalInterestExpenseRecognizedRelatedToNotesDetails": { "order": 3.0, "parentTag": "us-gaap_InterestExpenseDebt", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of amortization expense attributable to debt discount (premium) and debt issuance costs.", "label": "Amortization of Debt Issuance Costs and Discounts", "terseLabel": "Amortization of debt discount and issuance costs", "totalLabel": "Amortization of Debt Issuance Costs and Discounts, Total" } } }, "localname": "AmortizationOfFinancingCostsAndDiscounts", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://bridgebio.com/20220630/taxonomy/role/Role_DisclosureDebtAdditionalInformationDetails", "http://bridgebio.com/20220630/taxonomy/role/Role_DisclosureDebtScheduleOfTotalInterestExpenseRecognizedRelatedToNotesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AmortizationOfIntangibleAssets": { "auth_ref": [ "r100", "r242", "r248" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method.", "label": "Amortization of Intangible Assets", "totalLabel": "Amortization of Intangible Assets, Total", "verboseLabel": "Amortization expenses" } } }, "localname": "AmortizationOfIntangibleAssets", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://bridgebio.com/20220630/taxonomy/role/DisclosureIntangibleAssetsAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": { "auth_ref": [ "r152" ], "lang": { "en-us": { "role": { "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.", "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount", "terseLabel": "Antidilutive securities excluded from computation of diluted net loss per share" } } }, "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://bridgebio.com/20220630/taxonomy/role/Role_DisclosureNetLossPerShareScheduleOfCommonStockEquivalentsWereExcludedFromComputationOfDilutedNetLossPerShareDetail" ], "xbrltype": "sharesItemType" }, "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis": { "auth_ref": [ "r152" ], "lang": { "en-us": { "role": { "documentation": "Information by type of antidilutive security.", "label": "Antidilutive Securities [Axis]", "terseLabel": "Antidilutive Securities" } } }, "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://bridgebio.com/20220630/taxonomy/role/Role_DisclosureNetLossPerShareScheduleOfCommonStockEquivalentsWereExcludedFromComputationOfDilutedNetLossPerShareDetail" ], "xbrltype": "stringItemType" }, "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]", "terseLabel": "Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]" } } }, "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://bridgebio.com/20220630/taxonomy/role/Role_DisclosureNetLossPerShareScheduleOfCommonStockEquivalentsWereExcludedFromComputationOfDilutedNetLossPerShareDetail" ], "xbrltype": "stringItemType" }, "us-gaap_AntidilutiveSecuritiesNameDomain": { "auth_ref": [ "r152" ], "lang": { "en-us": { "role": { "documentation": "Incremental common shares attributable to securities that were not included in diluted earnings per share (EPS) because to do so would increase EPS amounts or decrease loss per share amounts for the period presented.", "label": "Antidilutive Securities, Name [Domain]", "terseLabel": "Antidilutive Securities, Name" } } }, "localname": "AntidilutiveSecuritiesNameDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://bridgebio.com/20220630/taxonomy/role/Role_DisclosureNetLossPerShareScheduleOfCommonStockEquivalentsWereExcludedFromComputationOfDilutedNetLossPerShareDetail" ], "xbrltype": "domainItemType" }, "us-gaap_ArrangementsAndNonarrangementTransactionsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.", "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Domain]", "terseLabel": "Collaborative Arrangement and Arrangement Other than Collaborative" } } }, "localname": "ArrangementsAndNonarrangementTransactionsMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://bridgebio.com/20220630/taxonomy/role/DisclosureIntangibleAssetsAdditionalInformationDetails", "http://bridgebio.com/20220630/taxonomy/role/DisclosureLicenseAndCollaborationAgreementsAdditionalInformationDetails", "http://bridgebio.com/20220630/taxonomy/role/Role_DisclosureDebtAdditionalInformationDetails", "http://bridgebio.com/20220630/taxonomy/role/Role_DisclosureEidosAdditionalInformationDetails", "http://bridgebio.com/20220630/taxonomy/role/Role_DisclosureLeasesAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_AssetAcquisitionLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Asset Acquisition [Line Items]" } } }, "localname": "AssetAcquisitionLineItems", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://bridgebio.com/20220630/taxonomy/role/DisclosureSaleOfNonfinancialAssetsAdditionalInformationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_AssetAcquisitionTable": { "auth_ref": [ "r463" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of information about asset acquisition.", "label": "Asset Acquisition [Table]" } } }, "localname": "AssetAcquisitionTable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://bridgebio.com/20220630/taxonomy/role/DisclosureSaleOfNonfinancialAssetsAdditionalInformationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_Assets": { "auth_ref": [ "r16", "r116", "r177", "r181", "r187", "r217", "r288", "r289", "r290", "r291", "r292", "r293", "r294", "r295", "r296", "r297", "r298", "r475", "r481", "r523", "r581", "r583", "r640", "r659" ], "calculation": { "http://bridgebio.com/20220630/taxonomy/role/Role_StatementCondensedConsolidatedBalanceSheets": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.", "label": "Assets", "totalLabel": "Total assets" } } }, "localname": "Assets", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://bridgebio.com/20220630/taxonomy/role/Role_StatementCondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AssetsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Assets [Abstract]", "terseLabel": "Assets" } } }, "localname": "AssetsAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://bridgebio.com/20220630/taxonomy/role/Role_StatementCondensedConsolidatedBalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_AssetsCurrent": { "auth_ref": [ "r9", "r32", "r116", "r217", "r288", "r289", "r290", "r291", "r292", "r293", "r294", "r295", "r296", "r297", "r298", "r475", "r481", "r523", "r581", "r583" ], "calculation": { "http://bridgebio.com/20220630/taxonomy/role/Role_StatementCondensedConsolidatedBalanceSheets": { "order": 0.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.", "label": "Assets, Current", "totalLabel": "Total current assets" } } }, "localname": "AssetsCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://bridgebio.com/20220630/taxonomy/role/Role_StatementCondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AssetsCurrentAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Assets, Current [Abstract]", "terseLabel": "Current assets:" } } }, "localname": "AssetsCurrentAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://bridgebio.com/20220630/taxonomy/role/Role_StatementCondensedConsolidatedBalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_AssetsFairValueDisclosure": { "auth_ref": [ "r512" ], "calculation": { "http://bridgebio.com/20220630/taxonomy/role/DisclosureFairValueMeasurementsFinancialAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Fair value portion of probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.", "label": "Assets, Fair Value Disclosure", "totalLabel": "Total financial assets" } } }, "localname": "AssetsFairValueDisclosure", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://bridgebio.com/20220630/taxonomy/role/DisclosureFairValueMeasurementsFinancialAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AssetsFairValueDisclosureAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Assets, Fair Value Disclosure [Abstract]", "terseLabel": "Assets" } } }, "localname": "AssetsFairValueDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://bridgebio.com/20220630/taxonomy/role/DisclosureFairValueMeasurementsFinancialAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails" ], "xbrltype": "stringItemType" }, "us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax": { "auth_ref": [ "r201" ], "calculation": { "http://bridgebio.com/20220630/taxonomy/role/Role_DisclosureCashEquivalentsAndMarketableSecuritiesScheduleOfCashEquivalentAndMarketableSecuritiesClassifiedAsAvailableForSaleDetails": { "order": 0.0, "parentTag": "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount, before tax, of unrealized gain in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).", "label": "Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Gain, before Tax", "terseLabel": "Unrealized Gains" } } }, "localname": "AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://bridgebio.com/20220630/taxonomy/role/Role_DisclosureCashEquivalentsAndMarketableSecuritiesScheduleOfCashEquivalentAndMarketableSecuritiesClassifiedAsAvailableForSaleDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax": { "auth_ref": [ "r202" ], "calculation": { "http://bridgebio.com/20220630/taxonomy/role/Role_DisclosureCashEquivalentsAndMarketableSecuritiesScheduleOfCashEquivalentAndMarketableSecuritiesClassifiedAsAvailableForSaleDetails": { "order": 1.0, "parentTag": "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount, before tax, of unrealized loss in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).", "label": "Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Loss, before Tax", "negatedLabel": "Unrealized Losses" } } }, "localname": "AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://bridgebio.com/20220630/taxonomy/role/Role_DisclosureCashEquivalentsAndMarketableSecuritiesScheduleOfCashEquivalentAndMarketableSecuritiesClassifiedAsAvailableForSaleDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis": { "auth_ref": [ "r199", "r235" ], "calculation": { "http://bridgebio.com/20220630/taxonomy/role/Role_DisclosureCashEquivalentsAndMarketableSecuritiesScheduleOfCashEquivalentAndMarketableSecuritiesClassifiedAsAvailableForSaleDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).", "label": "Debt Securities, Available-for-Sale, Amortized Cost", "totalLabel": "Amortized Cost Basis" } } }, "localname": "AvailableForSaleDebtSecuritiesAmortizedCostBasis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://bridgebio.com/20220630/taxonomy/role/Role_DisclosureCashEquivalentsAndMarketableSecuritiesScheduleOfCashEquivalentAndMarketableSecuritiesClassifiedAsAvailableForSaleDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AvailableForSaleSecuritiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Debt Securities, Available-for-Sale [Abstract]", "terseLabel": "Marketable securities:" } } }, "localname": "AvailableForSaleSecuritiesAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://bridgebio.com/20220630/taxonomy/role/DisclosureFairValueMeasurementsFinancialAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails" ], "xbrltype": "stringItemType" }, "us-gaap_AvailableForSaleSecuritiesDebtSecurities": { "auth_ref": [ "r195", "r200", "r235", "r645" ], "calculation": { "http://bridgebio.com/20220630/taxonomy/role/Role_DisclosureCashEquivalentsAndMarketableSecuritiesScheduleOfCashEquivalentAndMarketableSecuritiesClassifiedAsAvailableForSaleDetails": { "order": 2.0, "parentTag": "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).", "label": "Debt Securities, Available-for-Sale", "terseLabel": "Estimated Fair Value", "totalLabel": "Debt Securities, Available-for-sale, Total" } } }, "localname": "AvailableForSaleSecuritiesDebtSecurities", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://bridgebio.com/20220630/taxonomy/role/Role_DisclosureCashEquivalentsAndMarketableSecuritiesScheduleOfCashEquivalentAndMarketableSecuritiesClassifiedAsAvailableForSaleDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent": { "auth_ref": [ "r197", "r235" ], "calculation": { "http://bridgebio.com/20220630/taxonomy/role/DisclosureFairValueMeasurementsFinancialAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails": { "order": 1.0, "parentTag": "us-gaap_AssetsFairValueDisclosure", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), classified as current.", "label": "Debt Securities, Available-for-Sale, Current", "terseLabel": "Total marketable securities", "totalLabel": "Debt Securities, Available-for-sale, Current, Total" } } }, "localname": "AvailableForSaleSecuritiesDebtSecuritiesCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://bridgebio.com/20220630/taxonomy/role/DisclosureFairValueMeasurementsFinancialAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AwardTypeAxis": { "auth_ref": [ "r389", "r390", "r391", "r394", "r395", "r396", "r397", "r398", "r399", "r400", "r401", "r403", "r404", "r405", "r406", "r407", "r408", "r410", "r411", "r413", "r414", "r417", "r418", "r419", "r420", "r421" ], "lang": { "en-us": { "role": { "documentation": "Information by type of award under share-based payment arrangement.", "label": "Award Type [Axis]", "terseLabel": "Award Type", "verboseLabel": "Restricted Stock Units (RSUs)" } } }, "localname": "AwardTypeAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://bridgebio.com/20220630/taxonomy/role/DisclosureStockbasedCompensationScheduleOfAssumptionsUsedToDetermineFairValueOfStockPurchaseRightsUnderEsppDetails", "http://bridgebio.com/20220630/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetail", "http://bridgebio.com/20220630/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetails", "http://bridgebio.com/20220630/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfRecognizedStockBasedCompensationExpenseRelatedToRestrictedStockAwardActivityDetails", "http://bridgebio.com/20220630/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfRestrictedStockAwardActivityUnderPlansDetails", "http://bridgebio.com/20220630/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfRestrictedStockUnitsActivityDetails", "http://bridgebio.com/20220630/taxonomy/role/Role_DisclosureStockBasedCompensationTables", "http://bridgebio.com/20220630/taxonomy/role/StatementCondensedConsolidatedStatementsOfRedeemableConvertibleNoncontrollingInterestsAndStockholdersEquityUnaudited" ], "xbrltype": "stringItemType" }, "us-gaap_BalanceSheetLocationAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Information by location on balance sheet (statement of financial position).", "label": "Balance Sheet Location [Axis]", "terseLabel": "Balance Sheet Location" } } }, "localname": "BalanceSheetLocationAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://bridgebio.com/20220630/taxonomy/role/DisclosureLicenseAndCollaborationAgreementsAdditionalInformationDetails", "http://bridgebio.com/20220630/taxonomy/role/DisclosureRestructuringImpairmentAndRelatedChargesScheduleOfActivityRelatedToRestructuringLiabilitiesAssociatedToRestructuringInitiativesDeta", "http://bridgebio.com/20220630/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetail", "http://bridgebio.com/20220630/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetails", "http://bridgebio.com/20220630/taxonomy/role/Role_DisclosureLeasesAdditionalInformationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_BalanceSheetLocationDomain": { "auth_ref": [ "r493", "r495" ], "lang": { "en-us": { "role": { "documentation": "Location in the balance sheet (statement of financial position).", "label": "Balance Sheet Location [Domain]", "terseLabel": "Balance Sheet Location" } } }, "localname": "BalanceSheetLocationDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://bridgebio.com/20220630/taxonomy/role/DisclosureLicenseAndCollaborationAgreementsAdditionalInformationDetails", "http://bridgebio.com/20220630/taxonomy/role/DisclosureRestructuringImpairmentAndRelatedChargesScheduleOfActivityRelatedToRestructuringLiabilitiesAssociatedToRestructuringInitiativesDeta", "http://bridgebio.com/20220630/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetail", "http://bridgebio.com/20220630/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetails", "http://bridgebio.com/20220630/taxonomy/role/Role_DisclosureLeasesAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_BasisOfAccountingPolicyPolicyTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).", "label": "Basis of Accounting, Policy [Policy Text Block]", "terseLabel": "Basis of Presentation and Principles of Consolidation" } } }, "localname": "BasisOfAccountingPolicyPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://bridgebio.com/20220630/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_BusinessAcquisitionProFormaInformationAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Business Acquisition, Pro Forma Information [Abstract]" } } }, "localname": "BusinessAcquisitionProFormaInformationAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_BusinessCombinationConsiderationTransferred1": { "auth_ref": [ "r460", "r461", "r462" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of consideration transferred, consisting of acquisition-date fair value of assets transferred by the acquirer, liabilities incurred by the acquirer, and equity interest issued by the acquirer.", "label": "Business Combination, Consideration Transferred", "terseLabel": "Aggregate consideration", "totalLabel": "Business Combination, Consideration Transferred, Total" } } }, "localname": "BusinessCombinationConsiderationTransferred1", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://bridgebio.com/20220630/taxonomy/role/Role_DisclosureEidosAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessCombinationsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Business Combinations [Abstract]" } } }, "localname": "BusinessCombinationsAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_BusinessExitCosts1": { "auth_ref": [ "r100" ], "calculation": { "http://bridgebio.com/20220630/taxonomy/role/DisclosureRestructuringImpairmentAndRelatedChargesSummaryOfRestructuringImpairmentAndRelatedChargesDetails": { "order": 3.0, "parentTag": "us-gaap_RestructuringSettlementAndImpairmentProvisions", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of expenses associated with exit or disposal activities pursuant to an authorized plan. Includes, but is not limited to, one-time termination benefits, termination of an operating lease or other contract, consolidating or closing facilities, and relocating employees, and termination benefits associated with an ongoing benefit arrangement. Excludes expenses associated with special or contractual termination benefits, a discontinued operation or an asset retirement obligation.", "label": "Business Exit Costs", "terseLabel": "Exit and other related costs" } } }, "localname": "BusinessExitCosts1", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://bridgebio.com/20220630/taxonomy/role/DisclosureRestructuringImpairmentAndRelatedChargesSummaryOfRestructuringImpairmentAndRelatedChargesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_CapitalExpendituresIncurredButNotYetPaid": { "auth_ref": [ "r105", "r106", "r107" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Future cash outflow to pay for purchases of fixed assets that have occurred.", "label": "Capital Expenditures Incurred but Not yet Paid", "terseLabel": "Unpaid property and equipment" } } }, "localname": "CapitalExpendituresIncurredButNotYetPaid", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://bridgebio.com/20220630/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashAndCashEquivalentsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Cash and Cash Equivalents [Abstract]" } } }, "localname": "CashAndCashEquivalentsAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_CashAndCashEquivalentsAtCarryingValue": { "auth_ref": [ "r7", "r12", "r102" ], "calculation": { "http://bridgebio.com/20220630/taxonomy/role/Role_StatementCondensedConsolidatedBalanceSheets": { "order": 0.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 }, "http://bridgebio.com/20220630/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited": { "order": 0.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.", "label": "Cash and Cash Equivalents, at Carrying Value", "periodEndLabel": "Cash and Cash Equivalents, at Carrying Value, Ending Balance", "periodStartLabel": "Cash and Cash Equivalents, at Carrying Value, Beginning Balance", "terseLabel": "Cash and cash equivalents", "totalLabel": "Cash and Cash Equivalents, at Carrying Value, Total" } } }, "localname": "CashAndCashEquivalentsAtCarryingValue", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://bridgebio.com/20220630/taxonomy/role/Role_StatementCondensedConsolidatedBalanceSheets", "http://bridgebio.com/20220630/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashAndCashEquivalentsFairValueDisclosure": { "auth_ref": [], "calculation": { "http://bridgebio.com/20220630/taxonomy/role/DisclosureFairValueMeasurementsFinancialAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails": { "order": 3.0, "parentTag": "us-gaap_AssetsFairValueDisclosure", "weight": 1.0 }, "http://bridgebio.com/20220630/taxonomy/role/Role_DisclosureCashEquivalentsAndMarketableSecuritiesScheduleOfCashEquivalentAndMarketableSecuritiesClassifiedAsAvailableForSaleDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Fair value portion of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "Cash and Cash Equivalents, Fair Value Disclosure", "terseLabel": "Total cash equivalents", "totalLabel": "Cash Equivalents, Estimated Fair Value", "verboseLabel": "Cash Equivalents, Estimated Fair Value" } } }, "localname": "CashAndCashEquivalentsFairValueDisclosure", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://bridgebio.com/20220630/taxonomy/role/DisclosureFairValueMeasurementsFinancialAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails", "http://bridgebio.com/20220630/taxonomy/role/Role_DisclosureCashEquivalentsAndMarketableSecuritiesScheduleOfCashEquivalentAndMarketableSecuritiesClassifiedAsAvailableForSaleDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashAndCashEquivalentsLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Cash and Cash Equivalents [Line Items]", "terseLabel": "Cash And Cash Equivalents [Line Items]" } } }, "localname": "CashAndCashEquivalentsLineItems", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://bridgebio.com/20220630/taxonomy/role/Role_DisclosureCashEquivalentsAndMarketableSecuritiesScheduleOfCashEquivalentAndMarketableSecuritiesClassifiedAsAvailableForSaleDetails" ], "xbrltype": "stringItemType" }, "us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy": { "auth_ref": [ "r103", "r639" ], "lang": { "en-us": { "role": { "documentation": "Entity's cash and cash equivalents accounting policy with respect to restricted balances. Restrictions may include legally restricted deposits held as compensating balances against short-term borrowing arrangements, contracts entered into with others, or company statements of intention with regard to particular deposits; however, time deposits and short-term certificates of deposit are not generally included in legally restricted deposits.", "label": "Cash and Cash Equivalents, Restricted Cash and Cash Equivalents, Policy [Policy Text Block]", "terseLabel": "Restricted Cash" } } }, "localname": "CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://bridgebio.com/20220630/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_CashCashEquivalentsAndMarketableSecuritiesTextBlock": { "auth_ref": [ "r207" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure of cash, cash equivalents, and debt and equity securities, including any unrealized or realized gain (loss).", "label": "Cash, Cash Equivalents, and Marketable Securities [Text Block]", "terseLabel": "Cash Equivalents and Marketable Securities" } } }, "localname": "CashCashEquivalentsAndMarketableSecuritiesTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://bridgebio.com/20220630/taxonomy/role/Role_DisclosureCashEquivalentsAndMarketableSecurities" ], "xbrltype": "textBlockItemType" }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": { "auth_ref": [ "r96", "r102", "r108" ], "calculation": { "http://bridgebio.com/20220630/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents", "periodEndLabel": "Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Ending Balance", "periodStartLabel": "Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Beginning Balance", "totalLabel": "Total cash, cash equivalents and restricted cash at end of period shown in the condensed consolidated statements of cash flows" } } }, "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://bridgebio.com/20220630/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents [Abstract]", "terseLabel": "Reconciliation of Cash, Cash Equivalents and Restricted Cash:" } } }, "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://bridgebio.com/20220630/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited" ], "xbrltype": "stringItemType" }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations": { "auth_ref": [ "r96", "r102", "r108" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including, but not limited to, disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Including Disposal Group and Discontinued Operations", "periodEndLabel": "Cash, cash equivalents and restricted cash at end of period", "periodStartLabel": "Cash, cash equivalents and restricted cash at beginning of period", "totalLabel": "Total cash, cash equivalents and restricted cash shown in the condensed consolidated statements of cash flows" } } }, "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://bridgebio.com/20220630/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": { "auth_ref": [ "r96", "r533" ], "calculation": { "http://bridgebio.com/20220630/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect", "totalLabel": "Net increase in cash, cash equivalents and restricted cash" } } }, "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://bridgebio.com/20220630/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashEquivalentsAtCarryingValue": { "auth_ref": [ "r12" ], "calculation": { "http://bridgebio.com/20220630/taxonomy/role/Role_DisclosureCashEquivalentsAndMarketableSecuritiesScheduleOfCashEquivalentAndMarketableSecuritiesClassifiedAsAvailableForSaleDetails": { "order": 0.0, "parentTag": "us-gaap_CashAndCashEquivalentsFairValueDisclosure", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.", "label": "Cash Equivalents, at Carrying Value", "terseLabel": "Amortized Cost Basis Cash Equivalents", "totalLabel": "Cash Equivalents, at Carrying Value, Total" } } }, "localname": "CashEquivalentsAtCarryingValue", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://bridgebio.com/20220630/taxonomy/role/Role_DisclosureCashEquivalentsAndMarketableSecuritiesScheduleOfCashEquivalentAndMarketableSecuritiesClassifiedAsAvailableForSaleDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashFlowOperatingActivitiesLesseeAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Cash Flow, Operating Activities, Lessee [Abstract]", "terseLabel": "Cash paid for amounts included in the measurement of lease liabilities" } } }, "localname": "CashFlowOperatingActivitiesLesseeAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://bridgebio.com/20220630/taxonomy/role/Role_DisclosureLeasesScheduleOfSupplementalCashFlowInformationRelatedToLeasesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted": { "auth_ref": [ "r0", "r1", "r128", "r193", "r194", "r220", "r221", "r222", "r224", "r225", "r446", "r457", "r458", "r497", "r500", "r501", "r511", "r524", "r526", "r527", "r528", "r531", "r532", "r541", "r549", "r550", "r551", "r552", "r571", "r572", "r623", "r624", "r678", "r679" ], "lang": { "en-us": { "role": { "documentation": "Indicates (true false) whether accounting standards update was adopted.", "label": "Change in Accounting Principle, Accounting Standards Update, Adopted [true false]", "terseLabel": "Change in accounting principle, accounting standards update, adopted" } } }, "localname": "ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://bridgebio.com/20220630/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails" ], "xbrltype": "booleanItemType" }, "us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdoptionDate": { "auth_ref": [ "r0", "r1", "r135", "r193", "r194", "r220", "r221", "r222", "r224", "r225", "r446", "r457", "r458", "r459", "r497", "r500", "r501", "r502", "r505", "r511", "r524", "r526", "r527", "r528", "r531", "r532", "r541", "r549", "r550", "r551", "r552", "r571", "r572", "r623", "r624", "r678", "r679" ], "lang": { "en-us": { "role": { "documentation": "Date accounting standards update was adopted, in YYYY-MM-DD format.", "label": "Change in Accounting Principle, Accounting Standards Update, Adoption Date", "terseLabel": "Change in accounting principle, accounting standards update, adoption date" } } }, "localname": "ChangeInAccountingPrincipleAccountingStandardsUpdateAdoptionDate", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://bridgebio.com/20220630/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails" ], "xbrltype": "dateItemType" }, "us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateEarlyAdoption": { "auth_ref": [ "r4", "r128", "r194", "r220", "r223", "r226", "r447", "r459", "r497", "r502", "r505", "r511", "r525", "r526", "r529", "r530", "r532", "r542", "r549", "r551", "r552", "r625", "r678", "r679" ], "lang": { "en-us": { "role": { "documentation": "Indicates (true false) whether accounting standards update was early adopted.", "label": "Change in Accounting Principle, Accounting Standards Update, Early Adoption [true false]", "terseLabel": "Change in accounting principle, accounting standards update, early adoption" } } }, "localname": "ChangeInAccountingPrincipleAccountingStandardsUpdateEarlyAdoption", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://bridgebio.com/20220630/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails" ], "xbrltype": "booleanItemType" }, "us-gaap_ClassOfStockDomain": { "auth_ref": [ "r22", "r23", "r24", "r113", "r116", "r145", "r146", "r147", "r149", "r151", "r159", "r160", "r161", "r217", "r288", "r292", "r293", "r294", "r297", "r298", "r340", "r341", "r345", "r349", "r356", "r523", "r717" ], "lang": { "en-us": { "role": { "documentation": "Share of stock differentiated by the voting rights the holder receives. Examples include, but are not limited to, common stock, redeemable preferred stock, nonredeemable preferred stock, and convertible stock.", "label": "Class of Stock [Domain]", "terseLabel": "Class of Stock" } } }, "localname": "ClassOfStockDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://bridgebio.com/20220630/taxonomy/role/StatementCondensedConsolidatedStatementsOfRedeemableConvertibleNoncontrollingInterestsAndStockholdersEquityUnaudited" ], "xbrltype": "domainItemType" }, "us-gaap_CollaborativeArrangementAccountingPolicy": { "auth_ref": [ "r464" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for collaborative arrangements.", "label": "Collaborative Arrangement, Accounting Policy [Policy Text Block]", "terseLabel": "Collaborative Arrangements" } } }, "localname": "CollaborativeArrangementAccountingPolicy", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://bridgebio.com/20220630/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]", "terseLabel": "Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]" } } }, "localname": "CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://bridgebio.com/20220630/taxonomy/role/DisclosureLicenseAndCollaborationAgreementsAdditionalInformationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_CommercialPaperMember": { "auth_ref": [ "r286" ], "lang": { "en-us": { "role": { "documentation": "Unsecured promissory note (generally negotiable) that provides institutions with short-term funds.", "label": "Commercial Paper [Member]", "terseLabel": "Commercial Paper" } } }, "localname": "CommercialPaperMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://bridgebio.com/20220630/taxonomy/role/DisclosureFairValueMeasurementsFinancialAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails", "http://bridgebio.com/20220630/taxonomy/role/Role_DisclosureCashEquivalentsAndMarketableSecuritiesScheduleOfCashEquivalentAndMarketableSecuritiesClassifiedAsAvailableForSaleDetails" ], "xbrltype": "domainItemType" }, "us-gaap_CommitmentsAndContingencies": { "auth_ref": [ "r46", "r647", "r666" ], "calculation": { "http://bridgebio.com/20220630/taxonomy/role/Role_StatementCondensedConsolidatedBalanceSheets": { "order": 1.0, "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.", "label": "Commitments and Contingencies", "terseLabel": "Commitments and contingencies (Note 9)" } } }, "localname": "CommitmentsAndContingencies", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://bridgebio.com/20220630/taxonomy/role/Role_StatementCondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Commitments and Contingencies Disclosure [Abstract]" } } }, "localname": "CommitmentsAndContingenciesDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": { "auth_ref": [ "r277", "r278", "r279", "r285", "r707" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for commitments and contingencies.", "label": "Commitments and Contingencies Disclosure [Text Block]", "terseLabel": "Commitments and Contingencies" } } }, "localname": "CommitmentsAndContingenciesDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://bridgebio.com/20220630/taxonomy/role/Role_DisclosureCommitmentsAndContingencies" ], "xbrltype": "textBlockItemType" }, "us-gaap_CommonStockCapitalSharesReservedForFutureIssuance": { "auth_ref": [ "r48" ], "lang": { "en-us": { "role": { "documentation": "Aggregate number of common shares reserved for future issuance.", "label": "Common Stock, Capital Shares Reserved for Future Issuance", "terseLabel": "Common shares reserved for future issuance" } } }, "localname": "CommonStockCapitalSharesReservedForFutureIssuance", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://bridgebio.com/20220630/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockMember": { "auth_ref": [ "r124", "r125", "r508" ], "lang": { "en-us": { "role": { "documentation": "Stock that is subordinate to all other stock of the issuer.", "label": "Common Stock [Member]", "terseLabel": "Common Stock" } } }, "localname": "CommonStockMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://bridgebio.com/20220630/taxonomy/role/DisclosureEquityMethodAndOtherEquityInvestmentsAdditionalInformationDetail", "http://bridgebio.com/20220630/taxonomy/role/Role_DisclosureShareRepurchaseProgramAndShelfRegistrationAdditionalInformationDetails", "http://bridgebio.com/20220630/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetails", "http://bridgebio.com/20220630/taxonomy/role/StatementCondensedConsolidatedStatementsOfRedeemableConvertibleNoncontrollingInterestsAndStockholdersEquityUnaudited" ], "xbrltype": "domainItemType" }, "us-gaap_CommonStockParOrStatedValuePerShare": { "auth_ref": [ "r24" ], "lang": { "en-us": { "role": { "documentation": "Face amount or stated value per share of common stock.", "label": "Common Stock, Par or Stated Value Per Share", "terseLabel": "Common stock, par value" } } }, "localname": "CommonStockParOrStatedValuePerShare", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://bridgebio.com/20220630/taxonomy/role/Role_StatementCondensedConsolidatedBalanceSheetsParenthetical" ], "xbrltype": "perShareItemType" }, "us-gaap_CommonStockSharesAuthorized": { "auth_ref": [ "r24" ], "lang": { "en-us": { "role": { "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws.", "label": "Common Stock, Shares Authorized", "terseLabel": "Common stock, shares authorized" } } }, "localname": "CommonStockSharesAuthorized", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://bridgebio.com/20220630/taxonomy/role/Role_StatementCondensedConsolidatedBalanceSheetsParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockSharesIssued": { "auth_ref": [ "r24" ], "lang": { "en-us": { "role": { "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.", "label": "Common Stock, Shares, Issued", "terseLabel": "Common stock, shares issued", "totalLabel": "Common Stock, Shares, Issued, Total" } } }, "localname": "CommonStockSharesIssued", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://bridgebio.com/20220630/taxonomy/role/Role_StatementCondensedConsolidatedBalanceSheetsParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockSharesOutstanding": { "auth_ref": [ "r24", "r356" ], "lang": { "en-us": { "role": { "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.", "label": "Common Stock, Shares, Outstanding", "periodEndLabel": "Common Stock, Shares, Outstanding, Ending Balance", "periodStartLabel": "Common Stock, Shares, Outstanding, Beginning Balance", "terseLabel": "Common stock, shares outstanding" } } }, "localname": "CommonStockSharesOutstanding", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://bridgebio.com/20220630/taxonomy/role/Role_StatementCondensedConsolidatedBalanceSheetsParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockValue": { "auth_ref": [ "r24", "r583" ], "calculation": { "http://bridgebio.com/20220630/taxonomy/role/Role_StatementCondensedConsolidatedBalanceSheets": { "order": 1.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.", "label": "Common Stock, Value, Issued", "periodEndLabel": "Common Stock, Value, Issued, Ending Balance", "periodStartLabel": "Common Stock, Value, Issued, Beginning Balance", "terseLabel": "Common stock, $0.001 par value; 500,000,000 shares authorized; 154,434,958 shares issued and 148,243,197 shares outstanding as of June 30, 2022, 153,535,084 shares issued and 147,343,323 shares outstanding as of December 31, 2021", "totalLabel": "Common Stock, Value, Issued, Total" } } }, "localname": "CommonStockValue", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://bridgebio.com/20220630/taxonomy/role/Role_StatementCondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_ComprehensiveIncomeNetOfTax": { "auth_ref": [ "r61", "r63", "r64", "r71", "r650", "r670" ], "calculation": { "http://bridgebio.com/20220630/taxonomy/role/StatementCondensedConsolidatedStatementsOfComprehensiveLossUnaudited": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.", "label": "Comprehensive Income (Loss), Net of Tax, Attributable to Parent", "totalLabel": "Comprehensive loss attributable to common stockholders of BridgeBio" } } }, "localname": "ComprehensiveIncomeNetOfTax", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://bridgebio.com/20220630/taxonomy/role/StatementCondensedConsolidatedStatementsOfComprehensiveLossUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest": { "auth_ref": [ "r61", "r63", "r70", "r471", "r472", "r491", "r649", "r669" ], "calculation": { "http://bridgebio.com/20220630/taxonomy/role/StatementCondensedConsolidatedStatementsOfComprehensiveLossUnaudited": { "order": 1.0, "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income (loss) and other comprehensive income (loss), attributable to noncontrolling interests. Excludes changes in equity resulting from investments by owners and distributions to owners.", "label": "Comprehensive Income (Loss), Net of Tax, Attributable to Noncontrolling Interest", "negatedLabel": "Comprehensive loss (income) attributable to redeemable convertible noncontrolling interests and noncontrolling interests", "totalLabel": "Comprehensive Income (Loss), Net of Tax, Attributable to Noncontrolling Interest, Total" } } }, "localname": "ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://bridgebio.com/20220630/taxonomy/role/StatementCondensedConsolidatedStatementsOfComprehensiveLossUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest": { "auth_ref": [ "r61", "r63", "r69", "r470", "r491", "r648", "r668" ], "calculation": { "http://bridgebio.com/20220630/taxonomy/role/StatementCondensedConsolidatedStatementsOfComprehensiveLossUnaudited": { "order": 0.0, "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income. Excludes changes in equity resulting from investments by owners and distributions to owners.", "label": "Comprehensive Income (Loss), Net of Tax, Including Portion Attributable to Noncontrolling Interest", "totalLabel": "Comprehensive loss" } } }, "localname": "ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://bridgebio.com/20220630/taxonomy/role/StatementCondensedConsolidatedStatementsOfComprehensiveLossUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_ConstructionInProgressMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Structure or a modification to a structure under construction. Includes recently completed structures or modifications to structures that have not been placed into service.", "label": "Construction in Progress [Member]", "terseLabel": "Construction-in-Progress" } } }, "localname": "ConstructionInProgressMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://bridgebio.com/20220630/taxonomy/role/Role_DisclosureLeasesAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ContingentConsiderationByTypeAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Information by type of contingent consideration.", "label": "Contingent Consideration by Type [Axis]", "terseLabel": "Contingent Consideration by Type" } } }, "localname": "ContingentConsiderationByTypeAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://bridgebio.com/20220630/taxonomy/role/DisclosureIntangibleAssetsAdditionalInformationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ContingentConsiderationTypeDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Description of contingent payment arrangement.", "label": "Contingent Consideration Type [Domain]", "terseLabel": "Contingent Consideration Type" } } }, "localname": "ContingentConsiderationTypeDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://bridgebio.com/20220630/taxonomy/role/DisclosureIntangibleAssetsAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ContractualObligation": { "auth_ref": [], "calculation": { "http://bridgebio.com/20220630/taxonomy/role/Role_DisclosureDebtScheduleOfFutureMinimumPaymentsUnderNotesDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of contractual obligation, including but not limited to, long-term debt, capital lease obligations, operating lease obligations, purchase obligations, and other commitments.", "label": "Contractual Obligation", "totalLabel": "Total future payments" } } }, "localname": "ContractualObligation", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://bridgebio.com/20220630/taxonomy/role/DisclosureDebtScheduleOfFutureMinimumPaymentsUnderTermLoanAgreementDetails", "http://bridgebio.com/20220630/taxonomy/role/Role_DisclosureDebtScheduleOfFutureMinimumPaymentsUnderNotesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ContractualObligationDueInFourthYear": { "auth_ref": [], "calculation": { "http://bridgebio.com/20220630/taxonomy/role/Role_DisclosureDebtScheduleOfFutureMinimumPaymentsUnderNotesDetails": { "order": 4.0, "parentTag": "us-gaap_ContractualObligation", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of contractual obligation to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Contractual Obligation, to be Paid, Year Four", "terseLabel": "2026" } } }, "localname": "ContractualObligationDueInFourthYear", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://bridgebio.com/20220630/taxonomy/role/DisclosureDebtScheduleOfFutureMinimumPaymentsUnderTermLoanAgreementDetails", "http://bridgebio.com/20220630/taxonomy/role/Role_DisclosureDebtScheduleOfFutureMinimumPaymentsUnderNotesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ContractualObligationDueInNextTwelveMonths": { "auth_ref": [], "calculation": { "http://bridgebio.com/20220630/taxonomy/role/Role_DisclosureDebtScheduleOfFutureMinimumPaymentsUnderNotesDetails": { "order": 1.0, "parentTag": "us-gaap_ContractualObligation", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of contractual obligation to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Contractual Obligation, to be Paid, Year One", "terseLabel": "2023" } } }, "localname": "ContractualObligationDueInNextTwelveMonths", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://bridgebio.com/20220630/taxonomy/role/DisclosureDebtScheduleOfFutureMinimumPaymentsUnderTermLoanAgreementDetails", "http://bridgebio.com/20220630/taxonomy/role/Role_DisclosureDebtScheduleOfFutureMinimumPaymentsUnderNotesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ContractualObligationDueInSecondYear": { "auth_ref": [], "calculation": { "http://bridgebio.com/20220630/taxonomy/role/Role_DisclosureDebtScheduleOfFutureMinimumPaymentsUnderNotesDetails": { "order": 2.0, "parentTag": "us-gaap_ContractualObligation", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of contractual obligation to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Contractual Obligation, to be Paid, Year Two", "terseLabel": "2024" } } }, "localname": "ContractualObligationDueInSecondYear", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://bridgebio.com/20220630/taxonomy/role/DisclosureDebtScheduleOfFutureMinimumPaymentsUnderTermLoanAgreementDetails", "http://bridgebio.com/20220630/taxonomy/role/Role_DisclosureDebtScheduleOfFutureMinimumPaymentsUnderNotesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ContractualObligationDueInThirdYear": { "auth_ref": [], "calculation": { "http://bridgebio.com/20220630/taxonomy/role/Role_DisclosureDebtScheduleOfFutureMinimumPaymentsUnderNotesDetails": { "order": 3.0, "parentTag": "us-gaap_ContractualObligation", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of contractual obligation to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Contractual Obligation, to be Paid, Year Three", "terseLabel": "2025" } } }, "localname": "ContractualObligationDueInThirdYear", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://bridgebio.com/20220630/taxonomy/role/DisclosureDebtScheduleOfFutureMinimumPaymentsUnderTermLoanAgreementDetails", "http://bridgebio.com/20220630/taxonomy/role/Role_DisclosureDebtScheduleOfFutureMinimumPaymentsUnderNotesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ContractualObligationFutureMinimumPaymentsDueRemainderOfFiscalYear": { "auth_ref": [], "calculation": { "http://bridgebio.com/20220630/taxonomy/role/Role_DisclosureDebtScheduleOfFutureMinimumPaymentsUnderNotesDetails": { "order": 0.0, "parentTag": "us-gaap_ContractualObligation", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of contractual obligation to be paid in remainder of current fiscal year.", "label": "Contractual Obligation, to be Paid, Remainder of Fiscal Year", "terseLabel": "Remainder of 2022", "verboseLabel": "2022" } } }, "localname": "ContractualObligationFutureMinimumPaymentsDueRemainderOfFiscalYear", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://bridgebio.com/20220630/taxonomy/role/DisclosureDebtScheduleOfFutureMinimumPaymentsUnderTermLoanAgreementDetails", "http://bridgebio.com/20220630/taxonomy/role/Role_DisclosureDebtScheduleOfFutureMinimumPaymentsUnderNotesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ConvertibleLongTermNotesPayable": { "auth_ref": [ "r44" ], "calculation": { "http://bridgebio.com/20220630/taxonomy/role/Role_DisclosureDebtScheduleOfOutstandingNotesBalancesDetails": { "order": null, "parentTag": null, "root": true, "weight": null }, "http://bridgebio.com/20220630/taxonomy/role/Role_StatementCondensedConsolidatedBalanceSheets": { "order": 1.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying value as of the balance sheet date of long-term debt (with maturities initially due after one year or beyond the operating cycle if longer) identified as Convertible Notes Payable, excluding current portion. Convertible Notes Payable is a written promise to pay a note which can be exchanged for a specified amount of another, related security, at the option of the issuer and the holder.", "label": "Convertible Notes Payable, Noncurrent", "terseLabel": "Notes, net", "totalLabel": "Net carrying amount" } } }, "localname": "ConvertibleLongTermNotesPayable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://bridgebio.com/20220630/taxonomy/role/Role_DisclosureDebtScheduleOfOutstandingNotesBalancesDetails", "http://bridgebio.com/20220630/taxonomy/role/Role_StatementCondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_CorporateDebtSecuritiesMember": { "auth_ref": [ "r371", "r379", "r690" ], "lang": { "en-us": { "role": { "documentation": "Debt securities issued by domestic or foreign corporate business, banks and other entities with a promise of repayment.", "label": "Corporate Debt Securities [Member]", "terseLabel": "Corporate Debt Securities" } } }, "localname": "CorporateDebtSecuritiesMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://bridgebio.com/20220630/taxonomy/role/DisclosureFairValueMeasurementsFinancialAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails", "http://bridgebio.com/20220630/taxonomy/role/Role_DisclosureCashEquivalentsAndMarketableSecuritiesScheduleOfCashEquivalentAndMarketableSecuritiesClassifiedAsAvailableForSaleDetails" ], "xbrltype": "domainItemType" }, "us-gaap_CostsAndExpenses": { "auth_ref": [ "r75" ], "calculation": { "http://bridgebio.com/20220630/taxonomy/role/StatementCondensedConsolidatedStatementsOfOperationsUnaudited": { "order": 1.0, "parentTag": "us-gaap_OperatingIncomeLoss", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Total costs of sales and operating expenses for the period.", "label": "Costs and Expenses", "totalLabel": "Total operating costs and expenses" } } }, "localname": "CostsAndExpenses", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://bridgebio.com/20220630/taxonomy/role/StatementCondensedConsolidatedStatementsOfOperationsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_CostsAndExpensesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Costs and Expenses [Abstract]", "terseLabel": "Operating costs and expenses:" } } }, "localname": "CostsAndExpensesAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://bridgebio.com/20220630/taxonomy/role/StatementCondensedConsolidatedStatementsOfOperationsUnaudited" ], "xbrltype": "stringItemType" }, "us-gaap_CostsAssociatedWithExitOrDisposalActivitiesOrRestructuringsPolicyTextBlock": { "auth_ref": [ "r268", "r269", "r275" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for recognizing and reporting costs associated with exiting, disposing of, and restructuring certain operations.", "label": "Costs Associated with Exit or Disposal Activities or Restructurings, Policy [Policy Text Block]", "terseLabel": "Restructuring, Impairment and Related Charges" } } }, "localname": "CostsAssociatedWithExitOrDisposalActivitiesOrRestructuringsPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://bridgebio.com/20220630/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_DebtDisclosureAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Debt Disclosure [Abstract]" } } }, "localname": "DebtDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_DebtDisclosureTextBlock": { "auth_ref": [ "r112", "r305", "r306", "r307", "r308", "r309", "r310", "r311", "r316", "r323", "r324", "r326", "r338" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants.", "label": "Debt Disclosure [Text Block]", "terseLabel": "Debt" } } }, "localname": "DebtDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://bridgebio.com/20220630/taxonomy/role/Role_DisclosureDebt" ], "xbrltype": "textBlockItemType" }, "us-gaap_DebtInstrumentAxis": { "auth_ref": [ "r17", "r19", "r20", "r115", "r122", "r299", "r300", "r301", "r302", "r303", "r304", "r306", "r312", "r313", "r314", "r315", "r317", "r318", "r319", "r320", "r321", "r322", "r334", "r335", "r336", "r337", "r547", "r641", "r642", "r658" ], "lang": { "en-us": { "role": { "documentation": "Information by type of debt instrument, including, but not limited to, draws against credit facilities.", "label": "Debt Instrument [Axis]", "terseLabel": "Debt Instrument" } } }, "localname": "DebtInstrumentAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://bridgebio.com/20220630/taxonomy/role/DisclosureFairValueMeasurementsAdditionalInformationDetails", "http://bridgebio.com/20220630/taxonomy/role/Role_DisclosureDebtAdditionalInformationDetails", "http://bridgebio.com/20220630/taxonomy/role/Role_DisclosureDebtScheduleOfOutstandingNotesBalancesDetails", "http://bridgebio.com/20220630/taxonomy/role/Role_DisclosureDebtScheduleOfTotalInterestExpenseRecognizedRelatedToNotesDetails", "http://bridgebio.com/20220630/taxonomy/role/Role_DisclosureDebtTables", "http://bridgebio.com/20220630/taxonomy/role/Role_StatementCondensedConsolidatedBalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_DebtInstrumentBasisSpreadOnVariableRate1": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Percentage points added to the reference rate to compute the variable rate on the debt instrument.", "label": "Debt Instrument, Basis Spread on Variable Rate", "terseLabel": "Interest rate" } } }, "localname": "DebtInstrumentBasisSpreadOnVariableRate1", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://bridgebio.com/20220630/taxonomy/role/Role_DisclosureDebtAdditionalInformationDetails" ], "xbrltype": "percentItemType" }, "us-gaap_DebtInstrumentCarryingAmount": { "auth_ref": [ "r20", "r327", "r642", "r658" ], "calculation": { "http://bridgebio.com/20220630/taxonomy/role/DisclosureDebtScheduleOfBalancesOfBorrowingUnderLoanAgreementDetails": { "order": 0.0, "parentTag": "us-gaap_LongTermDebt", "weight": 1.0 }, "http://bridgebio.com/20220630/taxonomy/role/Role_DisclosureDebtScheduleOfOutstandingNotesBalancesDetails": { "order": 1.0, "parentTag": "us-gaap_ConvertibleLongTermNotesPayable", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount, before unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but is not limited to, notes payable, bonds payable, commercial loans, mortgage loans, convertible debt, subordinated debt and other types of debt.", "label": "Long-Term Debt, Gross", "terseLabel": "Principal value of term loans", "verboseLabel": "Principal" } } }, "localname": "DebtInstrumentCarryingAmount", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://bridgebio.com/20220630/taxonomy/role/DisclosureDebtScheduleOfBalancesOfBorrowingUnderLoanAgreementDetails", "http://bridgebio.com/20220630/taxonomy/role/Role_DisclosureDebtScheduleOfOutstandingNotesBalancesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DebtInstrumentConvertibleConversionPrice1": { "auth_ref": [ "r301", "r330" ], "lang": { "en-us": { "role": { "documentation": "The price per share of the conversion feature embedded in the debt instrument.", "label": "Debt Instrument, Convertible, Conversion Price", "terseLabel": "Initial conversion price per share" } } }, "localname": "DebtInstrumentConvertibleConversionPrice1", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://bridgebio.com/20220630/taxonomy/role/Role_DisclosureDebtAdditionalInformationDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_DebtInstrumentConvertibleConversionRatio1": { "auth_ref": [ "r42", "r301", "r357", "r358", "r360" ], "lang": { "en-us": { "role": { "documentation": "Ratio applied to the conversion of debt instrument into equity with equity shares divided by debt principal amount.", "label": "Debt Instrument, Convertible, Conversion Ratio", "terseLabel": "Conversion rate" } } }, "localname": "DebtInstrumentConvertibleConversionRatio1", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://bridgebio.com/20220630/taxonomy/role/Role_DisclosureDebtAdditionalInformationDetails" ], "xbrltype": "pureItemType" }, "us-gaap_DebtInstrumentConvertibleIfConvertedValueInExcessOfPrincipal": { "auth_ref": [ "r331" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The amount by which the convertible debt's if-converted value exceeds its principle amount at the balance sheet date, regardless of whether the instrument is currently convertible. This element applies to public companies only.", "label": "Debt Instrument, Convertible, If-converted Value in Excess of Principal", "terseLabel": "Debt instrument, convertible, if-converted value of notes in excess of principal amount" } } }, "localname": "DebtInstrumentConvertibleIfConvertedValueInExcessOfPrincipal", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://bridgebio.com/20220630/taxonomy/role/Role_DisclosureDebtAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DebtInstrumentConvertibleNumberOfEquityInstruments": { "auth_ref": [ "r42", "r301", "r357", "r358", "r360" ], "lang": { "en-us": { "role": { "documentation": "The number of equity instruments that the holder of the debt instrument would receive if the debt was converted to equity.", "label": "Debt Instrument, Convertible, Number of Equity Instruments", "terseLabel": "Debt instrument, conversion, equivalent shares of common stock" } } }, "localname": "DebtInstrumentConvertibleNumberOfEquityInstruments", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://bridgebio.com/20220630/taxonomy/role/Role_DisclosureDebtAdditionalInformationDetails" ], "xbrltype": "integerItemType" }, "us-gaap_DebtInstrumentConvertibleThresholdConsecutiveTradingDays1": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Threshold period of specified consecutive trading days within which common stock price to conversion price of convertible debt instrument must exceed threshold percentage for specified number of trading days to trigger conversion feature.", "label": "Debt Instrument, Convertible, Threshold Consecutive Trading Days", "terseLabel": "Debt instrument, convertible, threshold consecutive trading days" } } }, "localname": "DebtInstrumentConvertibleThresholdConsecutiveTradingDays1", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://bridgebio.com/20220630/taxonomy/role/Role_DisclosureDebtAdditionalInformationDetails" ], "xbrltype": "integerItemType" }, "us-gaap_DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Minimum percentage of common stock price to conversion price of convertible debt instruments to determine eligibility of conversion.", "label": "Debt Instrument, Convertible, Threshold Percentage of Stock Price Trigger", "terseLabel": "Debt instrument, convertible, threshold percentage of stock price trigger" } } }, "localname": "DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://bridgebio.com/20220630/taxonomy/role/Role_DisclosureDebtAdditionalInformationDetails" ], "xbrltype": "percentItemType" }, "us-gaap_DebtInstrumentConvertibleThresholdTradingDays": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Threshold number of specified trading days that common stock price to conversion price of convertible debt instruments must exceed threshold percentage within a specified consecutive trading period to trigger conversion feature.", "label": "Debt Instrument, Convertible, Threshold Trading Days", "terseLabel": "Debt instrument, convertible, threshold trading days" } } }, "localname": "DebtInstrumentConvertibleThresholdTradingDays", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://bridgebio.com/20220630/taxonomy/role/Role_DisclosureDebtAdditionalInformationDetails" ], "xbrltype": "integerItemType" }, "us-gaap_DebtInstrumentDateOfFirstRequiredPayment1": { "auth_ref": [ "r44", "r656" ], "lang": { "en-us": { "role": { "documentation": "Date the debt agreement requires the first payment to be made, in YYYY-MM-DD format.", "label": "Debt Instrument, Date of First Required Payment", "terseLabel": "Interest payable beginning date" } } }, "localname": "DebtInstrumentDateOfFirstRequiredPayment1", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://bridgebio.com/20220630/taxonomy/role/Role_DisclosureDebtAdditionalInformationDetails" ], "xbrltype": "dateItemType" }, "us-gaap_DebtInstrumentFaceAmount": { "auth_ref": [ "r299", "r334", "r335", "r545", "r547", "r548" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Face (par) amount of debt instrument at time of issuance.", "label": "Debt Instrument, Face Amount", "terseLabel": "Debt Instrument face amount", "verboseLabel": "Principal value" } } }, "localname": "DebtInstrumentFaceAmount", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://bridgebio.com/20220630/taxonomy/role/DisclosureFairValueMeasurementsAdditionalInformationDetails", "http://bridgebio.com/20220630/taxonomy/role/Role_DisclosureDebtAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DebtInstrumentFrequencyOfPeriodicPayment": { "auth_ref": [ "r44", "r656" ], "lang": { "en-us": { "role": { "documentation": "Description of the frequency of periodic payments (monthly, quarterly, annual).", "label": "Debt Instrument, Frequency of Periodic Payment", "terseLabel": "Debt instrument, frequency of interest payment" } } }, "localname": "DebtInstrumentFrequencyOfPeriodicPayment", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://bridgebio.com/20220630/taxonomy/role/Role_DisclosureDebtAdditionalInformationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DebtInstrumentInterestRateEffectivePercentage": { "auth_ref": [ "r39", "r332", "r545", "r547" ], "lang": { "en-us": { "role": { "documentation": "Effective interest rate for the funds borrowed under the debt agreement considering interest compounding and original issue discount or premium.", "label": "Debt Instrument, Interest Rate, Effective Percentage", "terseLabel": "Effective interest rate" } } }, "localname": "DebtInstrumentInterestRateEffectivePercentage", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://bridgebio.com/20220630/taxonomy/role/Role_DisclosureDebtScheduleOfTotalInterestExpenseRecognizedRelatedToNotesDetails" ], "xbrltype": "percentItemType" }, "us-gaap_DebtInstrumentInterestRateStatedPercentage": { "auth_ref": [ "r39", "r300" ], "lang": { "en-us": { "role": { "documentation": "Contractual interest rate for funds borrowed, under the debt agreement.", "label": "Debt Instrument, Interest Rate, Stated Percentage", "terseLabel": "Stated interest rate" } } }, "localname": "DebtInstrumentInterestRateStatedPercentage", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://bridgebio.com/20220630/taxonomy/role/Role_DisclosureDebtAdditionalInformationDetails" ], "xbrltype": "percentItemType" }, "us-gaap_DebtInstrumentLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Debt Instrument [Line Items]", "terseLabel": "Debt Instrument [Line Items]" } } }, "localname": "DebtInstrumentLineItems", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://bridgebio.com/20220630/taxonomy/role/DisclosureDebtScheduleOfBalancesOfBorrowingUnderLoanAgreementDetails", "http://bridgebio.com/20220630/taxonomy/role/DisclosureDebtScheduleOfFutureMinimumPaymentsUnderTermLoanAgreementDetails", "http://bridgebio.com/20220630/taxonomy/role/Role_DisclosureDebtAdditionalInformationDetails", "http://bridgebio.com/20220630/taxonomy/role/Role_DisclosureDebtScheduleOfFutureMinimumPaymentsUnderNotesDetails", "http://bridgebio.com/20220630/taxonomy/role/Role_DisclosureDebtScheduleOfOutstandingNotesBalancesDetails", "http://bridgebio.com/20220630/taxonomy/role/Role_DisclosureDebtScheduleOfTotalInterestExpenseRecognizedRelatedToNotesDetails", "http://bridgebio.com/20220630/taxonomy/role/Role_DisclosureDebtTables" ], "xbrltype": "stringItemType" }, "us-gaap_DebtInstrumentMaturityDate": { "auth_ref": [ "r40", "r302", "r516" ], "lang": { "en-us": { "role": { "documentation": "Date when the debt instrument is scheduled to be fully repaid, in YYYY-MM-DD format.", "label": "Debt Instrument, Maturity Date", "terseLabel": "Maturity date" } } }, "localname": "DebtInstrumentMaturityDate", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://bridgebio.com/20220630/taxonomy/role/Role_DisclosureDebtAdditionalInformationDetails" ], "xbrltype": "dateItemType" }, "us-gaap_DebtInstrumentNameDomain": { "auth_ref": [ "r44", "r115", "r122", "r299", "r300", "r301", "r302", "r303", "r304", "r306", "r312", "r313", "r314", "r315", "r317", "r318", "r319", "r320", "r321", "r322", "r334", "r335", "r336", "r337", "r547" ], "lang": { "en-us": { "role": { "documentation": "The name for the particular debt instrument or borrowing that distinguishes it from other debt instruments or borrowings, including draws against credit facilities.", "label": "Debt Instrument, Name [Domain]", "terseLabel": "Debt Instrument, Name" } } }, "localname": "DebtInstrumentNameDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://bridgebio.com/20220630/taxonomy/role/DisclosureFairValueMeasurementsAdditionalInformationDetails", "http://bridgebio.com/20220630/taxonomy/role/Role_DisclosureDebtAdditionalInformationDetails", "http://bridgebio.com/20220630/taxonomy/role/Role_DisclosureDebtScheduleOfOutstandingNotesBalancesDetails", "http://bridgebio.com/20220630/taxonomy/role/Role_DisclosureDebtScheduleOfTotalInterestExpenseRecognizedRelatedToNotesDetails", "http://bridgebio.com/20220630/taxonomy/role/Role_DisclosureDebtTables", "http://bridgebio.com/20220630/taxonomy/role/Role_StatementCondensedConsolidatedBalanceSheets" ], "xbrltype": "domainItemType" }, "us-gaap_DebtInstrumentOfferingDate1": { "auth_ref": [ "r20", "r357" ], "lang": { "en-us": { "role": { "documentation": "Date the debt instrument was offered for sale, in YYYY-MM-DD format.", "label": "Debt Instrument, Offering Date", "terseLabel": "Debt instrument issuance date" } } }, "localname": "DebtInstrumentOfferingDate1", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://bridgebio.com/20220630/taxonomy/role/Role_DisclosureDebtAdditionalInformationDetails" ], "xbrltype": "dateItemType" }, "us-gaap_DebtInstrumentPaymentTerms": { "auth_ref": [ "r41", "r656" ], "lang": { "en-us": { "role": { "documentation": "Description of the payment terms of the debt instrument (for example, whether periodic payments include principal and frequency of payments) and discussion about any contingencies associated with the payment.", "label": "Debt Instrument, Payment Terms", "terseLabel": "Description of payment terms of notes" } } }, "localname": "DebtInstrumentPaymentTerms", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://bridgebio.com/20220630/taxonomy/role/Role_DisclosureDebtAdditionalInformationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DebtInstrumentTable": { "auth_ref": [ "r44", "r115", "r122", "r299", "r300", "r301", "r302", "r303", "r304", "r306", "r312", "r313", "r314", "r315", "r317", "r318", "r319", "r320", "r321", "r322", "r325", "r334", "r335", "r336", "r337", "r357", "r359", "r360", "r361", "r544", "r545", "r547", "r548", "r657" ], "lang": { "en-us": { "role": { "documentation": "A table or schedule providing information pertaining to long-term debt instruments or arrangements, including identification, terms, features, collateral requirements and other information necessary to a fair presentation. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the company, if longer.", "label": "Schedule of Long-Term Debt Instruments [Table]", "terseLabel": "Debt Instrument [Table]" } } }, "localname": "DebtInstrumentTable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://bridgebio.com/20220630/taxonomy/role/DisclosureDebtScheduleOfBalancesOfBorrowingUnderLoanAgreementDetails", "http://bridgebio.com/20220630/taxonomy/role/DisclosureDebtScheduleOfFutureMinimumPaymentsUnderTermLoanAgreementDetails", "http://bridgebio.com/20220630/taxonomy/role/Role_DisclosureDebtAdditionalInformationDetails", "http://bridgebio.com/20220630/taxonomy/role/Role_DisclosureDebtScheduleOfFutureMinimumPaymentsUnderNotesDetails", "http://bridgebio.com/20220630/taxonomy/role/Role_DisclosureDebtScheduleOfOutstandingNotesBalancesDetails", "http://bridgebio.com/20220630/taxonomy/role/Role_DisclosureDebtScheduleOfTotalInterestExpenseRecognizedRelatedToNotesDetails", "http://bridgebio.com/20220630/taxonomy/role/Role_DisclosureDebtTables" ], "xbrltype": "stringItemType" }, "us-gaap_DebtInstrumentTerm": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Period of time between issuance and maturity of debt instrument, in PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.", "label": "Debt Instrument, Term", "terseLabel": "Expected life of notes" } } }, "localname": "DebtInstrumentTerm", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://bridgebio.com/20220630/taxonomy/role/Role_DisclosureDebtAdditionalInformationDetails" ], "xbrltype": "durationItemType" }, "us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet": { "auth_ref": [ "r312", "r328", "r334", "r335", "r546" ], "calculation": { "http://bridgebio.com/20220630/taxonomy/role/Role_DisclosureDebtScheduleOfOutstandingNotesBalancesDetails": { "order": 0.0, "parentTag": "us-gaap_ConvertibleLongTermNotesPayable", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of unamortized debt discount (premium) and debt issuance costs.", "label": "Debt Instrument, Unamortized Discount (Premium) and Debt Issuance Costs, Net", "negatedLabel": "Unamortized debt discount and issuance costs", "totalLabel": "Debt Instrument, Unamortized Discount (Premium) and Debt Issuance Costs, Net, Total" } } }, "localname": "DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://bridgebio.com/20220630/taxonomy/role/Role_DisclosureDebtScheduleOfOutstandingNotesBalancesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DebtInstrumentUnusedBorrowingCapacityAmount": { "auth_ref": [ "r43" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of unused borrowing capacity under the long-term financing arrangement that is available to the entity as of the balance sheet date.", "label": "Debt Instrument, Unused Borrowing Capacity, Amount", "terseLabel": "Debt instrument, amount available to be drawn" } } }, "localname": "DebtInstrumentUnusedBorrowingCapacityAmount", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://bridgebio.com/20220630/taxonomy/role/Role_DisclosureDebtAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger": { "auth_ref": [ "r205", "r237", "r240" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in continuous unrealized loss position for more than 12 months, without allowance for credit loss. Includes beneficial interest in securitized financial asset.", "label": "Debt Securities, Available-for-Sale, Continuous Unrealized Loss Position, 12 Months or Longer", "terseLabel": "Available-for-sale securities, continuous unrealized loss position, more than 12 months" } } }, "localname": "DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://bridgebio.com/20220630/taxonomy/role/Role_DisclosureCashEquivalentsAndMarketableSecuritiesAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DebtSecuritiesAvailableForSaleRealizedGainLoss": { "auth_ref": [ "r206" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of realized gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).", "label": "Debt Securities, Available-for-Sale, Realized Gain (Loss)", "terseLabel": "Realized gains or losses on available-for-sale securities", "totalLabel": "Debt Securities, Available-for-sale, Realized Gain (Loss), Total" } } }, "localname": "DebtSecuritiesAvailableForSaleRealizedGainLoss", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://bridgebio.com/20220630/taxonomy/role/Role_DisclosureCashEquivalentsAndMarketableSecuritiesAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredFinanceCostsNet": { "auth_ref": [ "r312", "r546" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount, after accumulated amortization, of debt issuance costs. Includes, but is not limited to, legal, accounting, underwriting, printing, and registration costs.", "label": "Debt Issuance Costs, Net", "negatedLabel": "Unamortized debt issuance costs", "terseLabel": "Debt issuance costs including initial purchasers discounts, legal and other professional fees", "totalLabel": "Debt Issuance Costs, Net, Total" } } }, "localname": "DeferredFinanceCostsNet", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://bridgebio.com/20220630/taxonomy/role/Role_DisclosureDebtAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredFinanceCostsNoncurrentNet": { "auth_ref": [ "r546" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount, after accumulated amortization, of debt issuance costs classified as noncurrent. Includes, but is not limited to, legal, accounting, underwriting, printing, and registration costs.", "label": "Debt Issuance Costs, Noncurrent, Net", "terseLabel": "Debt issuance costs allocated to liability component", "totalLabel": "Debt Issuance Costs, Noncurrent, Net, Total" } } }, "localname": "DeferredFinanceCostsNoncurrentNet", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://bridgebio.com/20220630/taxonomy/role/Role_DisclosureDebtAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredRevenue": { "auth_ref": [ "r21" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of deferred income and obligation to transfer product and service to customer for which consideration has been received or is receivable.", "label": "Deferred Revenue", "terseLabel": "Deferred Revenue", "totalLabel": "Deferred Revenue, Total" } } }, "localname": "DeferredRevenue", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://bridgebio.com/20220630/taxonomy/role/DisclosureLicenseAndCollaborationAgreementsAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredRevenueCurrent": { "auth_ref": [ "r19" ], "calculation": { "http://bridgebio.com/20220630/taxonomy/role/Role_StatementCondensedConsolidatedBalanceSheets": { "order": 6.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of deferred income and obligation to transfer product and service to customer for which consideration has been received or is receivable, classified as current.", "label": "Deferred Revenue, Current", "terseLabel": "Deferred revenue, current portion", "totalLabel": "Deferred Revenue, Current, Total" } } }, "localname": "DeferredRevenueCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://bridgebio.com/20220630/taxonomy/role/DisclosureLicenseAndCollaborationAgreementsAdditionalInformationDetails", "http://bridgebio.com/20220630/taxonomy/role/Role_StatementCondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredRevenueNoncurrent": { "auth_ref": [ "r21" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of deferred income and obligation to transfer product and service to customer for which consideration has been received or is receivable, classified as noncurrent.", "label": "Deferred Revenue, Noncurrent", "terseLabel": "Deferred Revenue Noncurrent", "totalLabel": "Deferred Revenue, Noncurrent, Total" } } }, "localname": "DeferredRevenueNoncurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://bridgebio.com/20220630/taxonomy/role/DisclosureLicenseAndCollaborationAgreementsAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxLiabilities": { "auth_ref": [ "r439", "r443" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount, after deferred tax asset, of deferred tax liability attributable to taxable differences without jurisdictional netting.", "label": "Deferred Tax Liabilities, Net", "terseLabel": "Deferred tax liability, net", "totalLabel": "Deferred Tax Liabilities, Net, Total" } } }, "localname": "DeferredTaxLiabilities", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://bridgebio.com/20220630/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DepreciationDepletionAndAmortization": { "auth_ref": [ "r100", "r175" ], "calculation": { "http://bridgebio.com/20220630/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited": { "order": 2.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.", "label": "Depreciation, Depletion and Amortization", "terseLabel": "Depreciation and amortization", "totalLabel": "Depreciation, Depletion and Amortization, Total" } } }, "localname": "DepreciationDepletionAndAmortization", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://bridgebio.com/20220630/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_DerivativeLiabilityMeasurementInput": { "auth_ref": [ "r516" ], "lang": { "en-us": { "role": { "documentation": "Value of input used to measure derivative liability.", "label": "Derivative Liability, Measurement Input", "terseLabel": "Measurement input" } } }, "localname": "DerivativeLiabilityMeasurementInput", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://bridgebio.com/20220630/taxonomy/role/DisclosureFairValueMeasurementsScheduleOfEstimatedFairValueOfLiabilityDetails" ], "xbrltype": "decimalItemType" }, "us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock": { "auth_ref": [ "r388", "r389", "r424", "r425", "r428", "r437" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for share-based payment arrangement.", "label": "Share-Based Payment Arrangement [Text Block]", "terseLabel": "Stock-Based Compensation" } } }, "localname": "DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://bridgebio.com/20220630/taxonomy/role/Role_DisclosureStockBasedCompensation" ], "xbrltype": "textBlockItemType" }, "us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Share-Based Payment Arrangement [Abstract]" } } }, "localname": "DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_DisposalGroupIncludingDiscontinuedOperationConsideration": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of consideration received or receivable for the disposal of assets and liabilities, including discontinued operation.", "label": "Disposal Group, Including Discontinued Operation, Consideration", "terseLabel": "Definitive agreement to sell" } } }, "localname": "DisposalGroupIncludingDiscontinuedOperationConsideration", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://bridgebio.com/20220630/taxonomy/role/DisclosureSaleOfNonfinancialAssetsAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DisposalGroupNotDiscontinuedOperationGainLossOnDisposal": { "auth_ref": [ "r100", "r251", "r255" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount before tax of gain (loss) recognized on the sale or disposal of a disposal group. Excludes discontinued operations.", "label": "Disposal Group, Not Discontinued Operation, Gain (Loss) on Disposal", "terseLabel": "Net gain recognized transaction costs", "verboseLabel": "Gain recognized, net of transactions costs" } } }, "localname": "DisposalGroupNotDiscontinuedOperationGainLossOnDisposal", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://bridgebio.com/20220630/taxonomy/role/DisclosureSaleOfNonfinancialAssetsAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain": { "auth_ref": [ "r380", "r383" ], "lang": { "en-us": { "role": { "documentation": "Name of disposal group.", "label": "Disposal Group Name [Domain]" } } }, "localname": "DisposalGroupsIncludingDiscontinuedOperationsNameDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://bridgebio.com/20220630/taxonomy/role/DisclosureSaleOfNonfinancialAssetsAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_EarningsPerShareAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Earnings Per Share [Abstract]" } } }, "localname": "EarningsPerShareAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_EarningsPerShareBasic": { "auth_ref": [ "r72", "r133", "r134", "r135", "r136", "r137", "r142", "r145", "r149", "r150", "r151", "r155", "r156", "r509", "r510", "r651", "r671" ], "lang": { "en-us": { "role": { "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.", "label": "Earnings Per Share, Basic", "terseLabel": "Net loss per share attributable to common stockholders of BridgeBio, basic", "totalLabel": "Earnings Per Share, Basic, Total" } } }, "localname": "EarningsPerShareBasic", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://bridgebio.com/20220630/taxonomy/role/StatementCondensedConsolidatedStatementsOfOperationsUnaudited" ], "xbrltype": "perShareItemType" }, "us-gaap_EarningsPerShareDiluted": { "auth_ref": [ "r72", "r133", "r134", "r135", "r136", "r137", "r145", "r149", "r150", "r151", "r155", "r156", "r509", "r510", "r651", "r671" ], "lang": { "en-us": { "role": { "documentation": "The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.", "label": "Earnings Per Share, Diluted", "terseLabel": "Net loss per share attributable to common stockholders of BridgeBio, diluted", "totalLabel": "Earnings Per Share, Diluted, Total" } } }, "localname": "EarningsPerShareDiluted", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://bridgebio.com/20220630/taxonomy/role/StatementCondensedConsolidatedStatementsOfOperationsUnaudited" ], "xbrltype": "perShareItemType" }, "us-gaap_EarningsPerShareTextBlock": { "auth_ref": [ "r152", "r153", "r154", "r157" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for earnings per share.", "label": "Earnings Per Share [Text Block]", "terseLabel": "Net Loss Per Share" } } }, "localname": "EarningsPerShareTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://bridgebio.com/20220630/taxonomy/role/Role_DisclosureNetLossPerShare" ], "xbrltype": "textBlockItemType" }, "us-gaap_EmbeddedDerivativeFairValueOfEmbeddedDerivativeLiability": { "auth_ref": [ "r494" ], "calculation": { "http://bridgebio.com/20220630/taxonomy/role/DisclosureFairValueMeasurementsFinancialAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails": { "order": 1.0, "parentTag": "us-gaap_FinancialLiabilitiesFairValueDisclosure", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Fair value as of the balance sheet date of the embedded derivative or group of embedded derivatives classified as a liability.", "label": "Embedded Derivative, Fair Value of Embedded Derivative Liability", "terseLabel": "Embedded derivative" } } }, "localname": "EmbeddedDerivativeFairValueOfEmbeddedDerivativeLiability", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://bridgebio.com/20220630/taxonomy/role/DisclosureFairValueMeasurementsFinancialAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_EmployeeRelatedLiabilitiesCurrent": { "auth_ref": [ "r37" ], "calculation": { "http://bridgebio.com/20220630/taxonomy/role/Role_StatementCondensedConsolidatedBalanceSheets": { "order": 1.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).", "label": "Employee-related Liabilities, Current", "terseLabel": "Accrued compensation and benefits", "totalLabel": "Employee-related Liabilities, Current, Total" } } }, "localname": "EmployeeRelatedLiabilitiesCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://bridgebio.com/20220630/taxonomy/role/Role_StatementCondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1": { "auth_ref": [ "r427" ], "lang": { "en-us": { "role": { "documentation": "Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.", "label": "Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition", "terseLabel": "Unrecognized compensation cost, period for recognition" } } }, "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://bridgebio.com/20220630/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetails" ], "xbrltype": "durationItemType" }, "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions": { "auth_ref": [ "r427" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cost to be recognized for nonvested award under share-based payment arrangement. Excludes share and unit options.", "label": "Share-Based Payment Arrangement, Nonvested Award, Excluding Option, Cost Not yet Recognized, Amount", "terseLabel": "Unrecognized compensation cost" } } }, "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://bridgebio.com/20220630/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions": { "auth_ref": [ "r427" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cost to be recognized for option under share-based payment arrangement.", "label": "Share-Based Payment Arrangement, Nonvested Award, Option, Cost Not yet Recognized, Amount", "terseLabel": "Unrecognized compensation cost" } } }, "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://bridgebio.com/20220630/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_EmployeeStockMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "An Employee Stock Purchase Plan is a tax-efficient means by which employees of a corporation can purchase the corporation's stock.", "label": "Employee Stock [Member]", "terseLabel": "Employee Stock Purchase Plan" } } }, "localname": "EmployeeStockMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://bridgebio.com/20220630/taxonomy/role/DisclosureStockbasedCompensationScheduleOfAssumptionsUsedToDetermineFairValueOfStockPurchaseRightsUnderEsppDetails", "http://bridgebio.com/20220630/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetails", "http://bridgebio.com/20220630/taxonomy/role/StatementCondensedConsolidatedStatementsOfRedeemableConvertibleNoncontrollingInterestsAndStockholdersEquityUnaudited" ], "xbrltype": "domainItemType" }, "us-gaap_EmployeeStockOptionMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Share-based payment arrangement granting right, subject to vesting and other restrictions, to purchase or sell certain number of shares at predetermined price for specified period of time.", "label": "Share-Based Payment Arrangement, Option [Member]", "terseLabel": "Employee Stock Options" } } }, "localname": "EmployeeStockOptionMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://bridgebio.com/20220630/taxonomy/role/DisclosureStockbasedCompensationScheduleOfAssumptionsUsedToDetermineFairValueOfStockPurchaseRightsUnderEsppDetails", "http://bridgebio.com/20220630/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_EquityComponentDomain": { "auth_ref": [ "r2", "r65", "r66", "r67", "r124", "r125", "r126", "r130", "r138", "r140", "r158", "r227", "r356", "r362", "r431", "r432", "r433", "r448", "r449", "r508", "r534", "r535", "r536", "r537", "r538", "r539", "r576", "r680", "r681", "r682" ], "lang": { "en-us": { "role": { "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc.", "label": "Equity Component [Domain]", "terseLabel": "Equity Component" } } }, "localname": "EquityComponentDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://bridgebio.com/20220630/taxonomy/role/DisclosureEquityMethodAndOtherEquityInvestmentsAdditionalInformationDetail", "http://bridgebio.com/20220630/taxonomy/role/Role_DisclosureEidosAdditionalInformationDetails", "http://bridgebio.com/20220630/taxonomy/role/Role_DisclosureShareRepurchaseProgramAndShelfRegistrationAdditionalInformationDetails", "http://bridgebio.com/20220630/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetails", "http://bridgebio.com/20220630/taxonomy/role/StatementCondensedConsolidatedStatementsOfRedeemableConvertibleNoncontrollingInterestsAndStockholdersEquityUnaudited" ], "xbrltype": "domainItemType" }, "us-gaap_EquityFairValueAdjustment": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of addition (reduction) to the amount at which an instrument classified in shareholders' equity could be incurred (settled) in a current transaction between willing parties.", "label": "Equity, Fair Value Adjustment", "terseLabel": "Unrealized loss on ongoing mark-to-market adjustments of investment in equity security" } } }, "localname": "EquityFairValueAdjustment", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://bridgebio.com/20220630/taxonomy/role/DisclosureEquityMethodAndOtherEquityInvestmentsAdditionalInformationDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeAxis": { "auth_ref": [ "r6", "r116", "r217", "r523" ], "lang": { "en-us": { "role": { "documentation": "Information by nonconsolidated equity method investee. Excludes information consolidated by reporting entity.", "label": "Equity Method Investment, Nonconsolidated Investee [Axis]" } } }, "localname": "EquityMethodInvestmentNonconsolidatedInvesteeAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://bridgebio.com/20220630/taxonomy/role/DisclosureFairValueMeasurementsAdditionalInformationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeDomain": { "auth_ref": [ "r6", "r116", "r217", "r523" ], "lang": { "en-us": { "role": { "documentation": "Nonconsolidated equity method investee. Excludes information consolidated by reporting entity.", "label": "Equity Method Investment, Nonconsolidated Investee [Domain]" } } }, "localname": "EquityMethodInvestmentNonconsolidatedInvesteeDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://bridgebio.com/20220630/taxonomy/role/DisclosureFairValueMeasurementsAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeOtherMember": { "auth_ref": [ "r6", "r116", "r217", "r523" ], "lang": { "en-us": { "role": { "documentation": "Nonconsolidated equity method investee classified as other. Excludes information consolidated by reporting entity.", "label": "Equity Method Investment, Nonconsolidated Investee, Other [Member]", "terseLabel": "Other investment" } } }, "localname": "EquityMethodInvestmentNonconsolidatedInvesteeOtherMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://bridgebio.com/20220630/taxonomy/role/DisclosureFairValueMeasurementsAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_EquityMethodInvestmentOwnershipPercentage": { "auth_ref": [ "r215" ], "lang": { "en-us": { "role": { "documentation": "The percentage of ownership of common stock or equity participation in the investee accounted for under the equity method of accounting.", "label": "Equity Method Investment, Ownership Percentage", "terseLabel": "Ownership interest", "verboseLabel": "Equity interest" } } }, "localname": "EquityMethodInvestmentOwnershipPercentage", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://bridgebio.com/20220630/taxonomy/role/DisclosureEquityMethodAndOtherEquityInvestmentsAdditionalInformationDetail" ], "xbrltype": "percentItemType" }, "us-gaap_EquityMethodInvestments": { "auth_ref": [ "r13", "r178", "r214" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "This item represents the carrying amount on the entity's balance sheet of its investment in common stock of an equity method investee. This is not an indicator of the fair value of the investment, rather it is the initial cost adjusted for the entity's share of earnings and losses of the investee, adjusted for any distributions (dividends) and other than temporary impairment (OTTI) losses recognized.", "label": "Equity Method Investments", "terseLabel": "Ownership interest, value" } } }, "localname": "EquityMethodInvestments", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://bridgebio.com/20220630/taxonomy/role/DisclosureEquityMethodAndOtherEquityInvestmentsAdditionalInformationDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_EquityMethodInvestmentsAndJointVenturesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Equity Method Investments and Joint Ventures [Abstract]" } } }, "localname": "EquityMethodInvestmentsAndJointVenturesAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_EquitySecuritiesFvNi": { "auth_ref": [ "r8", "r18", "r522" ], "calculation": { "http://bridgebio.com/20220630/taxonomy/role/DisclosureFairValueMeasurementsFinancialAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails": { "order": 2.0, "parentTag": "us-gaap_AssetsFairValueDisclosure", "weight": 1.0 }, "http://bridgebio.com/20220630/taxonomy/role/Role_StatementCondensedConsolidatedBalanceSheets": { "order": 2.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI), classified as current.", "label": "Equity Securities, FV-NI, Current", "terseLabel": "Investment in equity securities", "verboseLabel": "Equity security investment" } } }, "localname": "EquitySecuritiesFvNi", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://bridgebio.com/20220630/taxonomy/role/DisclosureEquityMethodAndOtherEquityInvestmentsAdditionalInformationDetail", "http://bridgebio.com/20220630/taxonomy/role/DisclosureFairValueMeasurementsAdditionalInformationDetails", "http://bridgebio.com/20220630/taxonomy/role/DisclosureFairValueMeasurementsFinancialAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails", "http://bridgebio.com/20220630/taxonomy/role/Role_StatementCondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_EquitySecuritiesFvNiGainLoss": { "auth_ref": [ "r212" ], "calculation": { "http://bridgebio.com/20220630/taxonomy/role/DisclosureFairValueMeasurementsSummaryOfTotalRealizedAndUnrealizedGainsAndLossesAssociatedWithInvestmentInEquitySecuritiesDetails": { "order": null, "parentTag": null, "root": true, "weight": null }, "http://bridgebio.com/20220630/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited": { "order": 4.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of unrealized and realized gain (loss) on investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI).", "label": "Equity Securities, FV-NI, Gain (Loss)", "negatedLabel": "Net loss from investment in equity securities", "terseLabel": "Gains and losses from investment in equity securities", "totalLabel": "Total net losses included in \"Other income (expense), net\"" } } }, "localname": "EquitySecuritiesFvNiGainLoss", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://bridgebio.com/20220630/taxonomy/role/DisclosureFairValueMeasurementsAdditionalInformationDetails", "http://bridgebio.com/20220630/taxonomy/role/DisclosureFairValueMeasurementsSummaryOfTotalRealizedAndUnrealizedGainsAndLossesAssociatedWithInvestmentInEquitySecuritiesDetails", "http://bridgebio.com/20220630/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_EquitySecuritiesFvNiRealizedGainLoss": { "auth_ref": [ "r212", "r672" ], "calculation": { "http://bridgebio.com/20220630/taxonomy/role/DisclosureFairValueMeasurementsSummaryOfTotalRealizedAndUnrealizedGainsAndLossesAssociatedWithInvestmentInEquitySecuritiesDetails": { "order": 0.0, "parentTag": "us-gaap_EquitySecuritiesFvNiGainLoss", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of realized gain (loss) from sale of investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI).", "label": "Equity Securities, FV-NI, Realized Gain (Loss)", "terseLabel": "Net realized losses recognized on investment in equity securities sold", "totalLabel": "Equity Securities, FV-NI, Realized Gain (Loss), Total" } } }, "localname": "EquitySecuritiesFvNiRealizedGainLoss", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://bridgebio.com/20220630/taxonomy/role/DisclosureFairValueMeasurementsSummaryOfTotalRealizedAndUnrealizedGainsAndLossesAssociatedWithInvestmentInEquitySecuritiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_EquitySecuritiesFvNiUnrealizedLoss": { "auth_ref": [ "r212" ], "calculation": { "http://bridgebio.com/20220630/taxonomy/role/DisclosureFairValueMeasurementsSummaryOfTotalRealizedAndUnrealizedGainsAndLossesAssociatedWithInvestmentInEquitySecuritiesDetails": { "order": 1.0, "parentTag": "us-gaap_EquitySecuritiesFvNiGainLoss", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of unrealized loss on investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI).", "label": "Equity Securities, FV-NI, Unrealized Loss", "negatedLabel": "Net unrealized losses recognized on investment in equity securities held as of the end of the period", "terseLabel": "Net unrealized losses recognized on investment in equity securities held as of the end of the period" } } }, "localname": "EquitySecuritiesFvNiUnrealizedLoss", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://bridgebio.com/20220630/taxonomy/role/DisclosureFairValueMeasurementsSummaryOfTotalRealizedAndUnrealizedGainsAndLossesAssociatedWithInvestmentInEquitySecuritiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FairValueAdjustmentOfWarrants": { "auth_ref": [ "r100", "r339" ], "calculation": { "http://bridgebio.com/20220630/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited": { "order": 10.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of expense (income) related to adjustment to fair value of warrant liability.", "label": "Fair Value Adjustment of Warrants", "terseLabel": "Fair value adjustment of warrants" } } }, "localname": "FairValueAdjustmentOfWarrants", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://bridgebio.com/20220630/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]", "terseLabel": "Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]" } } }, "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://bridgebio.com/20220630/taxonomy/role/DisclosureFairValueMeasurementsAdditionalInformationDetails", "http://bridgebio.com/20220630/taxonomy/role/DisclosureFairValueMeasurementsFinancialAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable": { "auth_ref": [ "r512", "r513", "r520" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of information about asset and liability measured at fair value on recurring and nonrecurring basis.", "label": "Fair Value, Recurring and Nonrecurring [Table]", "terseLabel": "Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Table]" } } }, "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://bridgebio.com/20220630/taxonomy/role/DisclosureFairValueMeasurementsAdditionalInformationDetails", "http://bridgebio.com/20220630/taxonomy/role/DisclosureFairValueMeasurementsFinancialAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Fair Value Measurement Inputs and Valuation Techniques [Line Items]", "terseLabel": "Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis Valuation Techniques [Line Items]" } } }, "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://bridgebio.com/20220630/taxonomy/role/DisclosureFairValueMeasurementsScheduleOfEstimatedFairValueOfLiabilityDetails", "http://bridgebio.com/20220630/taxonomy/role/DisclosureFairValueMeasurementsTables" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable": { "auth_ref": [ "r514" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of information about input and valuation technique used to measure fair value and change in valuation approach and technique for each separate class of asset and liability measured on recurring and nonrecurring basis.", "label": "Fair Value Measurement Inputs and Valuation Techniques [Table]", "terseLabel": "Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis Valuation Techniques [Table]" } } }, "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://bridgebio.com/20220630/taxonomy/role/DisclosureFairValueMeasurementsScheduleOfEstimatedFairValueOfLiabilityDetails", "http://bridgebio.com/20220630/taxonomy/role/DisclosureFairValueMeasurementsTables" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock": { "auth_ref": [ "r514" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of input and valuation technique used to measure fair value and change in valuation approach and technique for each separate class of asset and liability measured on recurring and nonrecurring basis.", "label": "Fair Value Measurement Inputs and Valuation Techniques [Table Text Block]", "terseLabel": "Schedule of Estimated Fair Value of Liability" } } }, "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://bridgebio.com/20220630/taxonomy/role/DisclosureFairValueMeasurementsTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain": { "auth_ref": [ "r517" ], "lang": { "en-us": { "role": { "documentation": "Class of asset.", "label": "Asset Class [Domain]", "terseLabel": "Asset Class" } } }, "localname": "FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://bridgebio.com/20220630/taxonomy/role/DisclosureFairValueMeasurementsFinancialAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails", "http://bridgebio.com/20220630/taxonomy/role/Role_DisclosureCashEquivalentsAndMarketableSecuritiesScheduleOfCashEquivalentAndMarketableSecuritiesClassifiedAsAvailableForSaleDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueByAssetClassAxis": { "auth_ref": [ "r512", "r520" ], "lang": { "en-us": { "role": { "documentation": "Information by class of asset.", "label": "Asset Class [Axis]", "terseLabel": "Asset Class" } } }, "localname": "FairValueByAssetClassAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://bridgebio.com/20220630/taxonomy/role/DisclosureFairValueMeasurementsFinancialAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails", "http://bridgebio.com/20220630/taxonomy/role/Role_DisclosureCashEquivalentsAndMarketableSecuritiesScheduleOfCashEquivalentAndMarketableSecuritiesClassifiedAsAvailableForSaleDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueByFairValueHierarchyLevelAxis": { "auth_ref": [ "r314", "r334", "r335", "r371", "r372", "r373", "r374", "r375", "r376", "r377", "r379", "r513", "r589", "r590", "r591" ], "lang": { "en-us": { "role": { "documentation": "Information by level within fair value hierarchy and fair value measured at net asset value per share as practical expedient.", "label": "Fair Value Hierarchy and NAV [Axis]", "terseLabel": "Fair Value Hierarchy and NAV" } } }, "localname": "FairValueByFairValueHierarchyLevelAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://bridgebio.com/20220630/taxonomy/role/DisclosureFairValueMeasurementsFinancialAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueByLiabilityClassAxis": { "auth_ref": [ "r519", "r520" ], "lang": { "en-us": { "role": { "documentation": "Information by class of liability.", "label": "Liability Class [Axis]", "terseLabel": "Liability Class" } } }, "localname": "FairValueByLiabilityClassAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://bridgebio.com/20220630/taxonomy/role/DisclosureFairValueMeasurementsScheduleOfEstimatedFairValueOfLiabilityDetails", "http://bridgebio.com/20220630/taxonomy/role/DisclosureFairValueMeasurementsSummaryOfChangeInEstimatedFairValueOfLiabilityRecordedInOtherIncomeExpenseNetDetails", "http://bridgebio.com/20220630/taxonomy/role/DisclosureFairValueMeasurementsTables" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueByMeasurementFrequencyAxis": { "auth_ref": [ "r512", "r513", "r515", "r516", "r521" ], "lang": { "en-us": { "role": { "documentation": "Information by measurement frequency.", "label": "Measurement Frequency [Axis]", "terseLabel": "Measurement Frequency" } } }, "localname": "FairValueByMeasurementFrequencyAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://bridgebio.com/20220630/taxonomy/role/DisclosureFairValueMeasurementsFinancialAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueDisclosuresAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Fair Value Disclosures [Abstract]" } } }, "localname": "FairValueDisclosuresAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_FairValueDisclosuresTextBlock": { "auth_ref": [ "r519" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.", "label": "Fair Value Disclosures [Text Block]", "terseLabel": "Fair Value Measurements" } } }, "localname": "FairValueDisclosuresTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://bridgebio.com/20220630/taxonomy/role/DisclosureFairValueMeasurements" ], "xbrltype": "textBlockItemType" }, "us-gaap_FairValueInputsLevel1Member": { "auth_ref": [ "r314", "r371", "r372", "r377", "r379", "r513", "r589" ], "lang": { "en-us": { "role": { "documentation": "Quoted prices in active markets for identical assets or liabilities that the reporting entity can access at the measurement date.", "label": "Fair Value, Inputs, Level 1 [Member]", "terseLabel": "Level 1" } } }, "localname": "FairValueInputsLevel1Member", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://bridgebio.com/20220630/taxonomy/role/DisclosureFairValueMeasurementsFinancialAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueInputsLevel2Member": { "auth_ref": [ "r314", "r334", "r335", "r371", "r372", "r377", "r379", "r513", "r590" ], "lang": { "en-us": { "role": { "documentation": "Inputs other than quoted prices included within level 1 that are observable for an asset or liability, either directly or indirectly, including, but not limited to, quoted prices for similar assets or liabilities in active markets, or quoted prices for identical or similar assets or liabilities in inactive markets.", "label": "Fair Value, Inputs, Level 2 [Member]", "terseLabel": "Level 2" } } }, "localname": "FairValueInputsLevel2Member", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://bridgebio.com/20220630/taxonomy/role/DisclosureFairValueMeasurementsFinancialAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueInputsLevel3Member": { "auth_ref": [ "r314", "r334", "r335", "r371", "r372", "r373", "r374", "r375", "r376", "r377", "r379", "r513", "r591" ], "lang": { "en-us": { "role": { "documentation": "Unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.", "label": "Fair Value, Inputs, Level 3 [Member]", "terseLabel": "Level 3" } } }, "localname": "FairValueInputsLevel3Member", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://bridgebio.com/20220630/taxonomy/role/DisclosureFairValueMeasurementsFinancialAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain": { "auth_ref": [ "r517" ], "lang": { "en-us": { "role": { "documentation": "Represents classes of liabilities measured and disclosed at fair value.", "label": "Fair Value by Liability Class [Domain]", "terseLabel": "Fair Value by Liability Class" } } }, "localname": "FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://bridgebio.com/20220630/taxonomy/role/DisclosureFairValueMeasurementsScheduleOfEstimatedFairValueOfLiabilityDetails", "http://bridgebio.com/20220630/taxonomy/role/DisclosureFairValueMeasurementsSummaryOfChangeInEstimatedFairValueOfLiabilityRecordedInOtherIncomeExpenseNetDetails", "http://bridgebio.com/20220630/taxonomy/role/DisclosureFairValueMeasurementsTables" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]", "terseLabel": "Fair Value Liabilities Measured On Recurring Basis Unobservable Input Reconciliation [Line Items]" } } }, "localname": "FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://bridgebio.com/20220630/taxonomy/role/DisclosureFairValueMeasurementsSummaryOfChangeInEstimatedFairValueOfLiabilityRecordedInOtherIncomeExpenseNetDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable": { "auth_ref": [ "r517", "r520" ], "lang": { "en-us": { "role": { "documentation": "Schedule of information required and determined to be provided for purposes of reconciling beginning and ending balances of fair value measurements of liabilities using significant unobservable inputs (level 3). Separately presenting changes during the period, attributable to: (1) total gains or losses for the period (realized and unrealized) and location reported in the statement of income (or activities); (2) purchases, sales, issuances, and settlements (net); (3) transfers in and/or out of Level 3.", "label": "Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table]", "terseLabel": "Fair Value Liabilities Measured On Recurring Basis Unobservable Input Reconciliation [Table]" } } }, "localname": "FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://bridgebio.com/20220630/taxonomy/role/DisclosureFairValueMeasurementsSummaryOfChangeInEstimatedFairValueOfLiabilityRecordedInOtherIncomeExpenseNetDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock": { "auth_ref": [ "r517", "r520" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the fair value measurement of liabilities using significant unobservable inputs (Level 3), a reconciliation of the beginning and ending balances, separately presenting changes attributable to the following: (1) total gains or losses for the period (realized and unrealized), segregating those gains or losses included in earnings (or changes in net assets), and gains or losses recognized in other comprehensive income (loss) and a description of where those gains or losses included in earnings (or changes in net assets) are reported in the statement of income (or activities); (2) purchases, sales, issues, and settlements (each type disclosed separately); and (3) transfers in and transfers out of Level 3 (for example, transfers due to changes in the observability of significant inputs) by class of liability.", "label": "Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table Text Block]", "terseLabel": "Summary of Change in Estimated Fair Value of Liability Recorded in Other Income (Expense), Net" } } }, "localname": "FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://bridgebio.com/20220630/taxonomy/role/DisclosureFairValueMeasurementsTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_FairValueMeasurementFrequencyDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Measurement frequency.", "label": "Measurement Frequency [Domain]", "terseLabel": "Measurement Frequency" } } }, "localname": "FairValueMeasurementFrequencyDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://bridgebio.com/20220630/taxonomy/role/DisclosureFairValueMeasurementsFinancialAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements": { "auth_ref": [ "r518" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of settlements of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.", "label": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Settlements", "negatedLabel": "Change in fair value upon notice of termination of the LEO call option" } } }, "localname": "FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://bridgebio.com/20220630/taxonomy/role/DisclosureFairValueMeasurementsSummaryOfChangeInEstimatedFairValueOfLiabilityRecordedInOtherIncomeExpenseNetDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue": { "auth_ref": [ "r517" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Fair value of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.", "label": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability Value", "periodEndLabel": "Ending balance", "periodStartLabel": "Beginning balance" } } }, "localname": "FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://bridgebio.com/20220630/taxonomy/role/DisclosureFairValueMeasurementsSummaryOfChangeInEstimatedFairValueOfLiabilityRecordedInOtherIncomeExpenseNetDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FairValueMeasurementsFairValueHierarchyDomain": { "auth_ref": [ "r314", "r334", "r335", "r371", "r372", "r373", "r374", "r375", "r376", "r377", "r379", "r589", "r590", "r591" ], "lang": { "en-us": { "role": { "documentation": "Categories used to prioritize the inputs to valuation techniques to measure fair value.", "label": "Fair Value Hierarchy and NAV [Domain]", "terseLabel": "Fair Value Hierarchy and NAV" } } }, "localname": "FairValueMeasurementsFairValueHierarchyDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://bridgebio.com/20220630/taxonomy/role/DisclosureFairValueMeasurementsFinancialAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueMeasurementsRecurringMember": { "auth_ref": [ "r519", "r521" ], "lang": { "en-us": { "role": { "documentation": "Frequent fair value measurement. Includes, but is not limited to, fair value adjustment for impairment of asset, liability or equity, frequently measured at fair value.", "label": "Fair Value, Recurring [Member]", "terseLabel": "Recurring" } } }, "localname": "FairValueMeasurementsRecurringMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://bridgebio.com/20220630/taxonomy/role/DisclosureFairValueMeasurementsFinancialAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FinanceLeaseInterestExpense": { "auth_ref": [ "r557", "r561", "r570" ], "calculation": { "http://bridgebio.com/20220630/taxonomy/role/Role_DisclosureLeasesComponentsOfLeaseCostDetails": { "order": 1.0, "parentTag": "us-gaap_LeaseCost", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of interest expense on finance lease liability.", "label": "Finance Lease, Interest Expense", "terseLabel": "Interest on finance lease liability", "verboseLabel": "Finance lease costs" } } }, "localname": "FinanceLeaseInterestExpense", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://bridgebio.com/20220630/taxonomy/role/Role_DisclosureLeasesComponentsOfLeaseCostDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FinanceLeaseInterestPaymentOnLiability": { "auth_ref": [ "r558", "r564" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of interest paid on finance lease liability.", "label": "Finance Lease, Interest Payment on Liability", "terseLabel": "Operating cash flows for finance lease" } } }, "localname": "FinanceLeaseInterestPaymentOnLiability", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://bridgebio.com/20220630/taxonomy/role/Role_DisclosureLeasesScheduleOfSupplementalCashFlowInformationRelatedToLeasesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent": { "auth_ref": [ "r567", "r570" ], "lang": { "en-us": { "role": { "documentation": "Weighted average discount rate for finance lease calculated at point in time.", "label": "Finance Lease, Weighted Average Discount Rate, Percent", "terseLabel": "Finance lease" } } }, "localname": "FinanceLeaseWeightedAverageDiscountRatePercent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://bridgebio.com/20220630/taxonomy/role/Role_DisclosureLeasesScheduleOfSupplementalInformationRelatedToRemainingLeaseTermAndDiscountRateDetails" ], "xbrltype": "percentItemType" }, "us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1": { "auth_ref": [ "r566", "r570" ], "lang": { "en-us": { "role": { "documentation": "Weighted average remaining lease term for finance lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.", "label": "Finance Lease, Weighted Average Remaining Lease Term", "terseLabel": "Finance lease" } } }, "localname": "FinanceLeaseWeightedAverageRemainingLeaseTerm1", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://bridgebio.com/20220630/taxonomy/role/Role_DisclosureLeasesScheduleOfSupplementalInformationRelatedToRemainingLeaseTermAndDiscountRateDetails" ], "xbrltype": "durationItemType" }, "us-gaap_FinancialInstrumentAxis": { "auth_ref": [ "r203", "r204", "r209", "r210", "r211", "r230", "r231", "r232", "r233", "r234", "r236", "r238", "r239", "r240", "r325", "r354", "r498", "r586", "r587", "r588", "r589", "r590", "r591", "r592", "r593", "r594", "r595", "r596", "r597", "r598", "r599", "r603", "r604", "r605", "r606", "r607", "r608", "r609", "r610", "r611", "r612", "r613", "r614", "r615", "r616", "r617", "r618", "r717", "r718", "r719", "r720", "r721", "r722", "r723" ], "lang": { "en-us": { "role": { "documentation": "Information by type of financial instrument.", "label": "Financial Instrument [Axis]", "terseLabel": "Financial Instrument" } } }, "localname": "FinancialInstrumentAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://bridgebio.com/20220630/taxonomy/role/DisclosureDebtScheduleOfFutureMinimumPaymentsUnderTermLoanAgreementDetails", "http://bridgebio.com/20220630/taxonomy/role/Role_DisclosureDebtScheduleOfFutureMinimumPaymentsUnderNotesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FinancialLiabilitiesFairValueDisclosure": { "auth_ref": [], "calculation": { "http://bridgebio.com/20220630/taxonomy/role/DisclosureFairValueMeasurementsFinancialAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Fair value of financial obligations, including, but not limited to, debt instruments, derivative liabilities, federal funds purchased and sold under agreements to repurchase, securities loaned or sold under agreements to repurchase, financial instruments sold not yet purchased, guarantees, line of credit, loans and notes payable, servicing liability, and trading liabilities.", "label": "Financial Liabilities Fair Value Disclosure", "totalLabel": "Total financial liabilities" } } }, "localname": "FinancialLiabilitiesFairValueDisclosure", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://bridgebio.com/20220630/taxonomy/role/DisclosureFairValueMeasurementsFinancialAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization": { "auth_ref": [ "r14", "r247" ], "calculation": { "http://bridgebio.com/20220630/taxonomy/role/DisclosureIntangibleAssetsSummaryOfRecognizedIntangibleAssetsDetails": { "order": 1.0, "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Accumulated amount of amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.", "label": "Finite-Lived Intangible Assets, Accumulated Amortization", "negatedLabel": "Less accumulated amortization", "terseLabel": "Intangible assets less accumulated amortization" } } }, "localname": "FiniteLivedIntangibleAssetsAccumulatedAmortization", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://bridgebio.com/20220630/taxonomy/role/DisclosureIntangibleAssetsSummaryOfRecognizedIntangibleAssetsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextRollingTwelveMonths": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of amortization expense for assets, excluding financial assets and goodwill, lacking physical substance with a finite life expected to be recognized in the next rolling twelve months following the latest balance sheet. For interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.", "label": "Finite-Lived Intangible Assets, Amortization Expense, Next Rolling 12 Months", "terseLabel": "Amortization expenses, 2022", "verboseLabel": "Amortization expenses, 2023" } } }, "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseNextRollingTwelveMonths", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://bridgebio.com/20220630/taxonomy/role/DisclosureIntangibleAssetsAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in remainder of current fiscal year.", "label": "Finite-Lived Intangible Asset, Expected Amortization, Remainder of Fiscal Year", "terseLabel": "Amortization expenses, remainder period", "verboseLabel": "Amortization expenses, remainder of 2022" } } }, "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://bridgebio.com/20220630/taxonomy/role/DisclosureIntangibleAssetsAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRollingYearFour": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of amortization expense for assets, excluding financial assets and goodwill, lacking physical substance with a finite life expected to be recognized in the fourth rolling twelve months following the latest balance sheet. For interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.", "label": "Finite-Lived Intangible Assets, Amortization Expense, Rolling Year Four", "terseLabel": "Amortization expenses, 2025", "verboseLabel": "Amortization expenses, 2026" } } }, "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseRollingYearFour", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://bridgebio.com/20220630/taxonomy/role/DisclosureIntangibleAssetsAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRollingYearThree": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of amortization expense for assets, excluding financial assets and goodwill, lacking physical substance with a finite life expected to be recognized in the third rolling twelve months following the latest balance sheet. For interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.", "label": "Finite-Lived Intangible Assets, Amortization Expense, Rolling Year Three", "terseLabel": "Amortization expenses, 2024", "verboseLabel": "Amortization expenses, 2025" } } }, "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseRollingYearThree", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://bridgebio.com/20220630/taxonomy/role/DisclosureIntangibleAssetsAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRollingYearTwo": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of amortization expense for assets, excluding financial assets and goodwill, lacking physical substance with a finite life expected to be recognized in the second rolling twelve months following the latest balance sheet. For interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.", "label": "Finite-Lived Intangible Assets, Amortization Expense, Rolling Year Two", "terseLabel": "Amortization expenses, 2023", "verboseLabel": "Amortization expenses, 2024" } } }, "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseRollingYearTwo", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://bridgebio.com/20220630/taxonomy/role/DisclosureIntangibleAssetsAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of amortization expense of assets, excluding financial assets, that lack physical substance, having a limited useful life.", "label": "Finite-Lived Intangible Assets Amortization Expense [Table Text Block]", "terseLabel": "Summary of intangible assets", "verboseLabel": "Summary of Recognized Intangible Assets" } } }, "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://bridgebio.com/20220630/taxonomy/role/DisclosureAssetAcquisitionsAndCollaborationAgreementTables", "http://bridgebio.com/20220630/taxonomy/role/DisclosureIntangibleAssetsTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_FiniteLivedIntangibleAssetsGross": { "auth_ref": [ "r247", "r626" ], "calculation": { "http://bridgebio.com/20220630/taxonomy/role/DisclosureIntangibleAssetsSummaryOfRecognizedIntangibleAssetsDetails": { "order": 0.0, "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount before amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.", "label": "Capitalization of finite-lived intangible asset", "terseLabel": "Intangible assets gross amount", "totalLabel": "Finite-Lived Intangible Assets, Gross, Total", "verboseLabel": "Gross amount" } } }, "localname": "FiniteLivedIntangibleAssetsGross", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://bridgebio.com/20220630/taxonomy/role/DisclosureIntangibleAssetsAdditionalInformationDetails", "http://bridgebio.com/20220630/taxonomy/role/DisclosureIntangibleAssetsSummaryOfRecognizedIntangibleAssetsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FiniteLivedIntangibleAssetsLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Finite-Lived Intangible Assets [Line Items]" } } }, "localname": "FiniteLivedIntangibleAssetsLineItems", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://bridgebio.com/20220630/taxonomy/role/DisclosureIntangibleAssetsAdditionalInformationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FiniteLivedIntangibleAssetsNet": { "auth_ref": [ "r247", "r622" ], "calculation": { "http://bridgebio.com/20220630/taxonomy/role/DisclosureIntangibleAssetsSummaryOfRecognizedIntangibleAssetsDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.", "label": "Finite-Lived Intangible Assets, Net", "periodEndLabel": "Finite-Lived Intangible Assets, Net, Ending Balance", "periodStartLabel": "Finite-Lived Intangible Assets, Net, Beginning Balance", "terseLabel": "Finite-lived intangible asset", "totalLabel": "Net book value", "verboseLabel": "Capitalization of finite-lived intangible asset" } } }, "localname": "FiniteLivedIntangibleAssetsNet", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://bridgebio.com/20220630/taxonomy/role/DisclosureIntangibleAssetsSummaryOfRecognizedIntangibleAssetsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_GainLossOnDispositionOfAssets1": { "auth_ref": [ "r100" ], "calculation": { "http://bridgebio.com/20220630/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited": { "order": 11.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of gain (loss) on sale or disposal of assets, including but not limited to property plant and equipment, intangible assets and equity in securities of subsidiaries or equity method investee.", "label": "Gain (Loss) on Disposition of Assets", "negatedLabel": "Loss on sale of certain assets", "totalLabel": "Gain (Loss) on Disposition of Assets, Total" } } }, "localname": "GainLossOnDispositionOfAssets1", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://bridgebio.com/20220630/taxonomy/role/DisclosureSaleOfNonfinancialAssetsAdditionalInformationDetails", "http://bridgebio.com/20220630/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_GainLossOnInvestmentsTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of realized and unrealized gain (loss) on investment in security.", "label": "Gain (Loss) on Securities [Table Text Block]", "terseLabel": "Summary of Total Realized and Unrealized Gains and Losses Associated with Investment in Equity Securities" } } }, "localname": "GainLossOnInvestmentsTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://bridgebio.com/20220630/taxonomy/role/DisclosureFairValueMeasurementsTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_GeneralAndAdministrativeExpenseMember": { "auth_ref": [ "r73" ], "lang": { "en-us": { "role": { "documentation": "Primary financial statement caption encompassing general and administrative expense.", "label": "General and Administrative Expense [Member]", "verboseLabel": "General and Administrative Expense" } } }, "localname": "GeneralAndAdministrativeExpenseMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://bridgebio.com/20220630/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfStockBasedCompensationForEmployeesAndNonEmployeesDetails" ], "xbrltype": "domainItemType" }, "us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Goodwill and Intangible Assets Disclosure [Abstract]" } } }, "localname": "GoodwillAndIntangibleAssetsDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_IPOMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "First sale of stock by a private company to the public.", "label": "IPO [Member]", "terseLabel": "Initial Public Offering" } } }, "localname": "IPOMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://bridgebio.com/20220630/taxonomy/role/DisclosureEquityMethodAndOtherEquityInvestmentsAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "us-gaap_ImpairmentOfInvestments": { "auth_ref": [ "r198" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The amount by which the fair value of an investment is less than the amortized cost basis or carrying amount of that investment at the balance sheet date and the decline in fair value is deemed to be other than temporary, before considering whether or not such amount is recognized in earnings or other comprehensive income.", "label": "Other than Temporary Impairment Losses, Investments", "terseLabel": "Impairments related investment", "totalLabel": "Other than Temporary Impairment Losses, Investments, Total" } } }, "localname": "ImpairmentOfInvestments", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://bridgebio.com/20220630/taxonomy/role/DisclosureEquityMethodAndOtherEquityInvestmentsAdditionalInformationDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_ImpairmentOfLongLivedAssetsHeldForUse": { "auth_ref": [ "r100", "r250", "r254" ], "calculation": { "http://bridgebio.com/20220630/taxonomy/role/DisclosureRestructuringImpairmentAndRelatedChargesSummaryOfRestructuringImpairmentAndRelatedChargesDetails": { "order": 1.0, "parentTag": "us-gaap_RestructuringSettlementAndImpairmentProvisions", "weight": 1.0 }, "http://bridgebio.com/20220630/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited": { "order": 12.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The aggregate amount of write-downs for impairments recognized during the period for long lived assets held for use (including those held for disposal by means other than sale).", "label": "Long-lived assets impairments and write-offs", "terseLabel": "Impairment of long-lived assets", "totalLabel": "Impairment, Long-Lived Asset, Held-for-Use, Total", "verboseLabel": "Impairment loss" } } }, "localname": "ImpairmentOfLongLivedAssetsHeldForUse", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://bridgebio.com/20220630/taxonomy/role/DisclosureRestructuringImpairmentAndRelatedChargesSummaryOfRestructuringImpairmentAndRelatedChargesDetails", "http://bridgebio.com/20220630/taxonomy/role/Role_DisclosureLeasesAdditionalInformationDetails", "http://bridgebio.com/20220630/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeStatementAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Income Statement [Abstract]" } } }, "localname": "IncomeStatementAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis": { "auth_ref": [ "r380", "r383" ], "lang": { "en-us": { "role": { "documentation": "Information by name of disposal group.", "label": "Disposal Group Name [Axis]" } } }, "localname": "IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://bridgebio.com/20220630/taxonomy/role/DisclosureSaleOfNonfinancialAssetsAdditionalInformationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_IncomeStatementLocationAxis": { "auth_ref": [ "r256", "r263" ], "lang": { "en-us": { "role": { "documentation": "Information by location in the income statement.", "label": "Income Statement Location [Axis]", "terseLabel": "Income Statement Location" } } }, "localname": "IncomeStatementLocationAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://bridgebio.com/20220630/taxonomy/role/DisclosureLicenseAndCollaborationAgreementsAdditionalInformationDetails", "http://bridgebio.com/20220630/taxonomy/role/DisclosureSaleOfNonfinancialAssetsAdditionalInformationDetails", "http://bridgebio.com/20220630/taxonomy/role/Role_DisclosureLeasesAdditionalInformationDetails", "http://bridgebio.com/20220630/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfStockBasedCompensationForEmployeesAndNonEmployeesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_IncomeStatementLocationDomain": { "auth_ref": [ "r263" ], "lang": { "en-us": { "role": { "documentation": "Location in the income statement.", "label": "Income Statement Location [Domain]", "terseLabel": "Income Statement Location" } } }, "localname": "IncomeStatementLocationDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://bridgebio.com/20220630/taxonomy/role/DisclosureLicenseAndCollaborationAgreementsAdditionalInformationDetails", "http://bridgebio.com/20220630/taxonomy/role/DisclosureSaleOfNonfinancialAssetsAdditionalInformationDetails", "http://bridgebio.com/20220630/taxonomy/role/Role_DisclosureLeasesAdditionalInformationDetails", "http://bridgebio.com/20220630/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfStockBasedCompensationForEmployeesAndNonEmployeesDetails" ], "xbrltype": "domainItemType" }, "us-gaap_IncomeTaxDisclosureAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Income Tax Disclosure [Abstract]" } } }, "localname": "IncomeTaxDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_IncomeTaxDisclosureTextBlock": { "auth_ref": [ "r117", "r441", "r442", "r444", "r450", "r452", "r454", "r455", "r456" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.", "label": "Income Tax Disclosure [Text Block]", "terseLabel": "Income Taxes" } } }, "localname": "IncomeTaxDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://bridgebio.com/20220630/taxonomy/role/Role_DisclosureIncomeTaxes" ], "xbrltype": "textBlockItemType" }, "us-gaap_IncomeTaxExpenseBenefit": { "auth_ref": [ "r118", "r139", "r140", "r176", "r440", "r451", "r453", "r673" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.", "label": "Income Tax Expense (Benefit)", "terseLabel": "Provision for income tax", "totalLabel": "Income Tax Expense (Benefit), Total" } } }, "localname": "IncomeTaxExpenseBenefit", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://bridgebio.com/20220630/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInAccountsPayable": { "auth_ref": [ "r99" ], "calculation": { "http://bridgebio.com/20220630/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited": { "order": 21.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.", "label": "Increase (Decrease) in Accounts Payable", "terseLabel": "Accounts payable", "totalLabel": "Increase (Decrease) in Accounts Payable, Total" } } }, "localname": "IncreaseDecreaseInAccountsPayable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://bridgebio.com/20220630/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInAccountsReceivable": { "auth_ref": [ "r99" ], "calculation": { "http://bridgebio.com/20220630/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited": { "order": 15.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services.", "label": "Increase (Decrease) in Accounts Receivable", "negatedLabel": "Accounts receivable" } } }, "localname": "IncreaseDecreaseInAccountsReceivable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://bridgebio.com/20220630/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities": { "auth_ref": [ "r99" ], "calculation": { "http://bridgebio.com/20220630/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited": { "order": 28.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) in accrued expenses, and obligations classified as other.", "label": "Increase (Decrease) in Accrued Liabilities and Other Operating Liabilities", "terseLabel": "Other accrued and other long-term liabilities" } } }, "localname": "IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://bridgebio.com/20220630/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInDeferredRevenue": { "auth_ref": [ "r99" ], "calculation": { "http://bridgebio.com/20220630/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited": { "order": 26.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) in deferred income and obligation to transfer product and service to customer for which consideration has been received or is receivable.", "label": "Increase (Decrease) in Deferred Revenue", "negatedLabel": "Deferred revenue", "terseLabel": "Deferred revenue" } } }, "localname": "IncreaseDecreaseInDeferredRevenue", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://bridgebio.com/20220630/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInDueFromRelatedParties": { "auth_ref": [ "r99" ], "calculation": { "http://bridgebio.com/20220630/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited": { "order": 18.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The increase (decrease) during the reporting period in receivables to be collected from other entities that could exert significant influence over the reporting entity.", "label": "Increase (Decrease) in Due from Related Parties", "negatedLabel": "Receivable from a related party", "totalLabel": "Increase (Decrease) in Due from Related Parties, Total" } } }, "localname": "IncreaseDecreaseInDueFromRelatedParties", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://bridgebio.com/20220630/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities": { "auth_ref": [ "r99" ], "calculation": { "http://bridgebio.com/20220630/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited": { "order": 22.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The increase (decrease) during the reporting period in the aggregate amount of obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits.", "label": "Increase (Decrease) in Employee Related Liabilities", "terseLabel": "Accrued compensation and benefits", "totalLabel": "Increase (Decrease) in Employee Related Liabilities, Total" } } }, "localname": "IncreaseDecreaseInEmployeeRelatedLiabilities", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://bridgebio.com/20220630/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Increase (Decrease) in Operating Capital [Abstract]", "terseLabel": "Changes in operating assets and liabilities:" } } }, "localname": "IncreaseDecreaseInOperatingCapitalAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://bridgebio.com/20220630/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited" ], "xbrltype": "stringItemType" }, "us-gaap_IncreaseDecreaseInOperatingLeaseLiability": { "auth_ref": [ "r99", "r564" ], "calculation": { "http://bridgebio.com/20220630/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited": { "order": 25.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) in obligation for operating lease.", "label": "Increase (Decrease) in Operating Lease Liability", "terseLabel": "Operating lease liabilities" } } }, "localname": "IncreaseDecreaseInOperatingLeaseLiability", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://bridgebio.com/20220630/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInOtherOperatingAssets": { "auth_ref": [ "r99" ], "calculation": { "http://bridgebio.com/20220630/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited": { "order": 20.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) in operating assets classified as other.", "label": "Increase (Decrease) in Other Operating Assets", "negatedLabel": "Other assets", "totalLabel": "Increase (Decrease) in Other Operating Assets, Total" } } }, "localname": "IncreaseDecreaseInOtherOperatingAssets", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://bridgebio.com/20220630/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets": { "auth_ref": [ "r99" ], "calculation": { "http://bridgebio.com/20220630/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited": { "order": 19.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) in prepaid expenses, and assets classified as other.", "label": "Increase (Decrease) in Prepaid Expense and Other Assets", "negatedLabel": "Prepaid expenses and other current assets", "totalLabel": "Increase (Decrease) in Prepaid Expense and Other Assets, Total" } } }, "localname": "IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://bridgebio.com/20220630/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_IntangibleAssetsDisclosureTextBlock": { "auth_ref": [ "r249" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for all or part of the information related to intangible assets.", "label": "Intangible Assets Disclosure [Text Block]", "terseLabel": "Intangible Assets" } } }, "localname": "IntangibleAssetsDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://bridgebio.com/20220630/taxonomy/role/DisclosureIntangibleAssets" ], "xbrltype": "textBlockItemType" }, "us-gaap_IntangibleAssetsNetExcludingGoodwill": { "auth_ref": [ "r241", "r245" ], "calculation": { "http://bridgebio.com/20220630/taxonomy/role/Role_StatementCondensedConsolidatedBalanceSheets": { "order": 5.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Sum of the carrying amounts of all intangible assets, excluding goodwill, as of the balance sheet date, net of accumulated amortization and impairment charges.", "label": "Intangible Assets, Net (Excluding Goodwill)", "terseLabel": "Intangible assets, net", "totalLabel": "Intangible Assets, Net (Excluding Goodwill), Total" } } }, "localname": "IntangibleAssetsNetExcludingGoodwill", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://bridgebio.com/20220630/taxonomy/role/DisclosureSaleOfNonfinancialAssetsAdditionalInformationDetails", "http://bridgebio.com/20220630/taxonomy/role/Role_StatementCondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_InterestExpense": { "auth_ref": [ "r68", "r174", "r543", "r546", "r652" ], "calculation": { "http://bridgebio.com/20220630/taxonomy/role/StatementCondensedConsolidatedStatementsOfOperationsUnaudited": { "order": 1.0, "parentTag": "us-gaap_NonoperatingIncomeExpense", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of the cost of borrowed funds accounted for as interest expense.", "label": "Interest Expense", "negatedLabel": "Interest expense", "totalLabel": "Interest Expense, Total" } } }, "localname": "InterestExpense", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://bridgebio.com/20220630/taxonomy/role/StatementCondensedConsolidatedStatementsOfOperationsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_InterestExpenseDebt": { "auth_ref": [ "r80", "r320", "r333", "r336", "r337" ], "calculation": { "http://bridgebio.com/20220630/taxonomy/role/Role_DisclosureDebtScheduleOfTotalInterestExpenseRecognizedRelatedToNotesDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of the cost of borrowed funds accounted for as interest expense for debt.", "label": "Interest Expense, Debt", "terseLabel": "Interest expense", "totalLabel": "Total interest and amortization expense" } } }, "localname": "InterestExpenseDebt", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://bridgebio.com/20220630/taxonomy/role/Role_DisclosureDebtAdditionalInformationDetails", "http://bridgebio.com/20220630/taxonomy/role/Role_DisclosureDebtScheduleOfTotalInterestExpenseRecognizedRelatedToNotesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_InterestExpenseDebtExcludingAmortization": { "auth_ref": [ "r82", "r321", "r336", "r337" ], "calculation": { "http://bridgebio.com/20220630/taxonomy/role/Role_DisclosureDebtScheduleOfTotalInterestExpenseRecognizedRelatedToNotesDetails": { "order": 0.0, "parentTag": "us-gaap_InterestExpenseDebt", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Represents the portion of interest incurred in the period on debt arrangements that was charged against earnings, excluding amortization of debt discount (premium) and financing costs.", "label": "Interest Expense, Debt, Excluding Amortization", "terseLabel": "Contractual interest expense" } } }, "localname": "InterestExpenseDebtExcludingAmortization", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://bridgebio.com/20220630/taxonomy/role/Role_DisclosureDebtScheduleOfTotalInterestExpenseRecognizedRelatedToNotesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_InterestPaidNet": { "auth_ref": [ "r92", "r97", "r104" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount.", "label": "Interest Paid, Excluding Capitalized Interest, Operating Activities", "terseLabel": "Cash paid for interest" } } }, "localname": "InterestPaidNet", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://bridgebio.com/20220630/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_InterestPayableCurrent": { "auth_ref": [ "r37" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying value as of the balance sheet date of [accrued] interest payable on all forms of debt, including trade payables, that has been incurred and is unpaid. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).", "label": "Interest Payable, Current", "terseLabel": "Interest payable" } } }, "localname": "InterestPayableCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://bridgebio.com/20220630/taxonomy/role/Role_DisclosureDebtAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_InterestPayableCurrentAndNoncurrent": { "auth_ref": [ "r646", "r667" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of interest payable on debt, including, but not limited to, trade payables.", "label": "Interest Payable", "terseLabel": "Interest payable" } } }, "localname": "InterestPayableCurrentAndNoncurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://bridgebio.com/20220630/taxonomy/role/Role_DisclosureDebtAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_InvestmentIncomeInterest": { "auth_ref": [ "r78", "r173" ], "calculation": { "http://bridgebio.com/20220630/taxonomy/role/StatementCondensedConsolidatedStatementsOfOperationsUnaudited": { "order": 0.0, "parentTag": "us-gaap_NonoperatingIncomeExpense", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount before accretion (amortization) of purchase discount (premium) of interest income on nonoperating securities.", "label": "Investment Income, Interest", "terseLabel": "Interest income" } } }, "localname": "InvestmentIncomeInterest", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://bridgebio.com/20220630/taxonomy/role/StatementCondensedConsolidatedStatementsOfOperationsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_InvestmentTextBlock": { "auth_ref": [ "r207", "r213", "r218", "r219" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for investment.", "label": "Investment [Text Block]", "terseLabel": "Equity Method and Other Equity Investments" } } }, "localname": "InvestmentTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://bridgebio.com/20220630/taxonomy/role/DisclosureEquityMethodAndOtherEquityInvestments" ], "xbrltype": "textBlockItemType" }, "us-gaap_InvestmentTypeAxis": { "auth_ref": [ "r691", "r692", "r693", "r694", "r695", "r696", "r697", "r698", "r699", "r700", "r701", "r702", "r703", "r704", "r705" ], "lang": { "en-us": { "role": { "documentation": "Information by type of investments.", "label": "Investment Type [Axis]", "terseLabel": "Investment Type" } } }, "localname": "InvestmentTypeAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://bridgebio.com/20220630/taxonomy/role/Role_DisclosureCashEquivalentsAndMarketableSecuritiesScheduleOfCashEquivalentAndMarketableSecuritiesClassifiedAsAvailableForSaleDetails" ], "xbrltype": "stringItemType" }, "us-gaap_InvestmentTypeCategorizationMember": { "auth_ref": [ "r691", "r692", "r693", "r694", "r695", "r696", "r697", "r698", "r699", "r700", "r701", "r702", "r703", "r704", "r705" ], "lang": { "en-us": { "role": { "documentation": "Asset obtained to generate income or appreciate in value.", "label": "Investments [Domain]", "terseLabel": "Investments" } } }, "localname": "InvestmentTypeCategorizationMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://bridgebio.com/20220630/taxonomy/role/Role_DisclosureCashEquivalentsAndMarketableSecuritiesScheduleOfCashEquivalentAndMarketableSecuritiesClassifiedAsAvailableForSaleDetails" ], "xbrltype": "domainItemType" }, "us-gaap_LeaseCost": { "auth_ref": [ "r568", "r570" ], "calculation": { "http://bridgebio.com/20220630/taxonomy/role/Role_DisclosureLeasesComponentsOfLeaseCostDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of lease cost recognized by lessee for lease contract.", "label": "Lease, Cost", "totalLabel": "Total lease cost" } } }, "localname": "LeaseCost", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://bridgebio.com/20220630/taxonomy/role/Role_DisclosureLeasesComponentsOfLeaseCostDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LeaseCostTableTextBlock": { "auth_ref": [ "r568" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of lessee's lease cost. Includes, but is not limited to, interest expense for finance lease, amortization of right-of-use asset for finance lease, operating lease cost, short-term lease cost, variable lease cost and sublease income.", "label": "Lease, Cost [Table Text Block]", "terseLabel": "Components of Lease Cost" } } }, "localname": "LeaseCostTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://bridgebio.com/20220630/taxonomy/role/Role_DisclosureLeasesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_LeasesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Leases [Abstract]" } } }, "localname": "LeasesAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_LesseeLeaseDescriptionLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Lessee, Lease, Description [Line Items]", "terseLabel": "Lessee Lease Description [Line Items]" } } }, "localname": "LesseeLeaseDescriptionLineItems", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://bridgebio.com/20220630/taxonomy/role/Role_DisclosureLeasesAdditionalInformationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_LesseeLeaseDescriptionTable": { "auth_ref": [ "r560" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of information about lessee's leases.", "label": "Lessee, Lease, Description [Table]", "terseLabel": "Lessee Lease Description [Table]" } } }, "localname": "LesseeLeaseDescriptionTable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://bridgebio.com/20220630/taxonomy/role/Role_DisclosureLeasesAdditionalInformationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue": { "auth_ref": [ "r569" ], "calculation": { "http://bridgebio.com/20220630/taxonomy/role/DisclosureLeasesScheduleOfFutureMinimumLeasePaymentsForNoncancelableLeasesDetails2": { "order": null, "parentTag": null, "root": true, "weight": null }, "http://bridgebio.com/20220630/taxonomy/role/Role_DisclosureLeasesScheduleOfFutureMinimumLeasePaymentsForNoncancelableLeasesDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease.", "label": "Lessee, Operating Lease, Liability, to be Paid", "totalLabel": "Operating leases, Total future minimum lease payments" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentsDue", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://bridgebio.com/20220630/taxonomy/role/Role_DisclosureLeasesScheduleOfFutureMinimumLeasePaymentsForNoncancelableLeasesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths": { "auth_ref": [ "r569" ], "calculation": { "http://bridgebio.com/20220630/taxonomy/role/Role_DisclosureLeasesScheduleOfFutureMinimumLeasePaymentsForNoncancelableLeasesDetails": { "order": 1.0, "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Lessee, Operating Lease, Liability, to be Paid, Year One", "terseLabel": "Operating leases, 2023" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://bridgebio.com/20220630/taxonomy/role/Role_DisclosureLeasesScheduleOfFutureMinimumLeasePaymentsForNoncancelableLeasesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour": { "auth_ref": [ "r569" ], "calculation": { "http://bridgebio.com/20220630/taxonomy/role/Role_DisclosureLeasesScheduleOfFutureMinimumLeasePaymentsForNoncancelableLeasesDetails": { "order": 4.0, "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Lessee, Operating Lease, Liability, to be Paid, Year Four", "terseLabel": "Operating leases, 2026" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearFour", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://bridgebio.com/20220630/taxonomy/role/Role_DisclosureLeasesScheduleOfFutureMinimumLeasePaymentsForNoncancelableLeasesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree": { "auth_ref": [ "r569" ], "calculation": { "http://bridgebio.com/20220630/taxonomy/role/Role_DisclosureLeasesScheduleOfFutureMinimumLeasePaymentsForNoncancelableLeasesDetails": { "order": 3.0, "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Lessee, Operating Lease, Liability, to be Paid, Year Three", "terseLabel": "Operating leases, 2025" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearThree", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://bridgebio.com/20220630/taxonomy/role/Role_DisclosureLeasesScheduleOfFutureMinimumLeasePaymentsForNoncancelableLeasesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo": { "auth_ref": [ "r569" ], "calculation": { "http://bridgebio.com/20220630/taxonomy/role/Role_DisclosureLeasesScheduleOfFutureMinimumLeasePaymentsForNoncancelableLeasesDetails": { "order": 2.0, "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Lessee, Operating Lease, Liability, to be Paid, Year Two", "terseLabel": "Operating leases, 2024" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearTwo", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://bridgebio.com/20220630/taxonomy/role/Role_DisclosureLeasesScheduleOfFutureMinimumLeasePaymentsForNoncancelableLeasesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear": { "auth_ref": [ "r569" ], "calculation": { "http://bridgebio.com/20220630/taxonomy/role/Role_DisclosureLeasesScheduleOfFutureMinimumLeasePaymentsForNoncancelableLeasesDetails": { "order": 0.0, "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease having initial or remaining lease term in excess of one year to be paid in remainder of current fiscal year.", "label": "Lessee, Operating Lease, Liability, to be Paid, Remainder of Fiscal Year", "terseLabel": "Operating leases, Remainder of 2022" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://bridgebio.com/20220630/taxonomy/role/Role_DisclosureLeasesScheduleOfFutureMinimumLeasePaymentsForNoncancelableLeasesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount": { "auth_ref": [ "r569" ], "calculation": { "http://bridgebio.com/20220630/taxonomy/role/DisclosureLeasesScheduleOfFutureMinimumLeasePaymentsForNoncancelableLeasesDetails2": { "order": 0.0, "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease.", "label": "Lessee, Operating Lease, Liability, Undiscounted Excess Amount", "negatedLabel": "Operating leases, Imputed interest", "negatedTerseLabel": "Operating leases, Imputed interest" } } }, "localname": "LesseeOperatingLeaseLiabilityUndiscountedExcessAmount", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://bridgebio.com/20220630/taxonomy/role/Role_DisclosureLeasesScheduleOfFutureMinimumLeasePaymentsForNoncancelableLeasesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_Liabilities": { "auth_ref": [ "r36", "r116", "r182", "r217", "r288", "r289", "r290", "r292", "r293", "r294", "r295", "r296", "r297", "r298", "r476", "r481", "r482", "r523", "r581", "r582" ], "calculation": { "http://bridgebio.com/20220630/taxonomy/role/Role_StatementCondensedConsolidatedBalanceSheets": { "order": 0.0, "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.", "label": "Liabilities", "totalLabel": "Total liabilities" } } }, "localname": "Liabilities", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://bridgebio.com/20220630/taxonomy/role/Role_StatementCondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesAndStockholdersEquity": { "auth_ref": [ "r31", "r116", "r217", "r523", "r583", "r644", "r664" ], "calculation": { "http://bridgebio.com/20220630/taxonomy/role/Role_StatementCondensedConsolidatedBalanceSheets": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.", "label": "Liabilities and Equity", "totalLabel": "Total liabilities, redeemable convertible noncontrolling interests and stockholders' deficit" } } }, "localname": "LiabilitiesAndStockholdersEquity", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://bridgebio.com/20220630/taxonomy/role/Role_StatementCondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesAndStockholdersEquityAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Liabilities and Equity [Abstract]", "terseLabel": "Liabilities, Redeemable Convertible Noncontrolling Interests and Stockholders' Deficit" } } }, "localname": "LiabilitiesAndStockholdersEquityAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://bridgebio.com/20220630/taxonomy/role/Role_StatementCondensedConsolidatedBalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_LiabilitiesCurrent": { "auth_ref": [ "r10", "r38", "r116", "r217", "r288", "r289", "r290", "r292", "r293", "r294", "r295", "r296", "r297", "r298", "r476", "r481", "r482", "r523", "r581", "r582", "r583" ], "calculation": { "http://bridgebio.com/20220630/taxonomy/role/Role_StatementCondensedConsolidatedBalanceSheets": { "order": 0.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.", "label": "Liabilities, Current", "totalLabel": "Total current liabilities" } } }, "localname": "LiabilitiesCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://bridgebio.com/20220630/taxonomy/role/Role_StatementCondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesCurrentAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Liabilities, Current [Abstract]", "terseLabel": "Current liabilities:" } } }, "localname": "LiabilitiesCurrentAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://bridgebio.com/20220630/taxonomy/role/Role_StatementCondensedConsolidatedBalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_LiabilitiesFairValueDisclosureAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Liabilities, Fair Value Disclosure [Abstract]", "terseLabel": "Liability" } } }, "localname": "LiabilitiesFairValueDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://bridgebio.com/20220630/taxonomy/role/DisclosureFairValueMeasurementsFinancialAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails" ], "xbrltype": "stringItemType" }, "us-gaap_LicenseAndServiceMember": { "auth_ref": [ "r368" ], "lang": { "en-us": { "role": { "documentation": "Right to use intangible asset and performance of related service. Intangible asset includes, but is not limited to, patent, copyright, technology, manufacturing process, software or trademark.", "label": "License and Service [Member]", "terseLabel": "License and Services Revenue" } } }, "localname": "LicenseAndServiceMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://bridgebio.com/20220630/taxonomy/role/StatementCondensedConsolidatedStatementsOfOperationsUnaudited" ], "xbrltype": "domainItemType" }, "us-gaap_LicenseMember": { "auth_ref": [ "r368" ], "lang": { "en-us": { "role": { "documentation": "Right to use intangible asset. Intangible asset includes, but is not limited to, patent, copyright, technology, manufacturing process, software or trademark.", "label": "License [Member]", "terseLabel": "License and Services Revenue" } } }, "localname": "LicenseMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://bridgebio.com/20220630/taxonomy/role/DisclosureLicenseAndCollaborationAgreementsAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_LineOfCreditFacilityAxis": { "auth_ref": [ "r34", "r115" ], "lang": { "en-us": { "role": { "documentation": "Information by name of lender, which may be a single entity (for example, but not limited to, a bank, pension fund, venture capital firm) or a group of entities that participate in the line of credit.", "label": "Lender Name [Axis]", "terseLabel": "Lender Name" } } }, "localname": "LineOfCreditFacilityAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://bridgebio.com/20220630/taxonomy/role/DisclosureDebtScheduleOfBalancesOfBorrowingUnderLoanAgreementDetails", "http://bridgebio.com/20220630/taxonomy/role/Role_DisclosureDebtAdditionalInformationDetails", "http://bridgebio.com/20220630/taxonomy/role/Role_DisclosureDebtTables" ], "xbrltype": "stringItemType" }, "us-gaap_LineOfCreditFacilityLenderDomain": { "auth_ref": [ "r34", "r115" ], "lang": { "en-us": { "role": { "documentation": "Identification of the lender, which may be a single entity (for example, a bank, pension fund, venture capital firm) or a group of entities that participate in the line of credit, including a letter of credit facility.", "label": "Line of Credit Facility, Lender [Domain]", "terseLabel": "Line of Credit Facility, Lender" } } }, "localname": "LineOfCreditFacilityLenderDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://bridgebio.com/20220630/taxonomy/role/DisclosureDebtScheduleOfBalancesOfBorrowingUnderLoanAgreementDetails", "http://bridgebio.com/20220630/taxonomy/role/Role_DisclosureDebtAdditionalInformationDetails", "http://bridgebio.com/20220630/taxonomy/role/Role_DisclosureDebtTables" ], "xbrltype": "domainItemType" }, "us-gaap_LongTermDebt": { "auth_ref": [ "r20", "r313", "r329", "r334", "r335", "r642", "r660" ], "calculation": { "http://bridgebio.com/20220630/taxonomy/role/DisclosureDebtScheduleOfBalancesOfBorrowingUnderLoanAgreementDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount, excluding unamortized premium (discount) and debt issuance cost, of long-term debt. Excludes lease obligation.", "label": "Long-Term Debt", "terseLabel": "Debt instrument drawn amount", "totalLabel": "Term Loan, net" } } }, "localname": "LongTermDebt", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://bridgebio.com/20220630/taxonomy/role/DisclosureDebtScheduleOfBalancesOfBorrowingUnderLoanAgreementDetails", "http://bridgebio.com/20220630/taxonomy/role/Role_DisclosureDebtAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LongTermDebtNoncurrentAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Long-Term Debt, Excluding Current Maturities [Abstract]", "terseLabel": "Liability component" } } }, "localname": "LongTermDebtNoncurrentAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://bridgebio.com/20220630/taxonomy/role/Role_DisclosureDebtScheduleOfOutstandingNotesBalancesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_LongTermLoansPayable": { "auth_ref": [ "r44" ], "calculation": { "http://bridgebio.com/20220630/taxonomy/role/Role_StatementCondensedConsolidatedBalanceSheets": { "order": 2.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying value as of the balance sheet date of loans payable (with maturities initially due after one year or beyond the operating cycle if longer), excluding current portion.", "label": "Loans Payable, Noncurrent", "terseLabel": "Term loan, net", "totalLabel": "Loans Payable, Noncurrent, Total" } } }, "localname": "LongTermLoansPayable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://bridgebio.com/20220630/taxonomy/role/Role_StatementCondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_LongtermDebtTypeAxis": { "auth_ref": [ "r44" ], "lang": { "en-us": { "role": { "documentation": "Information by type of long-term debt.", "label": "Long-Term Debt, Type [Axis]" } } }, "localname": "LongtermDebtTypeAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://bridgebio.com/20220630/taxonomy/role/DisclosureDebtScheduleOfBalancesOfBorrowingUnderLoanAgreementDetails", "http://bridgebio.com/20220630/taxonomy/role/DisclosureDebtScheduleOfFutureMinimumPaymentsUnderTermLoanAgreementDetails", "http://bridgebio.com/20220630/taxonomy/role/Role_DisclosureDebtAdditionalInformationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_LongtermDebtTypeDomain": { "auth_ref": [ "r44", "r287" ], "lang": { "en-us": { "role": { "documentation": "Type of long-term debt arrangement, such as notes, line of credit, commercial paper, asset-based financing, project financing, letter of credit financing. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the company, if longer.", "label": "Long-Term Debt, Type [Domain]" } } }, "localname": "LongtermDebtTypeDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://bridgebio.com/20220630/taxonomy/role/DisclosureDebtScheduleOfBalancesOfBorrowingUnderLoanAgreementDetails", "http://bridgebio.com/20220630/taxonomy/role/DisclosureDebtScheduleOfFutureMinimumPaymentsUnderTermLoanAgreementDetails", "http://bridgebio.com/20220630/taxonomy/role/Role_DisclosureDebtAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_MarketableSecuritiesCurrent": { "auth_ref": [], "calculation": { "http://bridgebio.com/20220630/taxonomy/role/Role_StatementCondensedConsolidatedBalanceSheets": { "order": 1.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of investment in marketable security, classified as current.", "label": "Marketable Securities, Current", "terseLabel": "Marketable securities", "totalLabel": "Marketable Securities, Current, Total" } } }, "localname": "MarketableSecuritiesCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://bridgebio.com/20220630/taxonomy/role/Role_StatementCondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_MeasurementInputDiscountRateMember": { "auth_ref": [ "r514" ], "lang": { "en-us": { "role": { "documentation": "Measurement input using interest rate to determine present value of future cash flows.", "label": "Measurement Input, Discount Rate [Member]", "terseLabel": "Discount Rate" } } }, "localname": "MeasurementInputDiscountRateMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://bridgebio.com/20220630/taxonomy/role/DisclosureFairValueMeasurementsScheduleOfEstimatedFairValueOfLiabilityDetails" ], "xbrltype": "domainItemType" }, "us-gaap_MeasurementInputPriceVolatilityMember": { "auth_ref": [ "r514" ], "lang": { "en-us": { "role": { "documentation": "Measurement input using rate at which price of security will increase (decrease) for given set of returns.", "label": "Measurement Input, Price Volatility [Member]", "terseLabel": "Expected Volatility" } } }, "localname": "MeasurementInputPriceVolatilityMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://bridgebio.com/20220630/taxonomy/role/DisclosureFairValueMeasurementsScheduleOfEstimatedFairValueOfLiabilityDetails" ], "xbrltype": "domainItemType" }, "us-gaap_MeasurementInputRiskFreeInterestRateMember": { "auth_ref": [ "r514" ], "lang": { "en-us": { "role": { "documentation": "Measurement input using interest rate on instrument with zero risk of financial loss.", "label": "Measurement Input, Risk Free Interest Rate [Member]", "terseLabel": "Risk-Free Interest Rate" } } }, "localname": "MeasurementInputRiskFreeInterestRateMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://bridgebio.com/20220630/taxonomy/role/DisclosureFairValueMeasurementsScheduleOfEstimatedFairValueOfLiabilityDetails" ], "xbrltype": "domainItemType" }, "us-gaap_MeasurementInputTypeAxis": { "auth_ref": [ "r514" ], "lang": { "en-us": { "role": { "documentation": "Information by type of measurement input used to determine value of asset and liability.", "label": "Measurement Input Type [Axis]", "terseLabel": "Measurement Input Type" } } }, "localname": "MeasurementInputTypeAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://bridgebio.com/20220630/taxonomy/role/DisclosureFairValueMeasurementsScheduleOfEstimatedFairValueOfLiabilityDetails" ], "xbrltype": "stringItemType" }, "us-gaap_MeasurementInputTypeDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Measurement input used to determine value of asset and liability.", "label": "Measurement Input Type [Domain]", "terseLabel": "Measurement Input Type" } } }, "localname": "MeasurementInputTypeDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://bridgebio.com/20220630/taxonomy/role/DisclosureFairValueMeasurementsScheduleOfEstimatedFairValueOfLiabilityDetails" ], "xbrltype": "domainItemType" }, "us-gaap_MinorityInterest": { "auth_ref": [ "r51", "r116", "r217", "r288", "r292", "r293", "r294", "r297", "r298", "r523", "r643", "r663" ], "calculation": { "http://bridgebio.com/20220630/taxonomy/role/Role_StatementCondensedConsolidatedBalanceSheets": { "order": 1.0, "parentTag": "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which is directly or indirectly attributable to that ownership interest in subsidiary equity which is not attributable to the parent (that is, noncontrolling interest, previously referred to as minority interest).", "label": "Stockholders' Equity Attributable to Noncontrolling Interest", "periodEndLabel": "Stockholders' Equity Attributable to Noncontrolling Interest, Ending Balance", "periodStartLabel": "Stockholders' Equity Attributable to Noncontrolling Interest, Beginning Balance", "terseLabel": "Noncontrolling interests", "totalLabel": "Stockholders' Equity Attributable to Noncontrolling Interest, Total" } } }, "localname": "MinorityInterest", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://bridgebio.com/20220630/taxonomy/role/Role_StatementCondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_MinorityInterestDecreaseFromRedemptions": { "auth_ref": [ "r362", "r473", "r474" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Decrease in noncontrolling interest (for example, but not limited to, redeeming or purchasing the interests of noncontrolling shareholders, issuance of shares (interests) by the non-wholly owned subsidiary to the parent entity for other than cash, and a buyback of shares (interest) by the non-wholly owned subsidiary from the noncontrolling interests).", "label": "Noncontrolling Interest, Decrease from Redemptions or Purchase of Interests", "negatedTerseLabel": "Difference recognized in equity", "terseLabel": "Repurchase of Eidos noncontrolling interests for cash and shares, including transaction costs of $70,734" } } }, "localname": "MinorityInterestDecreaseFromRedemptions", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://bridgebio.com/20220630/taxonomy/role/Role_DisclosureEidosAdditionalInformationDetails", "http://bridgebio.com/20220630/taxonomy/role/StatementCondensedConsolidatedStatementsOfRedeemableConvertibleNoncontrollingInterestsAndStockholdersEquityUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_MinorityInterestDisclosureTextBlock": { "auth_ref": [ "r492" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for noncontrolling interest in consolidated subsidiaries, which could include the name of the subsidiary, the ownership percentage held by the parent, the ownership percentage held by the noncontrolling owners, the amount of the noncontrolling interest, the location of this amount on the balance sheet (when not reported separately), an explanation of the increase or decrease in the amount of the noncontrolling interest, the noncontrolling interest share of the net Income or Loss of the subsidiary, the location of this amount on the income statement (when not reported separately), the nature of the noncontrolling interest such as background information and terms, the amount of the noncontrolling interest represented by preferred stock, a description of the preferred stock, and the dividend requirements of the preferred stock.", "label": "Noncontrolling Interest Disclosure [Text Block]", "terseLabel": "Noncontrolling Interests" } } }, "localname": "MinorityInterestDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://bridgebio.com/20220630/taxonomy/role/Role_DisclosureNoncontrollingInterests" ], "xbrltype": "textBlockItemType" }, "us-gaap_MinorityInterestPeriodIncreaseDecrease": { "auth_ref": [ "r469" ], "lang": { "en-us": { "role": { "documentation": "Net Increase or Decrease in balance of noncontrolling interest in the subsidiary during the reporting period.", "label": "Noncontrolling Interest, Period Increase (Decrease)", "terseLabel": "Transfers from (to) noncontrolling interests", "totalLabel": "Noncontrolling Interest, Period Increase (Decrease), Total" } } }, "localname": "MinorityInterestPeriodIncreaseDecrease", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://bridgebio.com/20220630/taxonomy/role/StatementCondensedConsolidatedStatementsOfRedeemableConvertibleNoncontrollingInterestsAndStockholdersEquityUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_MoneyMarketFundsMember": { "auth_ref": [ "r371" ], "lang": { "en-us": { "role": { "documentation": "Fund that invests in short-term money-market instruments, for example, but not limited to, commercial paper, banker's acceptances, repurchase agreements, government securities, certificates of deposit, and other highly liquid securities.", "label": "Money Market Funds [Member]", "terseLabel": "Money Market Funds" } } }, "localname": "MoneyMarketFundsMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://bridgebio.com/20220630/taxonomy/role/DisclosureFairValueMeasurementsFinancialAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails", "http://bridgebio.com/20220630/taxonomy/role/Role_DisclosureCashEquivalentsAndMarketableSecuritiesScheduleOfCashEquivalentAndMarketableSecuritiesClassifiedAsAvailableForSaleDetails" ], "xbrltype": "domainItemType" }, "us-gaap_NatureOfOperations": { "auth_ref": [ "r162", "r170" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for the nature of an entity's business, major products or services, principal markets including location, and the relative importance of its operations in each business and the basis for the determination, including but not limited to, assets, revenues, or earnings. For an entity that has not commenced principal operations, disclosures about the risks and uncertainties related to the activities in which the entity is currently engaged and an understanding of what those activities are being directed toward.", "label": "Nature of Operations [Text Block]", "terseLabel": "Organization and Description of Business" } } }, "localname": "NatureOfOperations", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://bridgebio.com/20220630/taxonomy/role/Role_DisclosureOrganizationAndDescriptionOfBusiness" ], "xbrltype": "textBlockItemType" }, "us-gaap_NetCashProvidedByUsedInFinancingActivities": { "auth_ref": [ "r96" ], "calculation": { "http://bridgebio.com/20220630/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited": { "order": 2.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.", "label": "Net Cash Provided by (Used in) Financing Activities", "totalLabel": "Net cash provided by (used in) financing activities" } } }, "localname": "NetCashProvidedByUsedInFinancingActivities", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://bridgebio.com/20220630/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Net Cash Provided by (Used in) Financing Activities [Abstract]", "terseLabel": "Financing activities:" } } }, "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://bridgebio.com/20220630/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited" ], "xbrltype": "stringItemType" }, "us-gaap_NetCashProvidedByUsedInInvestingActivities": { "auth_ref": [ "r96" ], "calculation": { "http://bridgebio.com/20220630/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited": { "order": 1.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.", "label": "Net Cash Provided by (Used in) Investing Activities", "totalLabel": "Net cash provided by (used in) investing activities" } } }, "localname": "NetCashProvidedByUsedInInvestingActivities", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://bridgebio.com/20220630/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Net Cash Provided by (Used in) Investing Activities [Abstract]", "terseLabel": "Investing activities:" } } }, "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://bridgebio.com/20220630/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited" ], "xbrltype": "stringItemType" }, "us-gaap_NetCashProvidedByUsedInOperatingActivities": { "auth_ref": [ "r96", "r98", "r101" ], "calculation": { "http://bridgebio.com/20220630/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited": { "order": 0.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0 } }, "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.", "label": "Net Cash Provided by (Used in) Operating Activities", "totalLabel": "Net cash used in operating activities" } } }, "localname": "NetCashProvidedByUsedInOperatingActivities", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://bridgebio.com/20220630/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Net Cash Provided by (Used in) Operating Activities [Abstract]", "terseLabel": "Operating activities:" } } }, "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://bridgebio.com/20220630/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited" ], "xbrltype": "stringItemType" }, "us-gaap_NetIncomeLossAttributableToNoncontrollingInterest": { "auth_ref": [ "r60", "r62", "r67", "r139", "r140", "r478", "r490" ], "calculation": { "http://bridgebio.com/20220630/taxonomy/role/StatementCondensedConsolidatedStatementsOfOperationsUnaudited": { "order": 1.0, "parentTag": "us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of Net Income (Loss) attributable to noncontrolling interest.", "label": "Net Income (Loss) Attributable to Noncontrolling Interest", "negatedLabel": "Net loss (income) attributable to redeemable convertible noncontrolling interests and noncontrolling interests", "totalLabel": "Net Income (Loss) Attributable to Noncontrolling Interest, Total" } } }, "localname": "NetIncomeLossAttributableToNoncontrollingInterest", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://bridgebio.com/20220630/taxonomy/role/StatementCondensedConsolidatedStatementsOfOperationsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic": { "auth_ref": [ "r133", "r134", "r135", "r136", "r142", "r143", "r148", "r151", "r177", "r180", "r183", "r186", "r188" ], "calculation": { "http://bridgebio.com/20220630/taxonomy/role/StatementCondensedConsolidatedStatementsOfOperationsUnaudited": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities; of income (loss) available to common shareholders.", "label": "Net Income (Loss) Available to Common Stockholders, Basic", "totalLabel": "Net loss attributable to common stockholders of BridgeBio" } } }, "localname": "NetIncomeLossAvailableToCommonStockholdersBasic", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://bridgebio.com/20220630/taxonomy/role/StatementCondensedConsolidatedStatementsOfOperationsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.", "label": "New Accounting Pronouncements, Policy [Policy Text Block]", "terseLabel": "Recent Accounting Pronouncements" } } }, "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://bridgebio.com/20220630/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_NoncashInvestingAndFinancingItemsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Noncash Investing and Financing Items [Abstract]", "terseLabel": "Supplemental Disclosures of Noncash Investing and Financing Information:" } } }, "localname": "NoncashInvestingAndFinancingItemsAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://bridgebio.com/20220630/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited" ], "xbrltype": "stringItemType" }, "us-gaap_NoncontrollingInterestAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Noncontrolling Interest [Abstract]" } } }, "localname": "NoncontrollingInterestAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_NoncontrollingInterestMember": { "auth_ref": [ "r124", "r125", "r126", "r362", "r468" ], "lang": { "en-us": { "role": { "documentation": "This element represents that portion of equity (net assets) in a subsidiary not attributable, directly or indirectly, to the parent. A noncontrolling interest is sometimes called a minority interest.", "label": "Noncontrolling Interest [Member]", "terseLabel": "Noncontrolling Interests" } } }, "localname": "NoncontrollingInterestMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://bridgebio.com/20220630/taxonomy/role/StatementCondensedConsolidatedStatementsOfRedeemableConvertibleNoncontrollingInterestsAndStockholdersEquityUnaudited" ], "xbrltype": "domainItemType" }, "us-gaap_NonoperatingIncomeExpense": { "auth_ref": [ "r79" ], "calculation": { "http://bridgebio.com/20220630/taxonomy/role/StatementCondensedConsolidatedStatementsOfOperationsUnaudited": { "order": 1.0, "parentTag": "us-gaap_ProfitLoss", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).", "label": "Nonoperating Income (Expense)", "totalLabel": "Total other income (expense), net" } } }, "localname": "NonoperatingIncomeExpense", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://bridgebio.com/20220630/taxonomy/role/StatementCondensedConsolidatedStatementsOfOperationsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_NonoperatingIncomeExpenseAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Nonoperating Income (Expense) [Abstract]", "terseLabel": "Other income (expense), net:" } } }, "localname": "NonoperatingIncomeExpenseAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://bridgebio.com/20220630/taxonomy/role/StatementCondensedConsolidatedStatementsOfOperationsUnaudited" ], "xbrltype": "stringItemType" }, "us-gaap_NotesPayableFairValueDisclosure": { "auth_ref": [ "r35" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Fair value portion of notes payable.", "label": "Notes Payable, Fair Value Disclosure", "terseLabel": "Estimated fair value of notes payable" } } }, "localname": "NotesPayableFairValueDisclosure", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://bridgebio.com/20220630/taxonomy/role/DisclosureFairValueMeasurementsAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingIncomeLoss": { "auth_ref": [ "r177", "r180", "r183", "r186", "r188" ], "calculation": { "http://bridgebio.com/20220630/taxonomy/role/StatementCondensedConsolidatedStatementsOfOperationsUnaudited": { "order": 0.0, "parentTag": "us-gaap_ProfitLoss", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The net result for the period of deducting operating expenses from operating revenues.", "label": "Operating Income (Loss)", "totalLabel": "Loss from operations" } } }, "localname": "OperatingIncomeLoss", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://bridgebio.com/20220630/taxonomy/role/StatementCondensedConsolidatedStatementsOfOperationsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseCost": { "auth_ref": [ "r562", "r570" ], "calculation": { "http://bridgebio.com/20220630/taxonomy/role/Role_DisclosureLeasesComponentsOfLeaseCostDetails": { "order": 0.0, "parentTag": "us-gaap_LeaseCost", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of single lease cost, calculated by allocation of remaining cost of lease over remaining lease term. Includes, but is not limited to, single lease cost, after impairment of right-of-use asset, calculated by amortization of remaining right-of-use asset and accretion of lease liability.", "label": "Operating Lease, Cost", "terseLabel": "Straight line operating lease costs" } } }, "localname": "OperatingLeaseCost", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://bridgebio.com/20220630/taxonomy/role/Role_DisclosureLeasesComponentsOfLeaseCostDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseImpairmentLoss": { "auth_ref": [ "r554" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of loss from impairment of right-of-use asset from operating lease.", "label": "Operating Lease, Impairment Loss", "terseLabel": "Impairment loss related to operating lease right-of-use assets" } } }, "localname": "OperatingLeaseImpairmentLoss", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://bridgebio.com/20220630/taxonomy/role/Role_DisclosureLeasesAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseLiability": { "auth_ref": [ "r556" ], "calculation": { "http://bridgebio.com/20220630/taxonomy/role/DisclosureLeasesScheduleOfFutureMinimumLeasePaymentsForNoncancelableLeasesDetails2": { "order": 1.0, "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0 }, "http://bridgebio.com/20220630/taxonomy/role/Role_DisclosureLeasesScheduleOfFutureMinimumLeasePaymentsForNoncancelableLeasesDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease.", "label": "Operating Lease, Liability", "terseLabel": "Operating lease liabilities", "totalLabel": "Total operating lease liabilities", "verboseLabel": "Operating lease liabilities" } } }, "localname": "OperatingLeaseLiability", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://bridgebio.com/20220630/taxonomy/role/Role_DisclosureLeasesScheduleOfFutureMinimumLeasePaymentsForNoncancelableLeasesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseLiabilityCurrent": { "auth_ref": [ "r556" ], "calculation": { "http://bridgebio.com/20220630/taxonomy/role/Role_DisclosureLeasesScheduleOfFutureMinimumLeasePaymentsForNoncancelableLeasesDetails": { "order": 0.0, "parentTag": "us-gaap_OperatingLeaseLiability", "weight": 1.0 }, "http://bridgebio.com/20220630/taxonomy/role/Role_StatementCondensedConsolidatedBalanceSheets": { "order": 4.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.", "label": "Operating Lease, Liability, Current", "terseLabel": "Operating lease liabilities, current portion" } } }, "localname": "OperatingLeaseLiabilityCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://bridgebio.com/20220630/taxonomy/role/Role_DisclosureLeasesScheduleOfFutureMinimumLeasePaymentsForNoncancelableLeasesDetails", "http://bridgebio.com/20220630/taxonomy/role/Role_StatementCondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseLiabilityNoncurrent": { "auth_ref": [ "r556" ], "calculation": { "http://bridgebio.com/20220630/taxonomy/role/Role_DisclosureLeasesScheduleOfFutureMinimumLeasePaymentsForNoncancelableLeasesDetails": { "order": 1.0, "parentTag": "us-gaap_OperatingLeaseLiability", "weight": 1.0 }, "http://bridgebio.com/20220630/taxonomy/role/Role_StatementCondensedConsolidatedBalanceSheets": { "order": 3.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.", "label": "Operating Lease, Liability, Noncurrent", "terseLabel": "Operating lease liabilities, net of current portion" } } }, "localname": "OperatingLeaseLiabilityNoncurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://bridgebio.com/20220630/taxonomy/role/Role_DisclosureLeasesScheduleOfFutureMinimumLeasePaymentsForNoncancelableLeasesDetails", "http://bridgebio.com/20220630/taxonomy/role/Role_StatementCondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeasePayments": { "auth_ref": [ "r559", "r564" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use.", "label": "Operating Lease, Payments", "terseLabel": "Operating cash flows for operating leases" } } }, "localname": "OperatingLeasePayments", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://bridgebio.com/20220630/taxonomy/role/Role_DisclosureLeasesScheduleOfSupplementalCashFlowInformationRelatedToLeasesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseRightOfUseAsset": { "auth_ref": [ "r555" ], "calculation": { "http://bridgebio.com/20220630/taxonomy/role/Role_StatementCondensedConsolidatedBalanceSheets": { "order": 3.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's right to use underlying asset under operating lease.", "label": "Operating Lease, Right-of-Use Asset", "terseLabel": "Operating lease right-of-use assets" } } }, "localname": "OperatingLeaseRightOfUseAsset", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://bridgebio.com/20220630/taxonomy/role/Role_StatementCondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent": { "auth_ref": [ "r567", "r570" ], "lang": { "en-us": { "role": { "documentation": "Weighted average discount rate for operating lease calculated at point in time.", "label": "Operating Lease, Weighted Average Discount Rate, Percent", "terseLabel": "Operating leases" } } }, "localname": "OperatingLeaseWeightedAverageDiscountRatePercent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://bridgebio.com/20220630/taxonomy/role/Role_DisclosureLeasesScheduleOfSupplementalInformationRelatedToRemainingLeaseTermAndDiscountRateDetails" ], "xbrltype": "percentItemType" }, "us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1": { "auth_ref": [ "r566", "r570" ], "lang": { "en-us": { "role": { "documentation": "Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.", "label": "Operating Lease, Weighted Average Remaining Lease Term", "terseLabel": "Operating leases" } } }, "localname": "OperatingLeaseWeightedAverageRemainingLeaseTerm1", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://bridgebio.com/20220630/taxonomy/role/Role_DisclosureLeasesScheduleOfSupplementalInformationRelatedToRemainingLeaseTermAndDiscountRateDetails" ], "xbrltype": "durationItemType" }, "us-gaap_OperatingLossCarryforwardsLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Operating Loss Carryforwards [Line Items]", "terseLabel": "Operating Loss Carryforwards [Line Items]" } } }, "localname": "OperatingLossCarryforwardsLineItems", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://bridgebio.com/20220630/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_OperatingLossCarryforwardsTable": { "auth_ref": [ "r445" ], "lang": { "en-us": { "role": { "documentation": "Schedule reflecting pertinent information, such as tax authority, amounts, and expiration dates, of net operating loss carryforwards, including an assessment of the likelihood of utilization.", "label": "Operating Loss Carryforwards [Table]", "terseLabel": "Operating Loss Carryforwards [Table]" } } }, "localname": "OperatingLossCarryforwardsTable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://bridgebio.com/20220630/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Organization, Consolidation and Presentation of Financial Statements [Abstract]" } } }, "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_OtherAccruedLiabilitiesCurrent": { "auth_ref": [ "r37" ], "calculation": { "http://bridgebio.com/20220630/taxonomy/role/Role_StatementCondensedConsolidatedBalanceSheets": { "order": 8.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer.", "label": "Other Accrued Liabilities, Current", "terseLabel": "Other accrued liabilities" } } }, "localname": "OtherAccruedLiabilitiesCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://bridgebio.com/20220630/taxonomy/role/DisclosureIntangibleAssetsAdditionalInformationDetails", "http://bridgebio.com/20220630/taxonomy/role/Role_StatementCondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherAssetsNoncurrent": { "auth_ref": [ "r15" ], "calculation": { "http://bridgebio.com/20220630/taxonomy/role/Role_StatementCondensedConsolidatedBalanceSheets": { "order": 6.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of noncurrent assets classified as other.", "label": "Other Assets, Noncurrent", "terseLabel": "Other assets", "totalLabel": "Other Assets, Noncurrent, Total" } } }, "localname": "OtherAssetsNoncurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://bridgebio.com/20220630/taxonomy/role/Role_StatementCondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Other Comprehensive Income (Loss), Net of Tax [Abstract]", "terseLabel": "Other comprehensive income (loss):" } } }, "localname": "OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://bridgebio.com/20220630/taxonomy/role/StatementCondensedConsolidatedStatementsOfComprehensiveLossUnaudited" ], "xbrltype": "stringItemType" }, "us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax": { "auth_ref": [ "r55", "r57" ], "calculation": { "http://bridgebio.com/20220630/taxonomy/role/StatementCondensedConsolidatedStatementsOfComprehensiveLossUnaudited": { "order": 1.0, "parentTag": "us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount, after tax and before adjustment, of unrealized holding gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale). Excludes unrealized gain (loss) on investment in debt security measured at amortized cost (held-to-maturity) from transfer to available-for-sale.", "label": "OCI, Debt Securities, Available-for-Sale, Unrealized Holding Gain (Loss), before Adjustment, after Tax", "terseLabel": "Unrealized gains (losses) on available-for-sale securities" } } }, "localname": "OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://bridgebio.com/20220630/taxonomy/role/StatementCondensedConsolidatedStatementsOfComprehensiveLossUnaudited", "http://bridgebio.com/20220630/taxonomy/role/StatementCondensedConsolidatedStatementsOfRedeemableConvertibleNoncontrollingInterestsAndStockholdersEquityUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherLiabilitiesMember": { "auth_ref": [ "r493", "r496" ], "lang": { "en-us": { "role": { "documentation": "Primary financial statement caption encompassing other liabilities.", "label": "Other Liabilities [Member]", "terseLabel": "Other liabilities" } } }, "localname": "OtherLiabilitiesMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://bridgebio.com/20220630/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_OtherLiabilitiesNoncurrent": { "auth_ref": [ "r45" ], "calculation": { "http://bridgebio.com/20220630/taxonomy/role/Role_StatementCondensedConsolidatedBalanceSheets": { "order": 4.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer.", "label": "Other Liabilities, Noncurrent", "terseLabel": "Other liabilities", "totalLabel": "Other Liabilities, Noncurrent, Total", "verboseLabel": "Other long-term liabilities" } } }, "localname": "OtherLiabilitiesNoncurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://bridgebio.com/20220630/taxonomy/role/DisclosureIntangibleAssetsAdditionalInformationDetails", "http://bridgebio.com/20220630/taxonomy/role/Role_StatementCondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherNoncashIncomeExpense": { "auth_ref": [ "r101" ], "calculation": { "http://bridgebio.com/20220630/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited": { "order": 14.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of income (expense) included in net income that results in no cash inflow (outflow), classified as other.", "label": "Other Noncash Income (Expense)", "negatedLabel": "Other noncash adjustments", "totalLabel": "Other Noncash Income (Expense), Total" } } }, "localname": "OtherNoncashIncomeExpense", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://bridgebio.com/20220630/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherNoncurrentAssetsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Primary financial statement caption encompassing other noncurrent assets.", "label": "Other Noncurrent Assets [Member]" } } }, "localname": "OtherNoncurrentAssetsMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://bridgebio.com/20220630/taxonomy/role/DisclosureLicenseAndCollaborationAgreementsAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_OtherNonoperatingIncomeExpense": { "auth_ref": [ "r81" ], "calculation": { "http://bridgebio.com/20220630/taxonomy/role/StatementCondensedConsolidatedStatementsOfOperationsUnaudited": { "order": 3.0, "parentTag": "us-gaap_NonoperatingIncomeExpense", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of income (expense) related to nonoperating activities, classified as other.", "label": "Other Nonoperating Income (Expense)", "terseLabel": "Other income (expense), net", "totalLabel": "Other Nonoperating Income (Expense), Total" } } }, "localname": "OtherNonoperatingIncomeExpense", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://bridgebio.com/20220630/taxonomy/role/StatementCondensedConsolidatedStatementsOfOperationsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherNonoperatingIncomeExpenseMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Primary financial statement caption encompassing other nonoperating income (expense).", "label": "Other Nonoperating Income (Expense) [Member]", "terseLabel": "Other income (expense), net" } } }, "localname": "OtherNonoperatingIncomeExpenseMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://bridgebio.com/20220630/taxonomy/role/DisclosureSaleOfNonfinancialAssetsAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ParentMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Portion of equity, or net assets, in the consolidated entity attributable, directly or indirectly, to the parent. Excludes noncontrolling interests.", "label": "Parent [Member]", "terseLabel": "Parent" } } }, "localname": "ParentMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://bridgebio.com/20220630/taxonomy/role/StatementCondensedConsolidatedStatementsOfRedeemableConvertibleNoncontrollingInterestsAndStockholdersEquityUnaudited" ], "xbrltype": "domainItemType" }, "us-gaap_PaymentInKindPIKNoteMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "A payment in kind note accrues interest over the term of the note and is repaid at maturity or upon refinancing. A PIK loan is typically unsecured.", "label": "Payment in Kind (PIK) Note [Member]", "terseLabel": "Payment in Kind" } } }, "localname": "PaymentInKindPIKNoteMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://bridgebio.com/20220630/taxonomy/role/DisclosureDebtScheduleOfBalancesOfBorrowingUnderLoanAgreementDetails", "http://bridgebio.com/20220630/taxonomy/role/DisclosureDebtScheduleOfFutureMinimumPaymentsUnderTermLoanAgreementDetails", "http://bridgebio.com/20220630/taxonomy/role/Role_DisclosureDebtAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_PaymentsForRepurchaseOfCommonStock": { "auth_ref": [ "r88" ], "calculation": { "http://bridgebio.com/20220630/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited": { "order": 4.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cash outflow to reacquire common stock during the period.", "label": "Payments for Repurchase of Common Stock", "negatedLabel": "Repurchases of common stock", "terseLabel": "Repurchase of common stock" } } }, "localname": "PaymentsForRepurchaseOfCommonStock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://bridgebio.com/20220630/taxonomy/role/Role_DisclosureDebtAdditionalInformationDetails", "http://bridgebio.com/20220630/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsForRestructuring": { "auth_ref": [ "r93", "r262" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of cash payments made as the result of exit or disposal activities. Excludes payments associated with a discontinued operation or an asset retirement obligation.", "label": "Payments for Restructuring", "negatedLabel": "Cash payments" } } }, "localname": "PaymentsForRestructuring", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://bridgebio.com/20220630/taxonomy/role/DisclosureRestructuringImpairmentAndRelatedChargesScheduleOfActivityRelatedToRestructuringLiabilitiesAssociatedToRestructuringInitiativesDeta" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsForTenantImprovements": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of cash outflow for the allowance granted to lessee and/or direct costs incurred by lessor used to prepare the leased premises for tenant's occupancy.", "label": "Payments for Tenant Improvements", "terseLabel": "Leasehold improvements paid by landlord" } } }, "localname": "PaymentsForTenantImprovements", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://bridgebio.com/20220630/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsOfDebtIssuanceCosts": { "auth_ref": [ "r90" ], "calculation": { "http://bridgebio.com/20220630/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited": { "order": 1.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cash outflow paid to third parties in connection with debt origination, which will be amortized over the remaining maturity period of the associated long-term debt.", "label": "Payments of Debt Issuance Costs", "negatedLabel": "Issuance costs and discounts associated with issuance of 2029 Notes" } } }, "localname": "PaymentsOfDebtIssuanceCosts", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://bridgebio.com/20220630/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsOfFinancingCosts": { "auth_ref": [ "r91" ], "calculation": { "http://bridgebio.com/20220630/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited": { "order": 2.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cash outflow for loan and debt issuance costs.", "label": "Payments of Financing Costs", "negatedLabel": "Issuance costs associated with term loan", "terseLabel": "Payment of debt discount and issuance costs", "totalLabel": "Payments of Financing Costs, Total" } } }, "localname": "PaymentsOfFinancingCosts", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://bridgebio.com/20220630/taxonomy/role/Role_DisclosureDebtAdditionalInformationDetails", "http://bridgebio.com/20220630/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation": { "auth_ref": [ "r88" ], "calculation": { "http://bridgebio.com/20220630/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited": { "order": 16.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of cash outflow to satisfy grantee's tax withholding obligation for award under share-based payment arrangement.", "label": "Payment, Tax Withholding, Share-Based Payment Arrangement", "negatedLabel": "Repurchase of shares to satisfy tax withholding" } } }, "localname": "PaymentsRelatedToTaxWithholdingForShareBasedCompensation", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://bridgebio.com/20220630/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsToAcquireAdditionalInterestInSubsidiaries": { "auth_ref": [ "r84" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cash outflow associated with the purchase of noncontrolling interest during the period.", "label": "Payments to Acquire Additional Interest in Subsidiaries", "terseLabel": "Cash consideration paid" } } }, "localname": "PaymentsToAcquireAdditionalInterestInSubsidiaries", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://bridgebio.com/20220630/taxonomy/role/Role_DisclosureEidosAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsToAcquireEquitySecuritiesFvNi": { "auth_ref": [ "r94", "r208" ], "calculation": { "http://bridgebio.com/20220630/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited": { "order": 2.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of cash outflow to acquire investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI), classified as investing activity.", "label": "Payments to Acquire Equity Securities, FV-NI", "negatedLabel": "Purchases of investment in equity securities" } } }, "localname": "PaymentsToAcquireEquitySecuritiesFvNi", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://bridgebio.com/20220630/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsToAcquireMarketableSecurities": { "auth_ref": [ "r196" ], "calculation": { "http://bridgebio.com/20220630/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited": { "order": 0.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of cash outflow for purchase of marketable security.", "label": "Payments to Acquire Marketable Securities", "negatedLabel": "Purchases of marketable securities", "totalLabel": "Payments to Acquire Marketable Securities, Total" } } }, "localname": "PaymentsToAcquireMarketableSecurities", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://bridgebio.com/20220630/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment": { "auth_ref": [ "r85" ], "calculation": { "http://bridgebio.com/20220630/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited": { "order": 13.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.", "label": "Payments to Acquire Property, Plant, and Equipment", "negatedLabel": "Purchases of property and equipment", "totalLabel": "Payments to Acquire Property, Plant, and Equipment, Total" } } }, "localname": "PaymentsToAcquirePropertyPlantAndEquipment", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://bridgebio.com/20220630/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_PlanNameAxis": { "auth_ref": [ "r389", "r390", "r391", "r394", "r395", "r396", "r397", "r398", "r399", "r400", "r401", "r403", "r404", "r405", "r406", "r407", "r408", "r410", "r411", "r413", "r414", "r417", "r418", "r419", "r420", "r421" ], "lang": { "en-us": { "role": { "documentation": "Information by plan name for share-based payment arrangement.", "label": "Plan Name [Axis]", "terseLabel": "Plan Name" } } }, "localname": "PlanNameAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://bridgebio.com/20220630/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetails", "http://bridgebio.com/20220630/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfRecognizedStockBasedCompensationExpenseRelatedToRestrictedStockAwardActivityDetails", "http://bridgebio.com/20220630/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfRestrictedStockAwardActivityUnderPlansDetails", "http://bridgebio.com/20220630/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfRestrictedStockUnitsActivityDetails", "http://bridgebio.com/20220630/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfStockOptionActivityUnderPlansDetails", "http://bridgebio.com/20220630/taxonomy/role/Role_DisclosureStockBasedCompensationTables" ], "xbrltype": "stringItemType" }, "us-gaap_PlanNameDomain": { "auth_ref": [ "r389", "r390", "r391", "r394", "r395", "r396", "r397", "r398", "r399", "r400", "r401", "r403", "r404", "r405", "r406", "r407", "r408", "r410", "r411", "r413", "r414", "r417", "r418", "r419", "r420", "r421" ], "lang": { "en-us": { "role": { "documentation": "Plan name for share-based payment arrangement.", "label": "Plan Name [Domain]", "terseLabel": "Plan Name" } } }, "localname": "PlanNameDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://bridgebio.com/20220630/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetails", "http://bridgebio.com/20220630/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfRecognizedStockBasedCompensationExpenseRelatedToRestrictedStockAwardActivityDetails", "http://bridgebio.com/20220630/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfRestrictedStockAwardActivityUnderPlansDetails", "http://bridgebio.com/20220630/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfRestrictedStockUnitsActivityDetails", "http://bridgebio.com/20220630/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfStockOptionActivityUnderPlansDetails", "http://bridgebio.com/20220630/taxonomy/role/Role_DisclosureStockBasedCompensationTables" ], "xbrltype": "domainItemType" }, "us-gaap_PreferredStockParOrStatedValuePerShare": { "auth_ref": [ "r23", "r340" ], "lang": { "en-us": { "role": { "documentation": "Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.", "label": "Preferred Stock, Par or Stated Value Per Share", "terseLabel": "Preferred stock, par value" } } }, "localname": "PreferredStockParOrStatedValuePerShare", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://bridgebio.com/20220630/taxonomy/role/Role_StatementCondensedConsolidatedBalanceSheetsParenthetical" ], "xbrltype": "perShareItemType" }, "us-gaap_PreferredStockSharesAuthorized": { "auth_ref": [ "r23" ], "lang": { "en-us": { "role": { "documentation": "The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.", "label": "Preferred Stock, Shares Authorized", "terseLabel": "Preferred stock, shares authorized" } } }, "localname": "PreferredStockSharesAuthorized", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://bridgebio.com/20220630/taxonomy/role/Role_StatementCondensedConsolidatedBalanceSheetsParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_PreferredStockSharesIssued": { "auth_ref": [ "r23", "r340" ], "lang": { "en-us": { "role": { "documentation": "Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.", "label": "Preferred Stock, Shares Issued", "terseLabel": "Preferred stock, shares issued", "totalLabel": "Preferred Stock, Shares Issued, Total" } } }, "localname": "PreferredStockSharesIssued", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://bridgebio.com/20220630/taxonomy/role/Role_StatementCondensedConsolidatedBalanceSheetsParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_PreferredStockSharesOutstanding": { "auth_ref": [ "r23" ], "lang": { "en-us": { "role": { "documentation": "Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.", "label": "Preferred Stock, Shares Outstanding", "periodEndLabel": "Preferred Stock, Shares Outstanding, Ending Balance", "periodStartLabel": "Preferred Stock, Shares Outstanding, Beginning Balance", "terseLabel": "Preferred stock, shares outstanding" } } }, "localname": "PreferredStockSharesOutstanding", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://bridgebio.com/20220630/taxonomy/role/Role_StatementCondensedConsolidatedBalanceSheetsParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_PreferredStockValue": { "auth_ref": [ "r23", "r583" ], "calculation": { "http://bridgebio.com/20220630/taxonomy/role/Role_StatementCondensedConsolidatedBalanceSheets": { "order": 0.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.", "label": "Preferred Stock, Value, Issued", "periodEndLabel": "Preferred Stock, Value, Issued, Ending Balance", "periodStartLabel": "Preferred Stock, Value, Issued, Beginning Balance", "terseLabel": "Undesignated preferred stock, $0.001 par value; 25,000,000 shares authorized; no shares issued and outstanding", "totalLabel": "Preferred Stock, Value, Issued, Total" } } }, "localname": "PreferredStockValue", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://bridgebio.com/20220630/taxonomy/role/Role_StatementCondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_PrepaidExpenseAndOtherAssetsCurrent": { "auth_ref": [ "r32" ], "calculation": { "http://bridgebio.com/20220630/taxonomy/role/Role_StatementCondensedConsolidatedBalanceSheets": { "order": 7.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.", "label": "Prepaid Expense and Other Assets, Current", "terseLabel": "Prepaid expenses and other current assets" } } }, "localname": "PrepaidExpenseAndOtherAssetsCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://bridgebio.com/20220630/taxonomy/role/Role_StatementCondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_PrimeRateMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Interest rate charged by financial institutions to their most creditworthy borrowers.", "label": "Prime Rate [Member]", "terseLabel": "Prime Rate" } } }, "localname": "PrimeRateMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://bridgebio.com/20220630/taxonomy/role/Role_DisclosureDebtAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_PriorPeriodReclassificationAdjustmentDescription": { "auth_ref": [ "r5" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for reclassification affecting comparability of financial statement. Excludes amendment to accounting standards, other change in accounting principle, and correction of error.", "label": "Reclassification, Comparability Adjustment [Policy Text Block]", "terseLabel": "Reclassifications" } } }, "localname": "PriorPeriodReclassificationAdjustmentDescription", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://bridgebio.com/20220630/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_ProceedsFromConvertibleDebt": { "auth_ref": [ "r87" ], "calculation": { "http://bridgebio.com/20220630/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited": { "order": 0.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The cash inflow from the issuance of a long-term debt instrument which can be exchanged for a specified amount of another security, typically the entity's common stock, at the option of the issuer or the holder.", "label": "Proceeds from Convertible Debt", "terseLabel": "Proceeds from issuance of 2029 Notes" } } }, "localname": "ProceedsFromConvertibleDebt", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://bridgebio.com/20220630/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromDebtNetOfIssuanceCosts": { "auth_ref": [ "r87" ], "calculation": { "http://bridgebio.com/20220630/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited": { "order": 8.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The cash inflow from additional borrowings, net of cash paid to third parties in connection with debt origination.", "label": "Proceeds from Debt, Net of Issuance Costs", "terseLabel": "Proceeds from term loan" } } }, "localname": "ProceedsFromDebtNetOfIssuanceCosts", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://bridgebio.com/20220630/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromIssuanceOfCommonStock": { "auth_ref": [ "r86" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The cash inflow from the additional capital contribution to the entity.", "label": "Proceeds from Issuance of Common Stock", "terseLabel": "Net proceeds issued from offerings" } } }, "localname": "ProceedsFromIssuanceOfCommonStock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://bridgebio.com/20220630/taxonomy/role/Role_DisclosureEidosAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities": { "auth_ref": [], "calculation": { "http://bridgebio.com/20220630/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited": { "order": 1.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The cash inflow associated with the aggregate amount received by the entity through sale or maturity of marketable securities (held-to-maturity or available-for-sale) during the period.", "label": "Proceeds from Sale and Maturity of Marketable Securities", "terseLabel": "Maturities of marketable securities", "totalLabel": "Proceeds from Sale and Maturity of Marketable Securities, Total" } } }, "localname": "ProceedsFromSaleAndMaturityOfMarketableSecurities", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://bridgebio.com/20220630/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromSaleOfEquitySecuritiesFvNi": { "auth_ref": [ "r94", "r208" ], "calculation": { "http://bridgebio.com/20220630/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited": { "order": 5.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow from sale of investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI), classified as investing activity.", "label": "Proceeds from Sale of Equity Securities, FV-NI", "terseLabel": "Sales of investment in equity securities" } } }, "localname": "ProceedsFromSaleOfEquitySecuritiesFvNi", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://bridgebio.com/20220630/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromSaleOfProductiveAssets": { "auth_ref": [ "r83" ], "calculation": { "http://bridgebio.com/20220630/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited": { "order": 8.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The cash inflow from the sale of property, plant and equipment (capital expenditures), software, and other intangible assets.", "label": "Proceeds from Sale of Productive Assets", "terseLabel": "Proceeds from sale of certain assets", "totalLabel": "Proceeds from Sale of Productive Assets, Total" } } }, "localname": "ProceedsFromSaleOfProductiveAssets", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://bridgebio.com/20220630/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromStockOptionsExercised": { "auth_ref": [ "r86", "r430" ], "calculation": { "http://bridgebio.com/20220630/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited": { "order": 17.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow from exercise of option under share-based payment arrangement.", "label": "Proceeds from Stock Options Exercised", "terseLabel": "Proceeds from stock option exercises, net of repurchases" } } }, "localname": "ProceedsFromStockOptionsExercised", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://bridgebio.com/20220630/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromStockPlans": { "auth_ref": [ "r86" ], "calculation": { "http://bridgebio.com/20220630/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited": { "order": 15.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The cash inflow associated with the amount received from the stock plan during the period.", "label": "Proceeds from Stock Plans", "terseLabel": "Proceeds from BridgeBio common stock issuances under ESPP" } } }, "localname": "ProceedsFromStockPlans", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://bridgebio.com/20220630/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProductMember": { "auth_ref": [ "r368" ], "lang": { "en-us": { "role": { "documentation": "Article or substance produced by nature, labor or machinery.", "label": "Product [Member]", "terseLabel": "Product Sales" } } }, "localname": "ProductMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://bridgebio.com/20220630/taxonomy/role/StatementCondensedConsolidatedStatementsOfOperationsUnaudited" ], "xbrltype": "domainItemType" }, "us-gaap_ProfitLoss": { "auth_ref": [ "r6", "r60", "r62", "r67", "r95", "r116", "r129", "r139", "r140", "r177", "r180", "r183", "r186", "r188", "r217", "r288", "r289", "r290", "r292", "r293", "r294", "r295", "r296", "r297", "r298", "r470", "r477", "r479", "r490", "r491", "r510", "r523", "r653" ], "calculation": { "http://bridgebio.com/20220630/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited": { "order": 0.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 }, "http://bridgebio.com/20220630/taxonomy/role/StatementCondensedConsolidatedStatementsOfComprehensiveLossUnaudited": { "order": 0.0, "parentTag": "us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest", "weight": 1.0 }, "http://bridgebio.com/20220630/taxonomy/role/StatementCondensedConsolidatedStatementsOfOperationsUnaudited": { "order": 0.0, "parentTag": "us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.", "label": "Net Income (Loss), Including Portion Attributable to Noncontrolling Interest", "terseLabel": "Net loss", "totalLabel": "Net income (loss)" } } }, "localname": "ProfitLoss", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://bridgebio.com/20220630/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited", "http://bridgebio.com/20220630/taxonomy/role/StatementCondensedConsolidatedStatementsOfComprehensiveLossUnaudited", "http://bridgebio.com/20220630/taxonomy/role/StatementCondensedConsolidatedStatementsOfOperationsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_PropertyPlantAndEquipmentByTypeAxis": { "auth_ref": [ "r253" ], "lang": { "en-us": { "role": { "documentation": "Information by type of long-lived, physical assets used to produce goods and services and not intended for resale.", "label": "Long-Lived Tangible Asset [Axis]", "terseLabel": "Long-Lived Tangible Asset" } } }, "localname": "PropertyPlantAndEquipmentByTypeAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://bridgebio.com/20220630/taxonomy/role/Role_DisclosureLeasesAdditionalInformationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_PropertyPlantAndEquipmentMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.", "label": "Property, Plant and Equipment [Member]", "terseLabel": "Property and Equipment" } } }, "localname": "PropertyPlantAndEquipmentMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://bridgebio.com/20220630/taxonomy/role/Role_DisclosureLeasesAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_PropertyPlantAndEquipmentNet": { "auth_ref": [ "r253", "r583", "r655", "r665" ], "calculation": { "http://bridgebio.com/20220630/taxonomy/role/Role_StatementCondensedConsolidatedBalanceSheets": { "order": 2.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.", "label": "Property, Plant and Equipment, Net", "periodEndLabel": "Property, Plant and Equipment, Net, Ending Balance", "periodStartLabel": "Property, Plant and Equipment, Net, Beginning Balance", "terseLabel": "Property and equipment, net", "totalLabel": "Property, Plant and Equipment, Net, Total" } } }, "localname": "PropertyPlantAndEquipmentNet", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://bridgebio.com/20220630/taxonomy/role/Role_StatementCondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_PropertyPlantAndEquipmentTypeDomain": { "auth_ref": [ "r252" ], "lang": { "en-us": { "role": { "documentation": "Listing of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale. Examples include land, buildings, machinery and equipment, and other types of furniture and equipment including, but not limited to, office equipment, furniture and fixtures, and computer equipment and software.", "label": "Long-Lived Tangible Asset [Domain]", "terseLabel": "Long-Lived Tangible Asset" } } }, "localname": "PropertyPlantAndEquipmentTypeDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://bridgebio.com/20220630/taxonomy/role/Role_DisclosureLeasesAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ReceivablesLongTermContractsOrPrograms": { "auth_ref": [ "r25" ], "calculation": { "http://bridgebio.com/20220630/taxonomy/role/Role_StatementCondensedConsolidatedBalanceSheets": { "order": 3.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount to be collected within one year of the balance sheet date (or one operating cycle, if longer) from customers in accordance with the contractual provisions of long-term contracts or programs including amounts billed and unbilled as of the balance sheet date.", "label": "Receivables, Long-Term Contracts or Programs", "terseLabel": "Receivable from licensing and collaboration agreements", "totalLabel": "Receivables, Long-term Contracts or Programs, Total" } } }, "localname": "ReceivablesLongTermContractsOrPrograms", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://bridgebio.com/20220630/taxonomy/role/DisclosureLicenseAndCollaborationAgreementsAdditionalInformationDetails", "http://bridgebio.com/20220630/taxonomy/role/Role_StatementCondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_RelatedPartyDomain": { "auth_ref": [ "r378", "r577", "r578" ], "lang": { "en-us": { "role": { "documentation": "Related parties include affiliates; other entities for which investments are accounted for by the equity method by the entity; trusts for benefit of employees; and principal owners, management, and members of immediate families. It also may include other parties with which the entity may control or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests.", "label": "Related Party [Domain]", "terseLabel": "Related Party" } } }, "localname": "RelatedPartyDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://bridgebio.com/20220630/taxonomy/role/DisclosureEquityMethodAndOtherEquityInvestmentsAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "us-gaap_RelatedPartyTransactionsByRelatedPartyAxis": { "auth_ref": [ "r378", "r577", "r579", "r627", "r628", "r629", "r630", "r631", "r632", "r633", "r634", "r635", "r636", "r637", "r638" ], "lang": { "en-us": { "role": { "documentation": "Information by type of related party. Related parties include, but not limited to, affiliates; other entities for which investments are accounted for by the equity method by the entity; trusts for benefit of employees; and principal owners, management, and members of immediate families. It also may include other parties with which the entity may control or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests.", "label": "Related Party [Axis]", "terseLabel": "Related Party" } } }, "localname": "RelatedPartyTransactionsByRelatedPartyAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://bridgebio.com/20220630/taxonomy/role/DisclosureEquityMethodAndOtherEquityInvestmentsAdditionalInformationDetail" ], "xbrltype": "stringItemType" }, "us-gaap_RepaymentsOfLongTermDebt": { "auth_ref": [ "r89" ], "calculation": { "http://bridgebio.com/20220630/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited": { "order": 11.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cash outflow for debt initially having maturity due after one year or beyond the normal operating cycle, if longer.", "label": "Repayments of Long-Term Debt", "negatedLabel": "Repayment of term loan", "terseLabel": "Repayment of term loan", "totalLabel": "Repayments of Long-Term Debt, Total", "verboseLabel": "Debt instrument prepaid includes final payment charge and prepayment fee" } } }, "localname": "RepaymentsOfLongTermDebt", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://bridgebio.com/20220630/taxonomy/role/Role_DisclosureDebtAdditionalInformationDetails", "http://bridgebio.com/20220630/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_ResearchAndDevelopmentExpense": { "auth_ref": [ "r438", "r620", "r711" ], "calculation": { "http://bridgebio.com/20220630/taxonomy/role/StatementCondensedConsolidatedStatementsOfOperationsUnaudited": { "order": 3.0, "parentTag": "us-gaap_CostsAndExpenses", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.", "label": "Research and Development Expense", "terseLabel": "Research and development", "totalLabel": "Research and Development Expense, Total" } } }, "localname": "ResearchAndDevelopmentExpense", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://bridgebio.com/20220630/taxonomy/role/DisclosureLicenseAndCollaborationAgreementsAdditionalInformationDetails", "http://bridgebio.com/20220630/taxonomy/role/StatementCondensedConsolidatedStatementsOfOperationsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_ResearchAndDevelopmentExpenseMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Primary financial statement caption in which the reported facts about research and development expense have been included.", "label": "Research and Development Expense [Member]", "terseLabel": "Research and Development Expense", "verboseLabel": "Research and Development Services Performance Obligation" } } }, "localname": "ResearchAndDevelopmentExpenseMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://bridgebio.com/20220630/taxonomy/role/DisclosureLicenseAndCollaborationAgreementsAdditionalInformationDetails", "http://bridgebio.com/20220630/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfStockBasedCompensationForEmployeesAndNonEmployeesDetails" ], "xbrltype": "domainItemType" }, "us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue": { "auth_ref": [ "r12", "r102", "r108" ], "calculation": { "http://bridgebio.com/20220630/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited": { "order": 1.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash and cash equivalents restricted as to withdrawal or usage, classified as current. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "Restricted Cash and Cash Equivalents, Current", "terseLabel": "Restricted cash - Included in \"Prepaid expenses and other current assets\"", "totalLabel": "Restricted Cash and Cash Equivalents, Current, Total" } } }, "localname": "RestrictedCashAndCashEquivalentsAtCarryingValue", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://bridgebio.com/20220630/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_RestrictedCashAndCashEquivalentsNoncurrent": { "auth_ref": [ "r102", "r108", "r706" ], "calculation": { "http://bridgebio.com/20220630/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited": { "order": 2.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash and cash equivalents restricted as to withdrawal or usage, classified as noncurrent. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "Restricted Cash and Cash Equivalents, Noncurrent", "terseLabel": "Restricted cash - Included in \"Other assets\"", "totalLabel": "Restricted Cash and Cash Equivalents, Noncurrent, Total" } } }, "localname": "RestrictedCashAndCashEquivalentsNoncurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://bridgebio.com/20220630/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_RestrictedStockMember": { "auth_ref": [ "r152" ], "lang": { "en-us": { "role": { "documentation": "Stock including a provision that prohibits sale or substantive sale of an equity instrument for a specified period of time or until specified performance conditions are met.", "label": "Restricted Stock [Member]", "terseLabel": "Restricted Stock Awards" } } }, "localname": "RestrictedStockMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://bridgebio.com/20220630/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetails", "http://bridgebio.com/20220630/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfRecognizedStockBasedCompensationExpenseRelatedToRestrictedStockAwardActivityDetails", "http://bridgebio.com/20220630/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfRestrictedStockAwardActivityUnderPlansDetails", "http://bridgebio.com/20220630/taxonomy/role/Role_DisclosureStockBasedCompensationTables" ], "xbrltype": "domainItemType" }, "us-gaap_RestrictedStockUnitsRSUMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Share instrument which is convertible to stock or an equivalent amount of cash, after a specified period of time or when specified performance conditions are met.", "label": "Restricted Stock Units (RSUs) [Member]", "verboseLabel": "Restricted Stock Units (RSUs)" } } }, "localname": "RestrictedStockUnitsRSUMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://bridgebio.com/20220630/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetails", "http://bridgebio.com/20220630/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfRestrictedStockUnitsActivityDetails" ], "xbrltype": "domainItemType" }, "us-gaap_RestructuringAndRelatedActivitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Restructuring and Related Activities [Abstract]" } } }, "localname": "RestructuringAndRelatedActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock": { "auth_ref": [ "r260", "r262", "r265", "r274", "r276" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for restructuring and related activities. Description of restructuring activities such as exit and disposal activities, include facts and circumstances leading to the plan, the expected plan completion date, the major types of costs associated with the plan activities, total expected costs, the accrual balance at the end of the period, and the periods over which the remaining accrual will be settled.", "label": "Restructuring and Related Activities Disclosure [Text Block]", "terseLabel": "Restructuring, Impairment and Related Charges" } } }, "localname": "RestructuringAndRelatedActivitiesDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://bridgebio.com/20220630/taxonomy/role/DisclosureRestructuringImpairmentAndRelatedCharges1" ], "xbrltype": "textBlockItemType" }, "us-gaap_RestructuringAndRelatedCostExpectedCost1": { "auth_ref": [ "r261", "r264", "r271", "r273" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount expected to be recognized in earnings for the specified restructuring cost.", "label": "Restructuring and Related Cost, Expected Cost", "terseLabel": "Estimated charges to be incurred", "totalLabel": "Restructuring and Related Cost, Expected Cost, Total" } } }, "localname": "RestructuringAndRelatedCostExpectedCost1", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://bridgebio.com/20220630/taxonomy/role/DisclosureRestructuringImpairmentAndRelatedChargesAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The number of positions eliminated during the period as a percentage of total positions eliminated during the period in connection with the restructuring plan(s).", "label": "Restructuring and Related Cost, Number of Positions Eliminated, Period Percent", "terseLabel": "Percentage of workforce elimination" } } }, "localname": "RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://bridgebio.com/20220630/taxonomy/role/DisclosureRestructuringImpairmentAndRelatedChargesAdditionalInformationDetails" ], "xbrltype": "percentItemType" }, "us-gaap_RestructuringCharges": { "auth_ref": [ "r100", "r259", "r268", "r271" ], "calculation": { "http://bridgebio.com/20220630/taxonomy/role/StatementCondensedConsolidatedStatementsOfOperationsUnaudited": { "order": 5.0, "parentTag": "us-gaap_CostsAndExpenses", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of expenses associated with exit or disposal activities pursuant to an authorized plan. Excludes expenses related to a discontinued operation or an asset retirement obligation.", "label": "Restructuring expenses incurred", "terseLabel": "Restructuring, impairment and related charges", "totalLabel": "Restructuring Charges, Total", "verboseLabel": "Restructuring expenses" } } }, "localname": "RestructuringCharges", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://bridgebio.com/20220630/taxonomy/role/DisclosureRestructuringImpairmentAndRelatedChargesAdditionalInformationDetails", "http://bridgebio.com/20220630/taxonomy/role/StatementCondensedConsolidatedStatementsOfOperationsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_RestructuringCostAndReserveLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Restructuring Cost and Reserve [Line Items]" } } }, "localname": "RestructuringCostAndReserveLineItems", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://bridgebio.com/20220630/taxonomy/role/DisclosureRestructuringImpairmentAndRelatedChargesAdditionalInformationDetails", "http://bridgebio.com/20220630/taxonomy/role/DisclosureRestructuringImpairmentAndRelatedChargesScheduleOfActivityRelatedToRestructuringLiabilitiesAssociatedToRestructuringInitiativesDeta" ], "xbrltype": "stringItemType" }, "us-gaap_RestructuringReserveCurrent": { "auth_ref": [ "r19", "r262", "r272" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying amount as of the balance sheet date of known and estimated obligations associated with exit from or disposal of business activities or restructurings pursuant to a duly authorized plan, which are expected to be paid in the next twelve months or in the normal operating cycle if longer. Costs of such activities include those for one-time termination benefits, termination of an operating lease or other contract, consolidating or closing facilities, relocating employees, and costs associated with an ongoing benefit arrangement, but excludes costs associated with the retirement of a long-lived asset.", "label": "Restructuring Reserve, Current", "periodEndLabel": "Restructuring liabilities, balance", "periodStartLabel": "Restructuring liabilities, balance", "terseLabel": "Restructuring liabilities" } } }, "localname": "RestructuringReserveCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://bridgebio.com/20220630/taxonomy/role/DisclosureRestructuringImpairmentAndRelatedChargesScheduleOfActivityRelatedToRestructuringLiabilitiesAssociatedToRestructuringInitiativesDeta", "http://bridgebio.com/20220630/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_RestructuringReserveSettledWithoutCash2": { "auth_ref": [ "r262", "r272" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of decrease in the reserve for full or partial settlement through consideration other than cash.", "label": "Restructuring Reserve, Settled without Cash", "negatedLabel": "Noncash activities" } } }, "localname": "RestructuringReserveSettledWithoutCash2", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://bridgebio.com/20220630/taxonomy/role/DisclosureRestructuringImpairmentAndRelatedChargesScheduleOfActivityRelatedToRestructuringLiabilitiesAssociatedToRestructuringInitiativesDeta" ], "xbrltype": "monetaryItemType" }, "us-gaap_RestructuringSettlementAndImpairmentProvisions": { "auth_ref": [ "r76" ], "calculation": { "http://bridgebio.com/20220630/taxonomy/role/DisclosureRestructuringImpairmentAndRelatedChargesSummaryOfRestructuringImpairmentAndRelatedChargesDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of restructuring charges, remediation cost, and asset impairment loss.", "label": "Restructuring, Settlement and Impairment Provisions", "terseLabel": "Restructuring, impairment and related charges", "totalLabel": "Total" } } }, "localname": "RestructuringSettlementAndImpairmentProvisions", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://bridgebio.com/20220630/taxonomy/role/DisclosureRestructuringImpairmentAndRelatedChargesScheduleOfActivityRelatedToRestructuringLiabilitiesAssociatedToRestructuringInitiativesDeta", "http://bridgebio.com/20220630/taxonomy/role/DisclosureRestructuringImpairmentAndRelatedChargesSummaryOfRestructuringImpairmentAndRelatedChargesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_RetainedEarningsAccumulatedDeficit": { "auth_ref": [ "r27", "r362", "r583", "r662", "r684", "r689" ], "calculation": { "http://bridgebio.com/20220630/taxonomy/role/Role_StatementCondensedConsolidatedBalanceSheets": { "order": 5.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.", "label": "Retained Earnings (Accumulated Deficit)", "periodEndLabel": "Retained Earnings (Accumulated Deficit), Ending Balance", "periodStartLabel": "Retained Earnings (Accumulated Deficit), Beginning Balance", "terseLabel": "Accumulated deficit", "totalLabel": "Retained Earnings (Accumulated Deficit), Total" } } }, "localname": "RetainedEarningsAccumulatedDeficit", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://bridgebio.com/20220630/taxonomy/role/Role_StatementCondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_RetainedEarningsMember": { "auth_ref": [ "r2", "r124", "r125", "r126", "r130", "r138", "r140", "r227", "r431", "r432", "r433", "r448", "r449", "r508", "r680", "r682" ], "lang": { "en-us": { "role": { "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.", "label": "Retained Earnings [Member]", "terseLabel": "Accumulated Deficit" } } }, "localname": "RetainedEarningsMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://bridgebio.com/20220630/taxonomy/role/StatementCondensedConsolidatedStatementsOfRedeemableConvertibleNoncontrollingInterestsAndStockholdersEquityUnaudited" ], "xbrltype": "domainItemType" }, "us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax": { "auth_ref": [ "r171", "r172", "r179", "r184", "r185", "r189", "r190", "r191", "r366", "r367", "r621" ], "calculation": { "http://bridgebio.com/20220630/taxonomy/role/StatementCondensedConsolidatedStatementsOfOperationsUnaudited": { "order": 0.0, "parentTag": "us-gaap_OperatingIncomeLoss", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.", "label": "Revenue from Contract with Customer, Excluding Assessed Tax", "terseLabel": "Total revenue", "totalLabel": "Revenue from Contract with Customer, Excluding Assessed Tax, Total" } } }, "localname": "RevenueFromContractWithCustomerExcludingAssessedTax", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://bridgebio.com/20220630/taxonomy/role/DisclosureLicenseAndCollaborationAgreementsAdditionalInformationDetails", "http://bridgebio.com/20220630/taxonomy/role/StatementCondensedConsolidatedStatementsOfOperationsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_RevenueRecognitionPolicyTextBlock": { "auth_ref": [ "r110", "r111" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for revenue. Includes revenue from contract with customer and from other sources.", "label": "Revenue [Policy Text Block]", "terseLabel": "Revenue Recognition" } } }, "localname": "RevenueRecognitionPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://bridgebio.com/20220630/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_RevenuesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Revenues [Abstract]", "terseLabel": "Revenue:" } } }, "localname": "RevenuesAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://bridgebio.com/20220630/taxonomy/role/StatementCondensedConsolidatedStatementsOfOperationsUnaudited" ], "xbrltype": "stringItemType" }, "us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability": { "auth_ref": [ "r565", "r570" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of increase in right-of-use asset obtained in exchange for operating lease liability.", "label": "Right-of-Use Asset Obtained in Exchange for Operating Lease Liability", "terseLabel": "Operating lease right-of-use assets obtained in exchange for operating lease obligations" } } }, "localname": "RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://bridgebio.com/20220630/taxonomy/role/Role_DisclosureLeasesScheduleOfSupplementalCashFlowInformationRelatedToLeasesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_SaleOfStockNameOfTransactionDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Sale of the entity's stock, including, but not limited to, initial public offering (IPO) and private placement.", "label": "Sale of Stock [Domain]", "terseLabel": "Sale of Stock" } } }, "localname": "SaleOfStockNameOfTransactionDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://bridgebio.com/20220630/taxonomy/role/DisclosureEquityMethodAndOtherEquityInvestmentsAdditionalInformationDetail", "http://bridgebio.com/20220630/taxonomy/role/DisclosureStockbasedCompensationScheduleOfAssumptionsUsedToDetermineFairValueOfStockPurchaseRightsUnderEsppDetails", "http://bridgebio.com/20220630/taxonomy/role/Role_DisclosureShareRepurchaseProgramAndShelfRegistrationAdditionalInformationDetails", "http://bridgebio.com/20220630/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ScheduleOfAcquiredFiniteLivedIntangibleAssetByMajorClassTable": { "auth_ref": [ "r243" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the major classes of acquired finite-lived intangible assets showing the amount, any significant residual value, weighted average amortization period, and other characteristics. A major class is composed of intangible assets that can be grouped together because they are similar, either by nature or by their use in the operations of the company.", "label": "Schedule of Acquired Finite-Lived Intangible Asset by Major Class [Table]" } } }, "localname": "ScheduleOfAcquiredFiniteLivedIntangibleAssetByMajorClassTable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://bridgebio.com/20220630/taxonomy/role/DisclosureIntangibleAssetsSummaryOfRecognizedIntangibleAssetsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable": { "auth_ref": [ "r152" ], "lang": { "en-us": { "role": { "documentation": "Schedule for securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by Antidilutive Securities.", "label": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]", "terseLabel": "Schedule Of Antidilutive Securities Excluded From Computation Of Earnings Per Share [Table]" } } }, "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://bridgebio.com/20220630/taxonomy/role/Role_DisclosureNetLossPerShareScheduleOfCommonStockEquivalentsWereExcludedFromComputationOfDilutedNetLossPerShareDetail" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock": { "auth_ref": [ "r152" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities.", "label": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]", "terseLabel": "Schedule of Common Stock Equivalents were Excluded from Computation of Diluted Net Loss per Share" } } }, "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://bridgebio.com/20220630/taxonomy/role/Role_DisclosureNetLossPerShareTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfCashAndCashEquivalentsTable": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Schedule of cash and cash equivalent balances. This table excludes restricted cash balances.", "label": "Schedule of Cash and Cash Equivalents [Table]", "terseLabel": "Schedule Of Cash And Cash Equivalents [Table]" } } }, "localname": "ScheduleOfCashAndCashEquivalentsTable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://bridgebio.com/20220630/taxonomy/role/Role_DisclosureCashEquivalentsAndMarketableSecuritiesScheduleOfCashEquivalentAndMarketableSecuritiesClassifiedAsAvailableForSaleDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable": { "auth_ref": [ "r465" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of information about collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.", "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Table]", "terseLabel": "Schedule Of Collaborative Arrangements And Noncollaborative Arrangement Transactions [Table]" } } }, "localname": "ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://bridgebio.com/20220630/taxonomy/role/DisclosureLicenseAndCollaborationAgreementsAdditionalInformationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfDebtInstrumentsTextBlock": { "auth_ref": [ "r44", "r122", "r334", "r336", "r357", "r359", "r360", "r361", "r544", "r545", "r548", "r657" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of long-debt instruments or arrangements, including identification, terms, features, collateral requirements and other information necessary to a fair presentation. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the entity, if longer.", "label": "Schedule of Long-Term Debt Instruments [Table Text Block]", "terseLabel": "Schedule of Loans Balances" } } }, "localname": "ScheduleOfDebtInstrumentsTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://bridgebio.com/20220630/taxonomy/role/Role_DisclosureDebtTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock": { "auth_ref": [ "r422" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement.", "label": "Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block]", "terseLabel": "Summary of Stock Based Compensation for Employees and Non Employees" } } }, "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://bridgebio.com/20220630/taxonomy/role/Role_DisclosureStockBasedCompensationTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfEquityMethodInvestmentsLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Schedule of Equity Method Investments [Line Items]", "terseLabel": "Schedule Of Equity Method Investments [Line Items]" } } }, "localname": "ScheduleOfEquityMethodInvestmentsLineItems", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://bridgebio.com/20220630/taxonomy/role/DisclosureEquityMethodAndOtherEquityInvestmentsAdditionalInformationDetail" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfEquityMethodInvestmentsTable": { "auth_ref": [ "r6", "r116", "r216", "r217", "r523" ], "lang": { "en-us": { "role": { "documentation": "Summarization of information required and determined to be disclosed concerning equity method investments in common stock. The summarized information includes: (a) the name of each investee or group of investees for which combined disclosure is appropriate, (2) the percentage ownership of common stock, (3) the difference, if any, between the carrying amount of an investment and the value of the underlying equity in the net assets and the accounting treatment of difference, if any, and (4) the aggregate value of each identified investment based on its quoted market price, if available.", "label": "Schedule of Equity Method Investments [Table]", "terseLabel": "Schedule Of Equity Method Investments [Table]" } } }, "localname": "ScheduleOfEquityMethodInvestmentsTable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://bridgebio.com/20220630/taxonomy/role/DisclosureEquityMethodAndOtherEquityInvestmentsAdditionalInformationDetail" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock": { "auth_ref": [ "r512", "r513" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of assets and liabilities, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3).", "label": "Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text Block]", "terseLabel": "Financial Assets and Liabilities Measured at Fair Value on Recurring Basis" } } }, "localname": "ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://bridgebio.com/20220630/taxonomy/role/DisclosureFairValueMeasurementsTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable": { "auth_ref": [ "r243", "r246", "r622" ], "lang": { "en-us": { "role": { "documentation": "Schedule of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.", "label": "Schedule of Finite-Lived Intangible Assets [Table]" } } }, "localname": "ScheduleOfFiniteLivedIntangibleAssetsTable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://bridgebio.com/20220630/taxonomy/role/DisclosureIntangibleAssetsAdditionalInformationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock": { "auth_ref": [ "r402" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the changes in outstanding nonvested restricted stock units.", "label": "Schedule of Nonvested Restricted Stock Units Activity [Table Text Block]", "terseLabel": "Summary of Restricted Stock Units Activity" } } }, "localname": "ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://bridgebio.com/20220630/taxonomy/role/Role_DisclosureStockBasedCompensationTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfRestructuringAndRelatedCostsTable": { "auth_ref": [ "r261", "r262", "r263", "r264", "r271", "r272", "r273" ], "lang": { "en-us": { "role": { "documentation": "Table presenting the description of the restructuring costs, such as the expected cost; the costs incurred during the period; the cumulative costs incurred as of the balance sheet date; the income statement caption within which the restructuring charges recognized for the period are included; and the amount of and periodic changes to an entity's restructuring reserve that occurred during the period associated with the exit from or disposal of business activities or restructurings for each major type of cost by type of restructuring.", "label": "Schedule of Restructuring and Related Costs [Table]" } } }, "localname": "ScheduleOfRestructuringAndRelatedCostsTable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://bridgebio.com/20220630/taxonomy/role/DisclosureRestructuringImpairmentAndRelatedChargesAdditionalInformationDetails", "http://bridgebio.com/20220630/taxonomy/role/DisclosureRestructuringImpairmentAndRelatedChargesScheduleOfActivityRelatedToRestructuringLiabilitiesAssociatedToRestructuringInitiativesDeta" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfRestructuringAndRelatedCostsTextBlock": { "auth_ref": [ "r266", "r267", "r270" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of costs incurred for restructuring including, but not limited to, exit and disposal activities, remediation, implementation, integration, asset impairment, and charges against earnings from the write-down of assets.", "label": "Restructuring and Related Costs [Table Text Block]", "terseLabel": "Summary of Restructuring, Impairment and Related Charges" } } }, "localname": "ScheduleOfRestructuringAndRelatedCostsTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://bridgebio.com/20220630/taxonomy/role/DisclosureRestructuringImpairmentAndRelatedChargesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfRestructuringReserveByTypeOfCostTextBlock": { "auth_ref": [ "r262", "r272" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of an entity's restructuring reserve that occurred during the period associated with the exit from or disposal of business activities or restructurings for each major type of cost. This element may also include a description of any reversal and other adjustment made during the period to the amount of an accrued liability for restructuring activities. This element may be used to encapsulate the roll forward presentations of an entity's restructuring reserve by type of cost and in total, and explanation of changes that occurred in the period.", "label": "Schedule of Restructuring Reserve by Type of Cost [Table Text Block]", "terseLabel": "Schedule of Activity Related to Restructuring Liabilities Associated to Restructuring Initiatives" } } }, "localname": "ScheduleOfRestructuringReserveByTypeOfCostTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://bridgebio.com/20220630/taxonomy/role/DisclosureRestructuringImpairmentAndRelatedChargesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable": { "auth_ref": [ "r385", "r387", "r389", "r390", "r391", "r394", "r395", "r396", "r397", "r398", "r399", "r400", "r401", "r403", "r404", "r405", "r406", "r407", "r408", "r410", "r411", "r413", "r414", "r417", "r418", "r419", "r420", "r421" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of information about share-based payment arrangement.", "label": "Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table]", "terseLabel": "Schedule Of Share Based Compensation Arrangements By Share Based Payment Award [Table]" } } }, "localname": "ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://bridgebio.com/20220630/taxonomy/role/DisclosureStockbasedCompensationScheduleOfAssumptionsUsedToDetermineFairValueOfStockPurchaseRightsUnderEsppDetails", "http://bridgebio.com/20220630/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetails", "http://bridgebio.com/20220630/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfRecognizedStockBasedCompensationExpenseRelatedToRestrictedStockAwardActivityDetails", "http://bridgebio.com/20220630/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfRestrictedStockAwardActivityUnderPlansDetails", "http://bridgebio.com/20220630/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfRestrictedStockUnitsActivityDetails", "http://bridgebio.com/20220630/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfStockOptionActivityUnderPlansDetails", "http://bridgebio.com/20220630/taxonomy/role/Role_DisclosureStockBasedCompensationTables" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock": { "auth_ref": [ "r393" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the number and weighted-average grant date fair value for restricted stock units that were outstanding at the beginning and end of the year, and the number of restricted stock units that were granted, vested, or forfeited during the year.", "label": "Share-Based Payment Arrangement, Restricted Stock Unit, Activity [Table Text Block]", "terseLabel": "Summary of Restricted Stock Award Activity" } } }, "localname": "ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://bridgebio.com/20220630/taxonomy/role/Role_DisclosureStockBasedCompensationTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock": { "auth_ref": [ "r393", "r409", "r412" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.", "label": "Share-Based Payment Arrangement, Option, Activity [Table Text Block]", "terseLabel": "Summary of Stock Option Activity" } } }, "localname": "ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://bridgebio.com/20220630/taxonomy/role/Role_DisclosureStockBasedCompensationTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock": { "auth_ref": [ "r416" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the significant assumptions used during the year to estimate the fair value of employee stock purchase plans, including, but not limited to: (a) expected term, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.", "label": "Schedule of Share-Based Payment Award, Employee Stock Purchase Plan, Valuation Assumptions [Table Text Block]", "terseLabel": "Schedule of Assumptions Used to Determine Fair Value of Stock Purchase Rights" } } }, "localname": "ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://bridgebio.com/20220630/taxonomy/role/Role_DisclosureStockBasedCompensationTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock": { "auth_ref": [ "r416" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.", "label": "Schedule of Share-Based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]", "terseLabel": "Schedule of Assumptions Used to Determine Fair Value of Stock Purchase Rights" } } }, "localname": "ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://bridgebio.com/20220630/taxonomy/role/Role_DisclosureStockBasedCompensationTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfVariableInterestEntitiesTable": { "auth_ref": [ "r475", "r476", "r481", "r482", "r483", "r484", "r486", "r487", "r488", "r600", "r601", "r602" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of qualitative and quantitative information related to variable interests the entity holds, whether or not such variable interest entity (VIE) is included in the reporting entity's consolidated financial statements. Includes, but is not limited to, description of the significant judgments and assumptions made in determining whether a variable interest (as defined) held by the entity requires the variable interest entity (VIE) (as defined) to be consolidated and (or) disclose information about its involvement with the VIE, individually or in aggregate (as applicable); the nature of restrictions, if any, on the consolidated VIE's assets and on the settlement of its liabilities reported by an entity in its statement of financial position, including the carrying amounts of such assets and liabilities; the nature of, and changes in, the risks associated with involvement in the VIE; how involvement with the VIE affects the entity's financial position, financial performance, and cash flows; the lack of recourse if creditors (or beneficial interest holders) of the consolidated VIE have no recourse to the general credit of the primary beneficiary (if applicable); the terms of arrangements, giving consideration to both explicit arrangements and implicit variable interests, if any, that could require the entity to provide financial support to the VIE, including events or circumstances that could expose the entity to a loss; the methodology used by the entity for determining whether or not it is the primary beneficiary of the variable interest entity; the significant factors considered and judgments made in determining that the power to direct the activities of a VIE that most significantly impact the VIE's economic performance are shared (as defined); the carrying amounts and classification of assets and liabilities of the VIE included in the statement of financial position; the entity's maximum exposure to loss, if any, as a result of its involvement with the VIE, including how the maximum exposure is determined and significant sources of the entity's exposure to the VIE; a tabular comparison of the carrying amounts of the assets and liabilities and the entity's maximum exposure to loss; information about any liquidity arrangements, guarantees, and (or) other commitments by third parties that may affect the fair value or risk of the entity's variable interest in the VIE; whether or not the entity has provided financial support or other support (explicitly or implicitly) to the VIE that it was not previously contractually required to provide or whether the entity intends to provide that support, including the type and amount of the support and the primary reasons for providing the support; and supplemental information the entity determines necessary to provide.", "label": "Schedule of Variable Interest Entities [Table]", "terseLabel": "Schedule Of Variable Interest Entities [Table]" } } }, "localname": "ScheduleOfVariableInterestEntitiesTable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://bridgebio.com/20220630/taxonomy/role/Role_DisclosureEidosAdditionalInformationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_SellingGeneralAndAdministrativeExpense": { "auth_ref": [ "r77" ], "calculation": { "http://bridgebio.com/20220630/taxonomy/role/StatementCondensedConsolidatedStatementsOfOperationsUnaudited": { "order": 4.0, "parentTag": "us-gaap_CostsAndExpenses", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The aggregate total costs related to selling a firm's product and services, as well as all other general and administrative expenses. Direct selling expenses (for example, credit, warranty, and advertising) are expenses that can be directly linked to the sale of specific products. Indirect selling expenses are expenses that cannot be directly linked to the sale of specific products, for example telephone expenses, Internet, and postal charges. General and administrative expenses include salaries of non-sales personnel, rent, utilities, communication, etc.", "label": "Selling, General and Administrative Expense", "terseLabel": "Selling, general and administrative", "totalLabel": "Selling, General and Administrative Expense, Total" } } }, "localname": "SellingGeneralAndAdministrativeExpense", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://bridgebio.com/20220630/taxonomy/role/StatementCondensedConsolidatedStatementsOfOperationsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_SellingGeneralAndAdministrativeExpensesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Primary financial statement caption encompassing selling, general and administrative expense.", "label": "Selling, General and Administrative Expenses [Member]", "terseLabel": "Selling, General and Administrative Expenses" } } }, "localname": "SellingGeneralAndAdministrativeExpensesMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://bridgebio.com/20220630/taxonomy/role/Role_DisclosureLeasesAdditionalInformationDetails", "http://bridgebio.com/20220630/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfStockBasedCompensationForEmployeesAndNonEmployeesDetails" ], "xbrltype": "domainItemType" }, "us-gaap_SeveranceCosts1": { "auth_ref": [ "r100" ], "calculation": { "http://bridgebio.com/20220630/taxonomy/role/DisclosureRestructuringImpairmentAndRelatedChargesSummaryOfRestructuringImpairmentAndRelatedChargesDetails": { "order": 2.0, "parentTag": "us-gaap_RestructuringSettlementAndImpairmentProvisions", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of expenses for special or contractual termination benefits provided to current employees involuntarily terminated under a benefit arrangement associated exit or disposal activities pursuant to an authorized plan. Excludes expenses related to one-time termination benefits, a discontinued operation or an asset retirement obligation.", "label": "Severance Costs", "terseLabel": "Severance and employee-related costs" } } }, "localname": "SeveranceCosts1", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://bridgebio.com/20220630/taxonomy/role/DisclosureRestructuringImpairmentAndRelatedChargesSummaryOfRestructuringImpairmentAndRelatedChargesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ShareBasedCompensation": { "auth_ref": [ "r99" ], "calculation": { "http://bridgebio.com/20220630/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited": { "order": 1.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of noncash expense for share-based payment arrangement.", "label": "Share-Based Payment Arrangement, Noncash Expense", "terseLabel": "Stock-based compensation", "totalLabel": "Share-based Payment Arrangement, Noncash Expense, Total" } } }, "localname": "ShareBasedCompensation", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://bridgebio.com/20220630/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1": { "auth_ref": [ "r389" ], "lang": { "en-us": { "role": { "documentation": "Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Period", "verboseLabel": "Vesting period" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://bridgebio.com/20220630/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetails" ], "xbrltype": "durationItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod": { "auth_ref": [ "r408" ], "lang": { "en-us": { "role": { "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeited in Period", "negatedLabel": "Unvested Shares of Restricted Stock Outstanding, Cancelled" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://bridgebio.com/20220630/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfRestrictedStockAwardActivityUnderPlansDetails", "http://bridgebio.com/20220630/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfRestrictedStockUnitsActivityDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue": { "auth_ref": [ "r408" ], "lang": { "en-us": { "role": { "documentation": "Weighted average fair value as of the grant date of equity-based award plans other than stock (unit) option plans that were not exercised or put into effect as a result of the occurrence of a terminating event.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value", "terseLabel": "Weighted-Average Grant Date Fair Value, Cancelled" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://bridgebio.com/20220630/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfRestrictedStockAwardActivityUnderPlansDetails", "http://bridgebio.com/20220630/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfRestrictedStockUnitsActivityDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod": { "auth_ref": [ "r406" ], "lang": { "en-us": { "role": { "documentation": "The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period", "terseLabel": "Unvested Shares of Restricted Stock Outstanding, Granted" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://bridgebio.com/20220630/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfRestrictedStockAwardActivityUnderPlansDetails", "http://bridgebio.com/20220630/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfRestrictedStockUnitsActivityDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": { "auth_ref": [ "r406" ], "lang": { "en-us": { "role": { "documentation": "The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value", "terseLabel": "Weighted-Average Grant Date Fair Value, Granted" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://bridgebio.com/20220630/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfRestrictedStockAwardActivityUnderPlansDetails", "http://bridgebio.com/20220630/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfRestrictedStockUnitsActivityDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber": { "auth_ref": [ "r403", "r404" ], "lang": { "en-us": { "role": { "documentation": "The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number", "periodEndLabel": "Unvested Shares of Restricted Stock Outstanding, Ending balance", "periodStartLabel": "Unvested Shares of Restricted Stock Outstanding, Beginning balance" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://bridgebio.com/20220630/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfRestrictedStockAwardActivityUnderPlansDetails", "http://bridgebio.com/20220630/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfRestrictedStockUnitsActivityDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue": { "auth_ref": [ "r403", "r404" ], "lang": { "en-us": { "role": { "documentation": "Per share or unit weighted-average fair value of nonvested award under share-based payment arrangement. Excludes share and unit options.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value", "periodEndLabel": "Weighted-Average Grant Date Fair Value, Ending balance", "periodStartLabel": "Weighted-Average Grant Date Fair Value, Beginning balance" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://bridgebio.com/20220630/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfRestrictedStockAwardActivityUnderPlansDetails", "http://bridgebio.com/20220630/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfRestrictedStockUnitsActivityDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod": { "auth_ref": [ "r407" ], "lang": { "en-us": { "role": { "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period", "negatedLabel": "Unvested Shares of Restricted Stock Outstanding, Vested" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://bridgebio.com/20220630/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfRestrictedStockAwardActivityUnderPlansDetails", "http://bridgebio.com/20220630/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfRestrictedStockUnitsActivityDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue": { "auth_ref": [ "r407" ], "lang": { "en-us": { "role": { "documentation": "The weighted average fair value as of grant date pertaining to an equity-based award plan other than a stock (or unit) option plan for which the grantee gained the right during the reporting period, by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash in accordance with the terms of the arrangement.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period, Weighted Average Grant Date Fair Value", "terseLabel": "Weighted-Average Grant Date Fair Value, Vested" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://bridgebio.com/20220630/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfRestrictedStockAwardActivityUnderPlansDetails", "http://bridgebio.com/20220630/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfRestrictedStockUnitsActivityDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate": { "auth_ref": [ "r419" ], "lang": { "en-us": { "role": { "documentation": "The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Dividend Rate", "terseLabel": "Dividend yield" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://bridgebio.com/20220630/taxonomy/role/DisclosureStockbasedCompensationScheduleOfAssumptionsUsedToDetermineFairValueOfStockPurchaseRightsUnderEsppDetails" ], "xbrltype": "percentItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The estimated measure of the maximum percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate, Maximum", "terseLabel": "Expected volatility, Maximum" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://bridgebio.com/20220630/taxonomy/role/DisclosureStockbasedCompensationScheduleOfAssumptionsUsedToDetermineFairValueOfStockPurchaseRightsUnderEsppDetails" ], "xbrltype": "percentItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The estimated measure of the minimum percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate, Minimum", "terseLabel": "Expected volatility, Minimum" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://bridgebio.com/20220630/taxonomy/role/DisclosureStockbasedCompensationScheduleOfAssumptionsUsedToDetermineFairValueOfStockPurchaseRightsUnderEsppDetails" ], "xbrltype": "percentItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The maximum risk-free interest rate assumption that is used in valuing an option on its own shares.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Maximum", "terseLabel": "Risk-free interest rate, Maximum" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://bridgebio.com/20220630/taxonomy/role/DisclosureStockbasedCompensationScheduleOfAssumptionsUsedToDetermineFairValueOfStockPurchaseRightsUnderEsppDetails" ], "xbrltype": "percentItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The minimum risk-free interest rate assumption that is used in valuing an option on its own shares.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Minimum", "terseLabel": "Risk-free interest rate, Minimum" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://bridgebio.com/20220630/taxonomy/role/DisclosureStockbasedCompensationScheduleOfAssumptionsUsedToDetermineFairValueOfStockPurchaseRightsUnderEsppDetails" ], "xbrltype": "percentItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]", "terseLabel": "Share Based Compensation Arrangement By Share Based Payment Award [Line Items]" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://bridgebio.com/20220630/taxonomy/role/DisclosureStockbasedCompensationScheduleOfAssumptionsUsedToDetermineFairValueOfStockPurchaseRightsUnderEsppDetails", "http://bridgebio.com/20220630/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetails", "http://bridgebio.com/20220630/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfRecognizedStockBasedCompensationExpenseRelatedToRestrictedStockAwardActivityDetails", "http://bridgebio.com/20220630/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfRestrictedStockAwardActivityUnderPlansDetails", "http://bridgebio.com/20220630/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfRestrictedStockUnitsActivityDetails", "http://bridgebio.com/20220630/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfStockOptionActivityUnderPlansDetails", "http://bridgebio.com/20220630/taxonomy/role/Role_DisclosureStockBasedCompensationTables" ], "xbrltype": "stringItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber": { "auth_ref": [ "r396" ], "lang": { "en-us": { "role": { "documentation": "The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Number", "terseLabel": "Options Outstanding, Exercisable" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://bridgebio.com/20220630/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfStockOptionActivityUnderPlansDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice": { "auth_ref": [ "r396" ], "lang": { "en-us": { "role": { "documentation": "The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Exercise Price", "terseLabel": "Weighted-Average Exercise Price per Option, Exercisable" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://bridgebio.com/20220630/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfStockOptionActivityUnderPlansDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue": { "auth_ref": [ "r411" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of accumulated difference between fair value of underlying shares on dates of exercise and exercise price on options exercised (or share units converted) into shares.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period, Intrinsic Value", "terseLabel": "Total intrinsic value of options exercised" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://bridgebio.com/20220630/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod": { "auth_ref": [ "r400" ], "lang": { "en-us": { "role": { "documentation": "The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures in Period", "negatedLabel": "Options Outstanding, Cancelled" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://bridgebio.com/20220630/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfStockOptionActivityUnderPlansDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross": { "auth_ref": [ "r398" ], "lang": { "en-us": { "role": { "documentation": "Gross number of share options (or share units) granted during the period.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross", "terseLabel": "Options Outstanding, Granted" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://bridgebio.com/20220630/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfStockOptionActivityUnderPlansDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": { "auth_ref": [ "r410" ], "lang": { "en-us": { "role": { "documentation": "The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value", "terseLabel": "Weighted-average grand date fair value of options granted" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://bridgebio.com/20220630/taxonomy/role/DisclosureStockbasedCompensationScheduleOfAssumptionsUsedToDetermineFairValueOfStockPurchaseRightsUnderEsppDetails", "http://bridgebio.com/20220630/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue": { "auth_ref": [ "r429" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Intrinsic Value", "terseLabel": "Aggregate Intrinsic Value, Outstanding, Ending balance" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://bridgebio.com/20220630/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfStockOptionActivityUnderPlansDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber": { "auth_ref": [ "r394", "r395" ], "lang": { "en-us": { "role": { "documentation": "Number of options outstanding, including both vested and non-vested options.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number", "periodEndLabel": "Options Outstanding, Outstanding, Ending balance", "periodStartLabel": "Options Outstanding, Outstanding, Beginning balance" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://bridgebio.com/20220630/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfStockOptionActivityUnderPlansDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice": { "auth_ref": [ "r394", "r395" ], "lang": { "en-us": { "role": { "documentation": "Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price", "periodEndLabel": "Weighted-Average Exercise Price per Option, Outstanding, Ending balance", "periodStartLabel": "Weighted-Average Exercise Price per Option, Outstanding, Beginning balance" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://bridgebio.com/20220630/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfStockOptionActivityUnderPlansDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationNumberOfEmployeesAffected": { "auth_ref": [ "r426" ], "lang": { "en-us": { "role": { "documentation": "Number of grantees affected by modification of award under share-based payment arrangement.", "label": "Share-Based Payment Arrangement, Plan Modification, Number of Grantees Affected", "terseLabel": "Number of grantees" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationNumberOfEmployeesAffected", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://bridgebio.com/20220630/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetails" ], "xbrltype": "integerItemType" }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": { "auth_ref": [ "r389", "r390", "r391", "r394", "r395", "r396", "r397", "r398", "r399", "r400", "r401", "r403", "r404", "r405", "r406", "r407", "r408", "r410", "r411", "r413", "r414", "r417", "r418", "r419", "r420", "r421" ], "lang": { "en-us": { "role": { "documentation": "Award under share-based payment arrangement.", "label": "Award Type [Domain]", "terseLabel": "Award Type" } } }, "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://bridgebio.com/20220630/taxonomy/role/DisclosureStockbasedCompensationScheduleOfAssumptionsUsedToDetermineFairValueOfStockPurchaseRightsUnderEsppDetails", "http://bridgebio.com/20220630/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetail", "http://bridgebio.com/20220630/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetails", "http://bridgebio.com/20220630/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfRecognizedStockBasedCompensationExpenseRelatedToRestrictedStockAwardActivityDetails", "http://bridgebio.com/20220630/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfRestrictedStockAwardActivityUnderPlansDetails", "http://bridgebio.com/20220630/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfRestrictedStockUnitsActivityDetails", "http://bridgebio.com/20220630/taxonomy/role/Role_DisclosureStockBasedCompensationTables", "http://bridgebio.com/20220630/taxonomy/role/StatementCondensedConsolidatedStatementsOfRedeemableConvertibleNoncontrollingInterestsAndStockholdersEquityUnaudited" ], "xbrltype": "domainItemType" }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice": { "auth_ref": [ "r399" ], "lang": { "en-us": { "role": { "documentation": "Weighted average price at which option holders acquired shares when converting their stock options into shares.", "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price", "terseLabel": "Weighted-Average Exercise Price per Option, Exercised" } } }, "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://bridgebio.com/20220630/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfStockOptionActivityUnderPlansDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice": { "auth_ref": [ "r400" ], "lang": { "en-us": { "role": { "documentation": "Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated.", "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price", "terseLabel": "Weighted-Average Exercise Price per Option, Cancelled" } } }, "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://bridgebio.com/20220630/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfStockOptionActivityUnderPlansDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice": { "auth_ref": [ "r398" ], "lang": { "en-us": { "role": { "documentation": "Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.", "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Grants in Period, Weighted Average Exercise Price", "terseLabel": "Weighted-Average Exercise Price per Option, Granted" } } }, "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://bridgebio.com/20220630/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfStockOptionActivityUnderPlansDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy": { "auth_ref": [ "r392", "r415", "r416", "r417", "r418", "r421", "r434", "r437" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for award under share-based payment arrangement. Includes, but is not limited to, methodology and assumption used in measuring cost.", "label": "Share-Based Payment Arrangement [Policy Text Block]", "terseLabel": "Stock-Based Compensation" } } }, "localname": "ShareBasedCompensationOptionAndIncentivePlansPolicy", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://bridgebio.com/20220630/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_SharePrice": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Price of a single share of a number of saleable stocks of a company.", "label": "Share Price", "terseLabel": "Repurchase of common stock price per share" } } }, "localname": "SharePrice", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://bridgebio.com/20220630/taxonomy/role/Role_DisclosureDebtAdditionalInformationDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareRepurchaseProgramAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Information by share repurchase program.", "label": "Share Repurchase Program [Axis]", "terseLabel": "Share Repurchase Program" } } }, "localname": "ShareRepurchaseProgramAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://bridgebio.com/20220630/taxonomy/role/Role_DisclosureDebtAdditionalInformationDetails", "http://bridgebio.com/20220630/taxonomy/role/Role_DisclosureShareRepurchaseProgramAndShelfRegistrationAdditionalInformationDetails", "http://bridgebio.com/20220630/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetails", "http://bridgebio.com/20220630/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfRecognizedStockBasedCompensationExpenseRelatedToRestrictedStockAwardActivityDetails", "http://bridgebio.com/20220630/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfRestrictedStockAwardActivityUnderPlansDetails", "http://bridgebio.com/20220630/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfStockOptionActivityUnderPlansDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ShareRepurchaseProgramDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the share repurchase program.", "label": "Share Repurchase Program [Domain]", "terseLabel": "Share Repurchase Program" } } }, "localname": "ShareRepurchaseProgramDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://bridgebio.com/20220630/taxonomy/role/Role_DisclosureDebtAdditionalInformationDetails", "http://bridgebio.com/20220630/taxonomy/role/Role_DisclosureShareRepurchaseProgramAndShelfRegistrationAdditionalInformationDetails", "http://bridgebio.com/20220630/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetails", "http://bridgebio.com/20220630/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfRecognizedStockBasedCompensationExpenseRelatedToRestrictedStockAwardActivityDetails", "http://bridgebio.com/20220630/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfRestrictedStockAwardActivityUnderPlansDetails", "http://bridgebio.com/20220630/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfStockOptionActivityUnderPlansDetails" ], "xbrltype": "domainItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardCompensationCost1": { "auth_ref": [ "r422" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cost expensed and capitalized for award under share-based payment arrangement.", "label": "Share-Based Payment Arrangement, Expensed and Capitalized, Amount", "terseLabel": "Stock-based compensation cost associated with performance-based milestone awards", "totalLabel": "Share-based Payment Arrangement, Expensed and Capitalized, Amount, Total" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardCompensationCost1", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://bridgebio.com/20220630/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1": { "auth_ref": [ "r417" ], "lang": { "en-us": { "role": { "documentation": "Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Term", "terseLabel": "Expected term (in years)" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://bridgebio.com/20220630/taxonomy/role/DisclosureStockbasedCompensationScheduleOfAssumptionsUsedToDetermineFairValueOfStockPurchaseRightsUnderEsppDetails" ], "xbrltype": "durationItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1": { "auth_ref": [ "r429" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Intrinsic Value", "terseLabel": "Aggregate Intrinsic Value, Exercisable" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://bridgebio.com/20220630/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfStockOptionActivityUnderPlansDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1": { "auth_ref": [ "r429" ], "lang": { "en-us": { "role": { "documentation": "Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term", "terseLabel": "Weighted-Average Remaining Contractual Life (years), Exercisable" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://bridgebio.com/20220630/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfStockOptionActivityUnderPlansDetails" ], "xbrltype": "durationItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2": { "auth_ref": [ "r413" ], "lang": { "en-us": { "role": { "documentation": "Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term", "terseLabel": "Weighted-Average Remaining Contractual Life (years), Outstanding, Ending balance" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://bridgebio.com/20220630/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfStockOptionActivityUnderPlansDetails" ], "xbrltype": "durationItemType" }, "us-gaap_SharesOutstanding": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number of shares issued which are neither cancelled nor held in the treasury.", "label": "Shares, Outstanding", "periodEndLabel": "Ending balance, shares", "periodStartLabel": "Beginning balance, shares" } } }, "localname": "SharesOutstanding", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://bridgebio.com/20220630/taxonomy/role/StatementCondensedConsolidatedStatementsOfRedeemableConvertibleNoncontrollingInterestsAndStockholdersEquityUnaudited" ], "xbrltype": "sharesItemType" }, "us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number of shares used to settle grantee's tax withholding obligation for award under share-based payment arrangement.", "label": "Share-Based Payment Arrangement, Shares Withheld for Tax Withholding Obligation", "negatedLabel": "Repurchase of shares to satisfy tax withholding, shares" } } }, "localname": "SharesPaidForTaxWithholdingForShareBasedCompensation", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://bridgebio.com/20220630/taxonomy/role/StatementCondensedConsolidatedStatementsOfRedeemableConvertibleNoncontrollingInterestsAndStockholdersEquityUnaudited" ], "xbrltype": "sharesItemType" }, "us-gaap_ShortTermInvestmentsMember": { "auth_ref": [ "r702", "r703", "r704", "r705" ], "lang": { "en-us": { "role": { "documentation": "Investments which are not otherwise included in another category or item that the entity has the intent to sell or dispose of within one year from the date of the balance sheet.", "label": "Short-Term Investments [Member]", "terseLabel": "Marketable Securities" } } }, "localname": "ShortTermInvestmentsMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://bridgebio.com/20220630/taxonomy/role/Role_DisclosureCashEquivalentsAndMarketableSecuritiesScheduleOfCashEquivalentAndMarketableSecuritiesClassifiedAsAvailableForSaleDetails" ], "xbrltype": "domainItemType" }, "us-gaap_SignificantAccountingPoliciesTextBlock": { "auth_ref": [ "r109", "r123" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for all significant accounting policies of the reporting entity.", "label": "Significant Accounting Policies [Text Block]", "terseLabel": "Summary of Significant Accounting Policies" } } }, "localname": "SignificantAccountingPoliciesTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://bridgebio.com/20220630/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_StatementClassOfStockAxis": { "auth_ref": [ "r22", "r23", "r24", "r113", "r116", "r145", "r146", "r147", "r149", "r151", "r159", "r160", "r161", "r217", "r288", "r292", "r293", "r294", "r297", "r298", "r340", "r341", "r345", "r349", "r356", "r523", "r717" ], "lang": { "en-us": { "role": { "documentation": "Information by the different classes of stock of the entity.", "label": "Class of Stock [Axis]", "terseLabel": "Class of Stock" } } }, "localname": "StatementClassOfStockAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://bridgebio.com/20220630/taxonomy/role/StatementCondensedConsolidatedStatementsOfRedeemableConvertibleNoncontrollingInterestsAndStockholdersEquityUnaudited" ], "xbrltype": "stringItemType" }, "us-gaap_StatementEquityComponentsAxis": { "auth_ref": [ "r2", "r50", "r65", "r66", "r67", "r124", "r125", "r126", "r130", "r138", "r140", "r158", "r227", "r356", "r362", "r431", "r432", "r433", "r448", "r449", "r508", "r534", "r535", "r536", "r537", "r538", "r539", "r576", "r680", "r681", "r682" ], "lang": { "en-us": { "role": { "documentation": "Information by component of equity.", "label": "Equity Components [Axis]", "terseLabel": "Equity Components" } } }, "localname": "StatementEquityComponentsAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://bridgebio.com/20220630/taxonomy/role/DisclosureEquityMethodAndOtherEquityInvestmentsAdditionalInformationDetail", "http://bridgebio.com/20220630/taxonomy/role/Role_DisclosureEidosAdditionalInformationDetails", "http://bridgebio.com/20220630/taxonomy/role/Role_DisclosureShareRepurchaseProgramAndShelfRegistrationAdditionalInformationDetails", "http://bridgebio.com/20220630/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetails", "http://bridgebio.com/20220630/taxonomy/role/StatementCondensedConsolidatedStatementsOfRedeemableConvertibleNoncontrollingInterestsAndStockholdersEquityUnaudited" ], "xbrltype": "stringItemType" }, "us-gaap_StatementLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Statement [Line Items]", "terseLabel": "Statement [Line Items]" } } }, "localname": "StatementLineItems", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://bridgebio.com/20220630/taxonomy/role/Role_StatementCondensedConsolidatedBalanceSheets", "http://bridgebio.com/20220630/taxonomy/role/StatementCondensedConsolidatedStatementsOfOperationsUnaudited", "http://bridgebio.com/20220630/taxonomy/role/StatementCondensedConsolidatedStatementsOfRedeemableConvertibleNoncontrollingInterestsAndStockholdersEquityUnaudited" ], "xbrltype": "stringItemType" }, "us-gaap_StatementOfCashFlowsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Statement of Cash Flows [Abstract]" } } }, "localname": "StatementOfCashFlowsAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_StatementOfFinancialPositionAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Statement of Financial Position [Abstract]" } } }, "localname": "StatementOfFinancialPositionAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Statement of Comprehensive Income [Abstract]" } } }, "localname": "StatementOfIncomeAndComprehensiveIncomeAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_StatementOfStockholdersEquityAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Statement of Stockholders' Equity [Abstract]" } } }, "localname": "StatementOfStockholdersEquityAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_StatementTable": { "auth_ref": [ "r124", "r125", "r126", "r158", "r621" ], "lang": { "en-us": { "role": { "documentation": "Schedule reflecting a Statement of Income, Statement of Cash Flows, Statement of Financial Position, Statement of Shareholders' Equity and Other Comprehensive Income, or other statement as needed.", "label": "Statement [Table]", "terseLabel": "Statement [Table]" } } }, "localname": "StatementTable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://bridgebio.com/20220630/taxonomy/role/Role_StatementCondensedConsolidatedBalanceSheets", "http://bridgebio.com/20220630/taxonomy/role/StatementCondensedConsolidatedStatementsOfOperationsUnaudited", "http://bridgebio.com/20220630/taxonomy/role/StatementCondensedConsolidatedStatementsOfRedeemableConvertibleNoncontrollingInterestsAndStockholdersEquityUnaudited" ], "xbrltype": "stringItemType" }, "us-gaap_StockCompensationPlanMember": { "auth_ref": [ "r152" ], "lang": { "en-us": { "role": { "documentation": "Share-based payment arrangement in which award of equity shares are granted. Arrangement includes, but is not limited to, grantor incurring liability for product and service based on price of its shares.", "label": "Share-Based Payment Arrangement [Member]", "terseLabel": "Equity Compensation Plans" } } }, "localname": "StockCompensationPlanMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://bridgebio.com/20220630/taxonomy/role/StatementCondensedConsolidatedStatementsOfRedeemableConvertibleNoncontrollingInterestsAndStockholdersEquityUnaudited" ], "xbrltype": "domainItemType" }, "us-gaap_StockIssuedDuringPeriodSharesNewIssues": { "auth_ref": [ "r23", "r24", "r356", "r362" ], "lang": { "en-us": { "role": { "documentation": "Number of new stock issued during the period.", "label": "Stock Issued During Period, Shares, New Issues", "verboseLabel": "Shares issued" } } }, "localname": "StockIssuedDuringPeriodSharesNewIssues", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://bridgebio.com/20220630/taxonomy/role/Role_DisclosureEidosAdditionalInformationDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation": { "auth_ref": [ "r23", "r24", "r356", "r362" ], "lang": { "en-us": { "role": { "documentation": "Number, after forfeiture, of shares or units issued under share-based payment arrangement. Excludes shares or units issued under employee stock ownership plan (ESOP).", "label": "Shares Issued, Shares, Share-Based Payment Arrangement, after Forfeiture", "terseLabel": "Issuance of shares, shares", "totalLabel": "Shares Issued, Shares, Share-based Payment Arrangement, after Forfeiture, Total" } } }, "localname": "StockIssuedDuringPeriodSharesShareBasedCompensation", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://bridgebio.com/20220630/taxonomy/role/StatementCondensedConsolidatedStatementsOfRedeemableConvertibleNoncontrollingInterestsAndStockholdersEquityUnaudited" ], "xbrltype": "sharesItemType" }, "us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised": { "auth_ref": [ "r23", "r24", "r356", "r362", "r399" ], "lang": { "en-us": { "role": { "documentation": "Number of share options (or share units) exercised during the current period.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period", "negatedLabel": "Options Outstanding, Exercised" } } }, "localname": "StockIssuedDuringPeriodSharesStockOptionsExercised", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://bridgebio.com/20220630/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfStockOptionActivityUnderPlansDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation": { "auth_ref": [ "r23", "r24", "r362", "r410" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Value, after forfeiture, of shares issued under share-based payment arrangement. Excludes employee stock ownership plan (ESOP).", "label": "Shares Issued, Value, Share-Based Payment Arrangement, after Forfeiture", "terseLabel": "Issuance of shares", "totalLabel": "Shares Issued, Value, Share-based Payment Arrangement, after Forfeiture, Total" } } }, "localname": "StockIssuedDuringPeriodValueShareBasedCompensation", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://bridgebio.com/20220630/taxonomy/role/StatementCondensedConsolidatedStatementsOfRedeemableConvertibleNoncontrollingInterestsAndStockholdersEquityUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockRepurchaseProgramAuthorizedAmount1": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of stock repurchase plan authorized.", "label": "Stock Repurchase Program, Authorized Amount", "terseLabel": "Share repurchase program, authorized amount" } } }, "localname": "StockRepurchaseProgramAuthorizedAmount1", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://bridgebio.com/20220630/taxonomy/role/Role_DisclosureShareRepurchaseProgramAndShelfRegistrationAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockRepurchasedDuringPeriodShares": { "auth_ref": [ "r23", "r24", "r356", "r362" ], "lang": { "en-us": { "role": { "documentation": "Number of shares that have been repurchased during the period and have not been retired and are not held in treasury. Some state laws may govern the circumstances under which an entity may acquire its own stock and prescribe the accounting treatment therefore. This element is used when state law does not recognize treasury stock.", "label": "Stock Repurchased During Period, Shares", "terseLabel": "Stock repurchased during period, shares" } } }, "localname": "StockRepurchasedDuringPeriodShares", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://bridgebio.com/20220630/taxonomy/role/Role_DisclosureDebtAdditionalInformationDetails", "http://bridgebio.com/20220630/taxonomy/role/Role_DisclosureShareRepurchaseProgramAndShelfRegistrationAdditionalInformationDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_StockRepurchasedDuringPeriodValue": { "auth_ref": [ "r23", "r24", "r356", "r362" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Equity impact of the value of stock that has been repurchased during the period and has not been retired and is not held in treasury. Some state laws may mandate the circumstances under which an entity may acquire its own stock and prescribe the accounting treatment therefore. This element is used when state law does not recognize treasury stock.", "label": "Stock Repurchased During Period, Value", "terseLabel": "Stock repurchased, value" } } }, "localname": "StockRepurchasedDuringPeriodValue", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://bridgebio.com/20220630/taxonomy/role/Role_DisclosureShareRepurchaseProgramAndShelfRegistrationAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockholdersEquity": { "auth_ref": [ "r24", "r29", "r30", "r116", "r192", "r217", "r523", "r583" ], "calculation": { "http://bridgebio.com/20220630/taxonomy/role/Role_StatementCondensedConsolidatedBalanceSheets": { "order": 0.0, "parentTag": "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.", "label": "Stockholders' Equity Attributable to Parent", "periodEndLabel": "Stockholders' Equity Attributable to Parent, Ending Balance", "periodStartLabel": "Stockholders' Equity Attributable to Parent, Beginning Balance", "totalLabel": "Total BridgeBio stockholders' deficit" } } }, "localname": "StockholdersEquity", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://bridgebio.com/20220630/taxonomy/role/Role_StatementCondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockholdersEquityAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Stockholders' Equity Attributable to Parent [Abstract]", "terseLabel": "Stockholders\u2019 equity (deficit):" } } }, "localname": "StockholdersEquityAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://bridgebio.com/20220630/taxonomy/role/Role_StatementCondensedConsolidatedBalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest": { "auth_ref": [ "r2", "r3", "r66", "r116", "r124", "r125", "r126", "r130", "r138", "r217", "r227", "r362", "r431", "r432", "r433", "r448", "r449", "r468", "r469", "r489", "r508", "r523", "r534", "r535", "r539", "r576", "r681", "r682" ], "calculation": { "http://bridgebio.com/20220630/taxonomy/role/Role_StatementCondensedConsolidatedBalanceSheets": { "order": 4.0, "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of stockholders' equity (deficit), net of receivables from officers, directors, owners, and affiliates of the entity, attributable to both the parent and noncontrolling interests. Amount excludes temporary equity. Alternate caption for the concept is permanent equity.", "label": "Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest", "periodEndLabel": "Ending balance", "periodStartLabel": "Beginning balance", "totalLabel": "Total stockholders' deficit" } } }, "localname": "StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://bridgebio.com/20220630/taxonomy/role/Role_StatementCondensedConsolidatedBalanceSheets", "http://bridgebio.com/20220630/taxonomy/role/StatementCondensedConsolidatedStatementsOfRedeemableConvertibleNoncontrollingInterestsAndStockholdersEquityUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockholdersEquityNoteDisclosureTextBlock": { "auth_ref": [ "r114", "r341", "r344", "r345", "r346", "r347", "r348", "r349", "r350", "r351", "r352", "r353", "r355", "r362", "r365", "r499" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.", "label": "Stockholders' Equity Note Disclosure [Text Block]", "terseLabel": "Share Repurchase Program and Shelf Registration" } } }, "localname": "StockholdersEquityNoteDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://bridgebio.com/20220630/taxonomy/role/Role_DisclosureShareRepurchaseProgramAndShelfRegistration" ], "xbrltype": "textBlockItemType" }, "us-gaap_SubsequentEventMember": { "auth_ref": [ "r540", "r584" ], "lang": { "en-us": { "role": { "documentation": "Identifies event that occurred after the balance sheet date but before financial statements are issued or available to be issued.", "label": "Subsequent Event [Member]", "terseLabel": "Subsequent Event" } } }, "localname": "SubsequentEventMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://bridgebio.com/20220630/taxonomy/role/DisclosureEquityMethodAndOtherEquityInvestmentsAdditionalInformationDetail", "http://bridgebio.com/20220630/taxonomy/role/Role_DisclosureDebtAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_SubsequentEventTypeAxis": { "auth_ref": [ "r540", "r584" ], "lang": { "en-us": { "role": { "documentation": "Information by event that occurred after the balance sheet date but before financial statements are issued or available to be issued.", "label": "Subsequent Event Type [Axis]" } } }, "localname": "SubsequentEventTypeAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://bridgebio.com/20220630/taxonomy/role/DisclosureEquityMethodAndOtherEquityInvestmentsAdditionalInformationDetail", "http://bridgebio.com/20220630/taxonomy/role/Role_DisclosureDebtAdditionalInformationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_SubsequentEventTypeDomain": { "auth_ref": [ "r540", "r584" ], "lang": { "en-us": { "role": { "documentation": "Event that occurred after the balance sheet date but before financial statements are issued or available to be issued.", "label": "Subsequent Event Type [Domain]" } } }, "localname": "SubsequentEventTypeDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://bridgebio.com/20220630/taxonomy/role/DisclosureEquityMethodAndOtherEquityInvestmentsAdditionalInformationDetail", "http://bridgebio.com/20220630/taxonomy/role/Role_DisclosureDebtAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_SubsidiarySaleOfStockAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Information by type of sale of the entity's stock.", "label": "Sale of Stock [Axis]", "terseLabel": "Sale of Stock" } } }, "localname": "SubsidiarySaleOfStockAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://bridgebio.com/20220630/taxonomy/role/DisclosureEquityMethodAndOtherEquityInvestmentsAdditionalInformationDetail", "http://bridgebio.com/20220630/taxonomy/role/DisclosureStockbasedCompensationScheduleOfAssumptionsUsedToDetermineFairValueOfStockPurchaseRightsUnderEsppDetails", "http://bridgebio.com/20220630/taxonomy/role/Role_DisclosureShareRepurchaseProgramAndShelfRegistrationAdditionalInformationDetails", "http://bridgebio.com/20220630/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_SupplementalCashFlowInformationAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Supplemental Cash Flow Information [Abstract]", "terseLabel": "Supplemental Disclosures of Cash Flow Information:" } } }, "localname": "SupplementalCashFlowInformationAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://bridgebio.com/20220630/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited" ], "xbrltype": "stringItemType" }, "us-gaap_TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests": { "auth_ref": [ "r47", "r116", "r217", "r523" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying amount, attributable to parent and noncontrolling interests, of an entity's issued and outstanding stock which is not included within permanent equity. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. Includes stock with a put option held by an ESOP and stock redeemable by a holder only in the event of a change in control of the issuer.", "label": "Temporary Equity, Carrying Amount, Including Portion Attributable to Noncontrolling Interests", "periodEndLabel": "Temporary equity, ending balance", "periodStartLabel": "Temporary equity, beginning balance", "terseLabel": "Redeemable convertible noncontrolling interests", "totalLabel": "Temporary Equity, Carrying Amount, Including Portion Attributable to Noncontrolling Interests, Total" } } }, "localname": "TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://bridgebio.com/20220630/taxonomy/role/StatementCondensedConsolidatedStatementsOfRedeemableConvertibleNoncontrollingInterestsAndStockholdersEquityUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_TemporaryEquityNetIncome": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The portion of net income or loss attributable to temporary equity interest.", "label": "Temporary Equity, Net Income", "terseLabel": "Temporary Equity, net loss" } } }, "localname": "TemporaryEquityNetIncome", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://bridgebio.com/20220630/taxonomy/role/StatementCondensedConsolidatedStatementsOfRedeemableConvertibleNoncontrollingInterestsAndStockholdersEquityUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain": { "auth_ref": [ "r203", "r204", "r209", "r210", "r211", "r325", "r354", "r498", "r586", "r587", "r588", "r589", "r590", "r591", "r592", "r593", "r594", "r595", "r596", "r597", "r598", "r599", "r603", "r604", "r605", "r606", "r607", "r608", "r609", "r610", "r611", "r612", "r613", "r614", "r615", "r616", "r617", "r618", "r717", "r718", "r719", "r720", "r721", "r722", "r723" ], "lang": { "en-us": { "role": { "documentation": "Instrument or contract that imposes a contractual obligation to deliver cash or another financial instrument or to exchange other financial instruments on potentially unfavorable terms and conveys a contractual right to receive cash or another financial instrument or to exchange other financial instruments on potentially favorable terms.", "label": "Financial Instruments [Domain]", "terseLabel": "Financial Instruments" } } }, "localname": "TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://bridgebio.com/20220630/taxonomy/role/DisclosureDebtScheduleOfFutureMinimumPaymentsUnderTermLoanAgreementDetails", "http://bridgebio.com/20220630/taxonomy/role/Role_DisclosureDebtScheduleOfFutureMinimumPaymentsUnderNotesDetails" ], "xbrltype": "domainItemType" }, "us-gaap_TreasuryStockAcquiredAverageCostPerShare": { "auth_ref": [ "r363" ], "lang": { "en-us": { "role": { "documentation": "Total cost of shares repurchased divided by the total number of shares repurchased.", "label": "Treasury Stock Acquired, Average Cost Per Share", "terseLabel": "Stock repurchased, average price per share" } } }, "localname": "TreasuryStockAcquiredAverageCostPerShare", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://bridgebio.com/20220630/taxonomy/role/Role_DisclosureShareRepurchaseProgramAndShelfRegistrationAdditionalInformationDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_TreasuryStockMember": { "auth_ref": [ "r49", "r363" ], "lang": { "en-us": { "role": { "documentation": "Shares of an entity that have been repurchased by the entity. This stock has no voting rights and receives no dividends. Note that treasury stock may be recorded at its total cost or separately as par (or stated) value and additional paid in capital. Classified within stockholders' equity if nonredeemable or redeemable solely at the option of the issuer. Classified within temporary equity if redemption is outside the control of the issuer.", "label": "Treasury Stock [Member]", "terseLabel": "Treasury Stock" } } }, "localname": "TreasuryStockMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://bridgebio.com/20220630/taxonomy/role/StatementCondensedConsolidatedStatementsOfRedeemableConvertibleNoncontrollingInterestsAndStockholdersEquityUnaudited" ], "xbrltype": "domainItemType" }, "us-gaap_TreasuryStockShares": { "auth_ref": [ "r49", "r363" ], "lang": { "en-us": { "role": { "documentation": "Number of common and preferred shares that were previously issued and that were repurchased by the issuing entity and held in treasury on the financial statement date. This stock has no voting rights and receives no dividends.", "label": "Treasury Stock, Shares", "periodEndLabel": "Treasury Stock, Shares, Ending Balance", "periodStartLabel": "Treasury Stock, Shares, Beginning Balance", "terseLabel": "Treasury stock, shares", "totalLabel": "Treasury Stock, Shares, Total" } } }, "localname": "TreasuryStockShares", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://bridgebio.com/20220630/taxonomy/role/Role_StatementCondensedConsolidatedBalanceSheetsParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_TreasuryStockSharesAcquired": { "auth_ref": [ "r24", "r356", "r362" ], "lang": { "en-us": { "role": { "documentation": "Number of shares that have been repurchased during the period and are being held in treasury.", "label": "Treasury Stock, Shares, Acquired", "negatedLabel": "Repurchase of common stock, shares" } } }, "localname": "TreasuryStockSharesAcquired", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://bridgebio.com/20220630/taxonomy/role/StatementCondensedConsolidatedStatementsOfRedeemableConvertibleNoncontrollingInterestsAndStockholdersEquityUnaudited" ], "xbrltype": "sharesItemType" }, "us-gaap_TreasuryStockValue": { "auth_ref": [ "r49", "r363", "r364" ], "calculation": { "http://bridgebio.com/20220630/taxonomy/role/Role_StatementCondensedConsolidatedBalanceSheets": { "order": 2.0, "parentTag": "us-gaap_StockholdersEquity", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The amount allocated to treasury stock. Treasury stock is common and preferred shares of an entity that were issued, repurchased by the entity, and are held in its treasury.", "label": "Treasury Stock, Value", "negatedLabel": "Treasury stock, at cost; 6,191,761 shares as of June 30, 2022 and December 31, 2021", "periodEndLabel": "Treasury Stock, Value, Ending Balance", "periodStartLabel": "Treasury Stock, Value, Beginning Balance", "totalLabel": "Treasury Stock, Value, Total" } } }, "localname": "TreasuryStockValue", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://bridgebio.com/20220630/taxonomy/role/Role_StatementCondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_TreasuryStockValueAcquiredCostMethod": { "auth_ref": [ "r356", "r362", "r363" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Equity impact of the cost of common and preferred stock that were repurchased during the period. Recorded using the cost method.", "label": "Treasury Stock, Value, Acquired, Cost Method", "negatedLabel": "Repurchase of common stock", "terseLabel": "Repurchase of common stock" } } }, "localname": "TreasuryStockValueAcquiredCostMethod", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://bridgebio.com/20220630/taxonomy/role/StatementCondensedConsolidatedStatementsOfRedeemableConvertibleNoncontrollingInterestsAndStockholdersEquityUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_TypeOfAdoptionMember": { "auth_ref": [ "r0", "r1", "r2", "r3", "r4", "r129", "r130", "r131", "r132", "r141", "r193", "r194", "r224", "r225", "r226", "r227", "r228", "r229", "r431", "r432", "r433", "r446", "r447", "r448", "r449", "r457", "r458", "r459", "r500", "r501", "r502", "r503", "r504", "r505", "r506", "r507", "r508", "r509", "r510", "r511", "r524", "r525", "r527", "r528", "r529", "r530", "r531", "r532", "r541", "r542", "r550", "r551", "r552", "r553", "r571", "r572", "r573", "r574", "r575", "r576", "r623", "r624", "r625", "r678", "r679", "r680", "r681", "r682", "r683", "r684", "r685", "r686", "r687", "r688", "r689" ], "lang": { "en-us": { "role": { "documentation": "Amendment to accounting standards.", "label": "Accounting Standards Update [Domain]", "terseLabel": "Accounting Standards Update" } } }, "localname": "TypeOfAdoptionMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://bridgebio.com/20220630/taxonomy/role/DisclosureLicenseAndCollaborationAgreementsAdditionalInformationDetails", "http://bridgebio.com/20220630/taxonomy/role/StatementCondensedConsolidatedStatementsOfRedeemableConvertibleNoncontrollingInterestsAndStockholdersEquityUnaudited" ], "xbrltype": "domainItemType" }, "us-gaap_TypeOfArrangementAxis": { "auth_ref": [ "r465" ], "lang": { "en-us": { "role": { "documentation": "Information by collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.", "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Axis]", "terseLabel": "Collaborative Arrangement and Arrangement Other than Collaborative" } } }, "localname": "TypeOfArrangementAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://bridgebio.com/20220630/taxonomy/role/DisclosureIntangibleAssetsAdditionalInformationDetails", "http://bridgebio.com/20220630/taxonomy/role/DisclosureLicenseAndCollaborationAgreementsAdditionalInformationDetails", "http://bridgebio.com/20220630/taxonomy/role/Role_DisclosureDebtAdditionalInformationDetails", "http://bridgebio.com/20220630/taxonomy/role/Role_DisclosureEidosAdditionalInformationDetails", "http://bridgebio.com/20220630/taxonomy/role/Role_DisclosureLeasesAdditionalInformationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_USTreasuryBillSecuritiesMember": { "auth_ref": [ "r654" ], "lang": { "en-us": { "role": { "documentation": "This category includes information about negotiable debt securities issued by the United States Department of the Treasury which generally have maturities of one year or less, are interest bearing, and are backed by the full faith and credit of the United States government.", "label": "US Treasury Bill Securities [Member]", "terseLabel": "U.S. Treasury Bills" } } }, "localname": "USTreasuryBillSecuritiesMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://bridgebio.com/20220630/taxonomy/role/DisclosureFairValueMeasurementsFinancialAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails" ], "xbrltype": "domainItemType" }, "us-gaap_USTreasurySecuritiesMember": { "auth_ref": [ "r119", "r371", "r379", "r654" ], "lang": { "en-us": { "role": { "documentation": "This category includes information about debt securities issued by the United States Department of the Treasury and backed by the United States government. Such securities primarily consist of treasury bills (short-term maturities - one year or less), treasury notes (intermediate term maturities - two to ten years), and treasury bonds (long-term maturities - ten to thirty years).", "label": "US Treasury Securities [Member]", "terseLabel": "U.S. Treasury Notes", "verboseLabel": "U.S. Treasury Notes" } } }, "localname": "USTreasurySecuritiesMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://bridgebio.com/20220630/taxonomy/role/DisclosureFairValueMeasurementsFinancialAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails", "http://bridgebio.com/20220630/taxonomy/role/Role_DisclosureCashEquivalentsAndMarketableSecuritiesScheduleOfCashEquivalentAndMarketableSecuritiesClassifiedAsAvailableForSaleDetails" ], "xbrltype": "domainItemType" }, "us-gaap_UseOfEstimates": { "auth_ref": [ "r163", "r164", "r165", "r166", "r167", "r168", "r169" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.", "label": "Use of Estimates, Policy [Policy Text Block]", "terseLabel": "Use of Estimates" } } }, "localname": "UseOfEstimates", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://bridgebio.com/20220630/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_VariableInterestEntityLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Variable Interest Entity [Line Items]", "terseLabel": "Variable Interest Entity [Line Items]" } } }, "localname": "VariableInterestEntityLineItems", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://bridgebio.com/20220630/taxonomy/role/Role_DisclosureEidosAdditionalInformationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_VariableInterestEntityOwnershipPercentage": { "auth_ref": [ "r485" ], "lang": { "en-us": { "role": { "documentation": "Percentage of the Variable Interest Entity's (VIE) voting interest owned by (or beneficial interest in) the reporting entity (directly or indirectly).", "label": "Variable Interest Entity, Qualitative or Quantitative Information, Ownership Percentage", "verboseLabel": "Voting shares" } } }, "localname": "VariableInterestEntityOwnershipPercentage", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://bridgebio.com/20220630/taxonomy/role/Role_DisclosureEidosAdditionalInformationDetails" ], "xbrltype": "percentItemType" }, "us-gaap_VariableInterestEntityPrimaryBeneficiaryMember": { "auth_ref": [ "r475", "r476", "r481", "r482", "r483" ], "lang": { "en-us": { "role": { "documentation": "Variable Interest Entities (VIE) in which the entity has a controlling financial interest (as defined) and of which it is therefore the primary beneficiary. A controlling financial interest is determined based on both: (a) the entity's power to direct activities of the VIE that most significantly impact the VIE's economic performance and (b) the entity's obligation to absorb losses of the VIE that could potentially be significant to the VIE or the right to receive benefits from the VIE that could potentially be significant to the VIE. VIEs of which the entity is the primary beneficiary are included in the consolidated financial statements of the entity.", "label": "Variable Interest Entity, Primary Beneficiary [Member]", "terseLabel": "Variable Interest Entity, Primary Beneficiary", "verboseLabel": "Variable Interest Entity, Primary Beneficiary" } } }, "localname": "VariableInterestEntityPrimaryBeneficiaryMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://bridgebio.com/20220630/taxonomy/role/Role_DisclosureEidosAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_VariableLeaseCost": { "auth_ref": [ "r563", "r570" ], "calculation": { "http://bridgebio.com/20220630/taxonomy/role/Role_DisclosureLeasesComponentsOfLeaseCostDetails": { "order": 6.0, "parentTag": "us-gaap_LeaseCost", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of variable lease cost, excluded from lease liability, recognized when obligation for payment is incurred for finance and operating leases.", "label": "Variable Lease, Cost", "terseLabel": "Variable lease costs" } } }, "localname": "VariableLeaseCost", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://bridgebio.com/20220630/taxonomy/role/Role_DisclosureLeasesComponentsOfLeaseCostDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_VariableRateAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Information by type of variable rate.", "label": "Variable Rate [Axis]", "terseLabel": "Variable Rate" } } }, "localname": "VariableRateAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://bridgebio.com/20220630/taxonomy/role/Role_DisclosureDebtAdditionalInformationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_VariableRateDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Interest rate that fluctuates over time as a result of an underlying benchmark interest rate or index.", "label": "Variable Rate [Domain]", "terseLabel": "Variable Rate" } } }, "localname": "VariableRateDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://bridgebio.com/20220630/taxonomy/role/Role_DisclosureDebtAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_WarrantsNotSettleableInCashFairValueDisclosure": { "auth_ref": [ "r512" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Fair value portion of warrants not settleable in cash classified as equity.", "label": "Warrants Not Settleable in Cash, Fair Value Disclosure", "terseLabel": "Fair value of warrants" } } }, "localname": "WarrantsNotSettleableInCashFairValueDisclosure", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://bridgebio.com/20220630/taxonomy/role/DisclosureEquityMethodAndOtherEquityInvestmentsAdditionalInformationDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding": { "auth_ref": [ "r144", "r151" ], "lang": { "en-us": { "role": { "documentation": "The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.", "label": "Weighted Average Number of Shares Outstanding, Diluted", "terseLabel": "Weighted-average shares used in computing net loss per share attributable to common stockholders of BridgeBio, diluted", "totalLabel": "Weighted Average Number of Shares Outstanding, Diluted, Total" } } }, "localname": "WeightedAverageNumberOfDilutedSharesOutstanding", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://bridgebio.com/20220630/taxonomy/role/StatementCondensedConsolidatedStatementsOfOperationsUnaudited" ], "xbrltype": "sharesItemType" }, "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": { "auth_ref": [ "r142", "r151" ], "lang": { "en-us": { "role": { "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.", "label": "Weighted Average Number of Shares Outstanding, Basic", "terseLabel": "Weighted-average shares used in computing net loss per share attributable to common stockholders of BridgeBio, basic", "totalLabel": "Weighted Average Number of Shares Outstanding, Basic, Total" } } }, "localname": "WeightedAverageNumberOfSharesOutstandingBasic", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://bridgebio.com/20220630/taxonomy/role/StatementCondensedConsolidatedStatementsOfOperationsUnaudited" ], "xbrltype": "sharesItemType" } }, "unitCount": 8 } }, "std_ref": { "r0": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "105", "URI": "https://asc.fasb.org/extlink&oid=126987489&loc=SL124442142-165695" }, "r1": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "105", "URI": "https://asc.fasb.org/extlink&oid=126987489&loc=SL124442142-165695" }, "r10": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6904-107765" }, "r100": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585" }, "r101": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585" }, "r102": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3044-108585" }, "r103": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=d3e4273-108586" }, "r104": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=d3e4297-108586" }, "r105": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=d3e4304-108586" }, "r106": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=d3e4313-108586" }, "r107": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=d3e4332-108586" }, "r108": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=SL98516268-108586" }, "r109": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=126899994&loc=d3e18726-107790" }, "r11": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(19)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r110": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=126899994&loc=d3e18823-107790" }, "r111": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=126899994&loc=d3e18823-107790" }, "r112": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(c))", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r113": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(d))", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r114": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(e)(1))", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r115": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(f))", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r116": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(g)(1)(ii))", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r117": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(h)(2))", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r118": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(h))", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r119": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(m)(1)(ii)(A))", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r12": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(1))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r120": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(m)(1)(iii))", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r121": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(m)(2)(ii))", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r122": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.12-04(a))", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e24072-122690" }, "r123": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "235", "URI": "https://asc.fasb.org/topic&trid=2122369" }, "r124": { "Name": "Accounting Standards Codification", "Paragraph": "23", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21914-107793" }, "r125": { "Name": "Accounting Standards Codification", "Paragraph": "24", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21930-107793" }, "r126": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21711-107793" }, "r127": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21728-107793" }, "r128": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794" }, "r129": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)(2)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794" }, "r13": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(10))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r130": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)(3)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794" }, "r131": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)(4)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794" }, "r132": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794" }, "r133": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794" }, "r134": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794" }, "r135": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22583-107794" }, "r136": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22595-107794" }, "r137": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794" }, "r138": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794" }, "r139": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22658-107794" }, "r14": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(16))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r140": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22663-107794" }, "r141": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 11.M.Q2)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=122038215&loc=d3e31137-122693" }, "r142": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1448-109256" }, "r143": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1377-109256" }, "r144": { "Name": "Accounting Standards Codification", "Paragraph": "16", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1505-109256" }, "r145": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1252-109256" }, "r146": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1278-109256" }, "r147": { "Name": "Accounting Standards Codification", "Paragraph": "55", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e2626-109256" }, "r148": { "Name": "Accounting Standards Codification", "Paragraph": "60B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=SL5780133-109256" }, "r149": { "Name": "Accounting Standards Codification", "Paragraph": "60B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=SL5780133-109256" }, "r15": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(17))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r150": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1337-109256" }, "r151": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257" }, "r152": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257" }, "r153": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3630-109257" }, "r154": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=109243012&loc=SL65017193-207537" }, "r155": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=128363288&loc=d3e3842-109258" }, "r156": { "Name": "Accounting Standards Codification", "Paragraph": "52", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=128363288&loc=d3e4984-109258" }, "r157": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "260", "URI": "https://asc.fasb.org/topic&trid=2144383" }, "r158": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "272", "URI": "https://asc.fasb.org/extlink&oid=125520817&loc=d3e70191-108054" }, "r159": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "272", "URI": "https://asc.fasb.org/extlink&oid=125520817&loc=d3e70229-108054" }, "r16": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(18))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r160": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "272", "URI": "https://asc.fasb.org/extlink&oid=6373374&loc=d3e70434-108055" }, "r161": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "272", "URI": "https://asc.fasb.org/extlink&oid=6373374&loc=d3e70478-108055" }, "r162": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "275", "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592" }, "r163": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "275", "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592" }, "r164": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "275", "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592" }, "r165": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6161-108592" }, "r166": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6191-108592" }, "r167": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6061-108592" }, "r168": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6132-108592" }, "r169": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6143-108592" }, "r17": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(19))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r170": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "275", "URI": "https://asc.fasb.org/topic&trid=2134479" }, "r171": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599" }, "r172": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599" }, "r173": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599" }, "r174": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599" }, "r175": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599" }, "r176": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599" }, "r177": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599" }, "r178": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8813-108599" }, "r179": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599" }, "r18": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(2))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r180": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599" }, "r181": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599" }, "r182": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599" }, "r183": { "Name": "Accounting Standards Codification", "Paragraph": "31", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8924-108599" }, "r184": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599" }, "r185": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599" }, "r186": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599" }, "r187": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599" }, "r188": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599" }, "r189": { "Name": "Accounting Standards Codification", "Paragraph": "40", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e9031-108599" }, "r19": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(20))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r190": { "Name": "Accounting Standards Codification", "Paragraph": "41", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e9038-108599" }, "r191": { "Name": "Accounting Standards Codification", "Paragraph": "42", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e9054-108599" }, "r192": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 4.E)", "Topic": "310", "URI": "https://asc.fasb.org/extlink&oid=122038336&loc=d3e74512-122707" }, "r193": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "310", "URI": "https://asc.fasb.org/extlink&oid=126986314&loc=SL124402458-218513" }, "r194": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "310", "URI": "https://asc.fasb.org/extlink&oid=126986314&loc=SL124402458-218513" }, "r195": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "320", "URI": "https://asc.fasb.org/extlink&oid=124260329&loc=d3e26610-111562" }, "r196": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "320", "URI": "https://asc.fasb.org/extlink&oid=124260329&loc=d3e26853-111562" }, "r197": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "320", "URI": "https://asc.fasb.org/extlink&oid=124260329&loc=d3e26626-111562" }, "r198": { "Name": "Accounting Standards Codification", "Paragraph": "8A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "320", "URI": "https://asc.fasb.org/extlink&oid=124260329&loc=SL6284422-111562" }, "r199": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "320", "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27161-111563" }, "r2": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "105", "URI": "https://asc.fasb.org/extlink&oid=126987489&loc=SL124442142-165695" }, "r20": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(22))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r200": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(aa)", "Topic": "320", "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27161-111563" }, "r201": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "320", "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27161-111563" }, "r202": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "320", "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27161-111563" }, "r203": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "320", "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27232-111563" }, "r204": { "Name": "Accounting Standards Codification", "Paragraph": "5A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "320", "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=SL120269820-111563" }, "r205": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "320", "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27337-111563" }, "r206": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "320", "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27357-111563" }, "r207": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "320", "URI": "https://asc.fasb.org/topic&trid=2196928" }, "r208": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "321", "URI": "https://asc.fasb.org/extlink&oid=123583714&loc=SL75117360-209713" }, "r209": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "321", "URI": "https://asc.fasb.org/extlink&oid=126980263&loc=SL75117539-209714" }, "r21": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(26)(c))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r210": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "321", "URI": "https://asc.fasb.org/extlink&oid=126980263&loc=SL75117539-209714" }, "r211": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "321", "URI": "https://asc.fasb.org/extlink&oid=126980263&loc=SL75117539-209714" }, "r212": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "321", "URI": "https://asc.fasb.org/extlink&oid=126980263&loc=SL75117546-209714" }, "r213": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "321", "URI": "https://asc.fasb.org/topic&trid=75115024" }, "r214": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "323", "URI": "https://asc.fasb.org/extlink&oid=109237563&loc=d3e33749-111570" }, "r215": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(1)", "Topic": "323", "URI": "https://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571" }, "r216": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(b)", "Topic": "323", "URI": "https://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571" }, "r217": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "323", "URI": "https://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571" }, "r218": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "323", "URI": "https://asc.fasb.org/topic&trid=2196965" }, "r219": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "325", "URI": "https://asc.fasb.org/topic&trid=2197064" }, "r22": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(27)(b))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r220": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Topic": "326", "URI": "https://asc.fasb.org/extlink&oid=122640432&loc=SL120254519-210437" }, "r221": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "326", "URI": "https://asc.fasb.org/extlink&oid=122640432&loc=SL120320025-210437" }, "r222": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "326", "URI": "https://asc.fasb.org/extlink&oid=122640432&loc=SL120320025-210437" }, "r223": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "326", "URI": "https://asc.fasb.org/extlink&oid=122640432&loc=SL120320025-210437" }, "r224": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "326", "URI": "https://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437" }, "r225": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "326", "URI": "https://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437" }, "r226": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "326", "URI": "https://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437" }, "r227": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "326", "URI": "https://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437" }, "r228": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(e)(3)", "Topic": "326", "URI": "https://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437" }, "r229": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(e)(4)", "Topic": "326", "URI": "https://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437" }, "r23": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(28))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r230": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "326", "URI": "https://asc.fasb.org/extlink&oid=124255953&loc=SL82919244-210447" }, "r231": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "326", "URI": "https://asc.fasb.org/extlink&oid=124255953&loc=SL82919249-210447" }, "r232": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "326", "URI": "https://asc.fasb.org/extlink&oid=124255953&loc=SL82919253-210447" }, "r233": { "Name": "Accounting Standards Codification", "Paragraph": "16", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "326", "URI": "https://asc.fasb.org/extlink&oid=124255953&loc=SL82919258-210447" }, "r234": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "326", "URI": "https://asc.fasb.org/extlink&oid=124255953&loc=SL82919230-210447" }, "r235": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "326", "URI": "https://asc.fasb.org/extlink&oid=124258926&loc=SL82898722-210454" }, "r236": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "326", "URI": "https://asc.fasb.org/extlink&oid=124269663&loc=SL82922888-210455" }, "r237": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "326", "URI": "https://asc.fasb.org/extlink&oid=124269663&loc=SL82922890-210455" }, "r238": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "326", "URI": "https://asc.fasb.org/extlink&oid=124269663&loc=SL82922895-210455" }, "r239": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "326", "URI": "https://asc.fasb.org/extlink&oid=124269663&loc=SL82922900-210455" }, "r24": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(29))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r240": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "55", "SubTopic": "30", "Topic": "326", "URI": "https://asc.fasb.org/extlink&oid=121590138&loc=SL82922954-210456" }, "r241": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=6388964&loc=d3e16212-109274" }, "r242": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=6388964&loc=d3e16225-109274" }, "r243": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275" }, "r244": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)(3)", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275" }, "r245": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "((a)(1),(b))", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275" }, "r246": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275" }, "r247": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)(1)", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275" }, "r248": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)(2)", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275" }, "r249": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "SubTopic": "30", "Topic": "350", "URI": "https://asc.fasb.org/subtopic&trid=2144471" }, "r25": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(3)(c))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r250": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "360", "URI": "https://asc.fasb.org/extlink&oid=126905981&loc=d3e2420-110228" }, "r251": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "360", "URI": "https://asc.fasb.org/extlink&oid=126905981&loc=d3e2443-110228" }, "r252": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "360", "URI": "https://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229" }, "r253": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "360", "URI": "https://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229" }, "r254": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "360", "URI": "https://asc.fasb.org/extlink&oid=109226691&loc=d3e2921-110230" }, "r255": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "360", "URI": "https://asc.fasb.org/extlink&oid=109226691&loc=d3e2941-110230" }, "r256": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "360", "URI": "https://asc.fasb.org/extlink&oid=109226691&loc=d3e2941-110230" }, "r257": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(c)", "Topic": "410", "URI": "https://asc.fasb.org/extlink&oid=6393242&loc=d3e13237-110859" }, "r258": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "35", "SubTopic": "10", "Topic": "420", "URI": "https://asc.fasb.org/extlink&oid=6394232&loc=d3e17558-110866" }, "r259": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "420", "URI": "https://asc.fasb.org/extlink&oid=109237686&loc=d3e17752-110868" }, "r26": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30)(a)(1))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r260": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "420", "URI": "https://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869" }, "r261": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)(1)", "Topic": "420", "URI": "https://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869" }, "r262": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)(2)", "Topic": "420", "URI": "https://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869" }, "r263": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "420", "URI": "https://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869" }, "r264": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "420", "URI": "https://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869" }, "r265": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "420", "URI": "https://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869" }, "r266": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "420", "URI": "https://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869" }, "r267": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB TOPIC 5.P.3)", "Topic": "420", "URI": "https://asc.fasb.org/extlink&oid=115931487&loc=d3e140864-122747" }, "r268": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 5.P.3)", "Topic": "420", "URI": "https://asc.fasb.org/extlink&oid=115931487&loc=d3e140864-122747" }, "r269": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Topic": "420", "URI": "https://asc.fasb.org/extlink&oid=115931487&loc=d3e140864-122747" }, "r27": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30)(a)(3))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r270": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB TOPIC 5.P.4)", "Topic": "420", "URI": "https://asc.fasb.org/extlink&oid=115931487&loc=d3e140904-122747" }, "r271": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 5.P.4(b)(1))", "Topic": "420", "URI": "https://asc.fasb.org/extlink&oid=115931487&loc=d3e140904-122747" }, "r272": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 5.P.4(b)(2))", "Topic": "420", "URI": "https://asc.fasb.org/extlink&oid=115931487&loc=d3e140904-122747" }, "r273": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 5.P.4(d))", "Topic": "420", "URI": "https://asc.fasb.org/extlink&oid=115931487&loc=d3e140904-122747" }, "r274": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 5.P.4(e))", "Topic": "420", "URI": "https://asc.fasb.org/extlink&oid=115931487&loc=d3e140904-122747" }, "r275": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 5.P.4)", "Topic": "420", "URI": "https://asc.fasb.org/extlink&oid=115931487&loc=d3e140904-122747" }, "r276": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "420", "URI": "https://asc.fasb.org/topic&trid=2175745" }, "r277": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "440", "URI": "https://asc.fasb.org/extlink&oid=123406679&loc=d3e25336-109308" }, "r278": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "440", "URI": "https://asc.fasb.org/extlink&oid=123406679&loc=d3e25336-109308" }, "r279": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "440", "URI": "https://asc.fasb.org/topic&trid=2144648" }, "r28": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30)(a)(4))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r280": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "450", "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14615-108349" }, "r281": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "450", "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14435-108349" }, "r282": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "450", "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14557-108349" }, "r283": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "20", "Subparagraph": "(SAB Topic 5.Y.Q2)", "Topic": "450", "URI": "https://asc.fasb.org/extlink&oid=27011672&loc=d3e149879-122751" }, "r284": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "20", "Subparagraph": "(SAB Topic 5.Y.Q4)", "Topic": "450", "URI": "https://asc.fasb.org/extlink&oid=27011672&loc=d3e149879-122751" }, "r285": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "450", "URI": "https://asc.fasb.org/topic&trid=2127136" }, "r286": { "Name": "Accounting Standards Codification", "Paragraph": "12A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=99376301&loc=SL5988623-112600" }, "r287": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123465755&loc=SL6230698-112601" }, "r288": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(i))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756" }, "r289": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(ii))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756" }, "r29": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r290": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756" }, "r291": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(iii))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756" }, "r292": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(iv))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756" }, "r293": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(5))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756" }, "r294": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(i))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756" }, "r295": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756" }, "r296": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756" }, "r297": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(iv))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756" }, "r298": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(5))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756" }, "r299": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611" }, "r3": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "105", "URI": "https://asc.fasb.org/extlink&oid=126987489&loc=SL124442142-165695" }, "r30": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(31))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r300": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611" }, "r301": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611" }, "r302": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611" }, "r303": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(e)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611" }, "r304": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(f)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611" }, "r305": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(g)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611" }, "r306": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(h)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611" }, "r307": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(i)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611" }, "r308": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611" }, "r309": { "Name": "Accounting Standards Codification", "Paragraph": "1C", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495334-112611" }, "r31": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(32))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r310": { "Name": "Accounting Standards Codification", "Paragraph": "1C", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495334-112611" }, "r311": { "Name": "Accounting Standards Codification", "Paragraph": "1C", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495334-112611" }, "r312": { "Name": "Accounting Standards Codification", "Paragraph": "1D", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611" }, "r313": { "Name": "Accounting Standards Codification", "Paragraph": "1D", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611" }, "r314": { "Name": "Accounting Standards Codification", "Paragraph": "1D", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611" }, "r315": { "Name": "Accounting Standards Codification", "Paragraph": "1E", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611" }, "r316": { "Name": "Accounting Standards Codification", "Paragraph": "1E", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611" }, "r317": { "Name": "Accounting Standards Codification", "Paragraph": "1E", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611" }, "r318": { "Name": "Accounting Standards Codification", "Paragraph": "1E", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611" }, "r319": { "Name": "Accounting Standards Codification", "Paragraph": "1F", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611" }, "r32": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(9))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r320": { "Name": "Accounting Standards Codification", "Paragraph": "1F", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611" }, "r321": { "Name": "Accounting Standards Codification", "Paragraph": "1F", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(1)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611" }, "r322": { "Name": "Accounting Standards Codification", "Paragraph": "1F", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(2)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611" }, "r323": { "Name": "Accounting Standards Codification", "Paragraph": "1I", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611" }, "r324": { "Name": "Accounting Standards Codification", "Paragraph": "1I", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611" }, "r325": { "Name": "Accounting Standards Codification", "Paragraph": "1I", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611" }, "r326": { "Name": "Accounting Standards Codification", "Paragraph": "1I", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611" }, "r327": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(1)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466204&loc=SL6031897-161870" }, "r328": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(2)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466204&loc=SL6031897-161870" }, "r329": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(3)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466204&loc=SL6031897-161870" }, "r33": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19(a))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r330": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466204&loc=SL6031898-161870" }, "r331": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466204&loc=SL6031898-161870" }, "r332": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466204&loc=SL6036836-161870" }, "r333": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466204&loc=SL6036836-161870" }, "r334": { "Name": "Accounting Standards Codification", "Paragraph": "69B", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466577&loc=SL123495735-112612" }, "r335": { "Name": "Accounting Standards Codification", "Paragraph": "69C", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466577&loc=SL123495737-112612" }, "r336": { "Name": "Accounting Standards Codification", "Paragraph": "69E", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466577&loc=SL123495743-112612" }, "r337": { "Name": "Accounting Standards Codification", "Paragraph": "69F", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466577&loc=SL123495745-112612" }, "r338": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "470", "URI": "https://asc.fasb.org/topic&trid=2208564" }, "r339": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "25", "SubTopic": "10", "Topic": "480", "URI": "https://asc.fasb.org/extlink&oid=109262497&loc=d3e20148-110875" }, "r34": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19(b),22(b))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r340": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644" }, "r341": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644" }, "r342": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644" }, "r343": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644" }, "r344": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(g)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644" }, "r345": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644" }, "r346": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(i)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644" }, "r347": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644" }, "r348": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496171-112644" }, "r349": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496171-112644" }, "r35": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19,20,22)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r350": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496171-112644" }, "r351": { "Name": "Accounting Standards Codification", "Paragraph": "16", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496180-112644" }, "r352": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496189-112644" }, "r353": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496189-112644" }, "r354": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496189-112644" }, "r355": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496189-112644" }, "r356": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21463-112644" }, "r357": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21475-112644" }, "r358": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21506-112644" }, "r359": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21506-112644" }, "r36": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19-26)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r360": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21521-112644" }, "r361": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21538-112644" }, "r362": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.3-04)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770" }, "r363": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=6405813&loc=d3e23239-112655" }, "r364": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=6405834&loc=d3e23315-112656" }, "r365": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "505", "URI": "https://asc.fasb.org/topic&trid=2208762" }, "r366": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130543-203045" }, "r367": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130545-203045" }, "r368": { "Name": "Accounting Standards Codification", "Paragraph": "91", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126920602&loc=SL49130690-203046-203046" }, "r369": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=123338486&loc=SL49131195-203048" }, "r37": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.20)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r370": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(i)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r371": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(ii)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r372": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(01)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r373": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(02)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r374": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(02)(A)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r375": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(02)(B)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r376": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(02)(C)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r377": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(03)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r378": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(n)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r379": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123450688&loc=d3e4179-114921" }, "r38": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.21)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r380": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "80", "Subparagraph": "(a)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=65877416&loc=SL14450702-114947" }, "r381": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "80", "Subparagraph": "(d)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=65877416&loc=SL14450657-114947" }, "r382": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "80", "Subparagraph": "(f)(3)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=65877416&loc=SL14450657-114947" }, "r383": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "80", "Subparagraph": "(a)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=65877416&loc=SL14450673-114947" }, "r384": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "55", "SubTopic": "80", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=35742348&loc=SL14450788-114948" }, "r385": { "Name": "Accounting Standards Codification", "Paragraph": "1D", "Publisher": "FASB", "Section": "35", "SubTopic": "10", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=126961718&loc=SL116886442-113899" }, "r386": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "35", "SubTopic": "10", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=126961718&loc=d3e4534-113899" }, "r387": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "35", "SubTopic": "10", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=126961718&loc=d3e4549-113899" }, "r388": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r389": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(1)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r39": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.22(a)(1))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r390": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(2)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r391": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(3)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r392": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r393": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r394": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(i)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r395": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(ii)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r396": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iii)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r397": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r398": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(01)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r399": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(02)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r4": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "105", "URI": "https://asc.fasb.org/extlink&oid=126987489&loc=SL124442142-165695" }, "r40": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.22(a)(2))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r400": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(03)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r401": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(04)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r402": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r403": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(i)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r404": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(ii)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r405": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(iii)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r406": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(iii)(01)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r407": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(iii)(02)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r408": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(iii)(03)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r409": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r41": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.22(a)(3))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r410": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)(1)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r411": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)(2)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r412": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r413": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)(1)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r414": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)(2)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r415": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(1)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r416": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r417": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(i)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r418": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(ii)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r419": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(iii)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r42": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.22(a)(5))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r420": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(iv)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r421": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(v)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r422": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)(1)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r423": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)(1)(i)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r424": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)(2)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r425": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)(2)(i)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r426": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)(2)(ii)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r427": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(i)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r428": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(l)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r429": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r43": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.22(b))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r430": { "Name": "Accounting Standards Codification", "Paragraph": "2A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=SL79508275-113901" }, "r431": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128097895&loc=SL121327923-165333" }, "r432": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(f)(1)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128097895&loc=SL121327923-165333" }, "r433": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(f)(2)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128097895&loc=SL121327923-165333" }, "r434": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 14.D.2.Q6)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=122041274&loc=d3e301413-122809" }, "r435": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=126964447&loc=d3e11149-113907" }, "r436": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=126964447&loc=d3e11178-113907" }, "r437": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "718", "URI": "https://asc.fasb.org/topic&trid=2228938" }, "r438": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "730", "URI": "https://asc.fasb.org/extlink&oid=6420194&loc=d3e21568-108373" }, "r439": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=123427490&loc=d3e31931-109318" }, "r44": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.22)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r440": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32672-109319" }, "r441": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32705-109319" }, "r442": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32809-109319" }, "r443": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32537-109319" }, "r444": { "Name": "Accounting Standards Codification", "Paragraph": "21", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32857-109319" }, "r445": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32559-109319" }, "r446": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=126983759&loc=SL121830611-158277" }, "r447": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=126983759&loc=SL121830611-158277" }, "r448": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(d)(2)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=126983759&loc=SL121830611-158277" }, "r449": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(d)(3)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=126983759&loc=SL121830611-158277" }, "r45": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.24)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r450": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB TOPIC 6.I.5.Q1)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817" }, "r451": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB TOPIC 6.I.7)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817" }, "r452": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 11.C)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330215-122817" }, "r453": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=123586238&loc=d3e38679-109324" }, "r454": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "270", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=6424409&loc=d3e44925-109338" }, "r455": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=6424122&loc=d3e41874-109331" }, "r456": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "740", "URI": "https://asc.fasb.org/topic&trid=2144680" }, "r457": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "65", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "805", "URI": "https://asc.fasb.org/extlink&oid=128092918&loc=SL128093175-196984" }, "r458": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "65", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "805", "URI": "https://asc.fasb.org/extlink&oid=128092918&loc=SL128093175-196984" }, "r459": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "65", "SubTopic": "20", "Subparagraph": "(d)", "Topic": "805", "URI": "https://asc.fasb.org/extlink&oid=128092918&loc=SL128093175-196984" }, "r46": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.25)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r460": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "30", "SubTopic": "30", "Topic": "805", "URI": "https://asc.fasb.org/extlink&oid=126966197&loc=d3e6578-128477" }, "r461": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "30", "SubTopic": "30", "Topic": "805", "URI": "https://asc.fasb.org/extlink&oid=126966197&loc=d3e6613-128477" }, "r462": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(b)", "Topic": "805", "URI": "https://asc.fasb.org/extlink&oid=126975305&loc=d3e6927-128479" }, "r463": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "15", "SubTopic": "50", "Topic": "805", "URI": "https://asc.fasb.org/extlink&oid=6911878&loc=d3e8732-128492" }, "r464": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "808", "URI": "https://asc.fasb.org/extlink&oid=6931272&loc=SL5834143-161434" }, "r465": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "808", "URI": "https://asc.fasb.org/extlink&oid=6931272&loc=SL5834143-161434" }, "r466": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "808", "URI": "https://asc.fasb.org/extlink&oid=118645555&loc=SL118645700-161420" }, "r467": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(g)", "Topic": "808", "URI": "https://asc.fasb.org/extlink&oid=118645555&loc=SL118645700-161420" }, "r468": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=126929396&loc=SL4568447-111683" }, "r469": { "Name": "Accounting Standards Codification", "Paragraph": "16", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=126929396&loc=SL4568740-111683" }, "r47": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.27(b))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r470": { "Name": "Accounting Standards Codification", "Paragraph": "19", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=126929396&loc=SL4569616-111683" }, "r471": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=126929396&loc=SL4569643-111683" }, "r472": { "Name": "Accounting Standards Codification", "Paragraph": "21", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=126929396&loc=SL4613674-111683" }, "r473": { "Name": "Accounting Standards Codification", "Paragraph": "23", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=126929396&loc=SL4569655-111683" }, "r474": { "Name": "Accounting Standards Codification", "Paragraph": "24", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=126929396&loc=SL4616395-111683" }, "r475": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988" }, "r476": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988" }, "r477": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(1)", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684" }, "r478": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(2)", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684" }, "r479": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684" }, "r48": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.29)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r480": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c),(3)", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684" }, "r481": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(bb)", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685" }, "r482": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685" }, "r483": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685" }, "r484": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=123419778&loc=d3e5728-111685" }, "r485": { "Name": "Accounting Standards Codification", "Paragraph": "5A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=123419778&loc=SL6759159-111685" }, "r486": { "Name": "Accounting Standards Codification", "Paragraph": "5A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=123419778&loc=SL6759159-111685" }, "r487": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=123419778&loc=d3e5747-111685" }, "r488": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=123419778&loc=SL6228884-111685" }, "r489": { "Name": "Accounting Standards Codification", "Paragraph": "4I", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=120409616&loc=SL4590271-111686" }, "r49": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.29,30)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r490": { "Name": "Accounting Standards Codification", "Paragraph": "4J", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=120409616&loc=SL4591551-111686" }, "r491": { "Name": "Accounting Standards Codification", "Paragraph": "4K", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=120409616&loc=SL4591552-111686" }, "r492": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "810", "URI": "https://asc.fasb.org/topic&trid=2197479" }, "r493": { "Name": "Accounting Standards Codification", "Paragraph": "4A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5618551-113959" }, "r494": { "Name": "Accounting Standards Codification", "Paragraph": "4B", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5624163-113959" }, "r495": { "Name": "Accounting Standards Codification", "Paragraph": "4B", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5624163-113959" }, "r496": { "Name": "Accounting Standards Codification", "Paragraph": "182", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=127000641&loc=SL5629052-113961" }, "r497": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "65", "SubTopic": "20", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=121483254&loc=SL120254523-199619" }, "r498": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "40", "Subparagraph": "(f)", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=126731327&loc=d3e90205-114008" }, "r499": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "40", "Subparagraph": "(a)", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=126731327&loc=SL126733271-114008" }, "r5": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "205", "URI": "https://asc.fasb.org/extlink&oid=124429488&loc=d3e326-107755" }, "r50": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.29-31)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r500": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(a)(1)", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011" }, "r501": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(a)(2)", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011" }, "r502": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(a)(3)", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011" }, "r503": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(b)(1)", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011" }, "r504": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(b)(2)", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011" }, "r505": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(c)", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011" }, "r506": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(d)", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011" }, "r507": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(e)(2)", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011" }, "r508": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(e)(3)", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011" }, "r509": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(e)(4)", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011" }, "r51": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.31)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r510": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(f)", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011" }, "r511": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(a)", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL126732908-238011" }, "r512": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "820", "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258" }, "r513": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "820", "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258" }, "r514": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(bbb)", "Topic": "820", "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258" }, "r515": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(bbb)(1)", "Topic": "820", "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258" }, "r516": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(bbb)(2)", "Topic": "820", "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258" }, "r517": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "820", "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258" }, "r518": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)", "Topic": "820", "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258" }, "r519": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "820", "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258" }, "r52": { "Name": "Accounting Standards Codification", "Paragraph": "16", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=99393222&loc=SL20226024-175313" }, "r520": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "820", "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19279-110258" }, "r521": { "Name": "Accounting Standards Codification", "Paragraph": "6A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "820", "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=SL6742756-110258" }, "r522": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "825", "URI": "https://asc.fasb.org/extlink&oid=123594786&loc=SL75136599-209740" }, "r523": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "825", "URI": "https://asc.fasb.org/extlink&oid=123596393&loc=d3e14064-108612" }, "r524": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "825", "URI": "https://asc.fasb.org/extlink&oid=126983955&loc=SL120254526-165497" }, "r525": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "825", "URI": "https://asc.fasb.org/extlink&oid=126983955&loc=SL120254526-165497" }, "r526": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Topic": "825", "URI": "https://asc.fasb.org/extlink&oid=126983955&loc=SL120254526-165497" }, "r527": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "825", "URI": "https://asc.fasb.org/extlink&oid=126983955&loc=SL121967933-165497" }, "r528": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "825", "URI": "https://asc.fasb.org/extlink&oid=126983955&loc=SL121967933-165497" }, "r529": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(c)(1)", "Topic": "825", "URI": "https://asc.fasb.org/extlink&oid=126983955&loc=SL121967933-165497" }, "r53": { "Name": "Accounting Standards Codification", "Paragraph": "21", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=99393222&loc=SL20226049-175313" }, "r530": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(c)(2)", "Topic": "825", "URI": "https://asc.fasb.org/extlink&oid=126983955&loc=SL121967933-165497" }, "r531": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "825", "URI": "https://asc.fasb.org/extlink&oid=126983955&loc=SL122642865-165497" }, "r532": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "825", "URI": "https://asc.fasb.org/extlink&oid=126983955&loc=SL122642865-165497" }, "r533": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "230", "Topic": "830", "URI": "https://asc.fasb.org/extlink&oid=123444420&loc=d3e33268-110906" }, "r534": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "830", "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32136-110900" }, "r535": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(a)", "Topic": "830", "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900" }, "r536": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(b)", "Topic": "830", "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900" }, "r537": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(c)", "Topic": "830", "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900" }, "r538": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(d)", "Topic": "830", "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900" }, "r539": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "830", "URI": "https://asc.fasb.org/extlink&oid=6450520&loc=d3e32583-110901" }, "r54": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=99393222&loc=SL20226052-175313" }, "r540": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "830", "URI": "https://asc.fasb.org/extlink&oid=6450520&loc=d3e32618-110901" }, "r541": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "832", "URI": "https://asc.fasb.org/extlink&oid=128342835&loc=SL128342857-244232" }, "r542": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "832", "URI": "https://asc.fasb.org/extlink&oid=128342835&loc=SL128342857-244232" }, "r543": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "835", "URI": "https://asc.fasb.org/extlink&oid=6450988&loc=d3e26243-108391" }, "r544": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "835", "URI": "https://asc.fasb.org/extlink&oid=124435984&loc=d3e28541-108399" }, "r545": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "835", "URI": "https://asc.fasb.org/extlink&oid=124435984&loc=d3e28551-108399" }, "r546": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "835", "URI": "https://asc.fasb.org/extlink&oid=124435984&loc=d3e28555-108399" }, "r547": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "835", "URI": "https://asc.fasb.org/extlink&oid=124429444&loc=SL124452920-239629" }, "r548": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "55", "SubTopic": "30", "Topic": "835", "URI": "https://asc.fasb.org/extlink&oid=114775985&loc=d3e28878-108400" }, "r549": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "842", "URI": "https://asc.fasb.org/extlink&oid=128293352&loc=SL120154346-209984" }, "r55": { "Name": "Accounting Standards Codification", "Paragraph": "10A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669646-108580" }, "r550": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "842", "URI": "https://asc.fasb.org/extlink&oid=128293352&loc=SL126838806-209984" }, "r551": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "842", "URI": "https://asc.fasb.org/extlink&oid=128293352&loc=SL126838806-209984" }, "r552": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "842", "URI": "https://asc.fasb.org/extlink&oid=128293352&loc=SL126838806-209984" }, "r553": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(d)(1)", "Topic": "842", "URI": "https://asc.fasb.org/extlink&oid=128293352&loc=SL126838806-209984" }, "r554": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "25", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "842", "URI": "https://asc.fasb.org/extlink&oid=123399704&loc=SL77918431-209957" }, "r555": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "842", "URI": "https://asc.fasb.org/extlink&oid=123391704&loc=SL77918627-209977" }, "r556": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "842", "URI": "https://asc.fasb.org/extlink&oid=123391704&loc=SL77918627-209977" }, "r557": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "842", "URI": "https://asc.fasb.org/extlink&oid=123391704&loc=SL77918638-209977" }, "r558": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "842", "URI": "https://asc.fasb.org/extlink&oid=123391704&loc=SL77918643-209977" }, "r559": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "842", "URI": "https://asc.fasb.org/extlink&oid=123391704&loc=SL77918643-209977" }, "r56": { "Name": "Accounting Standards Codification", "Paragraph": "10A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669646-108580" }, "r560": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "842", "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918673-209980" }, "r561": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "842", "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980" }, "r562": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "842", "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980" }, "r563": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)", "Topic": "842", "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980" }, "r564": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(g)(1)", "Topic": "842", "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980" }, "r565": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(g)(2)", "Topic": "842", "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980" }, "r566": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(g)(3)", "Topic": "842", "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980" }, "r567": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(g)(4)", "Topic": "842", "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980" }, "r568": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "842", "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980" }, "r569": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "842", "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918701-209980" }, "r57": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=d3e637-108580" }, "r570": { "Name": "Accounting Standards Codification", "Paragraph": "53", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "842", "URI": "https://asc.fasb.org/extlink&oid=123414884&loc=SL77918982-209971" }, "r571": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "848", "URI": "https://asc.fasb.org/extlink&oid=125980421&loc=SL122150809-237846" }, "r572": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "848", "URI": "https://asc.fasb.org/extlink&oid=125980421&loc=SL125981372-237846" }, "r573": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(a)(1)", "Topic": "848", "URI": "https://asc.fasb.org/extlink&oid=125980421&loc=SL125981372-237846" }, "r574": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(a)(2)", "Topic": "848", "URI": "https://asc.fasb.org/extlink&oid=125980421&loc=SL125981372-237846" }, "r575": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(a)(3)(iii)(01)", "Topic": "848", "URI": "https://asc.fasb.org/extlink&oid=125980421&loc=SL125981372-237846" }, "r576": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(a)(3)(iii)(03)", "Topic": "848", "URI": "https://asc.fasb.org/extlink&oid=125980421&loc=SL125981372-237846" }, "r577": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "850", "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864" }, "r578": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "850", "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864" }, "r579": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "850", "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39603-107864" }, "r58": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=d3e681-108580" }, "r580": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "852", "URI": "https://asc.fasb.org/extlink&oid=124437977&loc=d3e55792-112764" }, "r581": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "852", "URI": "https://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765" }, "r582": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "852", "URI": "https://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765" }, "r583": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "852", "URI": "https://asc.fasb.org/extlink&oid=84165509&loc=d3e56426-112766" }, "r584": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "855", "URI": "https://asc.fasb.org/extlink&oid=6842918&loc=SL6314017-165662" }, "r585": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "855", "URI": "https://asc.fasb.org/extlink&oid=6842918&loc=SL6314020-165662" }, "r586": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(2)(i)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r587": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(2)(ii)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r588": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(3)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r589": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(bb)(1)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r59": { "Name": "Accounting Standards Codification", "Paragraph": "14A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669686-108580" }, "r590": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(bb)(2)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r591": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(bb)(3)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r592": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)(1)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r593": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)(2)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r594": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)(3)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r595": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(1)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719" }, "r596": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(2)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719" }, "r597": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(3)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719" }, "r598": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719" }, "r599": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=66007379&loc=d3e113888-111728" }, "r6": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "205", "URI": "https://asc.fasb.org/extlink&oid=109222650&loc=SL51721683-107760" }, "r60": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669619-108580" }, "r600": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(b)(1)(i)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=109249958&loc=SL6224234-111729" }, "r601": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(b)(1)(ii)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=109249958&loc=SL6224234-111729" }, "r602": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(b)(2)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=109249958&loc=SL6224234-111729" }, "r603": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=109249958&loc=SL34722452-111729" }, "r604": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(1)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122625-111746" }, "r605": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(2)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122625-111746" }, "r606": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(3)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122625-111746" }, "r607": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(4)(i)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122625-111746" }, "r608": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(1)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746" }, "r609": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(2)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746" }, "r61": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669619-108580" }, "r610": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(3)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746" }, "r611": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(4)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746" }, "r612": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(5)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746" }, "r613": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(6)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746" }, "r614": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(7)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746" }, "r615": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(b)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746" }, "r616": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(e)(1)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746" }, "r617": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(e)(2)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746" }, "r618": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(e)(3)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746" }, "r619": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "910", "URI": "https://asc.fasb.org/extlink&oid=126937589&loc=SL119991595-234733" }, "r62": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669625-108580" }, "r620": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "25", "SubTopic": "730", "Topic": "912", "URI": "https://asc.fasb.org/extlink&oid=6472174&loc=d3e58812-109433" }, "r621": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 11.L)", "Topic": "924", "URI": "https://asc.fasb.org/extlink&oid=6472922&loc=d3e499488-122856" }, "r622": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "926", "URI": "https://asc.fasb.org/extlink&oid=120154696&loc=d3e54445-107959" }, "r623": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "926", "URI": "https://asc.fasb.org/extlink&oid=120154821&loc=SL120154904-197079" }, "r624": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "926", "URI": "https://asc.fasb.org/extlink&oid=120154821&loc=SL120154904-197079" }, "r625": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "926", "URI": "https://asc.fasb.org/extlink&oid=120154821&loc=SL120154904-197079" }, "r626": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "340", "Topic": "928", "URI": "https://asc.fasb.org/extlink&oid=6473545&loc=d3e61844-108004" }, "r627": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(a)", "Topic": "932", "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e61929-109447" }, "r628": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(b)", "Topic": "932", "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e61929-109447" }, "r629": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(a)", "Topic": "932", "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e62059-109447" }, "r63": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669625-108580" }, "r630": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(b)", "Topic": "932", "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e62059-109447" }, "r631": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(a)", "Topic": "932", "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e62395-109447" }, "r632": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(b)", "Topic": "932", "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e62395-109447" }, "r633": { "Name": "Accounting Standards Codification", "Paragraph": "33", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(a)", "Topic": "932", "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e62479-109447" }, "r634": { "Name": "Accounting Standards Codification", "Paragraph": "33", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(b)", "Topic": "932", "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e62479-109447" }, "r635": { "Name": "Accounting Standards Codification", "Paragraph": "35A", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(a)", "Topic": "932", "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=SL6807758-109447" }, "r636": { "Name": "Accounting Standards Codification", "Paragraph": "35A", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(b)", "Topic": "932", "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=SL6807758-109447" }, "r637": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(c)(1)", "Topic": "932", "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e61872-109447" }, "r638": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(c)(2)", "Topic": "932", "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e61872-109447" }, "r639": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(1)(a))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878" }, "r64": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=d3e557-108580" }, "r640": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(11))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878" }, "r641": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(13))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878" }, "r642": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(16))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878" }, "r643": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(22))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878" }, "r644": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(23))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878" }, "r645": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(6))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878" }, "r646": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03.15(5))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878" }, "r647": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03.17)", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878" }, "r648": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(24))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260" }, "r649": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(25))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260" }, "r65": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124442407-227067" }, "r650": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(26))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260" }, "r651": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(27))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260" }, "r652": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04.9)", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260" }, "r653": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "235", "Subparagraph": "(SX 210.9-05(b)(2))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=120399901&loc=d3e537907-122884" }, "r654": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "320", "Subparagraph": "(b)", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=126980459&loc=d3e62557-112803" }, "r655": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "360", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=124429447&loc=SL124453093-239630" }, "r656": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "470", "Subparagraph": "(c)", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=123599511&loc=d3e64711-112823" }, "r657": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "470", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=123599511&loc=d3e64711-112823" }, "r658": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(16))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910" }, "r659": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(12))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910" }, "r66": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124442411-227067" }, "r660": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(16))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910" }, "r661": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(23)(a)(3))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910" }, "r662": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910" }, "r663": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(24))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910" }, "r664": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(25))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910" }, "r665": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(8))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910" }, "r666": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03.(a),19)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910" }, "r667": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03.15(a))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910" }, "r668": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(20))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263" }, "r669": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(21))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263" }, "r67": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124452729-227067" }, "r670": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(22))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263" }, "r671": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(23))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263" }, "r672": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(3)(d))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263" }, "r673": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(9))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263" }, "r674": { "Name": "Accounting Standards Codification", "Paragraph": "4H", "Publisher": "FASB", "Section": "50", "SubTopic": "40", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=116884468&loc=SL65671331-158438" }, "r675": { "Name": "Accounting Standards Codification", "Paragraph": "7A", "Publisher": "FASB", "Section": "50", "SubTopic": "40", "Subparagraph": "(d)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=124506351&loc=SL117782755-158439" }, "r676": { "Name": "Accounting Standards Codification", "Paragraph": "13H", "Publisher": "FASB", "Section": "55", "SubTopic": "40", "Subparagraph": "(a)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126561865&loc=SL117783719-158441" }, "r677": { "Name": "Accounting Standards Codification", "Paragraph": "29F", "Publisher": "FASB", "Section": "55", "SubTopic": "40", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126561865&loc=SL117819544-158441" }, "r678": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(a)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641" }, "r679": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(b)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641" }, "r68": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(210.5-03(11))", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227" }, "r680": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(e)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641" }, "r681": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(f)(1)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641" }, "r682": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(f)(2)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641" }, "r683": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(g)(1)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641" }, "r684": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(g)(2)(i)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641" }, "r685": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(g)(2)(ii)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641" }, "r686": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(g)(2)(iii)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641" }, "r687": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(g)(2)(iv)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641" }, "r688": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(h)(1)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641" }, "r689": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(h)(2)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641" }, "r69": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(22))", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227" }, "r690": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "80", "Subparagraph": "(e)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=124508989&loc=d3e19393-158473" }, "r691": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-12B(Column B)(Footnote 1))", "Topic": "946", "URI": "https://asc.fasb.org/extlink&oid=122147990&loc=d3e611197-123010" }, "r692": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-12B(Column B)(Footnote 6))", "Topic": "946", "URI": "https://asc.fasb.org/extlink&oid=122147990&loc=d3e611197-123010" }, "r693": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-12B(Column B)(Footnote 7))", "Topic": "946", "URI": "https://asc.fasb.org/extlink&oid=122147990&loc=d3e611197-123010" }, "r694": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-12B(Column C)(Footnote 1))", "Topic": "946", "URI": "https://asc.fasb.org/extlink&oid=122147990&loc=d3e611197-123010" }, "r695": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-12B(Column C)(Footnote 6))", "Topic": "946", "URI": "https://asc.fasb.org/extlink&oid=122147990&loc=d3e611197-123010" }, "r696": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-12B(Column C)(Footnote 7))", "Topic": "946", "URI": "https://asc.fasb.org/extlink&oid=122147990&loc=d3e611197-123010" }, "r697": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-12B(Column D)(Footnote 1))", "Topic": "946", "URI": "https://asc.fasb.org/extlink&oid=122147990&loc=d3e611197-123010" }, "r698": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-12B(Column D)(Footnote 6))", "Topic": "946", "URI": "https://asc.fasb.org/extlink&oid=122147990&loc=d3e611197-123010" }, "r699": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-12B(Column D)(Footnote 7))", "Topic": "946", "URI": "https://asc.fasb.org/extlink&oid=122147990&loc=d3e611197-123010" }, "r7": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765" }, "r70": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(23))", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227" }, "r700": { "Name": "Accounting Standards Codification", "Paragraph": "5D", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-13D(Column B)(Footnote 2))", "Topic": "946", "URI": "https://asc.fasb.org/extlink&oid=122147990&loc=SL120429264-123010" }, "r701": { "Name": "Accounting Standards Codification", "Paragraph": "5D", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-13D(Column C)(Footnote 2))", "Topic": "946", "URI": "https://asc.fasb.org/extlink&oid=122147990&loc=SL120429264-123010" }, "r702": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-15(Column A))", "Topic": "946", "URI": "https://asc.fasb.org/extlink&oid=122147990&loc=d3e611379-123010" }, "r703": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-15(Column B))", "Topic": "946", "URI": "https://asc.fasb.org/extlink&oid=122147990&loc=d3e611379-123010" }, "r704": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-15(Column C))", "Topic": "946", "URI": "https://asc.fasb.org/extlink&oid=122147990&loc=d3e611379-123010" }, "r705": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-15(Column D))", "Topic": "946", "URI": "https://asc.fasb.org/extlink&oid=122147990&loc=d3e611379-123010" }, "r706": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "210", "Topic": "954", "URI": "https://asc.fasb.org/extlink&oid=120413173&loc=SL116631458-115580" }, "r707": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "440", "Subparagraph": "(a)", "Topic": "954", "URI": "https://asc.fasb.org/extlink&oid=6491277&loc=d3e6429-115629" }, "r708": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Footnote 4))", "Topic": "970", "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024" }, "r709": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "310", "Subparagraph": "(c)", "Topic": "976", "URI": "https://asc.fasb.org/extlink&oid=6497875&loc=d3e22274-108663" }, "r71": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(24))", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227" }, "r710": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "310", "Subparagraph": "(b)", "Topic": "978", "URI": "https://asc.fasb.org/extlink&oid=126945304&loc=d3e27327-108691" }, "r711": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "985", "URI": "https://asc.fasb.org/extlink&oid=6501960&loc=d3e128462-111756" }, "r712": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b" }, "r713": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-2" }, "r714": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "d1-1" }, "r715": { "Name": "Form 10-Q", "Number": "240", "Publisher": "SEC", "Section": "308", "Subsection": "a" }, "r716": { "Name": "Forms 10-K, 10-Q, 20-F", "Number": "240", "Publisher": "SEC", "Section": "13", "Subsection": "a-1" }, "r717": { "Name": "Regulation S-K (SK)", "Number": "229", "Paragraph": "(a)", "Publisher": "SEC", "Section": "1402" }, "r718": { "Name": "Regulation S-K (SK)", "Number": "229", "Paragraph": "(b)", "Publisher": "SEC", "Section": "1402", "Subparagraph": "(1)" }, "r719": { "Name": "Regulation S-K (SK)", "Number": "229", "Paragraph": "(b)", "Publisher": "SEC", "Section": "1402", "Subparagraph": "(2)" }, "r72": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(25))", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227" }, "r720": { "Name": "Regulation S-K (SK)", "Number": "229", "Paragraph": "(b)", "Publisher": "SEC", "Section": "1402", "Subparagraph": "(3)" }, "r721": { "Name": "Regulation S-K (SK)", "Number": "229", "Paragraph": "(c)", "Publisher": "SEC", "Section": "1402", "Subparagraph": "(2)(i)" }, "r722": { "Name": "Regulation S-K (SK)", "Number": "229", "Paragraph": "(c)", "Publisher": "SEC", "Section": "1402", "Subparagraph": "(2)(ii)" }, "r723": { "Name": "Regulation S-K (SK)", "Number": "229", "Paragraph": "(c)", "Publisher": "SEC", "Section": "1402", "Subparagraph": "(2)(iii)" }, "r724": { "Name": "Regulation S-K (SK)", "Number": "229", "Paragraph": "(a)", "Publisher": "SEC", "Section": "303", "Subparagraph": "(5)" }, "r725": { "Name": "Regulation S-T", "Number": "232", "Publisher": "SEC", "Section": "405" }, "r726": { "Name": "Regulation S-X (SX)", "Number": "210", "Publisher": "SEC", "Section": "11", "Subsection": "03" }, "r727": { "Footnote": "4", "Name": "Regulation S-X (SX)", "Number": "210", "Publisher": "SEC", "Section": "12", "Subsection": "28" }, "r728": { "Name": "Regulation S-X (SX)", "Number": "210", "Paragraph": "(a)", "Publisher": "SEC", "Section": "13", "Subparagraph": "(4)(i)", "Subsection": "01" }, "r729": { "Name": "Regulation S-X (SX)", "Number": "210", "Paragraph": "(a)", "Publisher": "SEC", "Section": "13", "Subparagraph": "(4)(iv)", "Subsection": "01" }, "r73": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(4))", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227" }, "r730": { "Name": "Regulation S-X (SX)", "Number": "210", "Paragraph": "(a)", "Publisher": "SEC", "Section": "13", "Subparagraph": "(4)(iv)", "Subsection": "02" }, "r731": { "Name": "Regulation S-X (SX)", "Number": "210", "Paragraph": "(m)", "Publisher": "SEC", "Section": "4", "Subparagraph": "(1)(iii)", "Subsection": "08" }, "r74": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(8))", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227" }, "r75": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03)", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227" }, "r76": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.3)", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227" }, "r77": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.4)", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227" }, "r78": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.7(b))", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227" }, "r79": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.7)", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227" }, "r8": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765" }, "r80": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.8)", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227" }, "r81": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.9)", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227" }, "r82": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "8", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227" }, "r83": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3179-108585" }, "r84": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3213-108585" }, "r85": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3213-108585" }, "r86": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3255-108585" }, "r87": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3255-108585" }, "r88": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3291-108585" }, "r89": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3291-108585" }, "r9": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765" }, "r90": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3291-108585" }, "r91": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3291-108585" }, "r92": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3367-108585" }, "r93": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3367-108585" }, "r94": { "Name": "Accounting Standards Codification", "Paragraph": "19", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3444-108585" }, "r95": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3000-108585" }, "r96": { "Name": "Accounting Standards Codification", "Paragraph": "24", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3521-108585" }, "r97": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3536-108585" }, "r98": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3536-108585" }, "r99": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585" } }, "version": "2.1" }